<SEC-DOCUMENT>0001104659-22-126998.txt : 20221214
<SEC-HEADER>0001104659-22-126998.hdr.sgml : 20221214
<ACCEPTANCE-DATETIME>20221214164707
ACCESSION NUMBER:		0001104659-22-126998
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		12
FILED AS OF DATE:		20221214
DATE AS OF CHANGE:		20221214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tekla World Healthcare Fund
		CENTRAL INDEX KEY:			0001635977
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			MA

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-267555
		FILM NUMBER:		221462723

	BUSINESS ADDRESS:	
		STREET 1:		100 FEDERAL STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		(617) 772-8515

	MAIL ADDRESS:	
		STREET 1:		100 FEDERAL STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm2226039d6_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:ck0001635977="http://www.teklacap.com/20221213" xmlns:dei="http://xbrl.sec.gov/dei/2022"  >
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
  <title>Tekla World Healthcare Fund - 1635977 - 2022</title>
</head>
<body>

<div style="display:none">
<ix:header>
  <ix:hidden>
    <ix:footnote id="FN20221209055746247" xml:lang="en-US">Represents the estimated commission with respect to the Common Shares being sold under this Prospectus Supplement and the accompanying Prospectus. There is no guarantee that there will be any sales of Common Shares under this Prospectus Supplement and the accompanying Prospectus. Actual sales of Common Shares under this Prospectus Supplement and the accompanying Prospectus, if any, may be less than as set forth under &#8220;Capitalization&#8221; below. In addition, the price per Common Share of any such sale may be greater or less than the price set forth under &#8220;Capitalization&#8221; below, depending on market price of the Common Shares at the time of any such sale.</ix:footnote>
    <ix:footnote id="FN20221209055759475" xml:lang="en-US">The expenses of administering the Trust&#8217;s Dividend Reinvestment and Stock Purchase Plan are included in &#8220;Other Expenses.&#8221; You will pay brokerage charges if you direct your broker or the plan agent to sell your Common Shares that you acquired pursuant to the Trust&#8217;s Dividend Reinvestment and Stock Purchase Plan. You may also pay a pro rata share of brokerage commissions incurred in connection with open-market purchases pursuant to the Trust&#8217;s Dividend Reinvestment and Stock Purchase Plan.</ix:footnote>
    <ix:footnote id="FN20221209055813226" xml:lang="en-US">The management fee is charged as a percentage of the Trust&#8217;s average daily Managed Assets (as defined herein), as opposed to net assets. If leverage is used, Managed Assets will be greater in amount than net assets, because Managed Assets includes borrowings for investment purposes. &#8220;Managed Assets&#8221; means the total assets of the Trust (including any assets attributable to borrowings for investment purposes) minus the sum of the Trust&#8217;s accrued liabilities (other than liabilities representing borrowings for investment purposes).</ix:footnote>
    <ix:footnote id="FN20221209055826642" xml:lang="en-US"> &#8220;Other Expenses&#8221; have been estimated for the current fiscal year.</ix:footnote>
    <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="C_20201001to20210930_cefSecurityAxis_ck0001635977LoanFacilityMember" id="Fxbrl_20221209173039070" unitRef="USD_Per_Share" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="C_20191001to20200930_cefSecurityAxis_ck0001635977LoanFacilityMember" id="Fxbrl_20221209173120190" unitRef="USD_Per_Share" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="C_20181001to20190930_cefSecurityAxis_ck0001635977LoanFacilityMember" id="Fxbrl_20221209173123789" unitRef="USD_Per_Share" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="C_20171001to20180930_cefSecurityAxis_ck0001635977LoanFacilityMember" id="Fxbrl_20221209173241279" unitRef="USD_Per_Share" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="C_20161001to20170930_cefSecurityAxis_ck0001635977LoanFacilityMember" id="Fxbrl_20221209173248397" unitRef="USD_Per_Share" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="C_20151001to20160930_cefSecurityAxis_ck0001635977LoanFacilityMember" id="Fxbrl_20221209173251957" unitRef="USD_Per_Share" xsi:nil="true"></ix:nonFraction>
    <ix:footnote id="FN20221209120220138" xml:lang="en-US">Total amount in $ millions of each class of senior securities outstanding at the end of the period presented.</ix:footnote>
    <ix:footnote id="FN20221209174101721" xml:lang="en-US">Not applicable because the senior securities are not registered for public trading.</ix:footnote>
    <ix:footnote id="FN20221209105548339" xml:lang="en-US">As reported by Bloomberg LLP.</ix:footnote>
    <ix:footnote id="FN20221209105630283" xml:lang="en-US">Based on the Trust&#8217;s computations, on the day that the high or low market price was recorded.</ix:footnote>
    <ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20221213to20221213" id="Fdei_AmendmentFlag20221209134115862" >false</ix:nonNumeric>
    <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20221213to20221213" id="Fdei_EntityCentralIndexKey20221209134133945" >0001635977</ix:nonNumeric>
    <ix:nonNumeric name="dei:DocumentType" contextRef="C_20221213to20221213" id="Fxbrl_20221209140522624" >424B5</ix:nonNumeric>
    <ix:footnote id="FN20221212115720547" xml:lang="en-US">The expenses of administering the Trust&#8217;s Dividend Reinvestment and Stock Purchase Plan are included in &#8220;Other Expenses.&#8221; You will pay brokerage charges if you direct your broker or the plan agent to sell your Shares that you acquired pursuant to the Trust&#8217;s Dividend Reinvestment and Stock Purchase Plan. You may also pay a pro rata share of brokerage commissions incurred in connection with open-market purchases pursuant to the Trust&#8217;s Dividend Reinvestment and Stock Purchase Plan. See &#8220;Dividend Reinvestment and Stock Purchase Plan.&#8221;</ix:footnote>
    <ix:footnote id="FN20221212120008060" xml:lang="en-US">&#8220;Other Expenses&#8221; for the current fiscal year.</ix:footnote>
    <ix:footnote id="FN20221212115946892" xml:lang="en-US">The management fee is charged as a percentage of the Trust&#8217;s average daily Managed Assets, as opposed to net assets. If leverage is used, Managed Assets will be greater in amount than net assets, because Managed Assets includes borrowings for investment purposes.</ix:footnote>
    </ix:hidden>
  <ix:references> <link:schemaRef xlink:type="simple" xlink:href="ck0001635977-20221213.xsd"/>
    </ix:references>
  <ix:resources>
    <xbrli:context id="C_20221213to20221213">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-13</xbrli:startDate>
        <xbrli:endDate>2022-12-13</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220906to20220906">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-06</xbrli:startDate>
        <xbrli:endDate>2022-09-06</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221206to20221206">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-06</xbrli:startDate>
        <xbrli:endDate>2022-12-06</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201001to20210930_cefSecurityAxis_ck0001635977LoanFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:SecurityAxis">ck0001635977:LoanFacilityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20191001to20200930_cefSecurityAxis_ck0001635977LoanFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:SecurityAxis">ck0001635977:LoanFacilityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20181001to20190930_cefSecurityAxis_ck0001635977LoanFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:SecurityAxis">ck0001635977:LoanFacilityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20171001to20180930_cefSecurityAxis_ck0001635977LoanFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:SecurityAxis">ck0001635977:LoanFacilityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20161001to20170930_cefSecurityAxis_ck0001635977LoanFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:SecurityAxis">ck0001635977:LoanFacilityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20151001to20160930_cefSecurityAxis_ck0001635977LoanFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:SecurityAxis">ck0001635977:LoanFacilityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211001to20220331">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201001to20210930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20191001to20200930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20181001to20190930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20171001to20180930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20161001to20170930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20191001to20191231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20200101to20200331">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20200401to20200630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20200701to20200930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201001to20201231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20210331">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210401to20210630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210701to20210930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211001to20211231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20220331">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220401to20220630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221201to20221201">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-01</xbrli:startDate>
        <xbrli:endDate>2022-12-01</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="USD_Per_Share"><xbrli:divide>
      <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator>
      <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide>
      </xbrli:unit>
    <ix:relationship fromRefs="Fxbrl_20221209055556812" toRefs="FN20221209055746247"/>
    <ix:relationship fromRefs="Fxbrl_20221209055609172" toRefs="FN20221209055759475"/>
    <ix:relationship fromRefs="Fxbrl_20221209055614851" toRefs="FN20221209055813226"/>
    <ix:relationship fromRefs="Fxbrl_20221209055614851" toRefs="FN20221209055759475"/>
    <ix:relationship fromRefs="Fxbrl_20221209055621581" toRefs="FN20221209055759475"/>
    <ix:relationship fromRefs="Fxbrl_20221209055626506" toRefs="FN20221209055826642"/>
    <ix:relationship fromRefs="Fxbrl_20221209055626506" toRefs="FN20221209055759475"/>
    <ix:relationship fromRefs="Fxbrl_20221209055631106" toRefs="FN20221209055759475"/>
    <ix:relationship fromRefs="Fxbrl_20221209112210937" toRefs="FN20221209120220138"/>
    <ix:relationship fromRefs="Fxbrl_20221209112259390_xbrl_20221209112210937" toRefs="FN20221209120220138"/>
    <ix:relationship fromRefs="Fxbrl_20221209112302627_xbrl_20221209112210937" toRefs="FN20221209120220138"/>
    <ix:relationship fromRefs="Fxbrl_20221209112304686_xbrl_20221209112210937" toRefs="FN20221209120220138"/>
    <ix:relationship fromRefs="Fxbrl_20221209112306740_xbrl_20221209112210937" toRefs="FN20221209120220138"/>
    <ix:relationship fromRefs="Fxbrl_20221209112309132_xbrl_20221209112210937" toRefs="FN20221209120220138"/>
    <ix:relationship fromRefs="Fxbrl_20221209173039070" toRefs="FN20221209174101721"/>
    <ix:relationship fromRefs="Fxbrl_20221209173120190" toRefs="FN20221209174101721"/>
    <ix:relationship fromRefs="Fxbrl_20221209173123789" toRefs="FN20221209174101721"/>
    <ix:relationship fromRefs="Fxbrl_20221209173241279" toRefs="FN20221209174101721"/>
    <ix:relationship fromRefs="Fxbrl_20221209173248397" toRefs="FN20221209174101721"/>
    <ix:relationship fromRefs="Fxbrl_20221209173251957" toRefs="FN20221209174101721"/>
    <ix:relationship fromRefs="Fxbrl_20221209105303397" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105328471" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105410129" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105432641" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105451232" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105504591" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105735391_xbrl_20221209105451232" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105735391_xbrl_20221209105432641" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105735391_xbrl_20221209105328471" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105735391_xbrl_20221209105303397" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105737683_xbrl_20221209105451232" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105737683_xbrl_20221209105432641" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105737683_xbrl_20221209105410129" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105737683_xbrl_20221209105328471" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105737683_xbrl_20221209105303397" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105739625_xbrl_20221209105504591" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105739625_xbrl_20221209105451232" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105739625_xbrl_20221209105432641" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105739625_xbrl_20221209105410129" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105739625_xbrl_20221209105328471" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105739625_xbrl_20221209105303397" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105741931_xbrl_20221209105504591" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105741931_xbrl_20221209105451232" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105741931_xbrl_20221209105432641" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105741931_xbrl_20221209105410129" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105741931_xbrl_20221209105328471" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105741931_xbrl_20221209105303397" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105743730_xbrl_20221209105451232" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105743730_xbrl_20221209105432641" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105743730_xbrl_20221209105410129" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105743730_xbrl_20221209105328471" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105743730_xbrl_20221209105303397" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105746378_xbrl_20221209105451232" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105746378_xbrl_20221209105432641" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105746378_xbrl_20221209105410129" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105746378_xbrl_20221209105328471" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105746378_xbrl_20221209105303397" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105748594_xbrl_20221209105504591" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105748594_xbrl_20221209105451232" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105748594_xbrl_20221209105432641" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105748594_xbrl_20221209105410129" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105748594_xbrl_20221209105328471" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105748594_xbrl_20221209105303397" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105750466_xbrl_20221209105504591" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105750466_xbrl_20221209105451232" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105750466_xbrl_20221209105432641" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105750466_xbrl_20221209105410129" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105750466_xbrl_20221209105328471" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105750466_xbrl_20221209105303397" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105752315_xbrl_20221209105451232" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105752315_xbrl_20221209105432641" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105752315_xbrl_20221209105410129" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105752315_xbrl_20221209105328471" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105752315_xbrl_20221209105303397" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105754425_xbrl_20221209105504591" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105754425_xbrl_20221209105451232" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105754425_xbrl_20221209105432641" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209105754425_xbrl_20221209105410129" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105754425_xbrl_20221209105328471" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209105754425_xbrl_20221209105303397" toRefs="FN20221209105548339"/>
    <ix:relationship fromRefs="Fxbrl_20221209114948366" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209115004831" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209115026176" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209115102859" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209115118483" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221209115212674" toRefs="FN20221209105630283"/>
    <ix:relationship fromRefs="Fxbrl_20221212110750235" toRefs="FN20221212115720547"/>
    <ix:relationship fromRefs="Fxbrl_20221212110756531" toRefs="FN20221212115720547"/>
    <ix:relationship fromRefs="Fxbrl_20221212110756531" toRefs="FN20221212120008060"/>
    <ix:relationship fromRefs="Fxbrl_20221212110803558" toRefs="FN20221212115720547"/>
    <ix:relationship fromRefs="Fxbrl_20221212110810366" toRefs="FN20221212115720547"/>
    <ix:relationship fromRefs="Fxbrl_20221212110810366" toRefs="FN20221212115946892"/>
    <ix:relationship fromRefs="Fxbrl_20221212110818655" toRefs="FN20221212115720547"/>
    </ix:resources>
  </ix:header></div>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:9.5pt Times New Roman, Times, Serif;margin:0pt 0;text-align:right"><strong>Filed Pursuant to Rule&#160;<span style="-sec-ix-hidden:Fxbrl_20221209140522624">424(b)(5)</span></strong></p>

<p style="font:9.5pt Times New Roman, Times, Serif;margin:0pt 0;text-align:right"><strong>Securities Act File No.&#160;333-267555</strong></p>

<p style="font:9.5pt Times New Roman, Times, Serif;margin:0pt 0;text-align:right"><strong>Investment Company Act File No.&#160;811-23037</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:9.5pt Times New Roman, Times, Serif;margin:0pt 0"><strong>PROSPECTUS SUPPLEMENT</strong></p>

<p style="font:9.5pt Times New Roman, Times, Serif;margin:0pt 0"><strong>(to Prospectus dated December&#160;6, 2022)</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:9.5pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong><ix:nonNumeric id="Fxbrl_20221209051558120" name="dei:EntityRegistrantName" contextRef="C_20221213to20221213">TEKLA
WORLD HEALTHCARE FUND</ix:nonNumeric></strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:9.5pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Common Shares of Beneficial Interests</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:9.5pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Having an Aggregate Initial Offering Price
of Up to $150,000,000</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">Tekla World Healthcare Fund (the &#8220;Trust&#8221;)
is a non-diversified, closed-end management investment company. The Trust&#8217;s investment objective is to seek current income and long-term
capital appreciation. Under normal market conditions, the Trust expects to invest at least 80% of its Managed Assets (as defined below)
in U.S. and non-U.S. companies engaged in the healthcare industries (&#8220;Healthcare Companies&#8221;) including equity securities and
debt securities. &#8220;Managed Assets&#8221; means the total assets of the Trust (including any assets attributable to borrowings for
investment purposes) minus the sum of the Trust&#8217;s accrued liabilities (other than liabilities representing borrowings for investment
purposes). The Trust&#8217;s 80% policy may only be changed with 60 days&#8217; prior notice to the Trust&#8217;s shareholders (the &#8220;Shareholders&#8221;).
The Trust will concentrate its investments in the healthcare industries. No assurance can be given that the Trust will achieve its investment
objective.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The Trust has entered into a Distribution Agreement,
dated December&#160;14, 2022 (the &#8220;Distribution Agreement&#8221;), among the Trust and Foreside Fund Services, LLC (&#8220;Foreside&#8221;)
relating to the Trust&#8217;s common shares of beneficial interest, par value $0.01 per share (the &#8220;Common Shares&#8221;), offered
by this Prospectus Supplement and the accompanying Prospectus. In accordance with the terms of the Distribution Agreement, the Trust may
offer and sell Common Shares having an aggregate initial offering price of up to $150,000,000, from time to time, through Foreside as
agent for the Trust for the offer and sale of Common Shares.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">Foreside may enter into sub-placement agent agreements
with one or more selected dealers. Foreside has entered into a sub-placement agent agreement, dated December&#160;14, 2022 (the &#8220;Sub-Placement
Agent Agreement&#8221;), with UBS Securities LLC (the &#8220;Sub-Placement Agent&#8221;), relating to the Common Shares offered by this
Prospectus Supplement and the accompanying Prospectus. In accordance with the terms of the Sub-Placement Agent Agreement, the Trust may
offer and sell Common Shares from time to time through the Sub-Placement Agent as sub-placement agent for the offer and sale of Common
Shares. The Trust will compensate Foreside with respect to sales of Common Shares at a commission rate of 1.00% of the gross proceeds
of the sale of Common Shares. Out of this commission, Foreside will compensate the Sub-Placement Agent at a rate of up to 0.80% of the
gross sales proceeds of the sale of the Common Shares sold by the Sub-Placement Agent<span>. In connection with the sale of the Common
Shares on behalf of the Trust, Foreside may be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act of 1933,
as amended (the &#8220;1933 Act&#8221;) and the compensation of Foreside may be deemed to be underwriting commissions or discounts.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in"><span>Sales of Common Shares, if any, under this Prospectus
Supplement and the accompanying Prospectus may be made in negotiated transactions or by any method permitted by law deemed to be an &#8220;at
the market offering&#8221; as defined in Rule&#160;415(a)(4)&#160;under the 1933 Act.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in"><span>The Trust&#8217;s currently outstanding Common
Shares are, and the Common Shares offered by this Prospectus Supplement and the accompanying Prospectus will be, listed on the New York
Stock Exchange (&#8220;NYSE&#8221;) under the symbol &#8220;THW.&#8221; As of December&#160;1, 2022, the net asset value per share of
the Trust&#8217;s Common Shares was $<ix:nonFraction id="Fxbrl_20221212124516544" name="cef:LatestNav" contextRef="C_20221201to20221201" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">13.59</ix:nonFraction>
and the last reported sale price for the Trust&#8217;s Common Shares on the NYSE was $<ix:nonFraction id="Fxbrl_20221212124532792" name="cef:LatestSharePrice" contextRef="C_20221201to20221201" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">15.03</ix:nonFraction>
per share, representing a premium to net asset value of <ix:nonFraction id="Fxbrl_20221212121322467" name="cef:LatestPremiumDiscountToNavPercent" contextRef="C_20221201to20221201" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">10.60</ix:nonFraction>%.
To the extent that the market price per Common Share, less any distributing commission or discount, is less than the then current net
asset value per Common Share on any given day, the Trust will instruct Foreside not to make any sales on such day.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">This Prospectus Supplement, together with the accompanying
Prospectus, dated December&#160;6, 2022, sets forth concisely the information that you should know before investing in the Trust&#8217;s
Common Shares. You should read this Prospectus Supplement and the accompanying Prospectus, which contain important information about the
Trust, before deciding whether to invest, and you should retain them for future reference. A Statement of Additional Information, dated
December&#160;6, 2022, (the &#8220;SAI&#8221;), as supplemented from time to time, containing additional information about the Trust,
has been filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) and is incorporated by reference in its entirety into this
Prospectus Supplement and the accompanying Prospectus. This Prospectus Supplement, the accompanying Prospectus and the SAI are part of
a &#8220;shelf&#8221; registration statement filed with the SEC. This Prospectus Supplement describes the specific details regarding this
offering, including the method of distribution. If information in this Prospectus Supplement is inconsistent with the accompanying Prospectus
or the SAI, you should rely on this Prospectus Supplement. You may request a free copy of the SAI or request other information about the
Trust (including the Trust&#8217;s annual and semi-annual</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<p style="margin:0pt">&#160;</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">reports)
or make shareholder inquiries by calling the Trust&#8217;s investment adviser, Tekla Capital Management LLC, at (617) 772-8500 or by writing
the Trust c/o Tekla Capital Management LLC, 100 Federal Street, 19th Floor Boston, MA 02110, or you may obtain a copy (and other information
regarding the Trust) from the SEC&#8217;s web site (<span style="color:rgb(5,99,193)"><span style="text-decoration:underline">http://www.sec.gov</span></span></span>).
Free copies of the Trust&#8217;s reports and the SAI also are available from the Trust&#8217;s website at www.teklacap.com.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The Trust&#8217;s Common Shares do not represent a deposit
or obligation of, and are not guaranteed or endorsed by, any bank or other insured depository institution and are not federally insured
by the Federal Deposit Insurance Corporation, the Federal Reserve Board or any other government agency.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">Capitalized terms used herein that are not otherwise
defined shall have the meanings assigned to them in the accompanying Prospectus.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="margin:0 auto;width:25%">

<div style="font-size:1pt;border-top:Black 1pt solid">&#160;</div> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in"><strong>Investing in the Trust&#8217;s Common Shares
involves certain risks. See &#8220;Risk Factors&#8221; beginning on page&#160;15 of the accompanying Prospectus. You should consider carefully
these risks together with all of the other information contained in this Prospectus Supplement and the accompanying Prospectus before
making a decision to purchase Common Shares.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in"><strong>Neither the SEC nor any state securities commission
has approved or disapproved of these securities or determined if this Prospectus Supplement or the accompanying Prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="margin:0 auto;width:25%">

<div style="font-size:1pt;border-top:Black 1pt solid">&#160;</div> </div>

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">This Prospectus Supplement is dated December 14, 2022.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>* &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</strong></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<p style="margin:0pt">&#160;</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>CAUTIONARY NOTICE REGARDING FORWARD-LOOKING
STATEMENTS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">Certain statements in this Prospectus Supplement, the
accompanying Prospectus and the SAI, including documents incorporated by reference herein and therein, constitute forward-looking statements,
which involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance
or achievements of the Trust to be materially different from any future results, levels of activity, performance or achievements expressed
or implied by such forward-looking statements. Such factors include, among others, those listed under &#8220;Risk Factors&#8221; and elsewhere
in this Prospectus Supplement. As a result of the foregoing and other factors, no assurance can be given as to the future results, levels
of activity or achievements, and neither the Trust nor any other person assumes responsibility for the accuracy and completeness of such
statements.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">Although the Trust believes that the expectations expressed
in any forward-looking statements are reasonable, actual results could differ materially from those expressed or implied in any forward-looking
statements. The Trust&#8217;s future financial condition and results of operations, as well as any forward-looking statements, are subject
to change and are subject to inherent risks and uncertainties, such as those disclosed in the &#8220;Risk Factors&#8221; section of the
accompanying Prospectus. You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements
contained or incorporated by reference in this Prospectus Supplement or the accompanying Prospectus are made as of the date of this Prospectus
Supplement or the accompanying Prospectus, as the case may be. Except for the Trust&#8217;s ongoing obligations under the federal securities
laws, the Trust does not intend, and the Trust undertakes no obligation, to update any forward-looking statement. The forward-looking
statements contained in this Prospectus Supplement, the accompanying Prospectus and the SAI are excluded from the safe harbor protection
provided by Section&#160;27A of the 1933 Act.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">Currently known risk factors that could cause actual
results to differ materially from the Trust&#8217;s expectations include, but are not limited to, the factors described in the &#8220;Risk
Factors&#8221; section of the accompanying Prospectus. The Trust urges you to review carefully those sections for a more detailed discussion
of the risks of an investment in our securities.</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<p style="font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">ii</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>TABLE OF CONTENTS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Prospectus Supplement</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td style="font:bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td><span style="font-size:10pt">&#160;</span></td>
    <td style="text-align:center"><span style="font-size:10pt"><strong>PAGE</strong>&#160;</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;width:91%"><span style="font-size:10pt">&#160;</span></td>
    <td style="width:1%"><span style="font-size:10pt">&#160;</span></td>
    <td style="text-align:right;width:8%"><span style="font-size:10pt">&#160;</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase;text-align:left;text-indent:-0.5in;padding-left:0.5in"><span style="font-size:10pt">PROSPECTUS
        SUPPLEMENT SUMMARY</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase;text-align:right"><span style="font-size:10pt">s-1</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase;text-align:left;text-indent:-0.5in;padding-left:0.5in"><span style="font-size:10pt">SUMMARY
        OF TRUST EXPENSES</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase;text-align:right"><span style="font-size:10pt">S-2</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase"><span style="font-size:10pt">CAPITALIZATION </span></td>
    <td><span style="font-size:10pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-size:10pt">S-3</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase;text-indent:-0.5in;padding-left:0.5in"><span style="font-size:10pt">USE
        OF PROCEEDS</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase;text-align:right"><span style="font-size:10pt">S-4</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase;text-indent:-0.5in;padding-left:0.5in"><span style="font-size:10pt">PLAN
        OF DISTRIBUTION</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase;text-align:right"><span style="font-size:10pt">S-4</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase;text-align:left;text-indent:-0.5in;padding-left:0.5in"><span style="font-size:10pt">LEGAL
        MATTERS</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase;text-align:right"><span style="font-size:10pt">S-5</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase;text-align:left;text-indent:-0.5in;padding-left:0.5in"><span style="font-size:10pt">INCORPORATION
        BY REFERENCE</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase;text-align:right"><span style="font-size:10pt">S-5</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase;text-align:left;text-indent:-0.5in;padding-left:0.5in"><span style="font-size:10pt">ADDITIONAL
        INFORMATION</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase;text-align:right"><span style="font-size:10pt">S-6</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td><span style="font-size:10pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-size:10pt">&#160;</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:center;font:bold 10pt Times New Roman, Times, Serif"><span style="font-size:10pt">Prospectus</span></td>
    <td><span style="font-size:10pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-size:10pt">&#160;</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td><span style="font-size:10pt">&#160;</span></td>
    <td style="text-align:right"><span style="font-size:10pt">&#160;</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-align:left"><span style="font-size:10pt">PROSPECTUS SUMMARY</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">6</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-align:left"><span style="font-size:10pt">TRUST EXPENSES</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">8</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-align:left"><span style="font-size:10pt">FINANCIAL HIGHLIGHTS AND INVESTMENT PERFORMANCE</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">10</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-align:left"><span style="font-size:10pt">SENIOR SECURITIES</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">13</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">USE OF PROCEEDS</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">14</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-align:left"><span style="font-size:10pt">INVESTMENT OBJECTIVE AND POLICIES</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">14</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-align:left"><span style="font-size:10pt">RISK FACTORS</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">15</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-align:left"><span style="font-size:10pt">THE TRUST</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">16</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">DESCRIPTION OF TRUST</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">19</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-align:left"><span style="font-size:10pt">PORTFOLIO TRANSACTIONS AND BROKERAGE</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">19</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">NET ASSET VALUE</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">20</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase"><span style="font-size:10pt">Plan of Distribution</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase;text-align:right"><span style="font-size:10pt">21</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-align:left"><span style="font-size:10pt">DIVIDENDS AND DISTRIBUTIONS</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">22</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-align:left"><span style="font-size:10pt">DIVIDEND REINVESTMENT AND STOCK PURCHASE
        PLAN</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">23</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">TAXATION</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">25</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-align:left"><span style="font-size:10pt">ADMINISTRATOR, CUSTODIAN, TRANSFER AGENT,
        DIVIDEND DISBURSING AGENT AND REGISTRAR</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">26</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-align:left"><span style="font-size:10pt">LEGAL MATTERS</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">26</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">EXPERTS</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">26</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-align:left"><span style="font-size:10pt">REPORTS TO SHAREHOLDERS</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">27</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase;text-align:left"><span style="font-size:10pt">Incorporation by
        Reference</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-transform:uppercase;text-align:right"><span style="font-size:10pt">27</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-align:left"><span style="font-size:10pt">ADDITIONAL INFORMATION</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">27</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-align:left"><span style="font-size:10pt">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">28</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;text-align:left"><span style="font-size:10pt">TABLE OF CONTENTS OF STATEMENT OF ADDITIONAL
        INFORMATION</span></td>
    <td style="font:10pt Times New Roman, Times, Serif"><span style="font-size:10pt">&#160;</span></td>
    <td style="font:10pt Times New Roman, Times, Serif;text-align:right"><span style="font-size:10pt">28</span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">You should rely only on the information contained or
incorporated by reference in this Prospectus Supplement and the accompanying Prospectus in making your investment decisions. The Trust
has not authorized any other person to provide you with different or inconsistent information. If anyone provides you with different or
inconsistent information, you should not rely on it. The Trust takes no responsibility for, and can provide no assurance as to the reliability
of, any other information that others may give you. This Prospectus Supplement and the accompanying Prospectus do not constitute an offer
to sell or solicitation of an offer to buy any securities in any jurisdiction where the offer or sale is not permitted. The information
appearing in this Prospectus Supplement and in the accompanying Prospectus is accurate only as of the respective dates on their front
covers. The Trust&#8217;s business, financial condition and prospects may have changed since such dates. The Trust will advise investors
of any material changes to the extent required by applicable law.</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<p style="font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">iii</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>PROSPECTUS SUPPLEMENT SUMMARY</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in"><i>This is only a summary of information contained elsewhere
in this Prospectus Supplement and the accompanying Prospectus. This summary does not contain all of the information that you should consider
before investing in the Trust&#8217;s Common Shares. You should carefully read the more detailed information contained in this Prospectus
Supplement and the accompanying Prospectus, dated December&#160;6, 2022, especially the information set forth under the headings &#8220;Investment
Objective and Policies&#8221; and &#8220;Risks Factors&#8221; prior to making an investment in the Trust. You may also wish to request
a copy of the Trust&#8217;s Statement of Additional Information, dated December&#160;6, 2022 (the &#8220;SAI&#8221;), which contains additional
information about the Trust and is incorporated by reference in its entirety into this Prospectus Supplement and the accompanying Prospectus.
Capitalized terms used herein that are not otherwise defined shall have the meanings assigned to them in the accompanying Prospectus.</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:0;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:25%"><strong>The Trust</strong></td>
    <td style="width:2%;text-align:left">&#160;</td>
    <td style="text-align:left;width:73%">The Trust is a non-diversified, closed-end management investment company. The Trust was organized as
        a Massachusetts business trust on March&#160;5, 2015, and commenced operations on June&#160;30, 2015. As of December&#160;1, 2022, the
        Trust had 37,569,605 Shares outstanding. Shares of the Trust are traded on the New York Stock Exchange (the &#8220;NYSE&#8221;) under
        the symbol &#8220;THW.&#8221; As of December&#160;1, 2022, the Trust&#8217;s NAV per Share was $13.59 and the Trust&#8217;s last reported
        share price of a Share on the NYSE was $15.03.</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Management of the Trust</strong></span></td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">Tekla Capital Management LLC (the &#8220;Investment Adviser&#8221;) serves as investment adviser to the Trust.
        The majority of the Board is unaffiliated with the Investment Adviser; nevertheless, the Trust may be subject to certain potential conflicts
        of interest.</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">Currently, Daniel R. Omstead, Ph.D., Jason C. Akus, M.D./M.B.A., Timothy Gasperoni, M.B.A., Ph.D., Ashton L. Wilson,
        Christopher Abbott, Robert Benson, Richard Goss, Loretta Tse, Ph.D., Jack Liu, M.B.A., Ph.D., Christopher Seitz, M.B.A., Graham Attipoe,
        M.B.A., M.D. and Kelly Girskis, Ph.D. are members of a team that analyzes investments on behalf of the Trust. Dr.&#160;Omstead exercises
        ultimate decision making authority with respect to investments.</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Listing and Symbol</strong></span></td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">Shares of the Trust are traded on the New York Stock Exchange (the &#8220;NYSE&#8221;) under the symbol &#8220;THW.&#8221;
        The net asset value (&#8220;NAV&#8221;) of the Common Shares at the close of business on December&#160;1, 2022 was $13.59 per share and
        the last sale price of the Common Shares on the NYSE on such date was $15.03, representing a premium to NAV of 10.60%. See &#8220;Net
        Asset Value&#8221; in the accompanying Prospectus.</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Investment Objective and Policies</strong></span></td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">
        <p style="margin:0pt 0;font:10pt Times New Roman, Times, Serif"><span style="background-color:white">Please refer to&#160;<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001635977/000110465922125461/tm2225215d1_ncsr.htm"><span style="color:#0070c0">the
        section of the Trust&#8217;s most recent annual report on Form&#160;N-CSR entitled &#8220;Investment Objective, Policies, and Risk Factors&#8212;Investment
        Objective and Policies&#8221;</span></a><span style="text-decoration:underline">,</span>&#160;which is incorporated by reference herein,
        for a discussion of the Trust&#8217;s investment objective and policies.</span></p> </td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Distributions</strong></span></td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">The Trust intends to make monthly distributions in cash at a rate of $0.1167 per Common Share to shareholders
        of realized capital gains in excess of the total distributed under this policy are generally included in the December&#160;distribution.
        The Trust&#8217;s monthly distribution policy may be changed by the Board of Trustees (the &#8220;Board&#8221;) without shareholder approval.</td>
        </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">The Trust&#8217;s distribution policy and the basis for establishing the rate of its monthly distributions may
        be changed at any time by the Board without shareholder approval. Pursuant to an exemptive order obtained from the Securities and Exchange
        Commission (the &#8220;SEC&#8221;) under Section&#160;19(b)&#160;of the Investment Company Act of 1940, as amended (the &#8220;1940 Act&#8221;),
        the Trust is permitted to distribute long-term capital gains to shareholders more than once per year.</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>The Offering</strong></span></td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">
        <p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0">The Trust has entered into a Distribution
        Agreement, dated December&#160;14, 2022 (the &#8220;Distribution Agreement&#8221;), among the Trust and Foreside Fund Services, LLC (&#8220;Foreside&#8221;)
        relating to the Trust&#8217;s common shares of beneficial interest, par value $0.01 per share (the &#8220;Common Shares&#8221;), offered
        by this Prospectus Supplement and the accompanying Prospectus. In accordance with the terms of the Distribution Agreement, the Trust may
        offer and sell Common Shares having an aggregate initial offering price of up to $150,000,000, from time to time, through Foreside as
        agent for the Trust for the offer and sale of Common Shares.</p>
        <p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>
        <p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0">Foreside may enter into sub-placement agent agreements
        with one or more selected dealers. Foreside has entered into a sub-placement agent agreement, dated December&#160;14, 2022 (the &#8220;Sub-Placement
        Agent Agreement&#8221;), with UBS Securities LLC (the &#8220;Sub-Placement Agent&#8221;), relating to the Common Shares offered by this
        Prospectus Supplement and the accompanying Prospectus. In accordance with the terms of the Sub-Placement Agent Agreement, the Trust may
        offer and sell Common Shares from time to time through the Sub-Placement Agent as sub-placement agent for the offer and sale of Common
        Shares. The Trust will compensate Foreside with respect to sales of Common Shares at a commission rate of 1.00% of the gross proceeds
        of the sale of Common Shares. Out of this commission, Foreside will compensate the Sub-Placement Agent at a rate of up to 0.80% of the
        gross sales proceeds of the sale of the Common Shares sold by the Sub-Placement Agent.</p> </td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">
        <p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0">Sales of Common Shares, if any, under this Prospectus
        Supplement and the accompanying Prospectus may be made in negotiated transactions or by any method permitted by law deemed to be an &#8220;at
        the market offering&#8221; as defined in Rule&#160;415(a)(4)&#160;under the Securities Act of 1933, as amended (the &#8220;1933 Act&#8221;).
        See &#8220;Plan of Distribution&#8221; in this Prospectus Supplement.</p>
        <p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>
        <p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Common Shares may not be sold through agents, underwriters
        or dealers without delivery or deemed delivery of this Prospectus Supplement and the accompanying Prospectus describing the method and
        terms of the offering of Common Shares.</p>
        <p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>
        <p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0">Under the 1940 Act, the Trust may not sell Common Shares
        at a price below the then current net asset value per Common Share, after taking into account any commission or discount.</p> </td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Risks</strong></span></td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">See &#8220;Risks Factors&#8221; beginning on page&#160;15 of the accompanying Prospectus for a discussion of factors
        you should carefully consider before deciding to invest in the Trust&#8217;s Common Shares.</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Use of Proceeds</strong></span></td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:left">
        <p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0">The Trust intends to invest the net proceeds
        of an offering of Common Shares in accordance with its investment objective and policies as appropriate investment opportunities are identified.
        It is currently anticipated that the Trust will be able to invest substantially all of the net proceeds of an offering of Common Shares
        in accordance with its investment objective and policies within three months after the completion of such offering, depending on market
        conditions and the availability of appropriate securities. U.S. securities and other U.S. financial instruments that are not registered
        or that are offered in an exempt non-public offering (&#8220;Restricted Securities&#8221;) may be purchased as appropriate opportunities
        arise, which could take up to six months, depending on market conditions. See &#8220;Use of Proceeds&#8221; in this Prospectus Supplement.</p>
        </td> </tr>
  </table>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<p style="text-align:center;font-size:10pt;margin-top:0pt;margin-bottom:0pt">S-1</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>SUMMARY OF TRUST EXPENSES</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The following table is intended to assist investors in understanding the
fees and expenses (annualized) that an investor in Common Shares would bear, directly or indirectly. The table is based on the capital
structure of the Trust as of September&#160;30, 2022.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The table shows Trust expenses as a percentage of net assets attributable
to the Common Shares. The following table should not be considered a representation of the Trust&#8217;s future expenses. Actual expenses
may be greater or less than those shown below.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> <ix:nonNumeric id="Fxbrl_20221209164044176" name="cef:ShareholderTransactionExpensesTableTextBlock" contextRef="C_20221213to20221213" escape="true">

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;width:85%;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Fees
        and Expenses</strong></span></td>
    <td style="padding-top:2pt;width:15%;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:5pt;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Shareholder
        Transaction Expenses</strong></span></td>
    <td style="padding-top:5pt;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Sales
        Load<sup>(1)</sup> </span></td>
    <td style="padding-top:2pt;text-align:right;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20221209055556812" name="cef:SalesLoadPercent" contextRef="C_20221213to20221213" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.00</ix:nonFraction>%</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Expenses
        Borne by Shareholders of the Trust </span></td>
    <td style="padding-top:2pt;text-align:right;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20221209055602682" name="cef:OtherTransactionExpensesPercent" contextRef="C_20221213to20221213" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>%</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Dividend
        Reinvestment and Stock Repurchase Plan Fees </span></td>
    <td style="padding-top:2pt;text-align:right;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20221209055609172" name="cef:DividendReinvestmentAndCashPurchaseFees" contextRef="C_20221213to20221213" unitRef="USD" scale="0" decimals="0" format="ixt-sec:numwordsen">None
        </ix:nonFraction><sup>(2)</sup></span></td> </tr>
  </table> </ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20221209164101502" name="cef:AnnualExpensesTableTextBlock" contextRef="C_20221213to20221213" escape="true">

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;padding-bottom:2pt;width:85%"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Annual
        Expenses (as a percentage of average net assets attributable to Shares)<sup>(2)</sup></strong></span></td>
    <td style="padding-top:2pt;text-align:right;padding-bottom:2pt;width:15%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Management
        Fee<sup>(3)</sup> </span></td>
    <td style="padding-top:2pt;text-align:right;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20221209055614851" name="cef:ManagementFeesPercent" contextRef="C_20221213to20221213" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.23</ix:nonFraction>%</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Interest
        Payments on Borrowed Funds </span></td>
    <td style="padding-top:2pt;text-align:right;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20221209055621581" name="cef:InterestExpensesOnBorrowingsPercent" contextRef="C_20221213to20221213" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.38</ix:nonFraction>%</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Other
        Expenses<sup>(4)</sup> </span></td>
    <td style="padding-top:2pt;text-align:right;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20221209055626506" name="cef:OtherAnnualExpensesPercent" contextRef="C_20221213to20221213" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.30</ix:nonFraction>%</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;padding-left:9pt;padding-bottom:2.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Total
        Annual Expenses </span></td>
    <td style="border-bottom:Black 2.5pt double;padding-top:2pt">
        <p style="border-top:Black 0.5pt solid;font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:right"><ix:nonFraction id="Fxbrl_20221209055631106" name="cef:TotalAnnualExpensesPercent" contextRef="C_20221213to20221213" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.91</ix:nonFraction>%</p>
        </td> </tr>
  </table> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-size:1pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">___________________</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">(1)</td>
    <td>Represents the estimated commission with respect to the Common Shares being sold under this Prospectus Supplement and the accompanying
        Prospectus. There is no guarantee that there will be any sales of Common Shares under this Prospectus Supplement and the accompanying
        Prospectus. Actual sales of Common Shares under this Prospectus Supplement and the accompanying Prospectus, if any, may be less than as
        set forth under &#8220;Capitalization&#8221; below. In addition, the price per Common Share of any such sale may be greater or less than
        the price set forth under &#8220;Capitalization&#8221; below, depending on market price of the Common Shares at the time of any such sale.</td>
        </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">(2)</td>
    <td>The expenses of administering the Trust&#8217;s Dividend Reinvestment and Stock Purchase Plan are included in &#8220;Other Expenses.&#8221;
        You will pay brokerage charges if you direct your broker or the plan agent to sell your Common Shares that you acquired pursuant to the
        Trust&#8217;s Dividend Reinvestment and Stock Purchase Plan. You may also pay a pro rata share of brokerage commissions incurred in connection
        with open-market purchases pursuant to the Trust&#8217;s Dividend Reinvestment and Stock Purchase Plan.</td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">(3)</td>
    <td> <ix:nonNumeric id="Fxbrl_20221209164954240" name="cef:ManagementFeeNotBasedOnNetAssetsNoteTextBlock" contextRef="C_20221213to20221213" escape="true">The
        management fee is charged as a percentage of the Trust&#8217;s average daily Managed Assets (as defined herein), as opposed to net assets.
        If leverage is used, Managed Assets will be greater in amount than net assets, because Managed Assets includes borrowings for investment
        purposes. &#8220;Managed Assets&#8221; means the total assets of the Trust (including any assets attributable to borrowings for investment
        purposes) minus the sum of the Trust&#8217;s accrued liabilities (other than liabilities representing borrowings for investment purposes).</ix:nonNumeric>
        </td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">(4)</td>
    <td> <ix:nonNumeric id="Fxbrl_20221209173218788" name="cef:OtherExpensesNoteTextBlock" contextRef="C_20221213to20221213" escape="true">&#8220;Other
        Expenses&#8221; have been estimated for the current fiscal year.</ix:nonNumeric> </td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Hypothetical Example</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">As required by relevant SEC regulation, the following
hypothetical example demonstrates the projected dollar amount of total cumulative expenses that would be incurred over various periods
with respect to a hypothetical investment in Common Shares of the Trust. These amounts are based upon payment by the Trust of investment
advisory fees and other expenses at the levels set forth in the table above.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">You would directly or indirectly pay the following expenses
on a $1,000 investment in the Trust, assuming (i)&#160;all dividends and other distributions are reinvested at NAV per Common Share, (ii)&#160;the
market price at the time of investment was equal to the NAV per Common Share, (iii)&#160;the percentage amounts listed under Annual Expenses
above remain the same in the years shown, and (iv)&#160;a 5% annual return:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> <ix:nonNumeric id="Fxbrl_20221209172819743" name="cef:ExpenseExampleTableTextBlock" contextRef="C_20221213to20221213" escape="true">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td colspan="2" style="font:bold 10pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1pt solid">1 Year</td>
    <td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="font:bold 10pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1pt solid">3 Years</td>
    <td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="font:bold 10pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1pt solid">5 Years</td>
    <td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="font:bold 10pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1pt solid">10 Years</td>
    <td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td colspan="2" style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif;text-align:center">&#160;</td>
    <td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif;text-align:center">&#160;</td>
    <td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif;text-align:center">&#160;</td>
    <td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif;text-align:center">&#160;</td>
    <td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-left:-0.25in;width:22%;text-align:right"><ix:nonFraction id="Fxbrl_20221209055649420_xbrl_20221209053046419" name="cef:ExpenseExampleYear01" contextRef="C_20221213to20221213" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">19</ix:nonFraction>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="width:2%;font:10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="width:22%;font:10pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fxbrl_20221209055649420_xbrl_20221209053117548" name="cef:ExpenseExampleYears1to3" contextRef="C_20221213to20221213" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">60</ix:nonFraction>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="width:2%;font:10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="width:21%;font:10pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fxbrl_20221209055649420_xbrl_20221209053127722" name="cef:ExpenseExampleYears1to5" contextRef="C_20221213to20221213" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">103</ix:nonFraction>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="width:2%;font:10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="width:21%;font:10pt Times New Roman, Times, Serif;text-align:right"><ix:nonFraction id="Fxbrl_20221209055649420_xbrl_20221209053136666" name="cef:ExpenseExampleYears1to10" contextRef="C_20221213to20221213" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">223</ix:nonFraction>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> <ix:nonNumeric id="Fxbrl_20221209055714418" name="cef:PurposeOfFeeTableNoteTextBlock" contextRef="C_20221213to20221213" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The purpose of the table above is to assist you in understanding
the various cost and expenses that you will bear directly or indirectly as an investor in the Trust. For more information on the management
fees paid by the Trust, please refer to the section of the accompanying Prospectus entitled &#8220;The Trust&#8212;Compensation of Investment
Adviser.&#8221;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The purpose of the table above is to assist you in understanding
the various costs and expenses that you will bear directly or indirectly as an investor in the Trust. For more information regarding the
management fees paid by the Trust, refer to the section of the accompanying Prospectus entitled &#8220;Management of the Trust&#8212;Investment
Adviser.&#8221;</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The above tables and the assumption in the hypothetical
example of a 5% annual return are required by regulations of the SEC applicable to all investment companies. The example should not be
considered a representation of future expenses and includes the expenses of the offering under this Prospectus Supplement and the accompanying
Prospectus. The example assumes that the estimated &#8220;Other Expenses&#8221; set forth in the table are accurate and that all dividends
and distributions are reinvested at the NAV per Common Share. Actual expenses may be greater or less than those assumed. Moreover, the
Trust&#8217;s actual rate of return may be greater or less than the hypothetical 5% annual return shown in the example below. The assumed
5% annual return is not a prediction of, and does not represent, the projected or actual performance of the Trust&#8217;s Common Shares.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in"><strong>This Hypothetical Example should not be considered
a representation of past or future expenses, and the Trust&#8217;s actual expenses may be greater or less than those shown.</strong></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<p style="text-align:center;font-size:10pt;margin-top:0pt;margin-bottom:0pt">S-2</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>CAPITALIZATION</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">In accordance with the terms of the Distribution Agreement,
the Trust may offer and sell Common Shares having an aggregate initial offering price of up to $150,000,000 from time to time, through
Foreside as the Trust&#8217;s agent for the offer and sale of Common Shares under this Prospectus Supplement and the accompanying Prospectus.
The price per share of any Common Share sold hereunder may be greater or less than the price of $15.03 (the last reported sale price for
the Trust&#8217;s Common Shares on the NYSE as of December&#160;1, 2022) assumed herein, depending on the market price of the Common Shares
at the time of such sale. Furthermore, there is no guarantee that the Trust will sell all of the Common Shares available for sale hereunder
or that there will be any sales of Common Shares hereunder. To the extent that the market price per Common Share, less any distributing
commission or discount, is less than the then current NAV per Common Share on any given day, the Trust will instruct Foreside not to make
any sales on such day.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The following table sets forth the Fund&#8217;s capitalization
(1)&#160;on a historical basis as of September&#160;30, 2022 (unaudited); and (2)&#160;on a pro forma basis as adjusted to reflect the
assumed sale of $150,000,000 of Common Shares at $15.03 per share (the last reported sale price of the Fund&#8217;s Common Shares on NYSE
on December&#160;1, 2022) in an offering under this Prospectus Supplement and the accompanying Prospectus, after deducting the assumed
commission of $1,500,000 (representing an estimated commission to Foreside of 1.00% of the gross proceeds of the sale of Fund Common Shares,
out of which Foreside will compensate the Sub-Placement Agent at a rate of up to 0.80% of the gross sales proceeds of the sale of the
Fund&#8217;s common shares sold by the Sub-Placement Agent).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:90%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td rowspan="2">&#160;</td>
    <td colspan="2" style="text-align:right;border-bottom:black 1.5pt solid;padding-left:0.7in;text-indent:0.1in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Actual
        </strong></span>&#160;</td>
    <td colspan="2" style="border-bottom:black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>As
        Adjusted &#160;&#160;<br />(unaudited)</strong></span>&#160;&#160;&#160;</td> </tr>
  <tr style="vertical-align:top">
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td> </tr>
  <tr>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Common Shareholder&#8217;s Equity:</strong></span></td>
    <td colspan="2" style="vertical-align:top">&#160;</td>
    <td colspan="2" style="vertical-align:top">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonNumeric id="Fxbrl_20221209122812359" name="cef:SecurityTitleTextBlock" contextRef="C_20221213to20221213" escape="true">Common
        shares</ix:nonNumeric> of beneficial interest, par value $0.01 per share; unlimited shares authorized, 37,520,270 shares issued and outstanding
        (actual), <ix:nonFraction id="Fxbrl_20221209122842507" name="cef:OutstandingSecurityHeldShares" contextRef="C_20221213to20221213" unitRef="Shares" scale="0" decimals="0" format="ixt:num-dot-decimal">47,500,309</ix:nonFraction>
        shares issued and outstanding (as adjusted)</span></td>
    <td style="padding-left:19.8pt;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">$</span></td>
    <td style="padding-right:5pt;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">375,202</span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">$</span></td>
    <td style="padding-right:5pt;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">475,002</span></td>
        </tr>
  <tr>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Additional paid-in capital</span></td>
    <td colspan="2" style="padding-right:5pt;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">517,900,332</span></td>
    <td colspan="2" style="padding-right:5pt;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">666,002,127</span></td>
        </tr>
  <tr>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Total distributable earnings (loss)</span></td>
    <td colspan="2" style="padding-right:5pt;border-bottom:black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">(63,932,784)</span></td>
    <td colspan="2" style="padding-right:5pt;border-bottom:black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">(63,932,784)</span></td>
        </tr>
  <tr>
    <td style="width:66%"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Net assets</span></td>
    <td style="border-bottom:black 2.25pt double;padding-left:19.8pt;text-align:center;width:5%"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">$</span></td>
    <td style="border-bottom:black 2.25pt double;padding-right:5pt;padding-left:19.8pt;text-align:right;width:12%"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">454,342,750</span></td>
    <td style="border-bottom:black 2.25pt double;text-align:center;width:5%"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">$</span></td>
    <td style="border-bottom:black 2.25pt double;padding-right:5pt;text-align:right;width:12%"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">602,544,345</span></td>
        </tr>
  </table>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<p style="text-align:center;font-size:10pt;margin-top:0pt;margin-bottom:0pt">S-3</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>USE OF PROCEEDS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">Sales of Common Shares, if any, under this Prospectus
Supplement and the accompanying Prospectus may be made in negotiated transactions or by any method permitted by law deemed to be an &#8220;at
the market offering&#8221; as defined in Rule&#160;415(a)(4)&#160;under the 1933 Act. Assuming the sale of $150,000,000 of Common Shares
under this Prospectus Supplement and the accompanying Prospectus, the net proceeds to the Trust from this offering will be approximately
$148,201,595 after deducting the estimated commission and estimated offering expenses. There is no guarantee that there will be any sales
of Common Shares pursuant to the Prospectus Supplement. The price per share of any Common Share sold hereunder may be greater or less
than the price assumed herein, depending on the market price of the Common Shares at the time of such sale. Furthermore, there is no guarantee
that the Trust will sell all of the Common Shares available for sale hereunder or that there will be any sales of Common Shares hereunder.
To the extent that the market price per Common Share, less any distributing commission or discount, is less than the then current NAV
per Common Share on any given day, the Trust will instruct Foreside not to make any sales on such day. As a result, the actual net proceeds
received by the Trust may be less than the amount of net proceeds estimated in this paragraph.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The Trust intends to invest the net proceeds of the
offering of Common Shares in accordance with its investment objective and policies as stated in this Prospectus Supplement and the accompanying
Prospectus. It is currently anticipated that the Trust will be able to invest substantially all of the net proceeds of the offering of
Common Shares in accordance with its investment objective and policies within three months after the completion of such offering, depending
on market conditions and the availability of appropriate securities. Restricted Securities may be purchased as appropriate opportunities
arise, which could take up to six months, depending on market conditions. The Trust may choose to be more fully invested in publicly-traded
securities during such period. Pending investment in the securities described above, the proceeds will be held in short-term securities,
including, but not limited to, obligations of the U.S. Government, its agencies or instrumentalities (&#8220;U.S. Government Securities&#8221;),
highly rated money market instruments or mutual funds that invest in such instruments. As a result of this short-term investment of the
proceeds, a lower return may be realized.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>PLAN OF DISTRIBUTION</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Trust has entered into the Distribution Agreement with Foreside, pursuant to which the Trust may offer and sell Common Shares </span>having
an aggregate initial offering price of up to $150,000,000<span>, from time to time, through Foreside, in transactions that are deemed
to be &#8220;at the market&#8221; as defined in Rule&#160;415 under the 1933 Act. The minimum price on any day at which Common Shares
may be sold will not be less than the Minimum Price, which will be equal to the then current NAV per Common Share plus the per Common
Share amount of the commission to be paid to Foreside. The Trust and Foreside will determine whether any sales of Common Shares will be
authorized on a particular day. The Trust and Foreside, however, will not authorize sales of Common Shares if the price per share of the
Common Shares is less than the Minimum Price. The Trust and Foreside may elect not to authorize sales of Common Shares on a particular
day even if the price per share of the Common Shares is equal to or greater than the Minimum Price, or may only authorize a fixed number
of Common Shares to be sold on any particular day. The Trust and Foreside will have full discretion regarding whether sales of Common
Shares will be authorized on a particular day and, if so, in what amounts.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">Foreside may enter into sub-placement agent agreements
with one or more selected dealers. Foreside has entered into the Sub-Placement Agent Agreement with UBS Securities LLC relating to the
Common Shares offered by this Prospectus Supplement and the accompanying Prospectus. In accordance with the terms of the Sub-Placement
Agent Agreement, the Trust may offer and sell Common Shares from time to time through the Sub-Placement Agent as sub-placement agent for
the offer and sale of Common Shares.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">Foreside (or the Sub-Placement Agent) will provide written
confirmation to the Trust not later than the opening of the trading day on the NYSE following any trading day on which Common Shares are
sold under the Distribution Agreement. Each confirmation will include the number of Common Shares sold on the preceding day, the net proceeds
to the Trust and the compensation payable by the Trust to Foreside in connection with the sales.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The Trust will compensate Foreside with respect to sales
of Common Shares at a commission rate of 1.00% of the gross proceeds of the sale of Common Shares. Out of this commission, Foreside will
compensate the Sub-Placement Agent at a rate of up to 0.80% of the gross sales proceeds of the sale of the Common Shares sold by the Sub-Placement
Agent. There is no guarantee that there will be any sales of Common Shares pursuant to this Prospectus Supplement.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">Settlement for sales of Common Shares will occur on
the second business day following the date on which such sales are made. There is no arrangement for funds to be deposited in escrow,
trust or similar arrangement. In connection with the sale of Common Shares on behalf of the Trust, Foreside may be deemed to be an &#8220;underwriter&#8221;
within the meaning of the 1933 Act, and the compensation paid to Foreside may be deemed to be underwriting commissions or discounts.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The Trust has agreed to provide indemnification and
contribution to Foreside against certain civil liabilities, including liabilities under the 1933 Act. The Trust has also agreed to reimburse
Foreside for other specified expenses. Foreside has agreed to provide indemnification to the Sub-Placement Agent against certain civil
liabilities, including liabilities under the 1933 Act.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The offering of Common Shares pursuant to the Distribution
Agreement will terminate upon the earlier of (1)&#160;the issuance and sale of all Common Shares subject to the Distribution Agreement
or (2)&#160;the termination of the Distribution Agreement. The Distribution Agreement may be terminated by the Trust in its sole discretion
at any time by giving 60 days&#8217; notice to Foreside. In addition, Foreside may terminate the Distribution Agreement under the circumstances
specified in the Distribution Agreement by giving 60 days&#8217; notice to the Trust.</p> </div> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The Common Shares may not be sold through Foreside or
the Sub-Placement Agent without delivery or deemed delivery of this Prospectus Supplement and the accompanying Prospectus describing the
method and terms of the offering of the Common Shares.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The Sub-Placement Agent, its affiliates or their respective
employees hold or may hold in the future, directly or indirectly, investment interests in the Trust. The interests held by the Sub-Placement
Agent, its affiliates or their respective employees are not attributable to, and no investment discretion is held by, the Sub-Placement
Agent, its affiliates or their respective affiliates.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The principal business address of Foreside is Three
Canal Plaza, Suite&#160;100, Portland, Maine 04101. The principal business address of UBS Securities LLC is 1285 Avenue of the America,
New York, New York 10019.</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<p style="text-align:center;font-size:10pt;margin-top:0pt;margin-bottom:0pt">S-4</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>LEGAL MATTERS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The validity of the Common Shares offered hereby will
be passed on for the Trust by Dechert LLP, One International Place, 40th Floor, 100 Oliver Street, Boston, MA 02110. Certain legal matters
will be passed on by Dechert LLP, Boston, MA, as counsel to the Trust in connection with the offering of Common Shares.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>INCORPORATION BY REFERENCE</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">This Prospectus Supplement is part of the registration
statement on Form&#160;N-2 that has been filed with the SEC. Pursuant to the final rule&#160;and form amendments adopted by the SEC on
April&#160;8, 2020, to implement certain provisions of the Economic Growth, Regulatory Relief, and Consumer Protection Act, the Trust
may &#8220;incorporate by reference&#8221; the information that it files with the SEC, which means that the Trust can disclose important
information by referring to those documents. The information incorporated by reference is considered to be part of this Prospectus Supplement,
and later information that the Trust files with the SEC will automatically update and supersede this information.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The documents listed below, and any reports and other
documents subsequently filed with the SEC pursuant to Rule&#160;30(b)(2)&#160;under the 1940 Act and Sections 13(a), 13(c), 14 or 15(d)&#160;of
the Securities Exchange Act of 1934, as amended, prior to the termination of the offering, are incorporated by reference into this Prospectus
Supplement and deemed to be part of this Prospectus Supplement from the date of the filing of such reports and documents:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="font-size:10pt;width:0.25in"><span style="font-family:Times New Roman, Times, Serif;font-size:15pt">&#8226;</span></td>
    <td>the Trust&#8217;s SAI, dated December&#160;6, 2022, filed with the accompanying Prospectus;</td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-family:Times New Roman, Times, Serif;font-size:15pt">&#8226;</span></td>
    <td>the Trust&#8217;s definitive Proxy Statement, dated April&#160;18, 2022, filed with the SEC on April&#160;12, 2022;</td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-family:Times New Roman, Times, Serif;font-size:15pt">&#8226;</span></td>
    <td>the Trust&#8217;s annual report on Form&#160;N-CSR for the fiscal year ended September&#160;30, 2022, filed with the SEC on December&#160;8,
        2022;</td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-family:Times New Roman, Times, Serif;font-size:15pt">&#8226;</span></td>
    <td>the Trust&#8217;s semi-annual report on Form&#160;N-CSR for the period ended March&#160;31, 2022, filed with the SEC on June&#160;3, 2022;</td>
        </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-family:Times New Roman, Times, Serif;font-size:15pt">&#8226;</span></td>
    <td>the Trust&#8217;s description of Common Shares on Form&#160;8-A, filed with the SEC on June&#160;19, 2015</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The Trust will provide without charge to each person,
including any beneficial owner, to whom this Prospectus Supplement and the accompanying Prospectus are delivered, upon written or oral
request, a copy of any and all of the documents that have been or may be incorporated by reference in this Prospectus Supplement or the
accompanying Prospectus.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">You should direct requests for documents by contacting
the Investment Adviser at (617) 772-8500. You may also obtain this Prospectus Supplement, the accompanying Prospectus, the SAI, other
documents incorporated by reference herein and therein and other information the Trust files electronically, including reports and proxy
statements, on the SEC website (http://www.sec.gov) or with the payment of a duplication fee, by electronic request at publicinfo@sec.gov.
Information contained in, or that can be accessed through, the Trust&#8217;s website is not incorporated by reference into this Prospectus
Supplement and the accompanying Prospectus and should not be considered to be part of this Prospectus Supplement or the accompanying Prospectus.</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<p style="text-align:center;font-size:10pt;margin-top:0pt;margin-bottom:0pt">S-5</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>ADDITIONAL INFORMATION</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">This Prospectus Supplement and the accompanying Prospectus
constitutes a part of a registration statement on Form&#160;N-2 (together with the SAI and all the exhibits and appendices thereto, the
&#8220;Registration Statement&#8221;) filed by the Trust with the SEC under the 1933 Act and the 1940 Act. This Prospectus Supplement,
the accompanying Prospectus and the SAI do not contain all of the information set forth in the Registration Statement. Reference is hereby
made to the Registration Statement and related exhibits for further information with respect to the Trust and the Common Shares offered
hereby. Any statements contained herein concerning the provisions of documents are necessarily summaries of such documents, and each statement
is qualified in its entirety by reference to the copy of the applicable document filed with the SEC. The complete Registration Statement
may be obtained from the SEC upon payment of the fee prescribed by its rules&#160;and regulations or free of charge through the SEC&#8217;s
web site (http://www.sec.gov).</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<p style="text-align:center;font-size:10pt;margin-top:0pt;margin-bottom:0pt">S-6</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Common Shares of Beneficial Interests</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Having an Aggregate Initial Offering Price of
Up to $150,000,000</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Tekla World Healthcare Fund</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>PROSPECTUS SUPPLEMENT</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>December 14, 2022</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:justify;margin-top:0pt;margin-bottom:0pt"><strong>Until January 8, 2023 (25
days after the date of this Prospectus Supplement), all dealers that effect transactions in these securities, whether or not participating
in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#8217; obligation to deliver a prospectus
when acting as underwriters.</strong></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-top:Black 1pt solid;break-after:page">

<p style="margin-top:6pt;margin-bottom:12pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">PROSPECTUS</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>TEKLA WORLD HEALTHCARE FUND</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>$150,000,000&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Common Shares<br />New York Stock Exchange Symbol:
THW</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Tekla World Healthcare Fund (the &#8220;Trust&#8221;) is a non-diversified,
closed-end management investment company. The Trust&#8217;s investment objective is to seek current income and long-term capital appreciation.
Under normal market conditions, the Trust expects to invest at least 80% of its Managed Assets (as defined below) in U.S. and non-U.S.
companies engaged in the healthcare industries (&#8220;Healthcare Companies&#8221;) including equity securities and debt securities. &#8220;Managed
Assets&#8221; means the total assets of the Trust (including any assets attributable to borrowings for investment purposes) minus the
sum of the Trust&#8217;s accrued liabilities (other than liabilities representing borrowings for investment purposes). The Trust&#8217;s
80% policy may only be changed with 60 days&#8217; prior notice to the Trust&#8217;s shareholders (the &#8220;Shareholders&#8221;). The
Trust will concentrate its investments in the healthcare industries. No assurance can be given that the Trust will achieve its investment
objective.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may offer, from time to time, up to $150,000,000 aggregate initial
offering price of common shares of beneficial interest, par value $0.01 per share (&#8220;Common Shares&#8221;), The Trust may also offer
subscription rights to purchase Common Shares. Common Shares may be offered in one or more offerings. in amounts, at prices and on terms
set forth in one or more supplements to this Prospectus (each a &#8220;Prospectus Supplement&#8221;). You should read this Prospectus
and any related Prospectus Supplement carefully before you decide to invest in the Common Shares.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may offer Common Shares (1)&#160;directly to one or more purchasers,
including existing Shareholders in a rights offering, (2)&#160;through agents; (3)&#160;through underwriters; (4)&#160;through dealers;
or (5)&#160;pursuant to the Dividend Reinvestment and Stock Purchase Plan. The Prospectus Supplement relating to a particular offering
of Common Shares will identify any agents or underwriters involved in the sale of Common Shares, and will set forth any applicable purchase
price, fee, commission or discount arrangement between the Trust and agents or underwriters or among underwriters or the basis upon which
such amount may be calculated. The Prospectus Supplement relating to any offering of rights will set forth the number of Common Shares
issuable upon the exercise of each right (or number of rights) and the other terms of such rights offering. The Trust may not sell Common
Shares through agents, underwriters or dealers without delivery of this Prospectus and a Prospectus Supplement. See &#8220;Plan of Distribution.&#8221;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Shares of the Trust are traded on the New York Stock Exchange (the &#8220;NYSE&#8221;)
under the symbol &#8220;THW.&#8221; The net asset value (&#8220;NAV&#8221;) of the Common Shares at the close of business on September&#160;6,
2022 was $<ix:nonFraction id="Fxbrl_20221212124716584" name="cef:LatestNav" contextRef="C_20220906to20220906" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">12.72</ix:nonFraction>
per share and the last sale price of the Common Shares on the NYSE on such date was $<ix:nonFraction id="Fxbrl_20221212124703163" name="cef:LatestSharePrice" contextRef="C_20220906to20220906" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.42</ix:nonFraction>,
representing a premium to NAV of <ix:nonFraction id="Fxbrl_20221212121450193" name="cef:LatestPremiumDiscountToNavPercent" contextRef="C_20220906to20220906" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">13.36</ix:nonFraction>%.
See &#8220;Net Asset Value.&#8221;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Investing in the Trust&#8217;s Common Shares involves certain
risks. For a discussion of the risks associated with an investment in the Trust, see &#8220;Risk Factors,&#8221; beginning on page&#160;15
of this Prospectus.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust adopted a managed distribution policy (the &#8220;Policy&#8221;)
in August&#160;2015 pursuant to an exemptive order obtained from the Securities and Exchange Commission (&#8220;SEC&#8221; or &#8220;Commission&#8221;).
Under the current Policy, the Trust intends to make monthly distributions at a rate of $0.1167 per share to Shareholders of record. The
Trust&#8217;s Board of Trustees (the &#8220;Board&#8221;) may modify or terminate the Policy at any time; any such change or termination
may have an adverse effect on the market price for the Trust&#8217;s Shares.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">To the extent that the Trust&#8217;s taxable income in any fiscal year
exceeds the aggregate amount distributed pursuant to the managed distribution policy based on a fixed percentage of its NAV, the Trust
would make an additional distribution in the amount of that excess near the end of the fiscal year. <strong>To the extent that the aggregate
amount distributed by the Trust based on a fixed percentage of its NAV exceeds its current and accumulated earnings and profits, the amount
of that excess would constitute a</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">3&#160;</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>return of capital for tax purposes. </strong>A return of capital
is applied against and reduces the Shareholder&#8217;s basis in his or her Shares. While distributions that represent a return of capital
will generally not be taxable to Shareholders, these distributions may reduce a Shareholder&#8217;s cost basis, which could result in
Shareholders having to pay higher taxes in the future when Shares are sold, even when Shares are sold at a loss from the original investment.
Distributions beyond the Shareholder&#8217;s basis would be treated as a capital gain.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The actual sources of the Trust&#8217;s monthly distributions may be net
investment income, net realized capital gains, return of capital or a combination of the foregoing and may be subject to retroactive recharacterization
at the end of the Trust&#8217;s fiscal year based on tax regulations. The actual amounts attributable to each of these sources will be
reported to Shareholders in January&#160;of each year on Form&#160;1099-DIV.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">This Prospectus sets forth concisely the information about the Trust you
should know before investing, including information about risks. You should read this Prospectus and retain it for future reference. A
Statement of Additional Information dated December 6, 2022 (the &#8220;SAI&#8221;) containing additional information about the Trust has
been filed with the Commission and is incorporated by reference in its entirety into this Prospectus. A copy of the SAI, the table of
contents of which appears on page&#160;28 of this Prospectus, and the Trust&#8217;s annual and semiannual reports may be obtained without
charge by contacting the Investment Adviser at (617) 772-8500. The Commission maintains a website (<span style="text-decoration:underline">http://www.sec.gov</span>)
that contains material incorporated by reference and other information regarding the Trust. The Trust&#8217;s annual and semi-annual reports
are also available on the Trust&#8217;s website (www.teklacap.com).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s investment adviser is Tekla Capital Management LLC (the
&#8220;Investment Adviser&#8221;).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Information about the Trust is available at the Commission&#8217;s Internet
site at <span style="text-decoration:underline">www.sec.gov</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="margin:3pt auto;width:25%">

<div style="border-top:Black 1pt solid;font-size:1pt">&#160;</div> </div>

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">Prospectus dated December 6, 2022</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">4&#160;</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>TABLE OF CONTENTS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:center;padding-bottom:2pt"><strong>PAGE</strong></td>
    <td style="padding-top:2pt;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;width:87%;text-align:left;padding-bottom:2pt">PROSPECTUS SUMMARY</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;width:2%;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;width:10%;text-align:right;padding-bottom:2pt">6</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;width:1%;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">TRUST EXPENSES</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">8</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">FINANCIAL HIGHLIGHTS AND INVESTMENT
        PERFORMANCE</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">10</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">SENIOR SECURITIES</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">13</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">USE OF PROCEEDS</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">14</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">INVESTMENT OBJECTIVE AND POLICIES</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">14</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">RISK FACTORS</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">15</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">THE TRUST</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">16</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">DESCRIPTION OF TRUST</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">19</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">PORTFOLIO TRANSACTIONS AND BROKERAGE</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">19</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">NET ASSET VALUE</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">20</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-transform:uppercase;padding-bottom:2pt">Plan of Distribution</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-transform:uppercase;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-transform:uppercase;text-align:right;padding-bottom:2pt">21</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-transform:uppercase;text-align:left;padding-bottom:2pt">&#160;</td>
        </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">DIVIDENDS AND DISTRIBUTIONS</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">22</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">DIVIDEND REINVESTMENT AND STOCK PURCHASE
        PLAN</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">23</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">TAXATION</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">25</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">ADMINISTRATOR, CUSTODIAN, TRANSFER
        AGENT, DIVIDEND DISBURSING AGENT AND REGISTRAR</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">26</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">LEGAL MATTERS</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">26</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">EXPERTS</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">26</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">REPORTS TO SHAREHOLDERS</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">27</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-transform:uppercase;text-align:left;padding-bottom:2pt">Incorporation
        by Reference</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-transform:uppercase;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-transform:uppercase;text-align:right;padding-bottom:2pt">27</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-transform:uppercase;text-align:left;padding-bottom:2pt">&#160;</td>
        </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">ADDITIONAL INFORMATION</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">27</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">SPECIAL NOTE REGARDING FORWARD-LOOKING
        STATEMENTS</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">28</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">TABLE OF CONTENTS OF STATEMENT OF ADDITIONAL
        INFORMATION</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:right;padding-bottom:2pt">28</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">5&#160;</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>PROSPECTUS
SUMMARY</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">You should consider the matters discussed in this summary before investing
in the Trust. The following summary is qualified in its entirety by reference to the more detailed information appearing elsewhere in
this Prospectus.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="padding-right:5.4pt;padding-left:5.4pt">The Trust</td>
    <td colspan="2" style="padding-right:5.4pt;padding-left:5.4pt">The Trust is a non-diversified, closed-end management investment company. The
        Trust was organized as a Massachusetts business trust on March&#160;5, 2015, and commenced operations on June&#160;30, 2015. As of September&#160;6,
        2022, the Trust had 37,493,316 Shares outstanding. Shares of the Trust are traded on the New York Stock Exchange (the &#8220;NYSE&#8221;)
        under the symbol &#8220;THW.&#8221; As of September&#160;6, 2022, the Trust&#8217;s NAV per Share was $12.72 and the Trust&#8217;s last
        reported share price of a Share on the NYSE was $14.42.</td> </tr>
  <tr style="vertical-align:top">
    <td style="padding-right:5.4pt;padding-left:5.4pt">&#160;</td>
    <td colspan="2" style="padding-right:5.4pt;padding-left:5.4pt">&#160;</td> </tr>
  <tr style="vertical-align:top">
    <td style="padding-right:5.4pt;padding-left:5.4pt">The Offer</td>
    <td colspan="2" style="padding-right:5.4pt;padding-left:5.4pt">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may offer, from time to time, up to $150,000,000 aggregate initial
        offering price of common shares of beneficial interest, par value $0.01 per share (&#8220;Common Shares&#8221;), The Trust may also offer
        subscription rights to purchase Common Shares. Common Shares may be offered in one or more offerings. in amounts, at prices and on terms
        set forth in one or more supplements to this Prospectus (each a &#8220;Prospectus Supplement&#8221;). You should read this Prospectus
        and any related Prospectus Supplement carefully before you decide to invest in the Common Shares.</p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may offer Common Shares (1)&#160;directly to one or more purchasers,
        including existing Shareholders in a rights offering, (2)&#160;through agents that the Trust may designate from time to time or (3)&#160;to
        or through underwriters or dealers. The Prospectus Supplement relating to a particular offering of Common Shares will identify any agents
        or underwriters involved in the sale of Common Shares, and will set forth any applicable purchase price, fee, commission or discount arrangement
        between the Trust and agents or underwriters or among underwriters or the basis upon which such amount may be calculated. The Prospectus
        Supplement relating to any offering of rights will set forth the number of Common Shares issuable upon the exercise of each right (or
        number of rights) and the other terms of such rights offering. The Trust may not sell Common Shares through agents, underwriters or dealers
        without delivery of this Prospectus and a Prospectus Supplement. See &#8220;Plan of Distribution.&#8221;</p> </td> </tr>
  <tr style="vertical-align:top">
    <td style="padding-right:5.4pt;padding-left:5.4pt">&#160;</td>
    <td colspan="2" style="padding-right:5.4pt;padding-left:5.4pt">&#160;</td> </tr>
  <tr style="vertical-align:top">
    <td style="padding-right:5.4pt;padding-left:5.4pt">Use of Proceeds</td>
    <td colspan="2" style="padding-right:5.4pt;padding-left:5.4pt">Unless otherwise specified in a Prospectus Supplement, the Trust intends to
        invest the net proceeds of any offering of Common Shares in accordance with its investment objective and policies as appropriate investment
        opportunities are identified. It is currently anticipated that the Trust will be able to invest substantially all of the net proceeds
        of an offering of Common Shares in accordance with its investment objective and policies within three months after the completion of such
        offering, depending on market conditions and the availability of appropriate securities. U.S. securities and other U.S. financial instruments
        that are not registered or that are offered in an exempt non-public offering (&#8220;Restricted Securities&#8221;) may be purchased as
        appropriate opportunities arise, which could take up to six months, depending on market conditions. See &#8220;Use of Proceeds.&#8221;</td>
        </tr>
  <tr style="vertical-align:top">
    <td style="padding-right:5.4pt;padding-left:5.4pt">&#160;</td>
    <td colspan="2" style="padding-right:5.4pt;padding-left:5.4pt">&#160;</td> </tr>
  <tr style="vertical-align:top">
    <td style="padding-right:5.4pt;padding-left:5.4pt">Investment Objective and Policies</td>
    <td colspan="2" style="padding-right:5.4pt;padding-left:5.4pt">Please refer to <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001635977/000110465922125461/tm2225215d1_ncsr.htm"><span style="color:#0070C0">the
        section of the Trust&#8217;s most recent annual report on Form&#160;N-CSR entitled &#8220;Investment Objective, Policies, and Risk Factors&#8212;Investment
        Objective and Policies&#8221;</span></a><span style="text-decoration:underline">,</span> which is incorporated by reference herein, for
        a discussion of the Trust&#8217;s investment objective and policies.</td> </tr>
  <tr style="vertical-align:top">
    <td style="padding-right:5.4pt;padding-left:5.4pt">&#160;</td>
    <td colspan="2" style="padding-right:5.4pt;padding-left:5.4pt">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:30%;padding-right:5.4pt;padding-left:5.4pt">Distributions</td>
    <td style="vertical-align:top;width:69%;padding-right:5.4pt;padding-left:5.4pt">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust intends to make monthly distributions in cash at a rate of $0.1167
        per share to Shareholders of record. Net realized capital gains in excess of the total distributed under this policy are generally included
        in the December&#160;distribution. The Trust&#8217;s monthly distribution policy may be changed by the Board of Trustees (the &#8220;Board&#8221;)
        without</p> </td>
    <td style="width:1%">&#160;</td> </tr>
  </table>

<p style="margin:0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">6&#160;</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="margin:0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr>
    <td style="width:30%">&#160;</td>
    <td style="vertical-align:top;width:69%;padding-right:5.4pt;padding-left:5.4pt">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Shareholder approval.</p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s distribution policy and the basis for establishing the
        rate of its monthly distributions may be changed at any time by the Board without Shareholder approval. Pursuant to an exemptive order
        obtained from the Commission under Section&#160;19(b)&#160;of the Investment Company Act, the Trust is permitted to distribute long-term
        capital gains to Shareholders more than once per year. See &#8220;Dividends and Distributions.&#8221;</p> </td>
    <td style="width:1%">&#160;</td> </tr>
  </table>

<p style="margin:0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt;width:30%">Investment Adviser</td>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt;width:69%">Tekla Capital Management LLC (the &#8220;Investment Adviser&#8221;)
        serves as investment adviser to the Trust. See &#8220;Management of the Trust&#8212;Investment Adviser.&#8221; The majority of the Board
        is unaffiliated with the Investment Adviser; nevertheless, the Trust may be subject to certain potential conflicts of interest. See &#8220;Portfolio
        Transactions and Brokerage.&#8221;</td>
    <td style="width:1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">&#160;</td>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">&#160;</td>
    <td>&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">Portfolio Management</td>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">Currently, Daniel R. Omstead, Ph.D., Jason C. Akus, M.D./M.B.A., Timothy
        Gasperoni, M.B.A., Ph.D., Ashton L. Wilson, Christopher Abbott, Robert Benson, Richard Goss, Loretta Tse, Ph.D., Jack Liu, M.B.A., Ph.D.,
        Christopher Seitz, M.B.A., Graham Attipoe, M.B.A., M.D. and Kelly Girskis, Ph.D. are members of a team that analyzes investments on behalf
        of the Trust. Dr.&#160;Omstead exercises ultimate decision making authority with respect to investments. See &#8220;Management of the
        Trust&#8212;Investment Adviser.&#8221;</td>
    <td>&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">&#160;</td>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">&#160;</td>
    <td>&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">Compensation of Investment Adviser</td>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">For the services provided by the Investment Adviser under the Investment
        Advisory Agreement between the Investment Adviser and the Trust (&#8220;Advisory Agreement&#8221;), the Trust pays the Adviser a monthly
        fee at the rate when annualized of 1.00% of the average daily value of the Trust&#8217;s Managed Assets. Managed Assets means the total
        assets of the Trust minus the Trust&#8217;s liabilities other than the loan payable.</td>
    <td>&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">&#160;</td>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">&#160;</td>
    <td>&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">Custodian and Transfer Agent</td>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">State Street Bank and Trust Company serves as the Trust&#8217;s custodian,
        and Computershare Trust Company, N.A., serves as the Trust&#8217;s transfer agent.</td>
    <td>&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">&#160;</td>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">&#160;</td>
    <td>&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">Administrator</td>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">State Street Bank and Trust Company serves as the Trust&#8217;s administrator.</td>
    <td>&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">&#160;</td>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">&#160;</td>
    <td>&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">Risk Factors</td>
    <td style="vertical-align:top;padding-right:5.4pt;padding-left:5.4pt">An investment in common shares of the Trust involves risk. Please refer
        <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001635977/000110465922125461/tm2225215d1_ncsr.htm"><span style="color:#0070C0">to
        the section of the Trust&#8217;s most recent annual report on Form&#160;N-CSR entitled &#8220;Investment Objectives, Policies and Risks&#8212;Risk
        Factors&#8221;</span></a>, which is incorporated by reference herein, for a discussion of the risks of investing in the Trust. You should
        carefully consider those risks before making an investment in the Trust.</td>
    <td>&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">7&#160;</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>TRUST
EXPENSES</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:left">The following table is intended to assist investors in
understanding the fees and expenses (annualized) that an investor in Shares would bear, directly or indirectly. The table is based on
the capital structure of the Trust as of September 30, 2022.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The table shows Trust expenses as a percentage of net assets attributable
to the Shares. The following table should not be considered a representation of the Trust&#8217;s future expenses. Actual expenses may
be greater or less than those shown below.</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="color:rgb(0, 0, 0);line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</span></p>
<ix:nonNumeric id="Fxbrl_20221212110108013" name="cef:ShareholderTransactionExpensesTableTextBlock" contextRef="C_20221206to20221206" escape="true">

<div>

<table style="font:13px Times New Roman, Times, serif;text-decoration-style:initial;text-decoration-color:initial;border-collapse:collapse;width:100%;border:0px">
  <tr>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px;font-weight:bold">Fees and Expenses</span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td>
    <td colspan="2" style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td> </tr>
  <tr>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px;font-weight:bold">Shareholder Transaction Expenses (</span> <ix:nonNumeric id="Fxbrl_20221212171636665" name="cef:BasisOfTransactionFeesNoteTextBlock" contextRef="C_20221206to20221206" escape="true"><span style="font-size:13px;font-weight:bold">as
        a percentage of Subscription Price</span></ix:nonNumeric><span style="font-size:13px;font-weight:bold">)</span> </td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td>
    <td colspan="2" style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td> </tr>
  <tr>
    <td style="padding-left:0.125in;padding-top:3px;padding-bottom:3px"><span style="font-size:13px">Sales Load</span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td>
    <td colspan="2" style="padding-top:3px;text-align:right;padding-bottom:3px"><span style="font-size:13px"><ix:nonFraction id="Fxbrl_20221212110831436" name="cef:SalesLoadPercent" contextRef="C_20221206to20221206" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>%</span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td> </tr>
  <tr>
    <td style="padding-left:0.125in;padding-top:3px;padding-bottom:3px"><span style="font-size:13px">Expenses Borne by Shareholders of the Trust</span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td>
    <td colspan="2" style="padding-top:3px;text-align:right;padding-bottom:3px"><span style="font-size:13px"><ix:nonFraction id="Fxbrl_20221212110825428" name="cef:OtherTransactionExpense1Percent" contextRef="C_20221206to20221206" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>%</span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td> </tr>
  <tr>
    <td style="padding-left:0.125in;padding-top:3px;padding-bottom:3px"><span style="font-size:13px">Dividend Reinvestment and Stock Repurchase
        Plan Fees</span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td>
    <td colspan="2" style="padding-top:3px;text-align:right;padding-bottom:3px"><span style="font-size:13px"><ix:nonFraction id="Fxbrl_20221212110818655" name="cef:DividendReinvestmentAndCashPurchaseFees" contextRef="C_20221206to20221206" unitRef="USD" scale="0" decimals="0" format="ixt-sec:numwordsen">None</ix:nonFraction>&#160;<sup>(1)</sup></span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div> <ix:nonNumeric id="Fxbrl_20221212110124846" name="cef:AnnualExpensesTableTextBlock" contextRef="C_20221206to20221206" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="padding-top:2pt;font-size:10pt;font-weight:bold;text-align:left;padding-bottom:2pt"><strong>Annual Expenses (as a percentage of
        average net assets attributable to Shares) <sup>(1)</sup></strong></td>
    <td style="padding-top:2pt;font-size:10pt;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;font-size:10pt;text-align:right;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;width:83%;font-size:10pt;text-align:left;padding-left:9pt;padding-bottom:2pt">Management Fee <sup>(2)</sup></td>
    <td style="padding-top:2pt;width:2%;font-size:10pt;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;width:1%;font-size:10pt;text-align:left;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;width:13%;font-size:10pt;text-align:right;padding-bottom:2pt"><ix:nonFraction id="Fxbrl_20221212110810366" name="cef:ManagementFeesPercent" contextRef="C_20221206to20221206" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.23</ix:nonFraction>%</td>
    <td style="padding-top:2pt;width:1%;font-size:10pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="padding-top:2pt;font-size:10pt;text-align:left;padding-left:9pt;padding-bottom:2pt">Interest Payments on Borrowed Funds</td>
    <td style="padding-top:2pt;font-size:10pt;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;font-size:10pt;text-align:right;padding-bottom:2pt"><ix:nonFraction id="Fxbrl_20221212110803558" name="cef:InterestExpensesOnBorrowingsPercent" contextRef="C_20221206to20221206" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.38</ix:nonFraction>%</td>
    <td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt;padding-left:9pt">Other Expenses <sup>(3)</sup></td>
    <td style="padding-top:2pt;font-size:10pt;padding-bottom:2pt">&#160;</td>
    <td style="border-bottom:Black 1pt solid;padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt">&#160;</td>
    <td style="border-bottom:Black 1pt solid;padding-top:2pt;font-size:10pt;text-align:right;padding-bottom:2pt"><ix:nonFraction id="Fxbrl_20221212110756531" name="cef:OtherAnnualExpensesPercent" contextRef="C_20221206to20221206" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.30</ix:nonFraction>%</td>
    <td style="padding-top:2pt;padding-bottom:2pt;font-size:10pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt;padding-left:9pt">Total Annual Expenses</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="border-bottom:Black 2.5pt double;padding-top:2pt;font:10pt Times New Roman, Times, Serif;text-align:left;padding-bottom:2pt">&#160;</td>
    <td style="border-bottom:Black 2.5pt double;padding-top:2pt;font:10pt Times New Roman, Times, Serif;text-align:right;padding-bottom:2pt"><ix:nonFraction id="Fxbrl_20221212110750235" name="cef:TotalAnnualExpensesPercent" contextRef="C_20221206to20221206" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.91</ix:nonFraction>%</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="margin-top:3pt;margin-bottom:3pt;width:25%">

<div style="border-top:Black 1pt solid;font-size:1pt">&#160;</div> </div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">(1)</td>
    <td>The expenses of administering the Trust&#8217;s Dividend Reinvestment and Stock Purchase Plan are included in &#8220;Other Expenses.&#8221;
        You will pay brokerage charges if you direct your broker or the plan agent to sell your Shares that you acquired pursuant to the Trust&#8217;s
        Dividend Reinvestment and Stock Purchase Plan. You may also pay a pro rata share of brokerage commissions incurred in connection with
        open-market purchases pursuant to the Trust&#8217;s Dividend Reinvestment and Stock Purchase Plan. See &#8220;Dividend Reinvestment and
        Stock Purchase Plan.&#8221;</td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">(2)</td>
    <td> <ix:nonNumeric id="Fxbrl_20221212110159011" name="cef:ManagementFeeNotBasedOnNetAssetsNoteTextBlock" contextRef="C_20221206to20221206" escape="true">The
        management fee is charged as a percentage of the Trust&#8217;s average daily Managed Assets, as opposed to net assets. If leverage is
        used, Managed Assets will be greater in amount than net assets, because Managed Assets includes borrowings for investment purposes.</ix:nonNumeric>
        </td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">(3)</td>
    <td><ix:nonNumeric id="Fxbrl_20221212110239300" name="cef:OtherExpensesNoteTextBlock" contextRef="C_20221206to20221206" escape="true">&#8220;Other
        Expenses&#8221; for the current fiscal year.</ix:nonNumeric></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Hypothetical Example</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The following hypothetical example demonstrates the projected dollar amount
of total cumulative expenses that would be incurred over various periods with respect to a hypothetical investment in Shares of the Trust.
These amounts are based upon payment by the Trust of investment advisory fees and other expenses at the levels set forth in the table
above.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">You would directly or indirectly pay the following expenses on a $1,000
investment in the Trust, assuming (i)&#160;all dividends and other distributions are reinvested at NAV per Share, (ii)&#160;the market
price at the time of investment was equal to the NAV per share, (iii)&#160;the percentage amounts listed under Annual Expenses above remain
the same in the years shown, and (iv)&#160;a 5% annual return:</p> </div> <ix:nonNumeric id="Fxbrl_20221212110921823" name="cef:ExpenseExampleTableTextBlock" contextRef="C_20221206to20221206" escape="true">

<div>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td colspan="3" style="border-bottom:Black 1pt solid;font:bold 10pt Times New Roman, Times, Serif;text-align:center">1 Year</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="3" style="border-bottom:Black 1pt solid;font:bold 10pt Times New Roman, Times, Serif;text-align:center">3 Years</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="3" style="border-bottom:Black 1pt solid;font:bold 10pt Times New Roman, Times, Serif;text-align:center">5 Years</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="3" style="border-bottom:Black 1pt solid;font:bold 10pt Times New Roman, Times, Serif;text-align:center">10 Years</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="width:1%;font-size:10pt;text-align:left">$</td>
    <td style="width:22%;font-size:10pt;text-align:right"><ix:nonFraction id="Fxbrl_20221212110726974" name="cef:ExpenseExampleYear01" contextRef="C_20221206to20221206" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
    <td style="width:1%;font-size:10pt;text-align:left">&#160;</td>
    <td style="width:2%;font-size:10pt">&#160;</td>
    <td style="width:1%;font-size:10pt;text-align:left">$</td>
    <td style="width:22%;font-size:10pt;text-align:right"><ix:nonFraction id="Fxbrl_20221212110716631" name="cef:ExpenseExampleYears1to3" contextRef="C_20221206to20221206" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
    <td style="width:1%;font-size:10pt;text-align:left">&#160;</td>
    <td style="width:2%;font-size:10pt">&#160;</td>
    <td style="width:1%;font-size:10pt;text-align:left">$</td>
    <td style="width:21%;font-size:10pt;text-align:right"><ix:nonFraction id="Fxbrl_20221212110707826" name="cef:ExpenseExampleYears1to5" contextRef="C_20221206to20221206" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">103</ix:nonFraction></td>
    <td style="width:1%;font-size:10pt;text-align:left">&#160;</td>
    <td style="width:2%;font-size:10pt">&#160;</td>
    <td style="width:1%;font-size:10pt;text-align:left">$</td>
    <td style="width:21%;font-size:10pt;text-align:right"><ix:nonFraction id="Fxbrl_20221212110700589" name="cef:ExpenseExampleYears1to10" contextRef="C_20221206to20221206" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">223</ix:nonFraction></td>
    <td style="width:1%;font-size:10pt;text-align:left">&#160;</td> </tr>
  </table> </div> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">See &#8220;Financial Highlights&#8221; for the Trust&#8217;s actual ratio
of expenses to average net assets for the fiscal year ended September&#160;30, 2021 and for the six-month period ended March&#160;31,
2022.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div> <ix:nonNumeric id="Fxbrl_20221212110944247" name="cef:PurposeOfFeeTableNoteTextBlock" contextRef="C_20221206to20221206" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The purpose of the table above is to assist you in understanding the various
cost and expenses that you will bear directly or indirectly as an investor in the Trust. For more information on the management fees paid
by the Trust, see &#8220;The Trust&#8212;Compensation of Investment Adviser.&#8221;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The purpose of the table above is to assist you in understanding the various
costs and expenses that you will bear directly or indirectly as an investor in the Trust. For more information regarding the management
fees paid by the Trust, refer to the section of this Prospectus entitled &#8220;Management of the Trust&#8212;Investment Adviser.&#8221;</p>
</div> </ix:nonNumeric> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">8&#160;</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The above tables and the assumption in the hypothetical example of a 5%
annual return are required by regulations of the Commission applicable to all investment companies. The example should not be considered
a representation of future expenses and includes the expenses of the offering. The example assumes that the estimated &#8220;Other Expenses&#8221;
set forth in the table are accurate and that all dividends and distributions are reinvested at the Share NAVs. Actual expenses may be
greater or less than those assumed. Moreover, the Trust&#8217;s actual rate of return may be greater or less than the hypothetical 5%
annual return shown in the example below. The assumed 5% annual return is not a prediction of, and does not represent, the projected or
actual performance of the Trust&#8217;s Shares.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>This Hypothetical Example should not be considered a representation
of past or future expenses, and the Trust&#8217;s actual expenses may be greater or less than those shown.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">9&#160;</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>FINANCIAL
HIGHLIGHTS AND INVESTMENT PERFORMANCE</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Financial Highlights</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The financial highlights table is intended to help you understand the
Trust&#8217;s financial performance. The selected financial data below sets forth per Share operating performance data, total investment
return, ratios and supplemental data for the periods presented. Certain information reflects financial results from a single Trust Share.
The information in this table for the fiscal year ended 2021, 2020, 2019, 2018 and 2017 is derived from the Trust&#8217;s financial statements
and was audited by Deloitte &#38; Touche LLP, an independent registered public accounting firm. This information should be read in conjunction
with the audited financial statements and accompanying notes as of and for the fiscal year ended September&#160;30, 2021, which are incorporated
by reference in the SAI. See &#8220;Financial Statements&#8221; in the SAI.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>FINANCIAL HIGHLIGHTS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%">
  <tr>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:2.5pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td colspan="3" style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:2.5pt"><span style="font-size:7pt">Six months<br />ended<br />March&#160;31,
        2022</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td colspan="19" style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:3pt"><span style="font-size:7pt">Years
        ended September&#160;30,</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td colspan="3" style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">(Unaudited)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td colspan="3" style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">2021</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td colspan="3" style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">2020</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td colspan="3" style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">2019</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td colspan="3" style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">2018</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td colspan="3" style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">2017</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:#CCEEFF">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:2pt;padding-right:0.7pt"><span style="font-size:7pt"><strong>OPERATING PERFORMANCE
        FOR A SHARE OUTSTANDING THROUGHOUT EACH PERIOD</strong></span></td>
    <td colspan="24" style="font-size:7pt;vertical-align:bottom;padding-top:2pt;padding-right:0.7pt">&#160;</td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;width:25%"><span style="font-size:7pt">Net asset value
        per share, beginning of period</span></td>
    <td style="font-size:7pt;width:1%"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right;width:1%"><span style="font-size:7pt">$</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right;width:7%"><span style="font-size:7pt">15.18</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;width:5%"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;width:1%"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right;width:1%"><span style="font-size:7pt">$</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right;width:7%"><span style="font-size:7pt">14.14</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;width:3%"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;width:1%"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right;width:1%"><span style="font-size:7pt">$</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right;width:7%"><span style="font-size:7pt">13.51</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;width:3%"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;width:1%"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right;width:1%"><span style="font-size:7pt">$</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right;width:7%"><span style="font-size:7pt">15.24</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;width:3%"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;width:1%"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right;width:1%"><span style="font-size:7pt">$</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right;width:7%"><span style="font-size:7pt">15.55</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;width:3%"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;width:1%"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right;width:1%"><span style="font-size:7pt">$</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right;width:7%"><span style="font-size:7pt">16.08</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;width:3%"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;width:1%"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:#CCEEFF">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Net investment income <sup>(1)</sup></span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.05</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.08</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.10</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.06</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.11</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.12</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Net realized and unrealized
        gain (loss)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.24</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">2.36</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">1.93</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(0.40</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.96</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.74</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:#CCEEFF">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Total increase (decrease)
        from investment operations</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.29</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">2.44</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">2.03</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(0.34</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">1.07</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.86</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Distributions to shareholders
        from:</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td colspan="7" style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td colspan="7" style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td colspan="7" style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:#CCEEFF">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Net investment income</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(0.70</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(0.14</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(0.05</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(0.19</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(0.60</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(1.30</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Net realized capital gains</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">&#8212;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">&#8212;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">&#8212;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">&#8212;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">&#8212;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(0.03</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:#CCEEFF">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Return of capital (tax basis)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">&#8212;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(1.26</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(1.35</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(1.21</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(0.80</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(0.07</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:baseline;padding-top:0.5pt;padding-right:0.7pt;height:15px"><span style="font-size:7pt">Total distributions</span></td>
    <td style="font-size:7pt;vertical-align:baseline;height:15px"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;height:15px"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;text-align:right;height:15px"><span style="font-size:7pt">(<ix:nonFraction id="Fxbrl_20221209165819673" name="cef:AnnualDividendPayment" contextRef="C_20211001to20220331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.70</ix:nonFraction></span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;height:15px"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt;vertical-align:baseline;height:15px"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;height:15px"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;text-align:right;height:15px"><span style="font-size:7pt">(<ix:nonFraction id="Fxbrl_20221212174428329" name="cef:AnnualDividendPayment" contextRef="C_20201001to20210930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.40</ix:nonFraction></span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;height:15px"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt;vertical-align:baseline;height:15px"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;height:15px"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;text-align:right;height:15px"><span style="font-size:7pt">(<ix:nonFraction id="Fxbrl_20221212174546307" name="cef:AnnualDividendPayment" contextRef="C_20191001to20200930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.40</ix:nonFraction></span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;height:15px"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt;vertical-align:baseline;height:15px"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;height:15px"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;text-align:right;height:15px"><span style="font-size:7pt">(<ix:nonFraction id="Fxbrl_20221212174607715" name="cef:AnnualDividendPayment" contextRef="C_20181001to20190930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.40</ix:nonFraction></span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;height:15px"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt;vertical-align:baseline;height:15px"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;height:15px"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;text-align:right;height:15px"><span style="font-size:7pt">(<ix:nonFraction id="Fxbrl_20221212174623688" name="cef:AnnualDividendPayment" contextRef="C_20171001to20180930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.40</ix:nonFraction></span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;height:15px"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt;vertical-align:baseline;height:15px"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;height:15px"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;text-align:right;height:15px"><span style="font-size:7pt">(<ix:nonFraction id="Fxbrl_20221212174641868" name="cef:AnnualDividendPayment" contextRef="C_20161001to20170930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.40</ix:nonFraction></span></td>
    <td style="border-top:1pt solid black;font-size:7pt;vertical-align:baseline;border-bottom:1pt solid black;padding-top:1pt;padding-right:0.7pt;height:15px"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt;vertical-align:baseline;height:15px"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:#CCEEFF">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Increase resulting from
        shares repurchased <sup>(1)</sup></span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">&#8212;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">&#8212;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">&#8212;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt"><sup>(2)</sup>&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.01</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.02</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.01</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Net asset value per share,
        end of period</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">14.77</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">15.18</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">14.14</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">13.51</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">15.24</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">15.55</span></td>
    <td style="border-top:black 1pt solid;font-size:7pt;vertical-align:bottom;border-bottom:black 2.25pt double;padding-top:1pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:#CCEEFF">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Per share market value,
        end of period</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">15.23</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">16.45</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">14.33</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">13.44</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">14.03</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">14.56</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Total investment return
        at market value</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">2.98</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%*</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">26.00</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">18.14</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">6.80</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">6.91</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">9.47</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:#CCEEFF">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Total investment return
        at net asset value</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">1.89</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%*</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">17.91</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">15.97</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(1.10</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">8.66</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">6.74</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td colspan="25" style="font-size:7pt;vertical-align:bottom;padding-top:2pt;padding-right:0.7pt"><span style="font-size:7pt"><strong>RATIOS</strong></span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:#CCEEFF">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Net investment income to
        average net assets</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.61</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%**</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.53</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.68</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.45</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.78</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.77</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Expenses to average net
        assets</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">1.71</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%**</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">1.74</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">2.16</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">2.53</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">2.28</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">2.05</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:#CCEEFF">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Expenses, excluding interest
        expense, to average net assets</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">1.46</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%**</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">1.51</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">1.57</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">1.59</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">1.57</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">1.55</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td colspan="25" style="font-size:7pt;vertical-align:bottom;padding-top:2pt;padding-right:0.7pt"><span style="font-size:7pt"><strong>SUPPLEMENTAL
        DATA</strong></span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:#CCEEFF">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Net assets at end of period
        (in millions)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">552</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">566</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">427</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">407</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">463</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">480</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Portfolio turnover rate</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">19.70</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%*</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">69.37</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">48.11</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">55.17</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">54.60</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">58.05</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:#CCEEFF">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Senior securities (loan
        facility) outstanding (in millions)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt"><ix:nonFraction id="Fxbrl_20221209102707857" name="cef:SeniorSecuritiesAmount" contextRef="C_20211001to20220331" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt"><ix:nonFraction id="Fxbrl_20221209103219200" name="cef:SeniorSecuritiesAmount" contextRef="C_20201001to20210930" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt"><ix:nonFraction id="Fxbrl_20221209103224493" name="cef:SeniorSecuritiesAmount" contextRef="C_20191001to20200930" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt"><ix:nonFraction id="Fxbrl_20221209103228580" name="cef:SeniorSecuritiesAmount" contextRef="C_20181001to20190930" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt"><ix:nonFraction id="Fxbrl_20221209103232259" name="cef:SeniorSecuritiesAmount" contextRef="C_20171001to20180930" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt"><ix:nonFraction id="Fxbrl_20221209103235704" name="cef:SeniorSecuritiesAmount" contextRef="C_20161001to20170930" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Asset coverage ratio on
        revolving credit facility at period end</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">560</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">571</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">455</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">440</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">486</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">500</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:#CCEEFF">
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">Asset coverage per $1,000
        on revolving credit facility at period end</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt"><ix:nonFraction id="Fxbrl_20221209105043194_xbrl_20221209102707857" name="cef:SeniorSecuritiesCoveragePerUnit" contextRef="C_20211001to20220331" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">5,601</ix:nonFraction></span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt"><ix:nonFraction id="Fxbrl_20221209105043194_xbrl_20221209103219200" name="cef:SeniorSecuritiesCoveragePerUnit" contextRef="C_20201001to20210930" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">5,714</ix:nonFraction></span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt"><ix:nonFraction id="Fxbrl_20221209105043194_xbrl_20221209103224493" name="cef:SeniorSecuritiesCoveragePerUnit" contextRef="C_20191001to20200930" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,554</ix:nonFraction></span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt"><ix:nonFraction id="Fxbrl_20221209105043194_xbrl_20221209103228580" name="cef:SeniorSecuritiesCoveragePerUnit" contextRef="C_20181001to20190930" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,396</ix:nonFraction></span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt"><ix:nonFraction id="Fxbrl_20221209105043194_xbrl_20221209103232259" name="cef:SeniorSecuritiesCoveragePerUnit" contextRef="C_20171001to20180930" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,861</ix:nonFraction></span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt;text-align:right"><span style="font-size:7pt"><ix:nonFraction id="Fxbrl_20221209105043194_xbrl_20221209103235704" name="cef:SeniorSecuritiesCoveragePerUnit" contextRef="C_20161001to20170930" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,999</ix:nonFraction></span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-top:0.5pt;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">10</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">______________</p>

<p style="font:7pt Times New Roman, Times, Serif;margin:0pt 0 3pt"><span style="font-size:2pt">&#160;</span></p>

<p style="font:7pt Times New Roman, Times, Serif;margin:0pt 0 3pt">*&#160;&#160;Not annualized.</p>

<p style="font:7pt Times New Roman, Times, Serif;margin:0pt 0 3pt">**&#160;&#160;Annualized.</p>

<p style="font:7pt Times New Roman, Times, Serif;margin:0pt 0 3pt">(1)&#160;&#160;Computed using average shares outstanding.</p>

<p style="font:7pt Times New Roman, Times, Serif;margin:0pt 0">(2)&#160;&#160;Amount represents less than $0.005 per share.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%">
  <tr>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td colspan="3" style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:0.5pt"><span style="font-size:7pt">Year
        ended ,<br />September&#160;30,<br />2016</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td colspan="3" style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:0.5pt"><span style="font-size:7pt">For
        the period<br />June&#160;30,<br />2015 to<br />September&#160;30,<br />2015 <sup>(1)</sup></span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:rgb(204,238,255)">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt"><strong>OPERATING PERFORMANCE FOR A SHARE
        OUTSTANDING THROUGHOUT EACH PERIOD</strong></span></td>
    <td colspan="8" style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;width:40%;padding-right:0.7pt"><span style="font-size:7pt">Net asset value per share, beginning
        of period</span></td>
    <td style="font-size:7pt;width:2%"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;width:2%;padding-right:0.7pt;padding-bottom:0.5pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;width:23%;padding-right:0.7pt;padding-bottom:0.5pt;text-align:right"><span style="font-size:7pt">17.38</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;width:2%;padding-right:0.7pt;padding-bottom:0.5pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;width:2%"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;width:2%;padding-right:0.7pt;padding-bottom:0.5pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;width:23%;padding-right:0.7pt;padding-bottom:0.5pt;text-align:right"><span style="font-size:7pt">19.10</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;width:2%;padding-right:0.7pt;padding-bottom:0.5pt"><span style="font-size:7pt"><sup>(2)</sup>&#160;</span></td>
    <td style="font-size:7pt;width:2%"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:rgb(204,238,255)">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">Net investment income (loss) <sup>(3)</sup></span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.09</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(0.02</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">Net realized and unrealized gain (loss)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(0.06</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(1.47</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:rgb(204,238,255)">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">Total increase (decrease) from investment
        operations</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:black 1pt solid;border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:0.5pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:black 1pt solid;border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:0.5pt;text-align:right"><span style="font-size:7pt">0.03</span></td>
    <td style="border-top:black 1pt solid;border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:0.5pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:black 1pt solid;border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:0.5pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:black 1pt solid;border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:0.5pt;text-align:right"><span style="font-size:7pt">(1.49</span></td>
    <td style="border-top:black 1pt solid;border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:0.5pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td colspan="9" style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">Distributions to shareholders
        from:</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:rgb(204,238,255)">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt">Net investment income</td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(1.38</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">)<sup>(4)</sup>&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(0.23</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt">Net realized capital gains</td>
    <td style="font-size:7pt">&#160;</td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt">&#160;</td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right">(0.02</td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt">)<sup>(4)</sup>&#160;</td>
    <td style="font-size:7pt">&#160;</td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt">&#160;</td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right">&#8212;</td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt">&#160;</td>
    <td style="font-size:7pt">&#160;</td> </tr>
  <tr style="font-size:7pt;background-color:rgb(204,238,255)">
    <td style="padding-bottom:1pt;font-size:7pt;vertical-align:bottom;padding-right:0.7pt">Return of capital (tax basis)</td>
    <td style="padding-bottom:1pt;font-size:7pt">&#160;</td>
    <td style="border-bottom:Black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt">&#160;</td>
    <td style="border-bottom:Black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right">&#8212;</td>
    <td style="border-bottom:Black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt">&#160;</td>
    <td style="padding-bottom:1pt;font-size:7pt">&#160;</td>
    <td style="border-bottom:Black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt">&#160;</td>
    <td style="border-bottom:Black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right">&#8212;</td>
    <td style="border-bottom:Black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt">&#160;</td>
    <td style="padding-bottom:1pt;font-size:7pt">&#160;</td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">Total distributions</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:0.5pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:0.5pt;text-align:right"><span style="font-size:7pt">(1.40</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:0.5pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:0.5pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:0.5pt;text-align:right"><span style="font-size:7pt">(0.23</span></td>
    <td style="border-bottom:black 1pt solid;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:0.5pt"><span style="font-size:7pt">)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:rgb(204,238,255)">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">Increase resulting from shares repurchased
        <sup>(3)</sup></span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.07</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">&#8212;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">Net asset value per share, end of period</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:black 1pt solid;border-bottom:black 2.25pt double;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:1.1pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="border-top:black 1pt solid;border-bottom:black 2.25pt double;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:1.1pt;text-align:right"><span style="font-size:7pt">16.08</span></td>
    <td style="border-top:black 1pt solid;border-bottom:black 2.25pt double;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:1.1pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="border-top:black 1pt solid;border-bottom:black 2.25pt double;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:1.1pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="border-top:black 1pt solid;border-bottom:black 2.25pt double;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:1.1pt;text-align:right"><span style="font-size:7pt">17.38</span></td>
    <td style="border-top:black 1pt solid;border-bottom:black 2.25pt double;font-size:7pt;vertical-align:bottom;padding-right:0.7pt;padding-bottom:1.1pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:rgb(204,238,255)">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">Per share market value, end of period</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">14.68</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">14.38</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">Total investment return at market value</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">12.34</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(27.07</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">%)*</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:rgb(204,238,255)">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">Total investment return at net asset value</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">1.81</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(7.46</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">%)*</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td colspan="9" style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt"><strong>RATIOS</strong></span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:rgb(204,238,255)">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">Expenses to average net assets</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">1.70</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">1.32</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">%**</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">Expenses, excluding interest expense, to average
        net assets</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">1.47</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">1.32</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">%**</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:rgb(204,238,255)">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">Net investment income (loss) to average net
        assets</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">0.53</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">(0.37</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">%)**</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td colspan="9" style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt"><strong>SUPPLEMENTAL DATA</strong></span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt;background-color:rgb(204,238,255)">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">Net assets at end of period (in millions)</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">499</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">$</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">542</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  <tr style="font-size:7pt">
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">Portfolio turnover rate</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">67.00</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">%</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">&#160;</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt;text-align:right"><span style="font-size:7pt">58.96</span></td>
    <td style="font-size:7pt;vertical-align:bottom;padding-right:0.7pt"><span style="font-size:7pt">%*</span></td>
    <td style="font-size:7pt"><span style="font-size:7pt">&#160;</span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:7pt Times New Roman, Times, Serif;margin:0pt 0 3pt">* Not Annualized.</p>

<p style="font:7pt Times New Roman, Times, Serif;margin:0pt 0 3pt">** Annualized.</p>

<p style="font:7pt Times New Roman, Times, Serif;margin:0pt 0 3pt">(1)&#160;Commenced operations on June&#160;30, 2015.</p>

<p style="font:7pt Times New Roman, Times, Serif;margin:0pt 0 3pt">(2)&#160;Net asset value beginning of period reflects a deduction of
$0.90 per share sales charge from the initial offering price of $20.00 per share.</p>

<p style="font:7pt Times New Roman, Times, Serif;margin:0pt 0">(3)&#160;Computed using average shares outstanding.</p>

<p style="font:7pt Times New Roman, Times, Serif;margin:0pt 0">(4) Amount previously presented incorrectly as solely distributions from
income has been revised to refect the proper classification.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Share Price and NAV</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s Shares are publicly-held and have been listed and are
trading on the NYSE under the symbol &#8220;THW.&#8221; The following table sets forth for the quarters indicated the high and low closing
prices per Share on the NYSE, the corresponding NAV per Share, the percentage premium or discount at such closing prices, and the number
of Shares traded.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">11</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The NAV per Share as of the close of business on September&#160;6, 2022
was $<ix:nonFraction id="Fxbrl_20221209120159437" name="cef:LatestNav" contextRef="C_20220906to20220906" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">12.72</ix:nonFraction>
and the last reported sales price of a Share that day was $<ix:nonFraction id="Fxbrl_20221209120206515" name="cef:LatestSharePrice" contextRef="C_20220906to20220906" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.42</ix:nonFraction>.</p>
<ix:nonNumeric id="Fxbrl_20221209115709953" name="cef:SharePriceTableTextBlock" contextRef="C_20221206to20221206" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="width:12%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Quarter<br />Ending</strong></p>
        </td>
    <td style="width:1%">&#160;</td>
    <td style="width:12%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Market<br />Price(1)&#160;High</strong></p>
        </td>
    <td style="width:1%">&#160;</td>
    <td style="width:10%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Corresponding<br />Net Asset<br />Value(2)</strong></p>
        </td>
    <td style="width:1%">&#160;</td>
    <td style="width:11%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Market<br />Premium/ (Discount)(2)</strong></p>
        </td>
    <td style="width:1%">&#160;</td>
    <td style="width:12%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Corresponding Price(1)&#160;Low</strong></p>
        </td>
    <td style="width:1%">&#160;</td>
    <td style="width:12%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Net Asset<br />Value(2)</strong></p>
        </td>
    <td style="width:1%">&#160;</td>
    <td style="width:12%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Premium/ (Discount)(2)</strong></p>
        </td>
    <td style="width:1%">&#160;</td>
    <td style="width:12%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Trading<br />Volume(1)</strong></p>
        </td> </tr>
  <tr style="vertical-align:bottom">
    <td>Fiscal 2020</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:6pt">Dec.&#160;31</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105303397" name="cef:HighestPriceOrBid" contextRef="C_20191001to20191231" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">13.97</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105328471" name="cef:HighestPriceOrBidNav" contextRef="C_20191001to20191231" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.84</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">-<ix:nonFraction id="Fxbrl_20221209105410129" name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20191001to20191231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">5.86</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105432641" name="cef:LowestPriceOrBid" contextRef="C_20191001to20191231" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">13.00</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105451232" name="cef:LowestPriceOrBidNav" contextRef="C_20191001to20191231" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">13.32</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">-<ix:nonFraction id="Fxbrl_20221209105504591" name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20191001to20191231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">2.40</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">7,311,726</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:6pt">Mar.&#160;31</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105735391_xbrl_20221209105303397" name="cef:HighestPriceOrBid" contextRef="C_20200101to20200331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.49</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105735391_xbrl_20221209105328471" name="cef:HighestPriceOrBidNav" contextRef="C_20200101to20200331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">15.25</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">-<ix:nonFraction id="Fxbrl_20221209114948366" name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20200101to20200331" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">4.98</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105735391_xbrl_20221209105432641" name="cef:LowestPriceOrBid" contextRef="C_20200101to20200331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">8.89</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105735391_xbrl_20221209105451232" name="cef:LowestPriceOrBidNav" contextRef="C_20200101to20200331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">10.50</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">-<ix:nonFraction id="Fxbrl_20221209115004831" name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20200101to20200331" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">15.33</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">13,080,124</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:6pt">June&#160;30</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105737683_xbrl_20221209105303397" name="cef:HighestPriceOrBid" contextRef="C_20200401to20200630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.76</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105737683_xbrl_20221209105328471" name="cef:HighestPriceOrBidNav" contextRef="C_20200401to20200630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.58</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right"><ix:nonFraction id="Fxbrl_20221209105737683_xbrl_20221209105410129" name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20200401to20200630" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.24</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105737683_xbrl_20221209105432641" name="cef:LowestPriceOrBid" contextRef="C_20200401to20200630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">10.83</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105737683_xbrl_20221209105451232" name="cef:LowestPriceOrBidNav" contextRef="C_20200401to20200630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">12.29</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">-<ix:nonFraction id="Fxbrl_20221209115026176" name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20200401to20200630" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">11.88</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">13,241,814</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:6pt">Sept. 30</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105739625_xbrl_20221209105303397" name="cef:HighestPriceOrBid" contextRef="C_20200701to20200930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.99</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105739625_xbrl_20221209105328471" name="cef:HighestPriceOrBidNav" contextRef="C_20200701to20200930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.67</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right"><ix:nonFraction id="Fxbrl_20221209105739625_xbrl_20221209105410129" name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20200701to20200930" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.18</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105739625_xbrl_20221209105432641" name="cef:LowestPriceOrBid" contextRef="C_20200701to20200930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">13.82</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105739625_xbrl_20221209105451232" name="cef:LowestPriceOrBidNav" contextRef="C_20200701to20200930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">13.76</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right"><ix:nonFraction id="Fxbrl_20221209105739625_xbrl_20221209105504591" name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20200701to20200930" unitRef="Pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">0.436</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">6,999,269</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Fiscal 2021</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:6pt">Dec.&#160;31</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105741931_xbrl_20221209105303397" name="cef:HighestPriceOrBid" contextRef="C_20201001to20201231" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">16.07</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105741931_xbrl_20221209105328471" name="cef:HighestPriceOrBidNav" contextRef="C_20201001to20201231" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.68</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right"><ix:nonFraction id="Fxbrl_20221209105741931_xbrl_20221209105410129" name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20201001to20201231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.47</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105741931_xbrl_20221209105432641" name="cef:LowestPriceOrBid" contextRef="C_20201001to20201231" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">13.43</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105741931_xbrl_20221209105451232" name="cef:LowestPriceOrBidNav" contextRef="C_20201001to20201231" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">13.25</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right"><ix:nonFraction id="Fxbrl_20221209105741931_xbrl_20221209105504591" name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20201001to20201231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.36</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">6,759,018</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-left:6pt">Mar.&#160;31</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105743730_xbrl_20221209105303397" name="cef:HighestPriceOrBid" contextRef="C_20210101to20210331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">17.92</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105743730_xbrl_20221209105328471" name="cef:HighestPriceOrBidNav" contextRef="C_20210101to20210331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">15.29</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right"><ix:nonFraction id="Fxbrl_20221209105743730_xbrl_20221209105410129" name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20210101to20210331" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">17.20</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105743730_xbrl_20221209105432641" name="cef:LowestPriceOrBid" contextRef="C_20210101to20210331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.29</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105743730_xbrl_20221209105451232" name="cef:LowestPriceOrBidNav" contextRef="C_20210101to20210331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.63</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">-<ix:nonFraction id="Fxbrl_20221209115102859" name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20210101to20210331" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">2.32</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:bottom;text-align:right">12,830,000</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-left:6pt">June&#160;30</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105746378_xbrl_20221209105303397" name="cef:HighestPriceOrBid" contextRef="C_20210401to20210630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">16.69</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105746378_xbrl_20221209105328471" name="cef:HighestPriceOrBidNav" contextRef="C_20210401to20210630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">15.56</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right"><ix:nonFraction id="Fxbrl_20221209105746378_xbrl_20221209105410129" name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20210401to20210630" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">7.26</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105746378_xbrl_20221209105432641" name="cef:LowestPriceOrBid" contextRef="C_20210401to20210630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.86</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105746378_xbrl_20221209105451232" name="cef:LowestPriceOrBidNav" contextRef="C_20210401to20210630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">15.15</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">-<ix:nonFraction id="Fxbrl_20221209115118483" name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20210401to20210630" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">1.91</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">12,500,000</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-left:6pt">Sept. 30</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105748594_xbrl_20221209105303397" name="cef:HighestPriceOrBid" contextRef="C_20210701to20210930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">17.38</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105748594_xbrl_20221209105328471" name="cef:HighestPriceOrBidNav" contextRef="C_20210701to20210930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">16.22</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right"><ix:nonFraction id="Fxbrl_20221209105748594_xbrl_20221209105410129" name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20210701to20210930" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">7.15</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105748594_xbrl_20221209105432641" name="cef:LowestPriceOrBid" contextRef="C_20210701to20210930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">16.13</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105748594_xbrl_20221209105451232" name="cef:LowestPriceOrBidNav" contextRef="C_20210701to20210930" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">15.45</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right"><ix:nonFraction id="Fxbrl_20221209105748594_xbrl_20221209105504591" name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20210701to20210930" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.40</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">6,800,000</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Fiscal 2022</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-left:6pt">Dec.&#160;31</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105750466_xbrl_20221209105303397" name="cef:HighestPriceOrBid" contextRef="C_20211001to20211231" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">17.08</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105750466_xbrl_20221209105328471" name="cef:HighestPriceOrBidNav" contextRef="C_20211001to20211231" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">15.63</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:bottom;text-align:right"><ix:nonFraction id="Fxbrl_20221209105750466_xbrl_20221209105410129" name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20211001to20211231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.28</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105750466_xbrl_20221209105432641" name="cef:LowestPriceOrBid" contextRef="C_20211001to20211231" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">15.51</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105750466_xbrl_20221209105451232" name="cef:LowestPriceOrBidNav" contextRef="C_20211001to20211231" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.75</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right"><ix:nonFraction id="Fxbrl_20221209105750466_xbrl_20221209105504591" name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20211001to20211231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.15</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">6,310,000</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-left:6pt">Mar.&#160;31</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105752315_xbrl_20221209105303397" name="cef:HighestPriceOrBid" contextRef="C_20220101to20220331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">16.34</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105752315_xbrl_20221209105328471" name="cef:HighestPriceOrBidNav" contextRef="C_20220101to20220331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">15.63</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:bottom;text-align:right"><ix:nonFraction id="Fxbrl_20221209105752315_xbrl_20221209105410129" name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20220101to20220331" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.54</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105752315_xbrl_20221209105432641" name="cef:LowestPriceOrBid" contextRef="C_20220101to20220331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">13.29</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105752315_xbrl_20221209105451232" name="cef:LowestPriceOrBidNav" contextRef="C_20220101to20220331" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">13.86</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">-<ix:nonFraction id="Fxbrl_20221209115212674" name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20220101to20220331" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">4.11</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">8,990,000</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-left:6pt">June&#160;30</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105754425_xbrl_20221209105303397" name="cef:HighestPriceOrBid" contextRef="C_20220401to20220630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">10.39</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105754425_xbrl_20221209105328471" name="cef:HighestPriceOrBidNav" contextRef="C_20220401to20220630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.49</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:bottom;text-align:right"><ix:nonFraction id="Fxbrl_20221209105754425_xbrl_20221209105410129" name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20220401to20220630" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.70</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105754425_xbrl_20221209105432641" name="cef:LowestPriceOrBid" contextRef="C_20220401to20220630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">14.00</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$<ix:nonFraction id="Fxbrl_20221209105754425_xbrl_20221209105451232" name="cef:LowestPriceOrBidNav" contextRef="C_20220401to20220630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">12.40</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right"><ix:nonFraction id="Fxbrl_20221209105754425_xbrl_20221209105504591" name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="C_20220401to20220630" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">12.90</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">7,990,000</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">__________________</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">(1)</td>
    <td>As reported by Bloomberg LLP.</td> </tr>
  <tr style="vertical-align:top">
    <td style="width:0.25in">(2)</td>
    <td>Based on the Trust&#8217;s computations, on the day that the high or low market price was recorded.</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">12</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> <ix:nonNumeric id="Fxbrl_20221209111153102" name="cef:SeniorSecuritiesNoteTextBlock" contextRef="C_20221206to20221206" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>SENIOR SECURITIES</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Information about our senior securities is shown in the following table
as of the end of the last 10 fiscal years. The information in this table for the fiscal years ended 2021, 2020, 2019, 2018 and 2017 has
been audited by Deloitte &#38; Touche LLP, independent registered public accounting firm. The Trust&#8217;s audited financial statements
appearing in the Trust&#8217;s Annual Report to Shareholders for the year ended September&#160;30, 2021, including the report of Deloitte
&#38; Touche LLP thereon, including accompanying notes thereto, are incorporated by reference in the SAI. The &#8220;--&#8221; indicates
information that the SEC expressly does not require to be disclosed for certain types of senior securities.</p> <ix:nonNumeric id="Fxbrl_20221209112119281" name="cef:SeniorSecuritiesTableTextBlock" contextRef="C_20221206to20221206" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="width:32%"><strong>Class&#160;and Year</strong></td>
    <td style="width:17%"><strong>Total Amount Outstanding<br />Exclusive of Treasury Securities(1)</strong></td>
    <td style="width:17%"><strong>Asset Coverage Per<br />$1,000 of Indebtedness</strong></td>
    <td style="width:17%"><strong>Involuntary<br />Liquidating<br />Preferences Per Unit</strong></td>
    <td style="width:17%"><strong>Average Market<br />Value(2)</strong></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2021</td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112210937" name="cef:SeniorSecuritiesAmount" contextRef="C_20201001to20210930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112229768" name="cef:SeniorSecuritiesCoveragePerUnit" contextRef="C_20201001to20210930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">5,714</ix:nonFraction></td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112250751" name="cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit" contextRef="C_20201001to20210930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173039070">N/A</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2020</td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112259390_xbrl_20221209112210937" name="cef:SeniorSecuritiesAmount" contextRef="C_20191001to20200930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112259390_xbrl_20221209112229768" name="cef:SeniorSecuritiesCoveragePerUnit" contextRef="C_20191001to20200930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,554</ix:nonFraction></td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112259390_xbrl_20221209112250751" name="cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit" contextRef="C_20191001to20200930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173120190">N/A</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2019</td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112302627_xbrl_20221209112210937" name="cef:SeniorSecuritiesAmount" contextRef="C_20181001to20190930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112302627_xbrl_20221209112229768" name="cef:SeniorSecuritiesCoveragePerUnit" contextRef="C_20181001to20190930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,396</ix:nonFraction></td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112302627_xbrl_20221209112250751" name="cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit" contextRef="C_20181001to20190930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173123789">N/A</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2018</td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112304686_xbrl_20221209112210937" name="cef:SeniorSecuritiesAmount" contextRef="C_20171001to20180930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112304686_xbrl_20221209112229768" name="cef:SeniorSecuritiesCoveragePerUnit" contextRef="C_20171001to20180930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,861</ix:nonFraction></td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112304686_xbrl_20221209112250751" name="cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit" contextRef="C_20171001to20180930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173241279">N/A</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2017</td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112306740_xbrl_20221209112210937" name="cef:SeniorSecuritiesAmount" contextRef="C_20161001to20170930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112306740_xbrl_20221209112229768" name="cef:SeniorSecuritiesCoveragePerUnit" contextRef="C_20161001to20170930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,999</ix:nonFraction></td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112306740_xbrl_20221209112250751" name="cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit" contextRef="C_20161001to20170930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173248397">N/A</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2016</td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112309132_xbrl_20221209112210937" name="cef:SeniorSecuritiesAmount" contextRef="C_20151001to20160930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112309132_xbrl_20221209112229768" name="cef:SeniorSecuritiesCoveragePerUnit" contextRef="C_20151001to20160930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:num-dot-decimal">5,160</ix:nonFraction></td>
    <td>$<ix:nonFraction id="Fxbrl_20221209112309132_xbrl_20221209112250751" name="cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit" contextRef="C_20151001to20160930_cefSecurityAxis_ck0001635977LoanFacilityMember" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173251957">N/A</span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">_______________</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;margin-top:0pt;margin-bottom:0pt">
  <tr style="vertical-align:top">
    <td style="width:0.25in">(1)</td>
    <td>Total amount in $ millions of each class of senior securities outstanding at the end of the period presented.</td> </tr>
  <tr style="vertical-align:top">
    <td>(2)</td>
    <td>Not applicable because the senior securities are not registered for public trading.</td> </tr>
  </table> </div> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">13</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>USE OF
PROCEEDS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Unless otherwise specified in a Prospectus Supplement, the Trust intends
to invest the net proceeds of any offering of Common Shares in accordance with its investment objective and policies as stated herein.
It is currently anticipated that the Trust will be able to invest substantially all of the net proceeds of an offering of Common Shares
in accordance with its investment objective and policies within three months after the completion of such offering, depending on market
conditions and the availability of appropriate securities. Restricted Securities may be purchased as appropriate opportunities arise,
which could take up to six months, depending on market conditions. The Trust may choose to be more fully invested in publicly-traded securities
during such period. Pending investment in the securities described above, the proceeds will be held in short-term securities, including,
but not limited to, obligations of the U.S. Government, its agencies or instrumentalities (&#8220;U.S. Government Securities&#8221;),
highly rated money market instruments or mutual funds that invest in such instruments. As a result of this short-term investment of the
proceeds, a lower return may be realized.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>INVESTMENT
OBJECTIVE AND POLICIES</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Please refer to <span style="color:#0070c0"><span style="text-decoration:underline">the
</span></span><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001635977/000110465922125461/tm2225215d1_ncsr.htm"><span style="color:#0070c0"><span style="text-decoration:underline">section
of the Trust&#8217;s most recent annual report on Form N-CSR entitled &#8220;Investment Objective, Policies and Risk Factors&#8212;Investment
Objective and Policies,&#8221;</span></span></a> which is incorporated by reference herein, for discussion of the Trust&#8217;s investment
objective and policies.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">14</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>RISK
FACTORS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">An investment in common shares of the Trust involves risk. Please refer
<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001635977/000110465922125461/tm2225215d1_ncsr.htm"><span style="text-decoration:underline">to
the section of the Trust&#8217;s most recent annual report on Form N-CSR entitled &#8220;Investment Objectives, Policies and Risks&#8212;Risk
Factors,&#8221;</span></a> which is incorporated by reference herein, for a discussion of the risks of investing in the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>LEVERAGE</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust intends to use financial leverage for investment purposes. The
Trust may issue preferred shares of beneficial interest ("Preferred Shares"), borrow money and/or issue debt securities (&#8220;traditional
leverage&#8221;). The Trust intends to use traditional leverage through a credit facility representing up to 20% of the Trust&#8217;s
Managed Assets. In addition, the Trust may enter into reverse repurchase agreements, swaps, futures, forward contracts, securities lending,
short sales, and other derivative transactions, that have similar effects as leverage&#160;(collectively referred to as &#8220;effective
leverage&#8221;). Furthermore, at no time will the Trust&#8217;s use of leverage, either through traditional leverage or effective leverage,
exceed 30% of the Trust&#8217;s Managed Assets. Notwithstanding the foregoing, effective leverage incurred through the Trust&#8217;s option
strategy and use of derivatives for hedging purposes will not be counted toward the Trust&#8217;s limit on the use of effective leverage
or in the overall 30% leverage limitation.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s leveraged capital structure creates special risks not
associated with unleveraged funds having a similar investment objective and policies. These include the possibility of greater loss and
the likelihood of higher volatility of the NAV, market price and distributions of the Trust and the asset coverage for Preferred Shares,
if any. Such volatility may increase the likelihood of the Trust having to sell investments in order to meet its obligations to make distributions
on the Preferred Shares, or to redeem Preferred Shares when it may be disadvantageous to do so. Also, if the Trust is utilizing leverage,
a decline in NAV could affect the ability of the Trust to make distributions and such a failure to pay dividends or make distributions
could result in the Trust ceasing to qualify as a regulated investment company under the Code, as amended.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Other risks and special considerations include the risk that fluctuations
in interest rates on borrowings and short-term debt or in the interest or dividend rates on any leverage that the Trust must pay will
reduce the return to the Shareholders; the effects of leverage in a declining market, which are likely to cause a greater decline in the
NAV of the shares than if the Trust were not leveraged, which may result in a greater decline in the market price of the shares. If the
Trust uses leverage, the amount of fees paid to the Investment Adviser for its services will be higher than if the Trust did not use leverage
because the fees paid are calculated based on Managed Assets, which includes assets purchased with leverage. Therefore, the Investment
Adviser has a financial incentive to use leverage, which creates a conflict of interest between the Investment Adviser and common Shareholders,
as only the Trust&#8217;s common Shareholders would bear the fees and expenses incurred through the Trust&#8217;s use of leverage, including
the issuance of Preferred Shares, if any. Leverage may increase operating costs, which may reduce total return.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> <ix:nonNumeric id="Fxbrl_20221209170401245" name="cef:EffectsOfLeverageTextBlock" contextRef="C_20221206to20221206" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Effects of Leverage</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Assuming that leverage will represent approximately 20% of Managed Assets
and that the Trust will bear expenses relating to that leverage at an annual cost of 1.00%, Trust performance before leverage (net of
expenses) must exceed 0.2% in order to cover the expenses specifically related to the Trust&#8217;s use of leverage. Actual leverage expenses
will vary frequently and may be significantly higher or lower than the rate estimated above.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">As of September&#160;30, 2022 and the most recently signed line of credit
agreement, the Trust projects an annual leverage expense of 3.59%. The Trust had $120,000,000 of funds drawn on its line of credit which
was 18.9% of Managed Assets as of September&#160;30, 2022.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> <ix:nonNumeric id="Fxbrl_20221209170348825" name="cef:EffectsOfLeverageTableTextBlock" contextRef="C_20221206to20221206" escape="true">

<div> <ix:nonNumeric id="Fxbrl_20221209170422129" name="cef:EffectsOfLeveragePurposeTextBlock" contextRef="C_20221206to20221206" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The following table is furnished in response to requirements of the SEC.
It is designed to illustrate the effects of leverage on total returns from an investment in the Trust assuming investment portfolio returns
before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage representing 20% of the Trust&#8217;s Managed
Assets and the Trust&#8217;s currently projected annual leverage expense of 1.00%.</p> </ix:nonNumeric>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="border:black 1pt solid;width:50%">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Assumed Trust Return Before Leverage</p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">(Net of Expenses)</p> </td>
    <td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid">(10.00)%</td>
    <td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid">(5.00)%</td>
    <td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid">0.00%</td>
    <td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid">5.00%</td>
    <td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid">10.00%</td> </tr>
  <tr>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid;border-left:black 1pt solid">Assumed Trust Return Inclusive of Leverage</td>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid">(<ix:nonFraction id="Fxbrl_20221209110827193" name="cef:ReturnAtMinusTenPercent" contextRef="C_20221206to20221206" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">13.40</ix:nonFraction>)%</td>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid">(<ix:nonFraction id="Fxbrl_20221209110833929" name="cef:ReturnAtMinusFivePercent" contextRef="C_20221206to20221206" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">7.15</ix:nonFraction>)%</td>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid">(<ix:nonFraction id="Fxbrl_20221209110838143" name="cef:ReturnAtZeroPercent" contextRef="C_20221206to20221206" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal" sign="-">0.90</ix:nonFraction>)%</td>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid"><ix:nonFraction id="Fxbrl_20221209110841702" name="cef:ReturnAtPlusFivePercent" contextRef="C_20221206to20221206" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.35</ix:nonFraction>%</td>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid"><ix:nonFraction id="Fxbrl_20221209110845087" name="cef:ReturnAtPlusTenPercent" contextRef="C_20221206to20221206" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">11.60</ix:nonFraction>%</td>
        </tr>
  </table> </div>

<div><ix:exclude>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">15</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Assumed Trust performance before and inclusive of leverage are hypothetical
and are pro-vided to assist investors in understanding the effects of leverage. Actual performance experienced by the Trust may be lesser
or greater than that shown above.</p> </div> </ix:nonNumeric> </div> </ix:nonNumeric> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>THE TRUST</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Board of Trustees</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Under the Trust&#8217;s Declaration of Trust and the laws of the Commonwealth
of Massachusetts, the Trust&#8217;s business and affairs are managed under the direction of its Board. Investment decisions for the Trust
are made by the Investment Adviser, subject to any direction it may receive from the Board, which periodically reviews the Trust&#8217;s
investment performance. The <a href="#sai002integixanchorIntegixanchor_integixAnchor">SAI</a> includes additional information about the
members of the Board and is available, without charge, upon request, by calling the Investment Adviser at (617) 772-8500.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Investment Adviser</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Tekla Capital Management LLC, a limited liability company formed under
the laws of the State of Delaware, serves as the Investment Adviser to the Trust. The Investment Adviser is an investment adviser registered
under the Investment Advisers Act of 1940, as amended. The Investment Adviser is located at 100 Federal Street, 19th Floor, Boston, MA02110.
The Investment Adviser is owned by Daniel R. Omstead and Mary N. Omstead. Dr.&#160;Omstead is currently the President and Chief Executive
Officer of the Investment Adviser. Mary N. Omstead is Dr.&#160;Omstead&#8217;s wife.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Investment Adviser also provides investment advisory services to other
closed-end investment companies, Tekla Healthcare Investors (&#8220;HQH&#8221;), Tekla Life Sciences Investors (&#8220;HQL&#8221;),and
Tekla Healthcare Opportunities Fund (&#8220;THQ&#8221;), which invest in companies in the healthcare and life sciences industries. As
of June&#160;30, 2022, the Investment Adviser had assets under management of over $3 billion.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The investment advisory agreement between the Investment Adviser and the
Trust (the &#8220;Advisory Agreement&#8221;) provides that, subject to the supervision and direction of the Board, the Investment Adviser
is responsible for the actual management of the Trust&#8217;s portfolio. The Investment Adviser is also obligated to supervise or perform
certain administrative and management services for the Trust and is obligated to provide the office space, facilities, equipment and personnel
necessary to perform its duties under the Advisory Agreement. The responsibility for making decisions to buy, sell or hold a particular
security rests with the Investment Adviser. However, the Investment Adviser may consider investment analysis from various sources, including
broker-dealers with which the Trust does business.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Subject to the supervision and direction of the Board, the Investment
Adviser manages the Trust&#8217;s portfolio in accordance with the Trust&#8217;s investment objective and policies as stated in the Prospectus;
makes investment decisions for the Trust; places purchase and sale orders for portfolio transactions for the Trust; supplies the Trust
with office facilities (which may be in the Investment Adviser&#8217;s own offices), statistical and research data, data processing services,
clerical, internal executive and administrative services, and stationery and office supplies; directs and supervises a third party administrat
or or custodian in the provision to the Trust of accounting and bookkeeping services, the calculation of the NAV of Shares of the Trust,
internal auditing services, and other clerical services in connection therewith, and prepares or supervises and directs a third party
administrat or or custodian in the preparation of reports to Shareholders of the Trust, tax returns and reports to and filings with the
Commission and state securities authorities. In providing these services, the Investment Adviser provides investment research and supervision
of the Trust&#8217;s investments and conducts a continual program of investment, evaluation and, if appropriate, sale and reinvestment
of the Trust&#8217;s assets. In addition, the Investment Adviser For the services provided by the Investment Adviser under the Advisory
Agreement, the Trust will pay a fee, computed and payable monthly, equal when annualized to 1.00% of the average daily value of the Trust&#8217;s
Managed Assets.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A discussion regarding the basis for the Trust&#8217;s Board approval
of the Advisory Agreement is available in the Trust&#8217;s semi-annual report for the six months ended March&#160;31, 2022.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Under the Advisory Agreement, the Investment Adviser has agreed to bear
all expenses in connection with the performance of its services under the Advisory Agreement, including compensation of and office space
for officers and employees of the Trust connected with investment and economic research, trading and investment management of the Trust,
as well as the fees of all Trustees of the Trust who are &#8220;affiliated persons&#8221; of the Investment Adviser, as that term is defined
in the Investment Company Act, or any of its &#8220;affiliated persons.&#8221; Under the Advisory Agreement, the Trust must pay (or, if
Trust expenses are paid by the Investment Adviser,</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">16</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">shall reimburse the Investment Adviser for) all other expenses incurred
in the operation of the Trust including, among other things, expenses for legal and auditing services, costs of printing proxy statements,
prospectuses, share certificates and shareholder reports, charges of the custodian, any sub-custodian and transfer agent, expenses in
connection with the Dividend Reinvestment and Stock Purchase Plan, the Commission, and Financial Industry Regulatory Authority,&#160;Inc.(&#8220;FINRA&#8221;)
fees, fees and expenses of the Trustees who are not &#8220;affiliated persons&#8221; of the Investment Adviser or any of its &#8220;affiliated
persons,&#8221; accounting and valuation costs, administrator&#8217;s fees, membership fees in trade associations, fidelity bond coverage
for the Trust&#8217;s officers and employees, errors and omissions insurance coverage for Trustees and officers, interest, brokerage costs,
taxes, stock exchange listing fees and expenses, expenses of qualifying the Shares for sale in various states, expenses associated with
personnel performing exclusively Shareholder servicing functions, litigation and other extraordinary or non-recurring expenses, and other
expenses properly payable by the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Portfolio Management</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Currently, Daniel R. Omstead, Ph.D., Jason C. Akus, M.D./M.B.A., Timothy
Gasperoni, M.B.A., Ph.D., Ashton L. Wilson, Christopher Abbott, Robert Benson, Richard Goss, Loretta Tse, Ph.D., Jack Liu, M.B.A., Ph.D.,
Christopher Seitz, M.B.A., Graham Attipoe, M.B.A., M.D. and Kelly Girskis, Ph.D. are members of the team that analyzes investments on
behalf of the Investment Adviser. The team&#8217;s business experience for at least the last five years is included below. Dr.&#160;Omstead
exercises ultimate decision-making authority with respect to investments.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Daniel R. Omstead, Ph.D., is President and Chief Executive Officer of
the Investment Adviser since 2001. He is also President of the Trust, HQL, HQH and THQ and serves on their Valuation Committees. Prior
to joining the Investment Adviser, Dr.&#160;Omstead was President and CEO of Reprogenesis,&#160;Inc., a private development stage biotech
company developing therapies in the field of regenerative medicine. In 2000, Reprogenesis was merged with two other biotech companies
to form Curis,&#160;Inc. Before joining Reprogenesis, Dr.&#160;Omstead was Senior Vice President, Research and Development at Cytotherapeutics,&#160;Inc.,
a public biotech company that developed CNS therapies. Before entering the biotech industry, Dr.&#160;Omstead was employed for 14 years
in the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions
of Johnson&#160;&#38; Johnson and at Merck Sharpe&#160;&#38; Dohme Research Laboratories, a division of Merck&#160;&#38; Company,&#160;Inc.
While at Johnson&#160;&#38; Johnson, Dr.&#160;Omstead participated in the development of Orthoclone OKT3, Eprex /Procrit and other biological
products. While at Merck, he worked on the development of Recombivax, Mefoxin, Heartguard and other traditional drug products. Dr.&#160;Omstead
holds a Ph.D. and Master&#8217;s Degree in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil
Engineering from Lehigh University.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Jason Akus is responsible for investment research and due diligence in
the Medical Device, Diagnostic, and Biopharmaceutical areas. He joined the Investment Adviser in July&#160;of 2001 after graduating from
Tufts with an M.D. and M.B.A. Dr.&#160;Akus graduated from Tufts with a B.S. in Mathematics. During medical school, Dr.&#160;Akus consulted
for a variety of Healthcare IT companies.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Timothy Gasperoni joined the Investment Adviser in March&#160;2015. Previously
he was a Senior Analyst and Founding Member of Sabby Capital, a public and private equity fund focused on biotechnology and medical devices.
Dr.&#160;Gasperoni was head of Sabby&#8217;s research function and led the firm&#8217;s venture investment arm. Previously, Dr.&#160;Gasperoni
was a Partner and Senior Analyst at Crosswind Investments, LLC, a spin-off of Cowen&#160;&#38; Co that managed small-and mid-cap growth
funds. Prior to Crosswind, Dr.&#160;Gasperoni was the Senior Analyst at Andesite, LLC, a healthcare-dedicated long-short fund. He led
the firm&#8217;s research function and was responsible for all syndicate transactions. Prior to his career in financial services, Dr.&#160;Gasperoni
served in consulting, operating, and scientific roles in the biopharmaceutical industry. Dr.&#160;Gasperoni holds a B.A. from Swarthmore
College, an M.A. from the University of Pennsylvania, a Ph.D. in Neuroscience from UCLA, and an MBA from MIT.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Ashton Wilson joined the Investment Adviser in July&#160;of 2018. Previously,
he was a Vice President at Goldman Sachs&#160;&#38; Co. in equity derivative trading within the Securities Division for 6 years. Prior
to that, Mr.&#160;Wilson was an equity derivative trader at Bank of America Merrill Lynch for 5 years. Mr.&#160;Wilson holds a B.S. in
Finance from Virginia Tech.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Chris Abbott joined the Investment Adviser in June&#160;of 2016 as a Senior
Analyst. Previously, Mr.&#160;Abbott spent 8 years at Leerink Partners where he was a Vice President on the Equity Research team covering
the Healthcare IT and Healthcare Supply Chain group. Mr.&#160;Abbott&#8217;s research efforts also focused on Healthcare Strategy and
Healthcare Policy during his time at Leerink. Mr.&#160;Abbott graduated from Hamilton College with a B.A. in Economics and a focus in
Pre-Medical Studies.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Robert Benson joined the Investment Adviser in June&#160;2016 as a Senior
Analyst. Previously, Mr.&#160;Benson spent 12 years at State Street Global Advisors where he performed quantitative research for asset
allocation, equities, and alternatives teams. Prior to that, Mr.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">17</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Benson provided risk management and oversight of State Street Global Advisors
equity portfolio managers and also has investment management experience at Putnam Investments and Summa Capital. Mr.&#160;Benson holds
a B.S. in Management Science from MIT and a M.S. in Financial Engineering from the University of California, Berkeley and is a CFA and
CAIA charterholder.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Rich Goss joined the Investment Adviser in March&#160;2018 as a Senior
Analyst. Previously, Mr.&#160;Goss spent four years at Leerink Partners where he was a Vice President on the Large Pharma and Biotech
Equity Research teams. Prior to that, Mr.&#160;Goss spent six years as a Healthcare Analyst at Datamonitor and four years in market research
in Leerink&#8217;s MEDACorp division. Mr.&#160;Goss graduated from Cornell University with a B.A. in Biology.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Loretta Tse joined the Investment Adviser in July&#160;of 2015. Previously,
Dr.&#160;Tse ran a biotech consulting business and worked with various venture funds and start-up companies. Prior to that, Dr.&#160;Tse
was Managing Director, Technology Transfer and Industry Relations at Fred Hutchinson Cancer Research Center, where she ran an office that
was responsible for protection and commercialization of research output and formation of start-up companies, was an Associate at Oxford
Biosciences Partners, an early stage Life Sciences venture fund, and worked in business development at several early stage biotech companies
prior to joining Oxford. Dr.&#160;Tse holds a Ph.D. in Pharmacology from Johns Hopkins School of Medicine and a B.S. in Biochemistry from
University of California, Davis.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Jack Liu joined the Investment Adviser in August&#160;of 2019. Previously,
Dr.&#160;Liu was a Research Analyst covering healthcare equity at Weatherbie Capital. Prior to that, he held summer research analyst positions
at Fidelity Investments and King Tower Asset Management. Earlier in his career, Dr.&#160;Liu spent two years as a scientist at Synageva
Biopharma leading analytical projects in various stages of drug discovery and development. Dr.&#160;Liu holds a B.S. in Biological Science
from the Tsinghua University in Beijing, an MBA from the MIT Sloan School of Management and a Ph.D. in Chemistry from Northeastern University.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Christopher Seitz joined the Investment Adviser in 2021. Previously, Mr.&#160;Seitz
was a Healthcare Analyst Intern at Nantahala Capital Management, focusing on healthcare companies, specifically biotech (oncology, rare
disease, neuro, cardiovascular), medtech, services and digital health. Previously, he was an Associate at Excel Venture Management where
he supported deal execution, fund strategy and portfolio management. Prior to his employment at Excel, he was an Analyst/ Senior Analyst
at Health Advances. Mr.&#160;Seitz holds a M.B.A. in Healthcare Management from The Wharton School of Business and an B.A. in Biology&#160;&#38;
German, Pre-Medicine from Williams College.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Graham Attipoe joined the Investment Adviser in May&#160;of 2022. Previously,
Dr.&#160;Attipoe worked as a Research Analyst for Eagle Health Investments LP overseeing global short- and long-term equity for a healthcare
fund, focusing on biopharmaceuticals and healthcare services. Prior to that, Dr.&#160;Attipoe was as a M.B.A. Summer Consultant for the
Boston Consulting Group and held a seasonal Investment Associate position at Windham Venture Partners. Dr.&#160;Attipoe holds a M.B.A.
in Healthcare Management&#160;&#38; Finance from the Wharton School of Business, a M.D. from the School of Medicine at Vanderbilt University
and a B.S. in Biology with a minor in Chemistry from Duke University.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Kelly Girskis joined the Investment Adviser in August&#160;of 2021. Previously,
she was an Equity Research Associate, Biotechnology at SVB Leerink where she did support coverage for biotechnology companies with a focus
on rare disease companies. Prior to that, she worked as an intern at Ascentia Asset Management as a life sciences consultant. Dr.&#160;Girskis
has a Ph.D. in Neurobiology from Harvard University and a B.A. in Neuroscience from the University of Southern California.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The portfolio management team applies both bottom-up and top-down strategies
in its investment process. A bottom-up strategy is taken on the company level where individual opportunities are evaluated in three fundamental
bases as appropriate: the scientific basis, the market basis, and the financial basis. Scientifically, assets are evaluated on first principals;
the market basis evaluates the regulatory and competitive landscape faced by each company; financial evaluation takes place through a
variety of metrics relative to the subsector to which each company belongs. A top-down approach is taken on the level of sector allocation
within the portfolio. The investment team divides healthcare into a number of subsectors and utilizes a battery of measures to identify
relative value on a subsector basis. These measures include sector revenue multiples, earnings multiples, and forward growth estimates
and prospects. To stay current, the investment team evaluates subsectors on a continually rotating basis and allocation flows are adjusted
as appropriate.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">For additional information regarding the portfolio management of the Trust,
see &#8220;Investment Adviser and Investment Advisory Agreement &#8212; Portfolio Management&#8221; in the SAI.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">18</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Code of Ethics</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Board approved a Code of Ethics under Rule&#160;17j-1 of the Investment
Company Act that covers the Trust and the Investment Adviser. The Code of Ethics establishes procedures for personal investing and restricts
certain transactions. Employees subject to the Code of Ethics may invest in securities for their personal investment accounts, including,
in certain cases, securities that may be purchased or held by the Trust. See &#8220;Code of Ethics&#8221; in the SAI.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>DESCRIPTION
OF TRUST</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust is a non-diversified, closed-end management investment company.
The Trust was organized as a Massachusetts business trust on March&#160;5, 2015 pursuant to a Declaration of Trust governed by Massachusetts
law and commenced operations on June&#160;30, 2015. The Trust&#8217;s Declaration of Trust was amended and restated as of May&#160;18,
2015 (&#8220;Amended and Restated Declaration of Trust&#8221;). The Amended and Restated Declaration of Trust is referred to in this Prospectus
as the &#8220;Declaration of Trust&#8221; unless the context requires otherwise. The Trust&#8217;s principal offices are located at 100
Federal Street, 19th Floor, Boston, MA 02110.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> <ix:nonNumeric id="Fxbrl_20221209182229492" name="cef:CapitalStockTableTextBlock" contextRef="C_20221206to20221206" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s capitalization consists of an unlimited number of Shares
of beneficial interest, $0.01 par value. Each Share represents an equal proportionate beneficial interest in the Trust and, when issued
and outstanding, will be fully paid and non-assessable by the Trust. <ix:nonNumeric id="Fxbrl_20221209183002623" name="cef:SecurityLiquidationRightsTextBlock" contextRef="C_20221206to20221206" escape="true">Upon
any liquidation of the Trust, Shareholders will be entitled to share pro rata in the net assets of the Trust available for distribution
after paying or adequately providing for the payment of all liabilities.</ix:nonNumeric> The Trust will send annual and semi-annual financial
statements to Shareholders and may also issue more abbreviated interim reports to update Shareholders on a quarterly basis. The Trust
will hold annual meetings of its Shareholders in accordance with the provisions of the Trust&#8217;s By-laws and the rules&#160;of the
NYSE.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><ix:nonNumeric id="Fxbrl_20221209182946095" name="cef:SecurityVotingRightsTextBlock" contextRef="C_20221206to20221206" escape="true">Shareholders
are entitled to one vote for each whole Share held and a proportionate fractional vote for each fractional Share held. The Trust&#8217;s
Shares do not have cumulative voting rights, which means that the holders of more than 50% of the Shares of the Trust voting for the election
of Trustees can elect all of the Trustees, and, in such event, the holders of the remaining Shares will not be able to elect any Trustees.</ix:nonNumeric>
The Trust has a classified Board of three classes, whereby one class of Trustees is elected each year.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">For information regarding risk factors pertaining to the Trust, see &#8220;Risk
Factors.&#8221;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">As of September&#160;6, 2022, to the best of the Trust&#8217;s knowledge,
and based solely on Schedule 13D/G filings made with the Commission, there was no person who controlled the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>PORTFOLIO
TRANSACTIONS AND BROKERAGE</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Subject to policies established by the Board, the Investment Adviser is
primarily responsible for the execution of the Trust&#8217;s portfolio transactions and the allocation of brokerage. In executing such
transactions, the Investment Adviser will seek to obtain the best price and execution for the Trust, taking into account such factors
as price, size of order, difficulty of execution, operational facilities of the firm involved, the firm&#8217;s risk in positioning a
block of securities, and research, market and statistical information provided by such firm. While the Investment Adviser generally seeks
reasonably competitive commission rates, the Trust will not necessarily pay the lowest commission available.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust intends to purchase and hold securities for capital appreciation
and it is not anticipated that frequent portfolio changes will be made for short-term trading purposes or to take advantage of short-term
swings in the market. However, changes may be made in the portfolio consistent with the investment objective and policies of the Trust
whenever changes are believed by the Investment Adviser to be in the best interest of the Trust and its Shareholders. Risk factors, particularly
those relating to a specific security investment or to the market and economic conditions, may also affect the rate at which the Trust
buys and sells its portfolio holdings. The Trust has no fixed policy with respect to portfolio turnover rate. The Trust may engage in
short-term trading of portfolio securities, including initial public offerings, which may result in increasing the Trust&#8217;s portfolio
turnover rate. The portfolio turnover rate is calculated by dividing the lesser of purchases or sales of long-term portfolio securities
by the average monthly value of the Trust&#8217;s long-term portfolio securities. A high rate of portfolio turnover (100% or more) could
produce higher trading costs and taxable distributions, which would detract from the Trust&#8217;s performance. The Trust&#8217;s portfolio
turnover rate for the fiscal years ended September&#160;30, 2021 and September&#160;30, 2020 was 69.37% and 48.11%, respectively.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">19</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="text-transform:uppercase"><strong>NET
ASSET VALUE</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The NAV of the Trust&#8217;s Shares is calculated at the close of regular
trading on the NYSE (generally 4:00 p.m., Eastern Time) every day that the NYSE is open. The Trust makes this information available daily
by telephone (800) 451-2597, via its web site (<span style="text-decoration:underline">www.teklacap.com</span>) and through electronic
distribution for media publication, including major internet-based financial services web sites and portals (<i>e.g</i>., <span style="text-decoration:underline">bloomberg.com,
yahoo.com, cbsmarketwatch.com</span>,&#160;etc.). Currently, The Wall Street Journal, The New York Times and Barron&#8217;s publish NAVs
for closed-end investment companies at least weekly.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">NAV is calculated by dividing the Trust&#8217;s total assets (the value
of the securities held by the Trust plus any cash or other assets, including interest payable but not yet received) minus all liabilities
(including accrued expenses, dividends payable and any borrowings of the Trust) by the total number of Shares outstanding at such time.
If any Preferred Shares are outstanding, net assets available for common Shareholders are determined by deducting from net assets the
liquidation preference and any accrued dividends on the Preferred Shares.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Securities for which market quotations are readily available are valued
at market price. Portfolio securities that are traded on one or more U.S. national securities exchanges or in the over-the-counter market
that are National Market System securities are valued at the last sale price or, lacking any sales, at the mean between last bid and asked
prices. Other over-the-counter securities are valued at the most recent bid prices as obtained from one or more dealers that make markets
in the securities. Redeemable securities issued by a registered open-end investment company are valued at net asset value per share. Other
securities are valued at the mean between the closing bid and asked prices. Short-term investments that mature in 60 days or less are
valued at amortized cost, unless the Board determines that such valuation does not constitute fair value.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Bonds, other than convertible bonds, are valued using a third-party pricing
system. Convertible bonds are valued using this pricing system only on days when there is no sale reported. Temporary cash investments
with maturity of 60 days or less are valued at amortized cost. Puts and calls generally are valued at the close of regular trading on
the securities or commodities exchange on which they are primarily traded. Options on securities generally are valued at their last bid
price in the case of exchange-traded options or, in the case of OTC-traded options, the average of the last bid price as obtained from
two or more dealers unless there is only one dealer, in which case that dealer&#8217;s price is used. Forward foreign currency contracts
are valued on the basis of the value of the underlying currencies at the prevailing currency exchange rate. The prevailing currency exchange
rate shall be determined within one hour of when the most recently available exchange rate information has been received based on information
obtained from a bank or banks.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Securities that are primarily traded on foreign securities exchanges generally
are valued at the last sale price on the exchange on which they are primarily traded. Foreign securities that are primarily traded on
the foreign over-the-counter market are generally valued at the last sale quotation, if market quotations are available, or the last reported
bid price if there is no active trading in a particular security on a given day. However, if intervening events result in market volatility
that significantly affects the value of any such foreign securities after the close of trading on the relevant foreign market, but before
the Trust values its Shares on any particular day on which the Trust is required to value its Shares, the Trust may, but is not required
to, determine the value of such securities at &#8220;fair value,&#8221; as determined in good faith by or under the direction of the Board.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Quotations of foreign securities in foreign currencies are converted,
at current exchange rates, to their U.S. dollar equivalents to determine their current value. In addition, to the extent that the Trust
values its foreign securities (other than ADR&#8217;s and ADS&#8217;s) as of the close of trading on various exchanges and over-the-counter
markets throughout the world, the calculation of the Trust&#8217;s net asset value may not take place contemporaneously with the valuation
of foreign securities held by the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The value of any security or other asset for which market quotations are
not readily available shall be determined in a manner that most fairly reflects the security&#8217;s (or asset&#8217;s) &#8220;fair value.&#8221;
Each such determination is based on a consideration of all relevant factors, which are likely to vary from one pricing context to another.
Examples of such factors may include, but are not limited to: (1)&#160;the type of the security; (2)&#160;the size of the holding (including
percent of outstanding securities of issuer held by the Trust); (3)&#160;the initial cost of the security;(4)&#160;the existence of any
contractual restrictions on the security&#8217;s disposition and the time to freedom from such restrictions;(5)&#160;the price and extent
of public trading in similar securities of the issuer or of comparable companies; (6)&#160;quotations or prices from broker-dealers and/or
pricing services; (7)&#160;information obtained from the issuer, analysts, and/or the appropriate stock exchange (for exchange-traded
securities); (8)&#160;an analysis of the company&#8217;s financial statements; (9)&#160;an evaluation of the forces that influence the
issuer and the market(s)&#160;in which the security is purchased and sold (e.g., the existence of pending merger activity, public offerings
or tender offers that might affect the value of the security); and (10)&#160;with respect to certain Restricted Securities, the price
of securities in a subsequent round of financing of an issuer in an arm&#8217;s-length transaction, if the round includes a new third
party investor.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">20</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Sometimes a &#8220;significant valuation event&#8221; may cause the market
value of a security to differ from the fair market value of that security. A &#8220;significant valuation event&#8221; is an event that
causes or is likely to cause a market quotation to be unavailable or unreliable, and may include: situations relating to a single issue
in a market sector; significant fluctuations in U.S. or foreign markets; market disruptions or closings caused by human error, equipment
failures, natural disasters, armed conflicts, acts of God, governmental actions or other developments, as well as the same or similar
events which may affect specific issues or the securities markets even though not tied directly to the securities markets. A significant
valuation event occurring after the close of trading but before the time of valuation may mean that the closing price for the security
does not constitute a readily available market quotation. If a significant valuation event has occurred, the security will be valued at
fair value as determined in good faith by the Board in accordance with the procedures described above. Such valuations and procedures
will be reviewed periodically by the Board.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The fair value of investments for which no market exists cannot be precisely
determined. With respect to securities of a company in its early stage of development, valuation will typically be based upon the original
cost to the Trust. This methodology will typically be used until significant developments affecting the portfolio company provide a basis
for a change in valuation. The status of portfolio companies is monitored for progress against plan, advancement of the stage of product
development, and other factors. When revenues and earnings are present they are monitored. Valuation changes are event driven. When an
appropriate event occurs (e.g., the completion of a third party transaction or a significant change in business model) valuation is changed
accordingly. In addition the Trust will typically base changes in valuation on actual transactions or on actual firm offers by sophisticated
independent investors unaffiliated with the Adviser. Legal or contractual restrictions on the sale of portfolio securities by the Trust
will be considered in the valuation of such securities.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Other assets, which include cash, prepaid and accrued items, accounts
receivable and income on investments and from the sale of portfolio securities, are carried in accordance with generally accepted accounting
principles, as are all liabilities. Liabilities primarily include accrued expenses, sums owed for securities purchased and dividends payable.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>Plan
of Distribution</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may sell up to $150,000,000 in aggregate initial offering price
of Common Shares from time to time under this Prospectus and any related Prospectus Supplement (1)&#160;directly to one or more purchasers,
including existing Shareholders in a rights offering, (2)&#160;through agents; (3)&#160;through underwriters; (4)&#160;through dealers;
or (5)&#160;pursuant to the Dividend Reinvestment and Stock Purchase Plan. Each Prospectus Supplement relating to an offering of Common
Shares will state the terms of the offering, including:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td>the names of any agents, underwriters or dealers;</td> </tr>
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td>any sales loads or other items constituting underwriters&#8217; compensation;</td> </tr>
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td>any discounts, commissions, or fees allowed or paid to dealers or agents;</td> </tr>
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td>the public offering or purchase price of the offered Common Shares and the net proceeds the Trust will receive from the sale; and</td>
        </tr>
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td>any securities exchange on which the offered Common Shares may be listed.</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Direct Sales</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may sell Common Shares directly to, and solicit offers from,
institutional investors or others who may be deemed to be underwriters as defined in the Securities Act for any resales of the securities.
In this case, no underwriters or agents would be involved. The Trust may use electronic media, including the Internet, to sell offered
securities directly. The Trust will describe the terms of any of those sales in a Prospectus Supplement.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>By Agents</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may offer Common Shares through agents that the Trust may designate.
The Trust will name any agent involved in the offer and sale and describe any commissions payable by the Trust in the Prospectus Supplement.
Unless otherwise indicated in the Prospectus Supplement, the agents will be acting on a best efforts basis for the period of their appointment.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>By Underwriters</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may offer and sell Common Shares from time to time to one or
more underwriters who would purchase the Common Shares as principal for resale to the public, either on a firm commitment or best efforts
basis. If the Trust sells Common Shares to</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">21</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">underwriters, the Trust will execute an underwriting agreement with them
at the time of the sale and will name them in the Prospectus Supplement. In connection with these sales, the underwriters may be deemed
to have received compensation from the Trust in the form of underwriting discounts and commissions. The underwriters also may receive
commissions from purchasers of Common Shares for whom they may act as agent. Unless otherwise stated in the Prospectus Supplement, the
underwriters will not be obligated to purchase the Common Shares unless the conditions set forth in the underwriting agreement are satisfied,
and if the underwriters purchase any of the Common Shares, they will be required to purchase all of the offered Common Shares. The underwriters
may sell the offered Common Shares to or through dealers, and those dealers may receive discounts, concessions or commissions from the
underwriters as well as from the purchasers for whom they may act as agent. Any public offering price and any discounts or concessions
allowed or reallowed or paid to dealers may be changed from time to time.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">If a Prospectus Supplement so indicates, the Trust may grant the underwriters
an option to purchase additional Common Shares at the public offering price, less the underwriting discounts and commissions, within 45
days from the date of the Prospectus Supplement, to cover any overallotments.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>By Dealers</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may offer and sell Common Shares from time to time to one or
more dealers who would purchase the securities as principal. The dealers then may resell the offered Common Shares to the public at fixed
or varying prices to be determined by those dealers at the time of resale. The Trust will set forth the names of the dealers and the terms
of the transaction in the Prospectus Supplement.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>General Information</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Agents, underwriters, or dealers participating in an offering of Common
Shares may be deemed to be underwriters, and any discounts and commission received by them and any profit realized by them on resale of
the</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>DIVIDENDS
AND DISTRIBUTIONS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">For federal income tax purposes, the Trust is required to distribute substantially
all of its investment company taxable income for each taxable year. Capital gain (i.e., the excess of net long-term capital gain over
net short-term capital loss), if any, may be distributed or may be retained at the discretion of the Board. &#8220;Investment company
taxable income,&#8221; as used herein, includes all interest and other ordinary income earned by the Trust on its portfolio holdings and
net short-term capital gains in excess of net long-term capital losses, less the Trust&#8217;s expenses. See &#8220;Taxation &#8212;Distributions.&#8221;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">If the Trust is precluded from making distributions on the Shares because
of any applicable asset coverage requirements, the terms of the Preferred Shares (if any) may provide that any amounts so precluded from
being distributed, but required to be distributed for the Trust to meet the distribution requirements for qualification as a regulated
investment company for U.S. federal income tax purposes, will be paid to the holders of the Preferred Shares as a special distribution.
This distribution can be expected to decrease the amount that holders of Preferred Shares would be entitled to receive upon redemption
or liquidation of the shares.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust currently makes distributions in cash to its Shareholders of
all or a portion of its net investment income to Shareholders each month out of legally available funds. The Trust will pay Shareholders
at least annually all or substantially all of its net investment income after the payment of interest, fees or dividends, if any, owed
with respect to any forms of leverage utilized by the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust intends to pay any capital gains distributions at least annually.
Pursuant to an exemptive order obtained from the Commission under Section&#160;19(b)&#160;of the Investment Company Act, the Trust is
permitted to distribute long-term capital gains to Shareholders more than once per year.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s monthly distribution policy and the basis for establishing
the rate of its monthly distributions may be changed at any time by the Board without Shareholder approval.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Various factors will affect the level of the Trust&#8217;s income, including
the asset mix, the performance of the companies represented in the Trust&#8217;s portfolio, and the Trust&#8217;s use of hedging and fluctuations
in the rate of exchange between foreign currencies and the U.S. dollar to the extent the Trust has invested in Foreign Securities.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Notices will be provided in accordance with Section&#160;19(a)&#160;of
the Investment Company Act.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">22</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The SEC exemptive order authorizing the adoption of the Trust&#8217;s
managed distribution policy requires the Trust to adhere to certain conditions with respect to public offerings. The SEC exemptive order
requires that the Trust will not make a public offering of the Trust&#8217;s Shares other than: (i)&#160;a rights offering that is below
NAV to holders of the fund&#8217;s common share; (ii)&#160;an offering in connection with a dividend reinvestment plan, merger, consolidation,
acquisition, spin off or reorganization of the fund; or (iii)&#160;an offering in which the fund&#8217;s annualized distribution rate
for the six months ending on the last day of the month ended immediately prior to the most recent distribution record date, expressed
as a percentage of NAV as of such date, is no more than 1 percentage point greater than the Trust&#8217;s average annual total return
for the 5-year period ending on such date and the transmittal letter accompanying any registration statement filed with the SEC in connection
with the offering discloses that the Trust has a managed distribution policy exemptive order. Any offering of Common Shares will comply
with the conditions of the SEC exemptive order.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>DIVIDEND
REINVESTMENT AND STOCK PURCHASE PLAN</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Under the Dividend Reinvestment and Stock Purchase Plan, dividends and/or
distributions to a Shareholder will automatically be reinvested in additional Shares of the Trust. Each registered Shareholder may elect
to have dividends and distributions distributed in cash (i.e., &#8220;opt-out&#8221;) rather than participate in the Dividend Reinvestment
and Stock Purchase Plan. For any registered Shareholder that does not so elect (each, a &#8220;Participant&#8221; and collectively, &#8220;Participants&#8221;),
dividends and/or distributions on such Shareholder&#8217;s Shares will be reinvested by Computershare Trust Company, N.A. (the &#8220;Plan
Agent&#8221;), as agent for Shareholders in additional Shares, as set forth below. Participation in the Dividend Reinvestment and Stock
Purchase Plan is completely voluntary, and may be terminated or resumed at any time without penalty by internet, telephone or notice if
received and processed by the Plan Agent prior to the dividend record rate; otherwise such termination or resumption will be effective
with respect to any subsequently declared dividend or other distribution. Participants who hold their Shares through a broker or other
nominee and who wish to elect to receive any dividends and distributions in cash must contact their broker or nominee.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Plan Agent&#8217;s fees for the handling of the reinvestment of dividends
and distributions will be paid by the Trust. Each participant will pay a per Share fee (currently $0.05 per Share) incurred in connection
with open market purchases. If a participant elects to have the Plan Agent sell all or a part of his or her Shares and remit the proceeds
to the participant, the Plan Agent is authorized to deduct a $15 sales fee per trade and a per Share fee of $0.12from such proceeds. All
per Share fees include any applicable brokerage commissions the Plan Agent is required to pay. The automatic reinvestment of Dividends
will not relieve Participants of any federal, state or local income tax that may be payable (or required to be withheld) on such dividend.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Plan Agent will acquire shares for participants&#8217; accounts by
purchasing either newly issued shares from the Trust or outstanding shares in the open market, depending upon the circumstances. If on
the payment date of a dividend or distribution the NAV per share is equal to or less than the closing market price (plus estimated per
share fees in connection with the purchase of shares), the Plan Agent will invest the dividend or distribution in newly issued shares.
The number of newly issued shares to be credited to each participant&#8217;s account will be determined by dividing the amount of the
participant&#8217;s cash dividend or distribution by the greater of the NAY per share on the payment date or 95% of the closing market
price per share on the payment date. If on the payment date the NAY per share is greater than the closing market price per share (plus
per share fees), the Plan Agent will invest the dividend or distribution in shares acquired in open-market purchases. The per share price
for open-market purchases will be the weighted average price of the shares on the payment date.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">In the event of a market discount on the payment date for any Dividend,
the Plan Agent (or Plan Agent&#8217;s broker) will have until the last business day before the next date on which the Shares trade on
an &#8220;ex-dividend&#8221; basis or 30 days after the payment date for such Dividend, whichever is sooner (the &#8220;Last Purchase
Date&#8221;), to invest the Dividend amount in Shares acquired in Open-Market Purchases. Open-market purchases may be made on any securities
exchange where Shares are traded, in the over-the-counter market or in negotiated transactions, and may be on such terms as to price,
delivery and otherwise as the Plan Agent shall determine. The per Share purchase price for Open-Market Purchases will be the weighted
average price of the Shares on the payment date. If, before the Plan Agent has completed its Open-Market Purchases, the market price per
Share exceeds the NAV per Share, the average per Share purchase price paid by the Plan Agent may exceed the NAV of the Shares, resulting
in the acquisition of fewer Shares than if the Dividend had been paid in Newly Issued Shares on the Dividend payment date. Because of
the foregoing difficulty with respect to Open-Market Purchases, the Dividend Reinvestment and Stock Purchase Plan provides that if the
Plan Agent is unable to invest the full Dividend amount in Open-Market Purchases during the purchase period or if the market discount
shifts to a market premium during the purchase period, the Plan Agent may cease making Open-Market Purchases and may invest the uninvested
portion of the Dividend amount in Newly Issued Shares at the NAV per Share at the close of business on the Last Purchase Date provided
that, if the NAV is less than or equal to 95% of the then current market price per Share; the dollar amount of the Dividend will be divided
by 95% of the market price on the payment date.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">23</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Each Participant can voluntarily purchase additional Shares at any time
through the Plan Agent. The Plan Agent will purchase additional Shares through Open-Market Purchases. The minimum investment under this
option is $50. To make an investment online, participants may log on to <span style="text-decoration:underline">www.computershare.com/investor</span>,
in order to authorize recurring automatic monthly deductions from a U.S. bank account or a one-time online bank debit from a U.S. bank
account. Participants may also make optional cash investments in Shares by sending a check in U.S. dollars and drawn against a U.S. bank
to the Plan Agent along with a completed transaction form appended to each statement received from the Plan Agent. The Plan Agent will
not accept cash, traveler&#8217;s checks, money orders or third party checks. The Plan Agent will purchase whole and fractional Shares
to equal each amount a Participant invests, less any applicable fees. Each optional cash investment by check or one-time online bank debit
will entail a transaction fee of $5.00 plus $0.05 per Share purchased. If funds are deducted monthly and automatically from a U.S. bank
account, for each debit the transaction fee is $2.50 plus $0.05 per Share purchased. Shares will be purchased by the Plan Agent at least
monthly. The transaction will occur within five (5)&#160;business days after a Participant&#8217;s funds are received by the Plan Agent,
assuming the applicable market is open for trading. If due to unusual circumstances, the Plan Agent is unable to purchase Shares from
optional cash payments within 35 days, the Plan Agent will return such funds by check. If any Participant&#8217;s check for an optional
cash payment is returned unpaid for any reason, or an authorized electronic funds transfer is rejected, the Plan Agent will consider the
request for the investment of such funds null and void. The Plan Agent will immediately remove from the Participant&#8217;s Plan account
those Shares, if any, purchased upon the prior credit of such funds and will immediately sell such Shares. The Plan Agent will also sell
any additional Shares from the Participant&#8217;s Plan fee account as necessary to cover any costs, losses or fees. Participants will
be charged $25.00 for each returned check or rejected electronic funds transfer.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Plan Agent maintains all Participants&#8217; accounts in the Dividend
Reinvestment and Stock Purchase Plan and furnishes written confirmation of all transactions in the accounts, including information needed
by Participants for tax records. Shares in the account of each Participant will be held by the Plan Agent on behalf of the Participant
in book entry form in the Plan Agent&#8217;s name or the Plan Agent&#8217;s nominee. Each Shareholder proxy will include those Shares
purchased or received pursuant to the Dividend Reinvestment and Stock Purchase Plan. The Plan Agent will forward all proxy solicitation
materials to Participants and vote proxies for Shares held under the Dividend Reinvestment and Stock Purchase Plan in accordance with
the instructions of the Participants.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">In the case of Shareholders such as banks, brokers or nominees which hold
shares for others who are the beneficial owners, the Plan Agent will administer the Dividend Reinvestment and Stock Purchase Plan on the
basis of the number of Shares certified from time to time by the record Shareholder and held for the account of beneficial owners who
participate in the Dividend Reinvestment and Stock Purchase Plan.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Any stock dividends or split of Shares distributed by the Trust on Shares
held by the Plan Agent for Participants will be credited to their accounts. In the event that the Trust makes available to its Shareholders
rights to purchase additional Shares or other securities, the Shares held for each Participant under the Plan will be added to other Shares
held by the Participant in calculating the number of rights to be issued to each Participant.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">If a Participant elects by telephone, internet or written notice to the
Plan Agent to have the Plan Agent sell all or a part of his or her Shares and remit the proceeds to the Participant, the Plan Agent will
process all sale instructions received no later than five (5)&#160;business days after the date on which the order is received. Such sale
will be made through the Plan Agent&#8217;s broker on the relevant market and the sale price will not be determined until such time as
the broker completes the sale. In each case, the price to each Participant shall be the weighted average sale price obtained by the Plan
Agent&#8217;s broker net of fees for each aggregate order placed by the Plan Agent and executed by the broker. To maximize cost savings,
the Plan Agent will seek to sell Shares in round lot transactions. For this purpose the Plan Agent may combine a Participant&#8217;s Shares
with those of other selling Participants.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Each Participant may terminate his or her account under the Plan by notifying
the Plan Agent by telephone, through the internet or in writing prior to the dividend record date. Such termination will be effective
immediately if received by the Plan Agent prior to any dividend or distribution record date; otherwise such termination or resumption
will be effective with respect to any subsequently declared dividend or other distribution. Upon any withdrawal or termination, the Plan
Agent will cause to be delivered to each terminating Participant a statement of holdings for the appropriate number of the Trust&#8217;s
whole book-entry Shares and a check for the cash adjustment of any fractional share at the then current market value per Share less any
applicable fees.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust reserves the right to amend or terminate the Plan upon notice
in writing to each Participant at least 30 days prior to any record date for the payment of any dividend or distribution by the Trust.
Notice will be sent to Participants of any amendments as soon as practicable after such action by the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">24</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">All correspondence from a registered owner of Shares concerning the Dividend
Reinvestment and Stock Purchase Plan should be directed to the Plan Agent at Computershare Trust Company, N.A, P.O.&#160;Box 30170, College
Station, TX 77842-3170, with overnight correspondence being directed to the Plan Agent at Computershare Trust Company, N.A, 211 Quality
Circle, Suite&#160;210, College Station, TX 77845; by calling 1-800-426-5523; or through the Plan Agent&#8217;s website at <span style="text-decoration:underline">www.computershare.com/investor</span><span style="color:#0045FF">.</span>
Participants who hold their Shares through a broker or other nominee should direct correspondence or questions concerning the Dividend
Reinvestment and Stock Purchase Plan to their broker or nominee.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>TAXATION</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The following discussion is based upon the advice of Dechert LLP, counsel
for the Trust, and is a general summary of the principal U.S. federal income tax considerations regarding an investment in the Trust.
The discussion is based on laws, regulations, rulings and decisions currently in effect, all of which are subject to change (possibly
with retroactive effect) or different interpretations. The discussion below does not purport to deal with all of the federal income tax
consequences applicable to the Trust, or to all categories of investors, some of which may be subject to special rules. Each Shareholder
is urged to consult with his or her own tax adviser with respect to the specific federal, state, local, foreign and other tax consequences
of investing in Shares of the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Taxation of the Trust</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust intends to qualify and has elected to be treated each taxable
year as a regulated investment company (&#8220;RIC&#8221;) under the Code. The principal federal income tax benefits of qualifying as
a RIC, as compared to an ordinary taxable corporation, are that a RIC generally is not itself subject to federal income tax on ordinary
investment income and net capital gains that are currently distributed to its Shareholders, and that the character of long-term capital
gains which are recognized and properly reported by a RIC flows through to its Shareholders, who receive (or are deemed to receive) distributions
of such income. However, the Trust would be subject to corporate income tax (currently at a maximum rate of 21%) on any undistributed
income.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> <ix:nonNumeric id="Fxbrl_20221212174858245" name="cef:SecurityDividendsTextBlock" contextRef="C_20221206to20221206" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Distributions</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Dividends paid from investment company taxable income as calculated for
federal income tax purposes generally will be taxable to Shareholders as ordinary income whether paid in cash or reinvested in the Trust&#8217;s
Shares. The Trust intends to distribute to its Shareholders substantially all of its investment company taxable income(including distributions
of net short-term capital gains), if any, for each year. It is anticipated that the Trust&#8217;s income distributions will be paid annually
in additional Shares unless the Shareholder elects payment in cash.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A portion of the dividends paid by the Trust may be treated as &#8220;qualified
dividend income&#8221; which is taxable to individuals at the same rates that are applicable to long-term capital gains. A Trust distribution
is treated as qualified dividend income to the extent that the Trust receives dividend income from taxable domestic corporations and certain
qualified foreign corporations, provided that certain holding period and other requirements are met by both the Trust and the Shareholder.
Trust distributions generally will not qualify as qualified dividend income to the extent attributable to interest, capital gains, REIT
distributions and distributions from certain non-U.S. corporations.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">If a portion of the Trust&#8217;s income consists of dividends paid by
U.S. corporations, a portion of the dividends paid by the Trust may be eligible for the corporate dividends-received deduction provided
that certain holding period and other requirements are met by both the Trust and the corporate Shareholder.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Distributions of the excess, if any, of net long-term capital gains over
net short-term capital losses reported by the Trust as capital gain dividends will be taxable to Shareholders as long-term capital gains,
whether paid in cash or reinvested in the Trust&#8217;s Shares, regardless of how long the Shareholders have held the Trust&#8217;s Shares
and will not be eligible for the dividends received deduction for corporations.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Each year, Shareholders will be notified as to the amount and federal
tax status of all dividends and capital gains paid during the prior year. Such dividends and capital gains may also be subject to state
or local taxes. Dividends declared in October, November, or December&#160;with a record date in such month and paid during the following
January&#160;will be treated as having been paid by the Trust and received by Shareholders on December&#160;31 of the calendar year in
which declared, rather than the calendar year in which the dividends are actually received.</p>

<div><ix:exclude>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">25</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Gain or loss realized upon the sale or exchange of Shares will be a capital
gain or loss if the Shares are capital assets in the Shareholder&#8217;s hands and generally will be long-term or short-term, depending
upon the Shareholder&#8217;s holding period for the Shares. You should be aware that any loss realized upon the sale or exchange of Shares
held for six months or less will be treated as a long-term capital loss to the extent of any distributions or deemed distributions of
long-term capital gain to the Shareholder with respect to such Shares. In addition, any loss realized on a sale or exchange of Shares
will be disallowed to the extent the Shares disposed of are replaced within a period of 61 days beginning 30 days before and ending 30
days after the Shares are disposed of, such as pursuant to the Plan. In such case, the basis of Shares acquired will be adjusted to reflect
the disallowed loss.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">An additional 3.8% Medicare tax is imposed on certain net investment income
(including ordinary dividends and capital gain distributions received from the Trust and net gains from redemptions or other taxabledispositions
of Trust Shares) of U.S. individuals, estates and trusts to the extent that such person&#8217;s &#8220;modified adjusted gross income&#8221;
(in the case of an individual) or &#8220;adjusted gross income&#8221; (in the case of an estate or trust) exceeds certain threshold amounts.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">If a Shareholder has not furnished a certified correct taxpayer identification
number (generally a Social Security number) and has not certified that withholding does not apply, or if the Internal Revenue Service
has notified the Trust that the taxpayer identification number listed on the account is incorrect according to their records or that the
Shareholder is subject to backup withholding, federal law generally requires the Trust to withhold 24% from any dividends and/or redemptions
(including exchange redemptions). Amounts withheld are applied to federal tax liability; a refund may be obtained from the Service if
withholding results in overpayment of taxes. Federal law also requires the Trust to withhold up to 30% or the applicable tax treaty rate
from ordinary dividends paid to certain nonresident alien and other non-U.S. Shareholder accounts.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">This is a brief summary of some of the tax laws that affect an investment
in the Trust. Moreover, the foregoing does not address the many factors that may determine whether an investor will be liable for the
federal alternative minimum tax. Please see the SAI and a tax adviser for further information.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>ADMINISTRATOR,
CUSTODIAN, TRANSFER AGENT, DIVIDEND<br />DISBURSING AGENT AND REGISTRAR</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s securities and cash are held under a custodian contract
by State Street Bank and Trust Company (the &#8220;Custodian&#8221;), whose principal business address is One Lincoln Street, Boston,
MA 02111. The Custodian also performs certain accounting related functions for the Trust, including calculation of NAV and net income.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">State Street Bank and Trust Company (the &#8220;Administrator&#8221;)
serves as administrator to the Trust pursuant to an administration agreement between the Administrator and the Trust (the &#8220;Administration
Agreement&#8221;). Under the Administration Agreement the Trust&#8217;s assets are combined with assets of HQL, HQH and THQ. The combined
assets are charged fees computed and payable monthly at an annual rate of (i)&#160;3.4% of the first $150 million; (ii)&#160;2.4% of the
next $150 million; and (iii)&#160;1.4% on assets in excess of $300 million, subject to annual minimum fee of $77,500. The Administrative
Agreement covers administrative costs including out-of-pocket expenses incurred in the ordinary course of providing services under the
Administration Agreement.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Computershare Inc. serves as Dividend Disbursing Agent for the Trust.
Computershare Trust Company, N.A., a fully owned subsidiary of Computershare Inc., serves as (1)&#160;the Plan Agent for the Trust&#8217;s
Dividend Reinvestment Plan and (2)&#160;the Transfer Agent and Registrar for Shares of the Trust. Computershare Trust Company, N.A. and
Computershare Inc. have their principal business at 250 Royall Street, Canton, MA 02021.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>LEGAL
MATTERS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The validity of the Shares offered hereby will be passed on for the Trust
by Dechert LLP, One International Place, 40th Floor, 100 Oliver Street, Boston, MA 02110.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>EXPERTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s financial statements as of and for the fiscal year ended
September&#160;30, 2021, incorporated by reference in the SAI, have been incorporated in reliance on the report of Deloitte &#38; Touche
LLP, an independent registered public accounting firm, given on the authority of such firm as experts in auditing and accounting.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">26</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>REPORTS
TO SHAREHOLDERS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust will send unaudited semi annual reports and audited annual reports,
including a list of investments held, to Shareholders.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>Incorporation
by Reference</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">This Prospectus is part of the registration statement that has been filed
with the SEC. Pursuant to the final rule&#160;and form amendments adopted by the SEC on April&#160;8, 2020 to implement certain provisions
of the Economic Growth, Regulatory Relief, and Consumer Protection Act, the Trust may &#8220;incorporate by reference&#8221; the information
that it files with the SEC, which means that the Trust can disclose important information by referring to those documents. The information
incorporated by reference is considered to be part of this Prospectus, and later information that the Trust files with the SEC will automatically
update and supersede this information.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The documents listed below, and any reports and other documents subsequently
filed with the SEC pursuant to Rule&#160;30(b)(2)&#160;under the 1940 Act and Sections 13(a), 13(c), 14 or 15(d)&#160;of the Exchange
Act, prior to the termination of this offering, are incorporated by reference into this Prospectus and deemed to be part of this Prospectus
from the date of the filing of such reports and documents:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td>the Trust&#8217;s SAI, dated December 6, 2022, filed with this Prospectus;</td> </tr>
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/805267/000110465922045016/tm222535d1_def14a.htm" style="-sec-extract:exhibit">the Trust&#8217;s
        definitive Proxy Statement, dated April&#160;18, 2022, filed on April&#160;12, 2022</a>;</td> </tr>
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001635977/000110465922125461/tm2225215d1_ncsr.htm" style="-sec-extract:exhibit">the
        Trust&#8217;s annual report on Form&#160;N-CSR for the fiscal year ended September&#160;30, 2022, filed with the SEC on December&#160;8,
        2022</a>;</td> </tr>
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1635977/000110465922068028/tm228078d1_ncsrs.htm" style="-sec-extract:exhibit">the Trust&#8217;s
        semi-annual report on Form&#160;N-CSR for the fiscal period ended March&#160;31, 2022, filed with the SEC on June&#160;3, 2022</a>;</td>
        </tr>
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1635977/000110465915046396/a15-14451_18a12b.htm" style="-sec-extract:exhibit">the Trust&#8217;s
        description of Common Shares on Form&#160;8-A, filed on June&#160;19, 2015</a></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust will provide without charge to each person, including any beneficial
owner, to whom this Prospectus is delivered, upon written or oral request, a copy of any and all of the documents that have been or may
be incorporated by reference in this Prospectus or an accompanying Prospectus Supplement.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">You should direct requests for documents by calling the Investment Adviser
at (617) 772-8500 or by writing to the Trust at c/o Tekla Capital Management LLC, 100 Federal Street, 19th Floor Boston, MA 02110. The
Trust makes available this Prospectus, SAI and the Trust&#8217;s annual and semi-annual reports, free of charge, on the Trust&#8217;s
website (www.teklacap.com). You may also obtain this Prospectus, the SAI, other documents incorporated by reference and other information
the Trust files electronically, including reports and proxy statements, on the SEC website (http://www.sec.gov) or with the payment of
a duplication fee, by electronic request at publicinfo@sec.gov. Information contained in, or that can be accessed through, the Trust&#8217;s
website is not incorporated by reference into this Prospectus and should not be considered to be part of this Prospectus or the accompanying
prospectus supplement.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>ADDITIONAL
INFORMATION</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust is subject to the informational requirements of the Securities
Exchange Act of 1934, as amended, and the Investment Company Act and in accordance therewith is required to file reports, proxy statements
and other information with the Commission. Any such reports, proxy statements and other information filed by the Trust can be inspected
and copied (at prescribed rates) at the public reference facilities of the Commission, 100 F Street, NE, Washington, D.C. 20549. The Trust&#8217;s
Shares are listed on the NYSE. Reports, proxy statements and other information concerning the Trust can also be inspected and copied at
the Library of the NYSE, 20 Broad Street, New York, NY 10005.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">This Prospectus constitutes a part of a registration statement on Form&#160;N-2
(together with the SAI and all the exhibits and appendices thereto, the &#8220;Registration Statement&#8221;) filed by the Trust with
the Commission under the Securities Act and the Investment Company Act. This Prospectus and the SAI do not contain all of the information
set forth in the Registration Statement. Reference is hereby made to the Registration Statement and related exhibits for further information
with respect to the Trust and the Shares offered hereby. Statements contained herein concerning the provisions of documents are necessarily
summaries of such documents, and each statement is qualified in its entirety by reference to the copy of the applicable document filed
with the Commission.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">27</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Certain statements in this Prospectus constitute forward-looking statements,
which involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance
or achievements of the Trust to be materially different from any future results, levels of activity, performance or achievements expressed
or implied by such forward-looking statements. Such factors include, among others, those listed under &#8220;Risk Factors&#8221; and elsewhere
in this Prospectus. As a result of the foregoing and other factors, no assurance can be given as to the future results, levels of activity
or achievements, and neither the Trust nor any other person assumes responsibility for the accuracy and completeness of such statements.
To the extent required by law, the Trust undertakes to supplement this Prospectus to reflect any material changes to the Trust after the
date of this Prospectus.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>TABLE
OF CONTENTS OF STATEMENT OF ADDITIONAL INFORMATION</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="width:85%">&#160;</td>
    <td style="width:15%">
        <p style="border-bottom:Black 0.5pt solid;font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>PAGE</strong></p> </td> </tr>
  <tr style="vertical-align:bottom">
    <td>Additional Information About Investments,&#160;Investment Techniques and Risks</td>
    <td style="text-align:right">1</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Investment Restrictions</td>
    <td style="text-align:right">19</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Trustees and Officers</td>
    <td style="text-align:right">20</td> </tr>
  <tr style="vertical-align:bottom">
    <td>The Trust</td>
    <td style="text-align:right">28</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Investment Adviser and Investment Advisory Agreement</td>
    <td style="text-align:right">31</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Proxy Voting Policy and Procedures</td>
    <td style="text-align:right">33</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Code of Ethics</td>
    <td style="text-align:right">34</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Net Asset Value</td>
    <td style="text-align:right">34</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Portfolio Transactions and Brokerage</td>
    <td style="text-align:right">36</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Tax Matters</td>
    <td style="text-align:right">37</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Administrator, Custodian, Transfer Agent, Dividend Disbursing Agent and Registrar</td>
    <td style="text-align:right">44</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Incorporation By Reference</td>
    <td style="text-align:right">44</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Financial Statements</td>
    <td style="text-align:right">45</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Appendix A &#8212; Proxy Voting Policies and Procedures</td>
    <td style="text-align:right">A-1</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">28</p> </div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="display:none;margin:0 20%;width:680px"> <ix:nonNumeric id="Fxbrl_20221209105424414" name="cef:InvestmentObjectivesAndPracticesTextBlock" contextRef="C_20221206to20221206" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>INVESTMENT
OBJECTIVE AND POLICIES</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">Please
refer to&#160;</span><a href="https://www.sec.gov/Archives/edgar/data/1635977/000110465921146323/tm2129557d1_ncsr.htm"><span style="font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;font-weight:400;text-align:start;white-space:normal;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;color:#0070c0"><span style="text-decoration:underline">the&#160;</span></span><span style="color:#0070c0"><span style="text-decoration:underline">section
of the Trust&#8217;s most recent annual report on Form N-CSR entitled &#8220;Investment Objective, Policies and Risk Factors&#8212;Investment
Objective and Policies,&#8221;</span></span></a><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">&#160;which
is incorporated by reference herein, for discussion of the Trust&#8217;s investment objective and policies.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> <ix:nonNumeric id="Fxbrl_20221209105433017" name="cef:RiskFactorsTableTextBlock" contextRef="C_20221206to20221206" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>RISK
FACTORS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">An
investment in common shares of the Trust involves risk. Please refer&#160;</span><span style="color:#0070c0"><span style="text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1635977/000110465921146323/tm2129557d1_ncsr.htm"><span style="color:#0070c0"><span style="text-decoration:underline">to
the section of the Trust&#8217;s most recent annual report on Form N-CSR entitled &#8220;Investment Objectives, Policies and Risks&#8212;Risk
Factors,&#8221;</span></span></a></span></span><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">&#160;which
is incorporated by reference herein, for a discussion of the risks of investing in the Trust.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> <ix:nonNumeric id="Fxbrl_20221212113412854" name="cef:InvestmentObjectivesAndPracticesTextBlock" contextRef="C_20221213to20221213" escape="true">

<table style="font:13px Times New Roman, Times, serif;text-decoration-style:initial;text-decoration-color:initial;width:100%;border-collapse:collapse;border:0px">
  <tr>
    <td colspan="2" style="padding-right:7px;padding-left:7px">Please refer to&#160;<span style="color:#0070c0"><a href="https://www.sec.gov/Archives/edgar/data/1635977/000110465921146323/tm2129557d1_ncsr.htm"><span style="color:#0070c0">the
        section of the Trust&#8217;s most recent annual report on Form&#160;N-CSR entitled &#8220;Investment Objective, Policies, and Risk Factors&#8212;Investment
        Objective and Policies&#8221;</span></a></span><span style="text-decoration:underline"><span style="text-decoration:underline">,</span></span>&#160;which
        is incorporated by reference herein, for a discussion of the Trust&#8217;s investment objective and policies.</td> </tr>
  </table> </ix:nonNumeric>

<div>&#160;</div>

<div> <ix:nonNumeric id="Fxbrl_20221212113837813" name="cef:RiskFactorsTableTextBlock" contextRef="C_20221213to20221213" escape="true">

<table style="font:13px Times New Roman, Times, serif;text-decoration-style:initial;text-decoration-color:initial;width:100%;border-collapse:collapse;border:0px">
  <tr>
    <td style="vertical-align:top;padding-right:7px;padding-left:7px">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">See &#8220;Risks Factors&#8221; beginning
        on page&#160;15 of the accompanying Prospectus for a discussion of factors you should carefully consider before deciding to invest in
        the Trust&#8217;s Common Shares.</p> </td> </tr>
  </table> </ix:nonNumeric> </div>

<div>&#160;</div> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>TEKLA WORLD HEALTHCARE FUND</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>STATEMENT OF ADDITIONAL INFORMATION</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>December 6, 2022</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Tekla World Healthcare Fund (the &#8220;Trust&#8221;) is a non-diversified,
closed-end management investment company. The Trust&#8217;s investment objective is to seek current income and long-term capital appreciation.
Under normal market conditions, the Trust expects to invest at least 80% of its Managed Assets (as defined below) in U.S. and non-U.S.
companies engaged in the healthcare industry (&#8220;Healthcare Companies&#8221;) including equity securities and debt securities. &#8220;Managed
Assets&#8221; means the total assets of the Trust (including any assets attributable to borrowings for investment purposes) minus the
sum of the Trust&#8217;s accrued liabilities (other than liabilities representing borrowings for investment purposes). The Trust&#8217;s
80% policy may only be changed with 60 days&#8217; prior notice to the Trust&#8217;s shareholders (&#8220;Shareholders&#8221;). The Trust
will concentrate its investments in the healthcare industries. No assurance can be given that the Trust will achieve its investment objective.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A company will be deemed to be a Healthcare Company if, at the time the
Trust makes an investment in the company, 50% or more of such company&#8217;s sales, earnings or assets arise from or are dedicated to
healthcare products or services or medical technology activities. Healthcare Companies may include companies in one or more of the following
sub-sectors: pharmaceuticals, biotechnology, managed care, life science and tools, healthcare technology, healthcare services, healthcare
supplies, healthcare facilities, healthcare equipment, healthcare distributors and Healthcare REITs (as defined below). The Investment
Adviser (defined below) determines, in its discretion, whether a company is a Healthcare Company.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Under normal market conditions, the Trust expects to invest at least 40%
of its Managed Assets in companies organized or located outside the United States or companies that do a substantial amount of business
outside the United States. The Trust may invest up to 5% of its Managed Assets in securities of issuers located in emerging market countries
(&#8220;Emerging Markets&#8221;). The Trust may hedge its non-U.S. dollar exposure from 0%-100% at any given time, though it typically
expects to do so between 0% and 50% of such exposure.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust expects to invest 60-90% of its Managed Assets in equity securities
(which may include common stock, preferred stock and warrants or other rights to acquire common or preferred stock). The Trust will invest
in foreign securities and may buy and sell currencies for the purpose of settlement of transactions in foreign securities. The Trust may
invest up to 30% of its Managed Assets in convertible securities which may include securities that are non-investment grade. The Trust
may invest up to 20% of its Managed Assets as measured at the time of investment in non-convertible debt securities, including corporate
debt obligations and debt securities that are rated non-investment grade (that is, rated Ba1 or lower by Moody&#8217;s Investors Service,&#160;Inc.
(&#8220;Moody&#8217;s&#8221;), BB+ or lower by Standard&#160;&#38; Poor&#8217;s Ratings Group (&#8220;S&#38;P&#8221;), or BB+ by Fitch,&#160;Inc.
(&#8220;Fitch&#8221;) or comparably rated by another nationally recognized statistical rating organization (&#8220;NRSRO&#8221;), or,
if unrated, determined by the Investment Adviser to be of comparable credit quality) and not including convertible securities. The Trust
may invest up to 15% of its Managed Assets in non-convertible debt securities that are, at the time of investment, rated Caa1 or lower
by Moody&#8217;s and CCC+ or lower by S&#38;P or Fitch, or comparably rated by another nationally recognized statistical rating organization,
or, if unrated, determined by the Investment Adviser to be of comparable credit quality. Such securities are subject to a very high credit
risk. The Trust&#8217;s investments in non-investment grade investments and those deemed to be of similar quality are considered speculative
with respect to the issuer&#8217;s capacity to pay interest and repay principal and are commonly referred to as &#8220;junk&#8221; or
&#8220;high yield&#8221; securities.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest in derivatives, including but not limited to options,
futures, options on futures, forwards, swaps (including credit default, index, basis, total return, volatility and currency swaps), options
on swaps and other derivatives. Initially, the Trust intends to employ a strategy of writing (selling) covered call options on a portion
of the common stocks in its portfolio, writing (selling) put options on a portion of the common stocks in its portfolio and, to a lesser
extent, writing (selling) covered call and writing (selling) put options on indices of securities and sectors of securities generally
within the healthcare industry. This option strategy is intended to</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">i</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">generate current income from option premiums as a means to enhance distributions
payable to the Trust&#8217;s Shareholders and will be limited to 30% of the Trust&#8217;s Managed Assets. These option strategies are
not always profitable. The sale of a covered call option exposes the Trust during the term of the option to possible loss of opportunity
to realize appreciation in the market price of the underlying security or to possible loss due to continued holding of a security that
might otherwise have been sold to protect against depreciation in the market price of the security. Therefore, the Investment Adviser
may choose to decrease its use of the option writing strategy to the extent that it may negatively impact the Trust. Other than the Trust&#8217;s
option strategy and use of derivatives for hedging purposes, the Trust may invest up to 10% of its Managed Assets in derivatives.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest up to 10% of its Managed Assets in restricted securities,
including private investments in public equity (&#8220;PIPEs&#8221;) and venture capital investments.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest up to 20% of its Managed Assets in real estate investment
trusts that derive their income from the ownership, leasing, or financing of properties in the healthcare sector (&#8220;Healthcare REITs&#8221;).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may also invest in equity-linked notes, exchange-traded funds
and special purpose acquisition companies (&#8220;SPACs&#8221;).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may from time-to-time lend its portfolio securities. In addition,
the Trust may enter into when-issued and delayed delivery transactions, forward foreign currency contracts and repurchase agreements.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s investment adviser is Tekla Capital Management LLC (the
&#8220;Investment Adviser&#8221;).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">This Statement of Additional Information (&#8220;SAI&#8221;) is not a
prospectus, but should be read in conjunction with the prospectus for the Trust dated December 6, 2022 (the &#8220;Prospectus&#8221;),
and as it may be supplemented. This SAI does not include all information that a prospective investor should consider before purchasing
shares of beneficial interest (&#8220;Shares&#8221;) of the Trust, and investors should obtain and read the Prospectus prior to purchasing
Shares. A copy of the Prospectus may be obtained without charge, by calling the Investment Adviser at (617) 772-8500. This SAI incorporates
by reference the entire Prospectus.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s annual report may be obtained upon request by calling
(617) 772-8500.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Prospectus and this SAI omit certain of the information contained
in the Trust&#8217;s registration statement filed with the Securities and Exchange Commission (&#8220;SEC&#8221; or &#8220;Commission&#8221;).
Information about the Trust can be reviewed on the Commission&#8217;s Internet site at <span style="text-decoration:underline">www.sec.gov</span>.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">ii</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>TABLE OF CONTENTS</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="width:87%">&#160;</td>
    <td style="width:13%"><strong>PAGE</strong></td></tr>
  <tr style="vertical-align:bottom">
    <td>Additional Information About Investments,&#160;Investment Techniques and Risks</td>
    <td style="text-align:right">1</td></tr>
  <tr style="vertical-align:bottom">
    <td>Investment Restrictions</td>
    <td style="text-align:right">19</td></tr>
  <tr style="vertical-align:bottom">
    <td>Trustees and Officers</td>
    <td style="text-align:right">20</td></tr>
  <tr style="vertical-align:bottom">
    <td>The Trust</td>
    <td style="text-align:right">28</td></tr>
  <tr style="vertical-align:bottom">
    <td>Investment Adviser and Investment Advisory Agreement</td>
    <td style="text-align:right">31</td></tr>
  <tr style="vertical-align:bottom">
    <td>Proxy Voting Policy and Procedures</td>
    <td style="text-align:right">33</td></tr>
  <tr style="vertical-align:bottom">
    <td>Code of Ethics</td>
    <td style="text-align:right">34</td></tr>
  <tr style="vertical-align:bottom">
    <td>Net Asset Value</td>
    <td style="text-align:right">34</td></tr>
  <tr style="vertical-align:bottom">
    <td>Portfolio Transactions and Brokerage</td>
    <td style="text-align:right">36</td></tr>
  <tr style="vertical-align:bottom">
    <td>Tax Matters</td>
    <td style="text-align:right">37</td></tr>
  <tr style="vertical-align:bottom">
    <td>Administrator, Custodian, Transfer Agent, Dividend Disbursing Agent and Registrar</td>
    <td style="text-align:right">44</td></tr>
  <tr style="vertical-align:bottom">
    <td>Incorporation By Reference</td>
    <td style="text-align:right">44</td></tr>
  <tr style="vertical-align:bottom">
    <td>Financial Statements</td>
    <td style="text-align:right">45</td></tr>
  <tr style="vertical-align:bottom">
    <td>Appendix A &#8212; Proxy Voting Policies and Procedures</td>
    <td style="text-align:right">A-1</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">iii</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>ADDITIONAL
INFORMATION ABOUT INVESTMENTS,&#160;<br />INVESTMENT TECHNIQUES AND RISKS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Some of the different types of securities in which the Trust may invest,
subject to its investment objective, policies and restrictions, are described in the Prospectus under &#8220;Investment Objectives and
Policies&#8221; and &#8220;Risk Factors.&#8221; Additional information concerning certain of the Trust&#8217;s investments, investment
techniques and investment restrictions is set forth below. The Trust may utilize the following investment practices:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Healthcare Companies</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust expects to invest in U.S. and non-U.S. equity and debt securities
of companies in the healthcare industry, including, but not limited to, biotechnology, pharmaceutical, medical devices and healthcare
services companies. These investments are designed to take advantage of recent developments in certain healthcare sectors. For example,
demographic changes are driving an increase in medical products due to the high growth rate of the population of Americans age 65 and
older. Recent developments in the pharmaceutical, biotechnology, and medical technology industries have produced a series of products
that will extend or improve the quality of patients&#8217; lives, especially in the areas of oncology, infectious disease, inflammation
and orphan diseases. The Investment Adviser also believes that the following trends have investment potential: (i)&#160;biopharmaceuticals,
including products for novel targets; (ii)&#160;treatments for orphan and ultra-orphan (<i>i.e.</i>, rare and extremely rare) diseases,
including gene therapy; (iii)&#160;specialty pharmaceuticals; (iv)&#160;generic pharmaceuticals; (v)&#160;novel medical devices; (vi)&#160;life
sciences tools and diagnostics; and (vii)&#160;products that will benefit from changes in the regulatory landscape.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Healthcare Companies provide multiple diverse investment opportunities
in a number of subsectors including, but not limited to, the following: (i)&#160;pharmaceuticals, which includes large and small pharmaceutical,
specialty pharmaceutical and generic drug companies; (ii)&#160;biotechnology, which includes companies engaged in research into, and development
of, biological substances for the purposes of drug discovery and diagnostic development; (iii)&#160;managed care, which is a segment that
represents HMOs and insurers; (iv)&#160;life sciences and tools, which includes research organizations that help design and run clinical
trials, as well as life sciences research tools companies that offer instruments, reagents and services to scientists in academic, BioPharma
and applied market laboratories; (v)&#160;healthcare technology, which include companies involved in automating various processes for
hospitals and HMOs; (vi)&#160;healthcare services, which includes pharmacy benefits managers, alternative site care providers and laboratory
services companies; (vii)&#160;healthcare supplies, which include companies that provide products such as tubes and bandages used every
day in healthcare facilities and laboratories; (viii)&#160;healthcare facilities, which include hospitals and other brick and mortar facilities
used to treat patients; (ix)&#160;healthcare equipment, which include medical diagnostic and device companies; (x)&#160;healthcare distributors,
which distribute drugs and products to patients, hospitals and other facilities; and (xi)&#160;healthcare REITs, which are REITs that
derive their income from the ownership, leasing, or financing of properties in the healthcare sector.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Equity Securities</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust expects to invest 60-90% of its Managed Assets in equity securities,
which may include common stock, preferred stock and warrants or other rights to acquire common or preferred stock. Common stock represents
shares of a corporation or other entity that entitle the holder to a pro rata share of the profits of the entity, if any, without preference
over any other Shareholder or class of Shareholders, including holders of the entity&#8217;s preferred stock and other senior equity.
Common stock usually carries with it the right to vote and frequently an exclusive right to do so. The Trust may invest in preferred stocks,
which represent shares of a corporation or other entity that pay dividends at a specified rate and have precedence over common stock in
the payment of dividends. If the corporation or other entity is liquidated or declares bankruptcy, the claims of owners of preferred stock
will have precedence over the claims of owners of common stock, but not over the claims of owners of bonds. Some preferred stock dividends
are non-cumulative, but some are &#8220;cumulative,&#8221; meaning that they require that all or a portion of prior unpaid dividends be
paid to preferred shareholders before any dividends are paid to common shareholders. Certain preferred stock dividends are &#8220;participating&#8221;
and include an entitlement to a dividend exceeding the specified dividend rate in certain cases. Investments in preferred stocks carry
many of the same risks as investments in common stocks and debt securities.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Debt Securities</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest up to 20% of its Managed Assets as measured at the
time of investment in non-convertible debt securities, including corporate debt obligations and debt securities that are rated non-investment
grade (that is, rated Ba1 or lower by Moody&#8217;s, BB+ or lower by S&#38;P, or BB+ by Fitch or comparably rated by another NRSRO, or,
if unrated, determined by the Investment Adviser to be of comparable credit quality) and not including convertible securities. The Trust
may invest up to 15% of its Managed Assets in</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">1</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">non-convertible debt securities that are, at the time of investment, rated
Caa1 or lower by Moody&#8217;s and CCC+ or lower by S&#38;P or Fitch, or comparably rated by another nationally recognized statistical
rating organization, or, if unrated, determined by the Investment Adviser to be of comparable credit quality. Such securities are subject
to a very high credit risk. To the extent the Trust invests in the following types of debt securities, its net asset value may change
as the general levels of interest rates fluctuate. When interest rates decline, the value of debt securities can be expected to rise.
Conversely, when interest rates rise, the value of debt securities can be expected to decline. The Trust&#8217;s investments in debt securities
with longer terms to maturity are subject to greater volatility than the Trust&#8217;s shorter-term obligations. Debt securities may have
all types of interest rate payment and reset terms, including fixed rate, adjustable rate, zero coupon, contingent, deferred, payment
in kind and auction rate features.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Corporate debt obligations include bonds, notes, debentures and other
obligations of corporations to pay interest and repay principal. Corporate debt obligations are subject to the risk of an issuer&#8217;s
inability to meet principal and interest payments on the obligations and may also be subject to price volatility due to such factors as
market interest rates, market perception of the creditworthiness of the issuer and general market liquidity.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Corporate debt obligations rated BBB or Baa are considered medium grade
obligations with speculative characteristics, and adverse economic conditions or changing circumstances may weaken their issuers&#8217;
capacity to pay interest and repay principal. Medium to lower rated and comparable non-rated securities tend to offer higher yields than
higher rated securities with the same maturities because the historical financial condition of the issuers of such securities may not
have been as strong as that of other issuers. The price of corporate debt obligations will generally fluctuate in response to fluctuations
in supply and demand for similarly rated securities. In addition, the price of corporate debt obligations will generally fluctuate in
response to interest rate levels. Fluctuations in the prices of portfolio securities subsequent to their acquisition will not affect cash
income from such securities but will be reflected in the Trust&#8217;s net asset value (&#8220;NAV&#8221;).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Because medium to lower rated securities generally involve greater risks
of loss of income and principal than higher rated securities, investors should consider carefully the relative risks associated with investment
in securities which carry medium to lower ratings and in comparable unrated securities. In addition to the risk of default, there are
the related costs of recovery on defaulted issues. The Investment Adviser will attempt to reduce these risks through portfolio diversification
and by analysis of each issuer and its ability to make timely payments of income and principal, as well as broad economic trends and corporate
developments.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest in obligations issued or guaranteed by U.S. or foreign
banks. Bank obligations, including without limitation, time deposits, bankers&#8217; acceptances and certificates of deposit, which may
be general obligations of the parent bank or may be limited to the issuing branch by the terms of the specific obligations or by government
regulation. Banks are subject to extensive but different governmental regulations which may limit both the amount and types of loans which
may be made and interest rates which may be charged. In addition, the profitability of the banking industry is largely dependent upon
the availability and cost of funds for the purpose of financing lending operations under prevailing money market conditions. General economic
conditions as well as exposure to credit losses arising from possible financial difficulties of borrowers play an important part in the
operation of this industry.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Certificates of deposit are certificates evidencing the obligation of
a bank to repay funds deposited with it for a specified period of time at a specified rate. Certificates of deposit are negotiable instruments
and are similar to saving deposits but have a definite maturity and are evidenced by a certificate instead of a passbook entry. Banks
are required to keep reserves against all certificates of deposit. Fixed time deposits are bank obligations payable at a stated maturity
date and bearing interest at a fixed rate. Fixed time deposits may be withdrawn on demand by the investor, but may be subject to early
withdrawal penalties which vary depending upon market conditions and the remaining maturity of the obligation. The Trust may invest in
deposits in U.S. and European banks satisfying the standards set forth above.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Foreign Securities</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust will invest in securities of foreign issuers, including securities
quoted or denominated in a currency other than U.S. dollars. Investments in foreign securities may offer potential benefits not available
from investments solely in U.S. dollar-denominated or quoted securities of domestic issuers. Such benefits may include the opportunity
to invest in foreign issuers that appear, in the opinion of the Investment Adviser, to offer the potential for better long term growth
of capital and income than investments in U.S. securities, the opportunity to invest in foreign countries with economic policies or business
cycles different from those of the United States and the opportunity to reduce fluctuations in portfolio value by taking advantage of
foreign securities markets that do not necessarily move in a manner parallel to U.S. markets. Investing in the securities of foreign issuers
also involves, however, certain special risks, including those discussed in the Prospectus and those set forth below, which are not typically
associated with investing in U.S. dollar-</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">2</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">denominated securities or quoted securities of U.S. issuers. Many of these
risks are more pronounced for investments in emerging economies.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">With respect to investments in certain foreign countries, there exist
certain economic, political and social risks, including the risk of adverse political developments, nationalization, military unrest,
social instability, war and terrorism, confiscation without fair compensation, expropriation or confiscatory taxation, limitations on
the movement of funds and other assets between different countries, or diplomatic developments, any of which could adversely affect the
Trust&#8217;s investments in those countries. Governments in certain foreign countries continue to participate to a significant degree,
through ownership interest or regulation, in their respective economies. Action by these governments could have a significant effect on
market prices of securities and dividend payments.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Many countries throughout the world are dependent on a healthy U.S. economy
and are adversely affected when the U.S. economy weakens or its markets decline. Additionally, many foreign country economies are heavily
dependent on international trade and are adversely affected by protective trade barriers and economic conditions of their trading partners.
Protectionist trade legislation enacted by those trading partners could have a significant adverse effect on the securities markets of
those countries. Individual foreign economies may differ favorably or unfavorably from the U.S. economy in such respects as growth of
gross national product, rate of inflation, capital reinvestment, resource self-sufficiency and balance of payments position.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Economic sanctions or other similar measures may be, and have been, imposed
against certain countries, organizations, companies, entities and/or individuals. Economic sanctions and other similar governmental actions
or developments could, among other things, effectively restrict or eliminate the Trust&#8217;s ability to purchase or sell certain foreign
securities or groups of foreign securities, and thus may make the Trust&#8217;s investments in such securities less liquid or more difficult
to value. In addition, as a result of economic sanctions and other similar governmental actions or developments, the Trust may be forced
to sell or otherwise dispose of foreign investments at inopportune times or prices. The type and severity of sanctions and other similar
measures, including counter sanctions and other retaliatory actions, that have been impacted against Russia and other countries and that
may further be imposed could vary broadly in scope, and their impact is difficult to accurately predict. For example, the imposition of
sanctions and other similar measures likely would, among other things, cause a decline in the value and/or liquidity of securities issued
by the sanctioned country or companies located in or economically tied to the sanctioned country and increase market volatility and disruption
in the sanctioned country and throughout the world. Sanctions and other similar measures could significantly delay or prevent the settlement
of securities transactions or their valuation, and significantly impact the Trust&#8217;s liquidity and performance. Sanctions and other
similar measures may be in place for a substantial period of time and enacted with limited advanced notice.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Investments in foreign securities often involve currencies of foreign
countries. Accordingly, the Trust may be affected favorably or unfavorably by changes in currency rates and in exchange control regulations
and may incur costs in connection with conversions between various currencies. The Trust may be subject to currency exposure independent
of its securities positions. To the extent that the Trust is fully invested in foreign securities while also maintaining net currency
positions, it may be exposed to greater combined risk. Currency exchange rates may fluctuate significantly over short periods of time.
They generally are determined by the forces of supply and demand in the foreign exchange markets and the relative merits of investments
in different countries, actual or anticipated changes in interest rates and other complex factors, as seen from an international perspective.
Currency exchange rates also can be affected unpredictably by intervention (or the failure to intervene) by U.S. or foreign governments
or central banks or by currency controls or political developments in the United States or abroad.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Because foreign issuers generally are not subject to uniform accounting,
auditing and financial reporting standards, practices and requirements comparable to those applicable to U.S. companies, there may be
less publicly available information about a foreign company than about a U.S. company. Volume and liquidity in most foreign securities
markets are less than in the United States markets and securities of many foreign companies are less liquid and more volatile than securities
of comparable U.S. companies. The securities of foreign issuers may be listed on foreign securities exchanges or traded in foreign over-the-counter
(&#8220;OTC&#8221;) markets. Fixed commissions on foreign securities exchanges are generally higher than negotiated commissions on U.S.
exchanges, although the Trust endeavors to achieve the most favorable net results on its portfolio transactions. There is generally less
government supervision and regulation of foreign securities markets and exchanges, brokers, dealers and listed and unlisted companies
than in the United States, and the legal remedies for investors may be more limited than the remedies available in the United States.
For example, there may be no comparable provisions under certain foreign laws to insider trading and similar investor protections that
apply with respect to securities transactions consummated in the United States. Mail service between the United States and foreign countries
may be slower or less reliable than within the United States, thus increasing the risk of delayed settlement of portfolio transactions
or loss of certificates for portfolio securities.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">3</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Foreign markets also have different clearance and settlement procedures,
and in certain markets there have been times when settlements have been unable to keep pace with the volume of securities transactions,
making it difficult to conduct such transactions. Such delays in settlement could result in temporary periods when some of the Trust&#8217;s
assets are uninvested and no return is earned on such assets. The inability of the Trust to make intended security purchases due to settlement
problems could cause the Trust to miss attractive investment opportunities. Inability to dispose of portfolio securities due to settlement
problems could result either in losses to the Trust due to subsequent declines in value of the portfolio securities or, if the Trust has
entered into a contract to sell the securities, in possible liability to the purchaser.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest in foreign securities which take the form of sponsored
and unsponsored American depositary receipts (&#8220;ADRs&#8221;), global depositary receipts (&#8220;GDRs&#8221;), European depositary
receipts (&#8220;EDRs&#8221;) or other similar instruments representing securities of foreign issuers (together, &#8220;Depositary Receipts&#8221;).
ADRs represent the right to receive securities of foreign issuers deposited in a domestic bank or a correspondent bank. ADRs are traded
on domestic exchanges or in the U.S. OTC market and, generally, are in registered form. EDRs and GDRs are receipts evidencing an arrangement
with a non-U.S. bank similar to that for ADRs and are designed for use in the non-U.S. securities markets. EDRs and GDRs are not necessarily
quoted in the same currency as the underlying security. To the extent the Trust acquires Depositary Receipts through banks which do not
have a contractual relationship with the foreign issuer of the security underlying the Depositary Receipts to issue and service such unsponsored
Depositary Receipts, there may be an increased possibility that the Trust would not become aware of and be able to respond to corporate
actions such as stock splits or rights offerings involving the foreign issuer in a timely manner. In addition, the lack of information
may result in inefficiencies in the valuation of such instruments. Investment in Depositary Receipts does not eliminate all the risks
inherent in investing in securities of non-U.S. issuers. The market value of Depositary Receipts is dependent upon the market value of
the underlying securities and fluctuations in the relative value of the currencies in which the Depositary Receipts and the underlying
securities are quoted. However, by investing in Depositary Receipts, such as ADRs, which are quoted in U.S. dollars, the Trust may avoid
currency risks during the settlement period for purchases and sales.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">As described more fully below, the Trust may invest in countries with
emerging economies or securities markets. Political and economic structures in many of such countries may be undergoing significant evolution
and rapid development, and such countries may lack the social, political and economic stability characteristic of more developed countries.
Certain of such countries have in the past failed to recognize private property rights and have at times nationalized or expropriated
the assets of private companies. As a result, the risks described above, including the risks of nationalization or expropriation of assets,
may be heightened.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Investing in Europe. </i>The Trust may operate in euros and/ or may
hold euros and/or euro-denominated bonds and other obligations. The euro requires participation of multiple sovereign states forming the
Euro zone and is therefore sensitive to the credit, general economic and political position of each such state, including each state&#8217;s
actual and intended ongoing engagement with and/or support for the other sovereign states then forming the European Union, in particular
those within the Euro zone. Changes in these factors might materially adversely impact the value of securities that the Trust has invested
in.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">European countries can be significantly affected by the tight fiscal and
monetary controls that the European Economic and Monetary Union (&#8220;EMU&#8221;) imposes for membership. Europe&#8217;s economies are
diverse, its governments are decentralized, and its cultures vary widely. Several EU countries, including Greece,&#160;Ireland,&#160;Italy,
Spain and Portugal have faced budget issues, some of which may have negative long-term effects for the economies of those countries and
other EU countries. There is continued concern about national-level support for the euro and the accompanying coordination of fiscal and
wage policy among EMU member countries. Member countries are required to maintain tight control over inflation, public debt, and budget
deficit to qualify for membership in the EMU. These requirements can severely limit the ability of EMU member countries to implement monetary
policy to address regional economic conditions.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Investing in Canada. </i>The Trust may invest in issuers located in
Canada or that have significant exposure to the Canadian economy. The Canadian market is relatively concentrated in issuers involved in
the production and distribution of natural resources, and therefore the Canadian economy is very dependent on the supply and demand for
natural resources. There is a risk that any changes in these sectors could have an adverse impact on the Canadian economy. The Canadian
economy is dependent on the economy of the United States as the United States is Canada&#8217;s largest trading partner and foreign investor.
Reduction in spending on Canadian products and services or changes in the U.S. economy may cause an impact in the Canadian economy. Past
periodic demands by the Province of Quebec for sovereignty have also significantly affected equity valuations and foreign currency movements
in the Canadian market.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Investing in Emerging Countries. </i>The securities markets of emerging
countries (&#8220;Emerging Markets&#8221;) are less liquid and subject to greater price volatility, and have a smaller market capitalization,
than the U.S. securities markets. In certain countries, there may be</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">4</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">fewer publicly traded securities and the market may be dominated by a
few issues or sectors. Issuers and securities markets in such countries are not subject to as extensive and frequent accounting, financial
and other reporting requirements or as comprehensive government regulations as are issuers and securities markets in the U.S. In particular,
the assets and profits appearing on the financial statements of Emerging Markets issuers may not reflect their financial position or results
of operations in the same manner as financial statements for U.S. issuers. Substantially less information may be publicly available about
Emerging Markets issuers than is available about issuers in the United States.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Emerging Markets are typically marked by a high concentration of market
capitalization and trading volume in a small number of issuers representing a limited number of industries, as well as a high concentration
of ownership of such securities by a limited number of investors. The markets for securities in certain Emerging Markets are in the earliest
stages of their development. Even the markets for relatively widely traded securities in Emerging Markets may not be able to absorb, without
price disruptions, a significant increase in trading volume or trades of a size customarily undertaken by institutional investors in the
securities markets of developed countries. The limited size of many of these securities markets can cause prices to be erratic for reasons
apart from factors that affect the soundness and competitiveness of the securities issuers. For example, prices may be unduly influenced
by traders who control large positions in these markets. Additionally, market making and arbitrage activities are generally less extensive
in such markets, which may contribute to increased volatility and reduced liquidity of such markets. The limited liquidity of Emerging
Markets securities may also affect the Trust&#8217;s ability to accurately value its portfolio securities or to acquire or dispose of
securities at the price and time it wishes to do so or in order to meet redemption requests.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">With respect to investments in certain Emerging Markets, antiquated or
poorly established legal systems may have an adverse impact on the Trust. For example, while the potential liability of a shareholder
of a U.S. corporation with respect to acts of the corporation is generally limited to the amount of the shareholder&#8217;s investment,
the notion of limited liability is less clear in certain emerging market countries. Similarly, the rights of investors in emerging market
companies may be more limited than those of shareholders of U.S. corporations.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Transaction costs, including brokerage commissions or dealer mark-ups,
in Emerging Markets may be higher than in the United States and other developed securities markets. In addition, existing laws and regulations
are often inconsistently applied. As legal systems in Emerging Markets develop, foreign investors may be adversely affected by new or
amended laws and regulations. In circumstances where adequate laws exist, it may not be possible to obtain swift and equitable enforcement
of the law.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Custodial and/or settlement systems in Emerging Markets may not be fully
developed. To the extent the Trust invests in emerging markets, Trust assets that are traded in such markets and which have been entrusted
to such sub-custodians in those markets may be exposed to risks for which the sub-custodian will have no liability.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Foreign investment in Emerging Markets is restricted or controlled to
varying degrees. These restrictions may limit the Trust&#8217;s investment in Emerging Markets and may increase the expenses of the Trust.
Certain Emerging Markets require governmental approval prior to investments by foreign persons or limit investment by foreign persons
to only a specified percentage of an issuer&#8217;s outstanding securities or a specific class of securities which may have less advantageous
terms (including price) than securities of the company available for purchase by nationals. In addition, the repatriation of both investment
income and capital from Emerging Markets may be subject to restrictions which require governmental consents or prohibit repatriation entirely
for a period of time. Even where there is no outright restriction on repatriation of capital, the mechanics of repatriation may affect
certain aspects of the operation of the Trust. The Trust may be required to establish special custodial or other arrangements before investing
in certain Emerging Markets.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Emerging Markets may be subject to a substantially greater degree of economic,
political and social instability and disruption than is the case in the United States, Japan and most Western European countries. This
instability may result from, among other things, the following: (i)&#160;authoritarian governments or military involvement in political
and economic decision making, including changes or attempted changes in governments through extra-constitutional means; (ii)&#160;popular
unrest associated with demands for improved political, economic or social conditions; (iii)&#160;internal insurgencies; (iv)&#160;hostile
relations with neighboring countries; (v)&#160;ethnic, religious and racial disaffection or conflict; and (vi)&#160;the absence of developed
legal structures governing foreign private investments and private property. Such economic, political and social instability could disrupt
the principal financial markets in which the Trust may invest and adversely affect the value of the Trust&#8217;s assets. The Trust&#8217;s
investments can also be adversely affected by any increase in taxes or by political, economic or diplomatic developments.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may seek investment opportunities within former &#8220;Eastern
bloc&#8221; countries. Most of these countries had a centrally planned, socialist economy for a substantial period of time. The governments
of many of these countries have more recently been implementing</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">5</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">reforms directed at political and economic liberalization, including efforts
to decentralize the economic decision-making process and move towards a market economy. However, business entities in many of these countries
do not have an extended history of operating in a market-oriented economy, and the ultimate impact of these countries&#8217; attempts
to move toward more market-oriented economies is currently unclear. In addition, any change in the leadership or policies of these countries
may halt the expansion of or reverse the liberalization of foreign investment policies now occurring and adversely affect existing investment
opportunities.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The economies of Emerging Markets may differ unfavorably from the U.S.
economy in such respects as growth of gross domestic product, rate of inflation, capital reinvestment, resources, self-sufficiency and
balance of payments. Many Emerging Markets have experienced in the past, and continue to experience, high rates of inflation. In certain
countries inflation has at times accelerated rapidly to hyperinflationary levels, creating a negative interest rate environment and sharply
eroding the value of outstanding financial assets in those countries. Other Emerging Markets, on the other hand, have recently experienced
deflationary pressures and are in economic recessions. The economies of many Emerging Markets are heavily dependent upon international
trade and are accordingly affected by protective trade barriers and the economic conditions of their trading partners. In addition, the
economies of some Emerging Markets are vulnerable to weakness in world prices for their commodity exports.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s income and, in some cases, capital gains from foreign
stocks and securities will be subject to applicable taxation in certain of the countries in which it invests, and treaties between the
U.S. and such countries may not be available in some cases to reduce the otherwise applicable tax rates.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">From time to time, certain of the companies in which the Trust may invest
may operate in, or have dealings with, countries subject to sanctions or embargos imposed by the U.S. government and the United Nations
and/or countries identified by the U.S. government as state sponsors of terrorism. A company may suffer damage to its reputation if it
is identified as a company which operates in, or has dealings with, countries subject to sanctions or embargoes imposed by the U.S. government
as state sponsors of terrorism. As an investor in such companies, the Trust would be indirectly subject to those risks.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>REITs</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest up to 20% of its Managed Assets in Healthcare REITs.
The value of a REIT is affected by changes in the value of the properties owned by the REIT or securing mortgage loans held by the REIT.
REITs are dependent upon the ability of the REITs&#8217; managers, and are subject to heavy cash flow dependency, default by borrowers
and the qualification of the REITs under applicable regulatory requirements for favorable income tax treatment. REITs are also subject
to risks generally associated with investments in real estate including possible declines in the value of real estate, general and local
economic conditions, environmental problems and changes in interest rates. To the extent that assets underlying a REIT are concentrated
geographically, by property type or in certain other respects, these risks may be heightened. The Trust will indirectly bear its proportionate
share of any expenses, including management fees, paid by a REIT in which it invests. Healthcare REITs are REITs that derive their income
from the ownership, leasing, or financing of properties in the healthcare sector.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Derivatives</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may use various types of financial instruments, some of which
are derivatives, to attempt to manage the risk of the Trust&#8217;s investments or for investment purposes (<i>e.g.</i>, as a substitute
for investing in securities). These financial instruments include, among others, options, futures, options on futures, forwards, swaps
(including credit default, index, basis, total return, volatility and currency swaps), and options on swaps. Positions in these financial
instruments may expose the Trust to an obligation to another party. The Trust will not enter into any such transaction unless it owns
(1)&#160;an offsetting (&#8220;covered&#8221;) position in securities, currencies or other options, futures contracts or forward contracts
or (2)&#160;cash or liquid assets with a value, marked-to-market daily, sufficient to cover their obligations to the extent not covered
as provided in (1)&#160;above. The Trust will comply with Commission guidelines regarding cover for these instruments and will, if the
guidelines so require, designate the prescribed amount of cash or liquid assets as segregated.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Assets used as cover or held as segregated cannot be sold while the position
in the corresponding financial instrument is open unless they are replaced with other appropriate assets.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust intends to employ a strategy of writing (selling) covered call
options on a portion of the common stocks in its portfolio, writing (selling) put options on a portion of the common stocks in its portfolio
and, to a lesser extent, writing (selling) covered call and writing (selling) put options on indices of securities and sectors of securities
generally within the healthcare industry. This option</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">6</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">strategy is intended to generate current income from option premiums as
a means to enhance distributions payable to the Trust&#8217;s Shareholders and will be limited to 30% of the Trust&#8217;s Managed Assets.
These option strategies are not always profitable. The sale of a covered call option exposes the Trust during the term of the option to
possible loss of opportunity to realize appreciation in the market price of the underlying security or to possible loss due to continued
holding of a security that might otherwise have been sold to protect against depreciation in the market price of the security. To the
extent the Trust writes a covered put option, the Trust has assumed the obligation during the option period to purchase the security or
securities from the put buyer at the option&#8217;s exercise price if the put buyer exercises its option, regardless of whether the value
of the underlying investment falls below the exercise price. This means that a Trust that writes a put option may be required make payment
for such investment at the exercise price. This may result in losses to the Trust and may result in the Trust holding securities for some
period of time when it is disadvantageous to do so. Therefore, the Investment Adviser may choose to decrease its use of the option writing
strategy to the extent that it may negatively impact the Trust. Other than the Trust&#8217;s option strategy and use of derivatives for
hedging purposes, the Trust may invest up to 10% of its Managed Assets in derivatives. Derivative instruments can be illiquid, may disproportionately
increase losses, and may have a potentially large adverse impact on Trust performance.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Derivatives markets have been subject to increased regulation over the
past several years, which may continue, and consequently, may make derivatives trading more costly, may limit the availability of and
reduce the liquidity of derivatives or may otherwise adversely affect the value or performance of derivatives. Such potential adverse
future developments could increase the risks reduce the effectiveness of the Trust&#8217;s derivative transactions, and cause the Trust
to lose value. For instance, the Commission has adopted new regulations related to a registered investment company&#8217;s use of derivatives
and related instruments. These regulations may significantly impact the Trust&#8217;s ability to invest in derivatives and other instruments,
limit the Trust&#8217;s ability to employ certain strategies that use derivatives and/or adversely affect the Trust&#8217;s performance,
efficiency in implementing its strategy, liquidity and/or ability to pursue its investment objectives.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Initial Public Offerings</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest a portion of its assets in shares of IPOs, if consistent
with the Trust&#8217;s investment objective and policies. IPOs may have a magnified impact on the performance of a fund with a small asset
base. The impact of IPOs on a fund&#8217;s performance likely will decrease as such fund&#8217;s asset size increases, which could reduce
such fund&#8217;s returns. IPOs may not be consistently available to the Trust for investing. IPO shares frequently are volatile in price
due to the absence of a prior public market, the small number of shares available for trading and limited information about the issuer.
Therefore, the Trust may hold IPO shares for a very short period of time. This may increase turnover and may lead to increased expenses,
such as commissions and transaction costs all of which will be borne indirectly by the holders of Shares. In addition,&#160;IPO shares
can experience an immediate drop in value if the demand for the securities does not continue to support the offering price.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Convertible Securities</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest up to 30% of its Managed Assets in convertible securities.
Convertible securities are bonds, debentures, notes, preferred stocks or other securities that may be converted into or exchanged for
a specified amount of common stock (or other securities) of the same or different issuer within a particular period of time at a specified
price or formula. A convertible security entitles the holder to receive interest that is generally paid or accrued on debt or a dividend
that is paid or accrued on preferred stock until the convertible security matures or is redeemed, converted or exchanged. Convertible
securities have unique investment characteristics, in that they generally (i)&#160;have higher yields than common stocks, but lower yields
than comparable non-convertible securities, (ii)&#160;are less subject to fluctuation in value than the underlying common stock due to
their fixed income characteristics and (iii)&#160;provide the potential for capital appreciation if the market price of the underlying
common stock increases.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The value of a convertible security is a function of its &#8220;investment
value&#8221; (determined by its yield in comparison with the yields of other securities of comparable maturity and quality that do not
have a conversion privilege) and its conversion value (the security&#8217;s worth, at market value, if converted into the underlying common
stock). The investment value of a convertible security is influenced by changes in interest rates, with investment value normally declining
as interest rates increase and increasing as interest rates decline. The credit standing of the issuer and other factors may also have
an effect on the convertible security&#8217;s investment value. The conversion value of a convertible security is determined by the market
price of the underlying common stock. If the conversion value is low relative to the investment value, the price of the convertible security
is governed principally by its investment value. To the extent the market price of the underlying common stock approaches or exceeds the
conversion price, the price of the convertible security will be increasingly influenced by its conversion value. A convertible security
generally will sell at a premium over its conversion value by the extent to which investors place value on the right to acquire the underlying
common stock while holding a fixed income security.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">7</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A convertible security may be subject to redemption at the option of the
issuer at a price established in the convertible security&#8217;s governing instrument. If a convertible security held by the Trust is
called for redemption, the Trust will be required to convert the security into the underlying common stock, sell it to a third party or
permit the issuer to redeem the security. Any of these actions could have an adverse effect on the Trust&#8217;s ability to achieve its
investment objective, which, in turn, could result in losses to the Trust. To the extent that the Trust holds a convertible security,
or a security that is otherwise converted or exchanged for common stock (e.g., as a result of a restructuring), the Trust may, consistent
with its investment objective, hold such common stock in its portfolio.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">In evaluating a convertible security, the Investment Adviser will give
primary emphasis to the attractiveness of the underlying common stock. Convertible debt securities are equity investments for purposes
of the Trust&#8217;s investment policies.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Restricted Securities</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest up to 10% of its Managed Assets in U.S. securities
and other U.S. financial instruments that are not registered or that are offered in an exempt non-public offering (&#8220;Restricted Securities&#8221;)
under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), including securities eligible for resale to &#8220;qualified
institutional buyers&#8221; pursuant to Rule&#160;144A under the Securities Act, PIPEs and venture capital investments.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The purchase price and subsequent valuation of Restricted Securities may
reflect a discount from the price at which such securities trade when they are not restricted, because the restriction makes them less
liquid. The amount of the discount from the prevailing market price is expected to vary depending upon the type of security, the character
of the issuer, the party who will bear the expenses of registering the Restricted Securities and prevailing supply and demand conditions.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Pooled Investment Vehicles</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest in securities of pooled investment vehicles, including
other investment companies, ETFs and exchange-traded notes (&#8220;ETNs&#8221;). The Trust will indirectly bear its proportionate share
of any management fees and other expenses paid by pooled investment vehicles in which it invests, in addition to the management fees (and
other expenses) paid by the Trust. The Trust&#8217;s investments in pooled investment vehicles are subject to statutory limitations prescribed
by the Investment Company Act, including in certain circumstances a prohibition on the Trust acquiring more that 3% of the voting shares
of any other investment company, and a prohibition on investing more than 5% of the Trust&#8217;s total assets in securities of any one
investment company or more than 10% of its total assets in the securities of all investment companies. Many ETFs, however, have obtained
exemptive relief from the Commission to permit unaffiliated funds (such as the Trust) to invest in their shares beyond these statutory
limits, subject to certain conditions and pursuant to contractual arrangements between the ETFs and the investing funds. The Trust may
rely on these exemptive orders it invest in unaffiliated ETFs. Under an exemptive rule&#160;adopted by the Commission, the Trust may invest
in certain other investment companies and money market funds beyond the statutory limits described above.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may purchase shares of investment companies investing primarily
in foreign securities, including &#8220;country funds.&#8221; Country funds have portfolios consisting primarily of securities of issuers
located in specified foreign countries or regions.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">ETFs are pooled investment vehicles issuing shares which are traded like
traditional equity securities on a stock exchange. An ETF represents a portfolio of securities or other assets, which is often designed
to track a particular market segment or index. An investment in an ETF, like one in any pooled investment vehicle, carries the risks of
its underlying securities or other assets. An ETF may fail to accurately track the returns of the market segment or index that it is designed
to track, and the price of an ETF&#8217;s shares may fluctuate or lose money. In addition, because they, unlike other pooled investment
vehicles, are traded on an exchange, ETFs are subject to the following risks: (i)&#160;the market price of the ETF&#8217;s shares may
trade at a premium or discount to the ETF&#8217;s NAY; (ii)&#160;an active trading market for an ETF may not develop or be maintained;
and (iii)&#160;there is no assurance that the requirements of the exchange necessary to maintain the listing of the ETF will continue
to be met or remain unchanged. In the event substantial market or other disruptions affecting ETFs should occur in the future, the liquidity
and value of the Trust&#8217;s shares could also be substantially and adversely affected.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Options on Securities and Securities Indices</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Writing Covered Options. </i>The Trust may write (sell) covered call
and put options on any securities in which it may invest or any securities index consisting of securities in which it may invest. The
Trust may write such options on securities that are listed on</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">8</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">national domestic securities exchanges or foreign securities exchanges
or traded in the OTC market. A call option written by the Trust obligates the Trust to sell specified securities to the holder of the
option at a specified price if the option is exercised on or before the expiration date. Depending upon the type of call option, the purchaser
of a call option either (i)&#160;has the right to any appreciation in the value of the security over a fixed price (the &#8220;exercise
price&#8221;) on a certain date in the future (the &#8220;expiration date&#8221;) or (ii)&#160;has the right to any appreciation in the
value of the security over the exercise price at any time prior to the expiration of the option. If the purchaser does not exercise the
option, the Trust pays the purchaser the difference between the price of the security and the exercise price of the option. The premium,
the exercise price and the market value of the security determine the gain or loss realized by the Trust as the seller of the call option.
The Trust can also repurchase the call option prior to the expiration date, ending its obligation. In this case, the cost of entering
into closing purchase transactions will determine the gain or loss realized by the Trust. All call options written by the Trust are covered,
which means that the Trust will own the securities subject to the option as long as the option is outstanding or the Trust will use the
other methods described below. The Trust&#8217;s purpose in writing covered call options is to realize greater income than would be realized
on portfolio securities transactions alone. However, the Trust may forego the opportunity to profit from an increase in the market price
of the underlying security.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A put option written by the Trust would obligate the Trust to purchase
specified securities from the option holder at a specified price if, depending upon the type of put option, either (i)&#160;the option
is exercised at any time on or before the expiration date or (ii)&#160;the option is exercised on the expiration date. All put options
written by the Trust would be covered, which means that the Trust will segregate cash or liquid assets with a value at least equal to
the exercise price of the put option (less any margin on deposit) or will use the other methods described below. The purpose of writing
such options is to generate additional income for the Trust. However, in return for the option premium, the Trust accepts the risk that
it may be required to purchase the underlying securities at a price in excess of the securities&#8217; market value at the time of purchase.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">In the case of a call option, the option is &#8220;covered&#8221; if the
Trust owns the instrument underlying the call or has an absolute and immediate right to acquire that instrument without additional cash
consideration (or, if additional cash consideration is required, liquid assets in such amount are segregated) upon conversion or exchange
of other instruments held by it. A call option is also covered if the Trust holds a call on the same instrument as the option written
where the exercise price of the option held is (i)&#160;equal to or less than the exercise price of the option written, or (ii)&#160;greater
than the exercise price of the option written provided the Trust segregates liquid assets in the amount of the difference. A put option
is also covered if the Trust holds a put on the same instrument as the option written where the exercise price of the option held is (i)&#160;equal
to or higher than the exercise price of the option written, or (ii)&#160;less than the exercise price of the option written provided the
Trust segregates liquid assets in the amount of the difference. The Trust may also cover options on securities by segregating cash or
liquid assets, as permitted by applicable law, with a value, when added to any margin on deposit that is equal to the market value of
the securities in the case of a call option. Segregated cash or liquid assets may be quoted or denominated in any currency.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Options on securities indices are similar to options on securities, except
that the exercise of securities index options requires cash payments and does not involve the actual purchase or sale of securities. In
addition, securities index options are designed to reflect price fluctuations in a group of securities or segment of the securities market
rather than price fluctuations in a single security.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may cover call options on a securities index by owning securities
whose price changes are expected to be similar to those of the underlying index, or by having an absolute and immediate right to acquire
such securities without additional cash consideration (or for additional consideration which has been segregated by the Trust) upon conversion
or exchange of other securities in its portfolio. The Trust may also cover call and put options on a securities index by segregating cash
or liquid assets, as permitted by applicable law, with a value, when added to any margin on deposit, that is equal to the market value
of the underlying securities in the case of a call option, or the exercise price in the case of a put option, or by owning offsetting
options as described above.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may terminate its obligations under an exchange traded call
or put option by purchasing an option identical to the one it has written. Obligations under OTC options may be terminated only by entering
into an offsetting transaction with the counterparty to such option. Such purchases are referred to as &#8220;closing purchase transactions.&#8221;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Purchasing Options. </i>The Trust may purchase put and call options
on any securities in which it may invest or any securities index comprised of securities in which it may invest. The Trust may also enter
into closing sale transactions in order to realize gains or minimize losses on options it had purchased.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may purchase call options in anticipation of an increase, or
put options in anticipation of a decrease, in the market value of securities or other instruments of the type in which it may invest (&#8220;protective
puts&#8221;). The purchase of a call option would entitle the Trust, in return for the premium paid, to purchase specified securities
or other instruments at a specified price during the option period.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">9&#160;</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust would ordinarily realize a gain on the purchase of a call option
if, during the option period, the value of such securities exceeded the sum of the exercise price, the premium paid and transaction costs;
otherwise the Trust would realize either no gain or a loss on the purchase of the call option. The purchase of a put option would entitle
the Trust, in exchange for the premium paid, to sell specified securities at a specified price during the option period. The purchase
of protective puts is designed to offset or hedge against a decline in the market value of the Trust&#8217;s securities. Put options may
also be purchased by the Trust for the purpose of affirmatively benefiting from a decline in the price of securities which it does not
own. The Trust would ordinarily realize a gain if, during the option period, the value of the underlying securities decreased below the
exercise price sufficiently to cover the premium and transaction costs; otherwise the Trust would realize either no gain or a loss on
the purchase of the put option. Gains and losses on the purchase of put options may be offset by countervailing changes in the value of
the underlying portfolio securities.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust would purchase put and call options on securities indices for
the same purposes as it would purchase options on individual securities.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Risks Associated with Options Transactions. </i>There is no assurance
that a liquid secondary market on an options exchange will exist for any particular exchange-traded option or at any particular time.
If the Trust is unable to effect a closing purchase transaction with respect to covered options it has written, the Trust will not be
able to sell the underlying securities or dispose of segregated assets until the options expire or are exercised. Similarly, if the Trust
is unable to effect a closing sale transaction with respect to options it has purchased, it will have to exercise the options in order
to realize any profit and will incur transaction costs upon the purchase or sale of underlying securities.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Reasons for the absence of a liquid secondary market on an exchange include
the following: (i)&#160;there may be insufficient trading interest in certain options; (ii)&#160;restrictions may be imposed by an exchange
on opening or closing transactions or both; (iii)&#160;trading halts, suspensions or other restrictions may be imposed with respect to
particular classes or series of options; (iv)&#160;unusual or unforeseen circumstances may interrupt normal operations on an exchange;
(v)&#160;the facilities of an exchange or the Options Clearing Corporation may not at all times be adequate to handle current trading
volume; or (vi)&#160;one or more exchanges could, for economic or other reasons, decide or be compelled at some future date to discontinue
the trading of options (or a particular class or series of options), in which event the secondary market on that exchange (or in that
class or series of options) would cease to exist, although outstanding options on that exchange that had been issued by the Options Clearing
Corporation as a result of trades on that exchange would continue to be exercisable in accordance with their terms.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">There can be no assurance that higher trading activity, order flow or
other unforeseen events will not, at times, render certain of the facilities of the Options Clearing Corporation or various exchanges
inadequate. Such events have, in the past, resulted in the institution by an exchange of special procedures, such as trading rotations,
restrictions on certain types of order or trading halts or suspensions with respect to one or more options. These special procedures may
limit liquidity.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may purchase and sell both options that are traded on U.S. and
foreign exchanges and options traded OTC with broker-dealers who make markets in these options. The ability to terminate OTC options is
more limited than with exchange-traded options and may involve the risk that broker-dealers participating in such transactions will not
fulfill their obligations.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Transactions by the Trust in options will be subject to limitations established
by each of the exchanges, boards of trade or other trading facilities on which such options are traded governing the maximum number of
options in each class which may be written or purchased by a single investor or group of investors acting in concert regardless of whether
the options are written or purchased on the same or different exchanges, boards of trade or other trading facility or are held in one
or more accounts or through one or more brokers. Thus, the number of options which the Trust may write or purchase may be affected by
options written or purchased by other investment advisory clients of the Investment Adviser. An exchange, board of trade or other trading
facility may order the liquidation of positions found to be in excess of these limits, and it may impose certain other sanctions.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The writing and purchase of options is a highly specialized activity which
involves investment techniques and risks different from those associated with ordinary portfolio securities transactions. The use of options
to seek to increase total return involves the risk of loss if the Investment Adviser is incorrect in its expectation of fluctuations in
securities prices or interest rates. The successful use of options for hedging purposes also depends in part on the ability of the Investment
Adviser to manage future price fluctuations and the degree of correlation between the options and securities markets. If the Investment
Adviser is incorrect in its expectation of changes in securities prices or determination of the correlation between the securities or
securities indices on which options are written and purchased and the securities in the Trust&#8217;s investment portfolio, the Trust
may incur losses that it would not otherwise incur. The writing of options could increase the Trust&#8217;s portfolio turnover rate and,
therefore, associated brokerage commissions or spreads.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">10&#160;</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Futures Contracts and Options and Swaps on Futures Contracts</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Futures Contracts</i>. The Trust may enter into contracts for the purchase
or sale for future delivery (a &#8220;futures contract&#8221;) of baskets of securities, financial indices, financial instruments or foreign
currencies. The Trust may purchase or sell futures contracts to attempt to protect the value of its securities from market-wide price
movements and fluctuations in interest or foreign exchange rates without actually buying or selling securities or foreign currency.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A &#8220;sale&#8221; of a futures contract (or a &#8220;short&#8221; futures
position) means the assumption of a contractual obligation to deliver the securities or currency underlying the contract at a specified
price and at a specified future time. A &#8220;purchase&#8221; of a futures contract (or a &#8220;long&#8221; futures position) means
the assumption of a contractual obligation to acquire the securities or currency underlying the contract at a specified price and at a
specified future time.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Margin Requirements</i>. At the time a futures contract is purchased
or sold, the Trust must allocate cash or securities as a deposit payment (&#8220;initial margin&#8221;). It is expected that the initial
margin on U.S. exchanges may range from approximately 1% to approximately 10% of the value of the securities or commodities underlying
the contract. Under certain circumstances, however, such as periods of high volatility, the Trust may be required by an exchange to increase
the level of its initial margin payment. Additionally, initial margin requirements may be increased generally in the future by regulatory
action. An outstanding futures contract is valued daily and the payment in cash of &#8220;variation margin&#8221; may be required, a process
known as &#8220;mark to the market.&#8221;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Considerations Concerning Futures Contracts and Options on Futures
Contracts</i>. Futures contracts entail special risks. The ordinary spreads between values in the cash and futures markets, due to differences
in the character of these markets, are subject to distortions relating to (1)&#160;investor&#8217;s obligations to meet additional variation
margin requirements, (2)&#160;decisions to make or take delivery, rather than entering into offsetting transactions, and (3)&#160;the
difference between margin requirements in the securities markets and margin deposit requirements in the futures markets. The possibility
of such distortion means that a correct forecast of general market, foreign exchange rate or interest rate trends by the Investment Adviser
may still not result in a successful transaction. The Trust&#8217;s ability to establish and close out positions in futures contracts
and options on futures contracts will be subject to the development and maintenance of a liquid market. Although the Trust generally will
purchase or sell only those futures contracts and options for which there appears to be a liquid market, there is no assurance that a
liquid market on an exchange will exist for any particular futures contract or option at any particular time. Under certain circumstances,
exchanges may establish daily limits in the amount that the price of a futures contract may vary either up or down from the previous day&#8217;s
settlement price. Once the daily limit has been reached in a particular contract, no trades may be made that day at a price beyond that
limit.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Forward Contracts</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Forward contracts involve the purchase or sale of a specific quantity
of a commodity, government security, foreign currency, or other asset at a specified price, with delivery and settlement at a specified
future date. Because it is a completed contract, a purchase forward contract can be a cover for the sale of a futures contract. The Trust
may enter into forward contracts for hedging purposes and non-hedging purposes <i>(i.e</i>., to increase returns). Forward contracts may
be used by the Trust for hedging purposes to protect against uncertainty in the level of future foreign currency exchange rates, such
as when the Trust anticipates purchasing or selling a foreign security. For example, this technique would allow the Trust to &#8220;lock
in&#8221; the U.S. dollar price of the security. Forward contracts may also be used to attempt to protect the value of the Trust&#8217;s
existing holdings of foreign securities. There may be, however, an imperfect correlation between the Trust&#8217;s foreign securities
holdings and the forward contracts entered into with respect to those holdings. Forward contracts may also be used for non-hedging purposes
to pursue the Trust&#8217;s investment objective, such as when the Trust&#8217;s Investment Adviser anticipates that particular foreign
currencies will appreciate or depreciate in value, even though securities denominated in those currencies are not then held in the Trust&#8217;s
portfolio. There is no requirement that the Trust hedge all or any portion of its exposure to foreign currency risks.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Forward contracts, unlike futures contracts, are not traded on exchanges
and are not standardized; rather, banks and dealers act as principals in these markets, negotiating each transaction on an individual
basis. The principals who deal in the forward markets are not required to continue to make markets in the currencies or commodities they
trade and these markets can experience periods of illiquidity, sometimes of significant duration. There have been periods during which
certain participants in these markets have refused to quote prices for certain currencies or commodities or have quoted prices with an
unusually wide spread between the price at which they were prepared to buy and that at which they were prepared to sell. Disruptions can
occur in any market traded by the Investment Adviser due to unusually high trading volume, political intervention or other factors. Arrangements
to trade forward contracts may be made with only one or a few counterparties, and liquidity problems therefore might be greater than if
such arrangements were made with numerous counterparties. The imposition of controls by governmental authorities might also limit such
forward (and futures)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">11&#160;</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">trading to less than that which the Investment Adviser would otherwise
recommend, to the possible detriment of the Trust. Market illiquidity or disruption could result in major losses to the Trust. In addition,
the Trust will be exposed to credit risks with regard to counterparties with which it trades as well as risks relating to settlement default.
Such risks could result in substantial losses to the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Equity Swaps</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may enter into equity swap contracts to invest in a market without
owning or taking physical custody of securities in various circumstances, including circumstances where direct investment in the securities
is restricted for legal reasons or is otherwise impracticable. Equity swaps may also be used for hedging purposes or to seek to increase
total return. The counterparty to an equity swap contract will typically be a bank, investment banking firm or broker/dealer. Equity swap
contracts may be structured in different ways. For example, a counterparty may agree to pay the Trust the amount, if any, by which the
notional amount of the equity swap contract would have increased in value had it been invested in particular stocks (or an index of stocks),
plus the dividends that would have been received on those stocks. In these cases, the Trust may agree to pay to the counterparty a floating
rate of interest on the notional amount of the equity swap contract plus the amount, if any, by which that notional amount would have
decreased in value had it been invested in such stocks. Therefore, the return to the Trust on the equity swap contract should be the gain
or loss on the notional amount plus dividends on the stocks less the interest paid by the Trust on the notional amount. In other cases,
the counterparty and the Trust may each agree to pay the other the difference between the relative investment performances that would
have been achieved if the notional amount of the equity swap contract had been invested in different stocks (or indices of stocks).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust will generally enter into equity swaps on a net basis, which
means that the two payment streams are netted out, with the Trust receiving or paying, as the case may be, only the net amount of the
two payments.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Payments may be made at the conclusion of an equity swap contract or periodically
during its term. Equity swaps normally do not involve the delivery of securities or other underlying assets. Accordingly, the risk of
loss with respect to equity swaps is normally limited to the net amount of payments that the Trust is contractually obligated to make.
If the other party to an equity swap defaults, the Trust&#8217;s risk of loss consists of the net amount of payments that the Trust is
contractually entitled to receive, if any. Inasmuch as these transactions are entered into for hedging purposes or are offset by segregated
cash or liquid assets to cover the Trust&#8217;s exposure, the Trust and the Investment Adviser believe that such transactions do not
constitute senior securities under the Investment Company Act and, accordingly, will not treat them as being subject to the Trust&#8217;s
borrowing restrictions under the Investment Company Act but will count them against the Trust&#8217;s overall leverage limit.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust will not enter into swap transactions unless the unsecured commercial
paper, senior debt or claims paying ability of the other party thereto is considered to be investment grade by the Investment Adviser.
The Trust&#8217;s ability to enter into certain swap transactions may be limited by tax considerations.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Index Swaps,&#160;Interest Rate Swaps, Credit Swaps, Total Return
Swaps, Options on Swaps and Interest Rate Caps, Floors and Collars</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may enter into index, interest rate, credit and total return
swaps for both hedging purposes and to seek to increase total return. As examples, the Trust may enter into swap transactions for the
purpose of attempting to obtain or preserve a particular return or spread at a lower cost than obtaining a return or spread through purchases
and/or sales of instruments in other markets, as a duration management technique, to protect against any increase in the price of securities
the Trust anticipates purchasing at a later date, or to gain exposure to certain markets in an economical way. The Trust may also enter
into interest rate caps, floors and collars. The Trust may also purchase and write (sell) options contracts on swaps, commonly referred
to as swaptions.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">In a standard &#8220;swap&#8221; transaction, two parties agree to exchange
the returns, differentials in rates of return or some other amount earned or realized on particular predetermined investments or instruments,
which may be adjusted for an interest factor. The gross returns to be exchanged or &#8220;swapped&#8221; between the parties are generally
calculated with respect to a &#8220;notional amount,&#8221; <i>i.e.</i>, the return on or increase in value of a particular dollar amount
invested at a particular interest rate, in a particular security, or in a &#8220;basket&#8221; of securities representing a particular
index. Bilateral swap agreements are two party contracts entered into primarily by institutional investors. Cleared swaps are transacted
through futures commission merchants (&#8220;FCMs&#8221;) that are members of central clearinghouses with the clearinghouse serving as
a central counterparty similar to transactions in futures contracts. The Trust posts initial and variation margin by making payments to
its clearing member FCMs.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">12&#160;</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Interest rate swaps involve the exchange by the Trust with another party
of their respective commitments to pay or receive interest, such as an exchange of fixed rate payments for floating rate payments. Index
swaps involve the exchange by the Trust with another party of the respective amounts payable with respect to a notional principal amount
at interest rates equal to two specified indices. Credit swaps involve the exchange of a floating or fixed rate payment in return for
assuming potential credit losses of an underlying security, or pool of securities. Credit swaps involve the exchange of a floating or
fixed rate payment in return for assuming potential credit losses of an underlying security, or pool of securities. Total return swaps
are contracts that obligate a party to pay or receive interest in exchange for payment by the other party of the total return generated
by a security, a basket of securities, an index or an index component.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A swaption is an option to enter into a swap agreement. Like other types
of options, the buyer of a swaption pays a non-refundable premium for the option and obtains the right, but not the obligation, to enter
into an underlying swap or to modify the terms of an existing swap on agreed-upon terms. The seller of a swaption, in exchange for the
premium, becomes obligated (if the option is exercised) to enter into or modify an underlying swap on agreed-upon terms, which generally
entails a greater risk of loss than the Trust incurs in buying a swaption. The purchase of an interest rate cap entitles the purchaser,
to the extent that a specified index exceeds a predetermined interest rate, to receive payment of interest on a notional principal amount
from the party selling such interest rate cap. The purchase of an interest rate floor entitles the purchaser, to the extent that a specified
index falls below a predetermined interest rate, to receive payments of interest on a notional principal amount from the party selling
the interest rate floor. An interest rate collar is the combination of a cap and a floor that preserves a certain return within a predetermined
range of interest rates.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A great deal of flexibility may be possible in the way swap transactions
are structured. However, generally the Trust will enter into interest rate, total return, credit and index swaps on a net basis, which
means that the two payment streams are netted out, with the Trust receiving or paying, as the case may be, only the net amount of the
two payments. Interest rate, total return, credit and index swaps do not normally involve the delivery of securities, other underlying
assets or principal. Accordingly, the risk of loss with respect to interest rate, total return, credit and index swaps is normally limited
to the net amount of interest payments that the Trust is contractually obligated to make. If the other party to a bilateral swap agreement
defaults, the Trust&#8217;s risk of loss consists of the net amount of interest payments that the Trust is contractually entitled to receive.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A credit swap may have as reference obligations one or more securities
that may, or may not, be currently held by the Trust. The protection &#8220;buyer&#8221; in a credit swap is generally obligated to pay
the protection &#8220;seller&#8221; an upfront or a periodic stream of payments over the term of the swap provided that no credit event,
such as a default, on a reference obligation has occurred. If a credit event occurs, the seller generally must pay the buyer the &#8220;par
value&#8221; (full notional value) of the swap in exchange for an equal face amount of deliverable obligations of the reference entity
described in the swap, or the seller may be required to deliver the related net cash amount, if the swap is cash settled. The Trust may
be either the protection buyer or seller in the transaction. If the Trust is a buyer and no credit event occurs, the Trust may recover
nothing if the swap is held through its termination date. However, if a credit event occurs, the buyer generally may elect to receive
the full notional value of the swap in exchange for an equal face amount of deliverable obligations of the reference entity whose value
may have significantly decreased. As a seller, the Trust generally receives an upfront payment or a rate of income throughout the term
of the swap provided that there is no credit event. As the seller, the Trust would effectively add leverage to its portfolio because,
in addition to its total net assets, the Trust would be subject to investment exposure on the notional amount of the swap.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">If a credit event occurs, the value of any deliverable obligation received
by the Trust as seller, coupled with the upfront or periodic payments previously received, may be less than the full notional value it
pays to the buyer, resulting in a loss of value to the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">To the extent that the Trust&#8217;s exposure in a transaction involving
a swap, a swaption or an interest rate floor, cap or collar is covered by identifying on its books cash or liquid assets or is covered
by other means in accordance with Commission guidance, the Trust and the Investment Adviser believe that the transactions do not constitute
senior securities under the Investment Company Act and, accordingly, will not treat them as being subject to the Trust&#8217;s borrowing
restrictions under the Investment Company Act but will count them against the Trust&#8217;s overall leverage limit.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust will not enter into bilateral transactions involving swaps,
caps, floors or collars unless the unsecured commercial paper, senior debt or claims paying ability of the other party thereto (with respect
to bilateral swap transactions) is considered to be investment grade by the Investment Adviser. If there is a default by the other party
to such a transaction, the Trust will have contractual remedies pursuant to the agreements related to the transaction.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The use of swaps, swaptions and interest rate caps, floors and collars
is a highly specialized activity which creates effective leverage and involves investment techniques and risks different from those associated
with ordinary portfolio securities transactions. The use of</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">13&#160;</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">a swap requires an understanding not only of the referenced asset, reference
rate, or index but also of the swap itself, without the benefit of observing the performance of the swap under all possible market conditions.
If the Investment Adviser is incorrect in its forecasts of market values, credit quality and interest rates, or in its evaluation of the
creditworthiness of swap counterparties (with respect to bilateral swap transactions) and the issuers of the underlying assets, the investment
performance of the Trust would be less favorable than it would have been if these investment techniques were not used.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Currently, certain standardized swap transactions are subject to mandatory
central clearing. Although central clearing is expected to decrease counterparty risk and increase liquidity compared to bilaterally negotiated
swaps, central clearing does not eliminate counterparty risk or illiquidity risk entirely.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>When-Issued and Delayed Delivery Transactions</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may purchase securities on a &#8220;when issued&#8221; basis
or a &#8220;delayed delivery&#8221; basis. &#8220;When-issued&#8221; securities are securities whose terms are available and for which
a market exists, but which are not available for immediate delivery. &#8220;Delayed delivery&#8221; transactions are those in which the
Trust purchases a security but settlement of the transaction is to occur after the customary settlement date. The Trust will enter into
such transactions for the purpose of acquiring securities that it wishes to purchase but that are not currently available for purchase.
The Trust may dispose of a commitment to purchase prior to settlement. However, the Trust does not intend to make such purchases for speculative
purposes. When such transactions are negotiated, the purchase price is fixed at the time the commitment is made, but delivery and payment
for the securities take place at a later date. During the period between commitment and settlement, no payment is made for the securities
purchased, and no interest or dividends accrue to the Trust. However, the securities are subject to market fluctuation, and the value
at settlement may be less than the purchase price. While awaiting settlement, the Trust will maintain with its custodian a segregated
account consisting of liquid securities, which may include cash, obligations of the U.S. Government, its agencies or instrumentalities
(&#8220;U.S. Government Securities&#8221;), debt obligations or equity securities having a value at least equal to its purchase commitments.
The commitment to purchase a security for which payment will be made on a future date may be deemed a separate security and involves a
risk of loss if the security declines prior to the settlement date, which risk is in addition to the risk of decline of the Trust&#8217;s
other assets.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Repurchase Agreements</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A repurchase agreement is an agreement under which the Trust acquires
a security subject to the obligation of the seller to repurchase and the Trust to resell such security at a fixed time and price (representing
the Trust&#8217;s cost and interest). It is the Trust&#8217;s present intention to enter into repurchase agreements for a relatively short
period (usually not more than one week) only with commercial banks and registered broker-dealers and only with respect to U.S. Government
Securities and money market instruments. Repurchase agreements may also be viewed as loans made by the Trust, which are collateralized
by the securities subject to repurchase. The Trust intends to take possession of collateral, and the Investment Adviser will monitor repurchase
transactions to ensure that the value of the underlying securities will at all times be at least equal to the total amount of the repurchase
obligation, including the interest factor. If the seller defaults the Trust could realize a loss on the sale of the underlying security
to the extent that the proceeds of sale, including accrued interest, are less than the resale price provided in the agreement, including
interest. In addition, if the seller should be involved in bankruptcy or insolvency proceedings, the Trust may incur delay and costs in
selling the underlying security or may suffer a loss of principal and interest if the Trust is treated as an unsecured creditor and required
to return the underlying collateral to the seller.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Reverse Repurchase Agreements</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Reverse repurchase agreements involve the sale of securities held by the
Trust with an agreement by the Trust to repurchase the securities at an agreed upon price, date and interest payment. At the time the
Trust enters into a reverse repurchase agreement, it may establish and maintain a segregated account with the custodian containing cash
and/or liquid assets having a value not less than the repurchase price (including accrued interest). If the Trust establishes and maintains
such a segregated account, a reverse repurchase agreement will not be considered a borrowing by the Trust; however, under certain circumstances
in which the Trust does not establish and maintain such a segregated account, such reverse repurchase agreement will be considered a borrowing
for the purpose of the Trust&#8217;s limitation on borrowings. Reverse repurchase agreements create effective leverage. If the securities
held by the Trust decline in value while these transactions are outstanding, the NAY of the Trust&#8217;s outstanding shares will decline
in value by proportionately more than the decline in value of the securities. In addition, reverse repurchase agreements involve the risk
that the investment return earned by the Trust (from the investment of the proceeds) will be less than the interest expense of the transaction,
that the market value of the securities sold by the Trust will decline below the price the Trust is obligated to pay to repurchase the
securities, and that the securities may not be returned to the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">14&#160;</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may &#8220;set aside&#8221; liquid assets, or engage in other
appropriate measures to &#8220;cover&#8221; its obligations with respect to its transactions in reverse repurchase agreements. As a result
of such segregation, the Trust&#8217;s obligations under such transactions will not be considered senior securities representing indebtedness
for purposes of the Investment Company Act, and the Trust&#8217;s use of leverage through reverse repurchase agreements will not be limited
by the Investment Company Act, although it will be limited by the Trust&#8217;s overall limitation on leverage as described in the Prospectus.
However, the Trust&#8217;s use of leverage through reverse repurchase agreements will be considered to be financial leverage for purposes
of determining compliance with the Trust&#8217;s maximum overall leverage levels approved by the Board. The Trust&#8217;s use of leverage
through reverse repurchase agreements may be further limited by the availability of cash or liquid securities to earmark or segregate
in connection with such transactions.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">If the buyer of securities under a reverse repurchase agreement files
for bankruptcy or becomes insolvent, such buyer or its trustee or receiver may receive an extension of time to determine whether to enforce
the Trust&#8217;s obligation to repurchase the securities, and the Trust&#8217;s use of the proceeds of the reverse repurchase agreement
may effectively be restricted pending such decision. Also, the Trust would bear the risk of loss to the extent that the proceeds of the
reverse repurchase agreement are less than the value of the securities subject to such agreement.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">With respect to any reverse repurchase agreement or similar transaction,
the Trust&#8217;s Managed Assets shall include any proceeds from the sale of an asset of the Trust to a counterparty in such a transaction,
in addition to the value of the underlying asset as of the relevant measuring date.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Short Sales</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may engage in short sales and short sales against the box in
an amount not to exceed 5% of Managed Assets. Short sales are transactions in which the Trust sells a security it does not own in anticipation
of a decline in the market value of that security. To complete such a transaction, the Trust must borrow the security to make delivery
to the buyer. The Trust then is obligated to replace the security borrowed by purchasing it at the market price at the time of replacement.
The price at such time may be more or less than the price at which the security was sold by the Trust. Until the security is replaced,
the Trust is required to pay to the lender amounts equal to any dividend which accrues during the period of the loan. To borrow the security,
the Trust also may be required to pay a premium, which would increase the cost of the security sold. There will also be other costs associated
with short sales, which will be borne solely by the Trust&#8217;s common Shareholders.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust will incur a loss, which may be unlimited, as a result of the
short sale if the price of the security increases between the date of the short sale and the date on which the Trust replaces the borrowed
security. The Trust will realize a gain if the security declines in price between those dates. This result is the opposite of what one
would expect from a cash purchase of a long position in a security. The amount of any gain will be decreased, and the amount of any loss
increased, by the amount of any premium or amounts in lieu of interest the Trust may be required to pay in connection with a short sale,
and will be also decreased by any transaction or other costs.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Until the Trust replaces a borrowed security in connection with a short
sale, the Trust will (a)&#160;segregate cash or liquid assets at such a level that the segregated assets plus any amount deposited with
the broker as collateral will equal the current value of the security sold short or (b)&#160;otherwise cover its short position in accordance
with applicable law.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">There is no guarantee that the Trust will be able to close out a short
position at any particular time or at an acceptable price. During the time that the Trust is short a security, it is subject to the risk
that the lender of the security will terminate the loan at a time when the Trust is unable to borrow the same security from another lender.
If that occurs, the Trust may be &#8220;bought in&#8221; at the price required to purchase the security needed to close out the short
position, which may be a disadvantageous price.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may engage in short sales against the box. As noted above, a
short sale is made by selling a security the seller does not own. A short sale is &#8220;against the box&#8221; to the extent that the
seller contemporaneously owns or has the right to obtain, at no added cost, securities identical to those sold short. The Trust may enter
into a short sale against the box, for example, to lock in a sales price for a security the Trust does not wish to sell immediately. If
the Trust sells securities short against the box, it may protect itself from loss if the price of the securities declines in the future,
but will lose the opportunity to profit on such securities if the price rises. If the Trust effects a short sale of securities at a time
when it has an unrealized gain on the securities, it may be required to recognize that gain as if it had actually sold the securities
(as a &#8220;constructive sale&#8221;) on the date it effects the short sale. However, such constructive sale treatment may not apply
if the Trust closes out the short sale with securities other than the appreciated securities held at the time of the short sale and if
certain other conditions are satisfied. Uncertainty regarding the tax consequences of effecting short sales may limit the extent to which
the Trust may effect short sales.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">15&#160;</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Preferred Stock, Warrants and Stock Purchase Rights</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest in preferred stock, warrants and stock purchase rights
(or &#8220;rights&#8221;). Preferred stocks are securities that represent an ownership interest providing the holder with claims on the
issuer&#8217;s earnings and assets before common stock owners but after creditors and other debt holders. Unlike debt securities, the
obligations of an issuer of preferred stock, including dividend and other payment obligations, may not typically be accelerated by the
holders of such preferred stock on the occurrence of an event of default (such as a covenant default or filing of a bankruptcy petition)
or other non-compliance by the issuer with the terms of the preferred stock. Often, however, on the occurrence of any such event of default
or non-compliance by the issuer, preferred shareholders will be entitled to gain representation on the issuer&#8217;s board of directors
or increase their existing board representation. In addition, preferred shareholders may be granted voting rights with respect to certain
issues on the occurrence of any event of default.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Warrants and other rights are securities/contracts that are similar to
options but with different terms that entitle the holder to buy equity securities at a specific price for a specific period of time. The
Trust will invest in warrants and rights only if such equity securities are deemed appropriate by the Investment Adviser for investment
by the Trust. Warrants and rights have no voting rights, receive no dividends and have no rights with respect to the assets of the issuer.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Exchange-Traded Notes (&#8220;ETNs&#8221;)</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">ETNs are a type of senior, unsecured, unsubordinated debt security issued
by financial institutions that combines both aspects of bonds and ETFs. An ETN&#8217;s returns are based on the performance of a market
index minus fees and expenses. Similar to ETFs, ETNs are listed on an exchange and traded in the secondary market. However, unlike an
ETF, an ETN can be held until the ETN&#8217;s maturity, at which time the issuer will pay a return linked to the performance of the market
index to which the ETN is linked minus certain fees. Unlike regular bonds, ETNs do not make periodic interest payments and principal is
not protected. ETNs are subject to credit risk and the value of an ETN may drop due to a downgrade in the issuer&#8217;s credit rating,
despite the underlying market benchmark or strategy remaining unchanged. The value of an ETN may also be influenced by time to maturity,
level of supply and demand for the ETN, volatility and lack of liquidity in underlying assets, changes in the applicable interest rates,
changes in the issuer&#8217;s credit rating, and economic, legal, political, or geographic events that affect the referenced underlying
asset. When the Trust invests in ETNs it will bear its proportionate share of any fees and expenses borne by the ETN. The Trust&#8217;s
decision to sell its ETN holdings may be limited by the availability of a secondary market. In addition, although an ETN may be listed
on an exchange, the issuer may not be required to maintain the listing and there can be no assurance that a secondary market will exist
for an ETN.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Unseasoned Companies</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest in companies (including predecessors) which have
operated less than three years. The securities of such companies may have limited liquidity, which can result in their being priced higher
or lower than might otherwise be the case. In addition, investments in unseasoned companies are more speculative and entail greater risk
than do investments in companies with a longer and more established operating history.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>U.S. Government Securities</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest in securities issued or guaranteed by the U.S. Government
or its agencies or instrumentalities. Although U.S. Government securities issued directly by the U.S. Government are guaranteed by the
U.S. Treasury, other U.S. Government securities issued by an agency or instrumentality of the U.S. Government may not be. No assurance
can be given that the U.S. Government would provide financial support to its agencies and instrumentalities if not required to do so by
law.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Custodial Receipts and Trust Certificates</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest in custodial receipts and trust certificates, which
may be underwritten by securities dealers or banks, representing interests in securities held by a custodian or trustee. The securities
so held may include U.S. Government Securities, municipal securities or other types of securities in which the Trust may invest. The custodial
receipts or trust certificates are underwritten by securities dealers or banks and may evidence ownership of future interest payments,
principal payments or both on the underlying securities, or, in some cases, the payment obligation of a third party that has entered into
an interest rate swap or other arrangement with the custodian or trustee. For purposes of certain securities laws, custodial receipts
and trust certificates may not be considered obligations of the U.S. government or other issuer of the securities held by the custodian
or trustee. As a holder of</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">16&#160;</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">custodial receipts and trust certificates, the Trust will bear its proportionate
share of the fees and expenses charged to the custodial account or trust. The Trust may also invest in separately issued interests in
custodial receipts and trust certificates.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Although under the terms of a custodial receipt or trust certificate the
Trust would typically be authorized to assert its rights directly against the issuer of the underlying obligation, the Trust could be
required to assert through the custodian bank or trustee those rights as may exist against the underlying issuers. Thus, in the event
an underlying issuer fails to pay principal and/or interest when due, the Trust may be subject to delays, expenses and risks that are
greater than those that would have been involved if the Trust had purchased a direct obligation of the issuer. In addition, in the event
that the trust or custodial account in which the underlying securities have been deposited is determined to be an association taxable
as a corporation, instead of a non-taxable entity, the yield on the underlying securities would be reduced in recognition of any taxes
paid.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Certain custodial receipts and trust certificates may be synthetic or
derivative instruments that have interest rates that reset inversely to changing short-term rates and/or have embedded interest rate floors
and caps that require the issuer to pay an adjusted interest rate if market rates fall below or rise above a specified rate. Because some
of these instruments represent relatively recent innovations, and the trading market for these instruments is less developed than the
markets for traditional types of instruments, it is uncertain how these instruments will perform under different economic and interest-rate
scenarios. Also, because these instruments may be leveraged, their market values may be more volatile than other types of fixed income
instruments and may present greater potential for capital gain or loss. The possibility of default by an issuer or the issuer&#8217;s
credit provider may be greater for these derivative instruments than for other types of instruments. In some cases, it may be difficult
to determine the fair value of a derivative instrument because of a lack of reliable objective information and an established secondary
market for some instruments may not exist. In many cases, the Internal Revenue Service (the &#8220;IRS&#8221;) has not ruled on the tax
treatment of the interest or payments received on the derivative instruments and, accordingly, purchases of such instruments are based
on the opinion of counsel to the sponsors of the instruments.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Non-Investment Grade Securities</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest up to 20% of its Managed Assets in non-convertible
bonds rated BB+ or below by S&#38;P, Ba1 or below by Moody&#8217;s, or BB+ by Fitch or comparable rated and unrated securities. The Trust
may invest up to 15% of its Managed Assets in non-convertible debt securities that are, at the time of investment, rated Caa1 or lower
by Moody&#8217;s and CCC+ or lower by S&#38;P or Fitch, or comparably rated by another nationally recognized statistical rating organization,
or, if unrated, determined by the Investment Adviser to be of comparable credit quality. Such securities are subject to a very high credit
risk. These bonds are commonly referred to as &#8220;junk bonds&#8221; and are considered speculative. The ability of issuers of non-investment
grade securities to make principal and interest payments may be questionable because such issuers are often less creditworthy or are highly
leveraged and generally less able than more established or less leveraged entities to make scheduled payments of principal and interest.
Non-investment grade securities are also issued by governmental issuers that may have difficulty in making all scheduled interest and
principal payments. In some cases, non-investment grade securities may be highly speculative, have poor prospects for reaching investment
grade standing and be in default. As a result, investment in such bonds will entail greater risks than those associated with investment
in investment grade bonds (<i>i.e.</i>, bonds rated AAA, AA, A or BBB by Standard&#160;&#38; Poor&#8217;s, Aaa, Aa, A or Baa by Moody&#8217;s,
or AAA, AA, A, or BBB by Fitch). Analysis of the creditworthiness of issuers of non-investment grade securities may be more complex than
for issuers of higher quality debt securities, and the ability of the Trust to achieve its investment objective may, to the extent of
its investments in non-investment grade securities, be more dependent upon such creditworthiness analysis than would be the case if the
Trust were investing in higher quality securities.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The market values of non-investment grade securities tend to reflect individual
corporate or municipal developments to a greater extent than do those of higher rated securities, which react primarily to fluctuations
in the general level of interest rates. Issuers of non-investment grade securities that are highly leveraged may not be able to make use
of more traditional methods of financing. Their ability to service debt obligations may be more adversely affected by economic downturns
or their inability to meet specific projected business forecasts than would be the case for issuers of high-rated securities. Negative
publicity about the junk bond market and investor perceptions regarding lower-rated securities, whether or not based on fundamental analysis,
may depress the prices for non-investment grade securities. In the lower quality segments of the fixed income securities market, changes
in perceptions of issuers&#8217; creditworthiness tend to occur more frequently and in a more pronounced manner than do changes in higher
quality segments of the fixed income securities market, resulting in greater yield and price volatility. Another factor which causes fluctuations
in the prices of non-investment grade securities is the supply and demand for similarly rated securities. In addition, the prices of investments
fluctuate in response to the general level of interest rates.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">17&#160;</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Fluctuations in the prices of portfolio securities subsequent to their
acquisition will not affect cash income from such securities but will be reflected in the Trust&#8217;s NAY.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The risk of loss from default for the holders of non-investment grade
securities is significantly greater than is the case for holders of other debt securities because non-investment grade securities are
generally unsecured and are often subordinated to the rights of other creditors of the issuers of such securities. Investment by the Trust
in already defaulted securities poses an additional risk of loss should nonpayment of principal and interest continue in respect of such
securities. Even if such securities are held to maturity, recovery by the Trust of its initial investment and any anticipated income or
appreciation is uncertain. In addition, the Trust may incur additional expenses to the extent that it is required to seek recovery relating
to the default in the payment of principal or interest on such securities or otherwise protect its interests. The Trust may be required
to liquidate other portfolio securities to satisfy annual distribution obligations of the Trust in respect of accrued interest income
on securities which are subsequently written off, even though the Trust has not received any cash payments of such interest.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The secondary market for non-investment grade securities is concentrated
in relatively few markets and is dominated by institutional investors, including mutual funds, insurance companies and other financial
institutions. Accordingly, the secondary market for such securities may not be as liquid as and may be more volatile than the secondary
market for higher-rated securities. In addition, the trading volume for non-investment grade securities is generally lower than that of
higher rated securities. The secondary market for non-investment grade securities could contract under adverse market or economic conditions
independent of any specific adverse changes in the condition of a particular issuer. These factors may have an adverse effect on the ability
of the Trust to dispose of particular portfolio investments when needed to meet redemption requests or other liquidity needs. The Investment
Adviser could find it difficult to sell these investments or may be able to sell the investments only at prices lower than if such investments
were widely traded. Prices realized upon the sale of such lower rated or unrated securities, under these circumstances, may be less than
the prices used in calculating the NAY of the Trust. A less liquid secondary market also may make it more difficult for the Trust to obtain
precise valuations of the non-investment grade securities in its portfolio.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The adoption of new legislation could adversely affect the secondary market
for non-investment grade securities and the financial condition of issuers of these securities. The form of any future legislation, and
the probability of such legislation being enacted, is uncertain.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Non-investment grade securities also present risks based on payment expectations.
Non-investment grade securities frequently contain &#8220;call&#8221; or buy-back features which permit the issuer to call or repurchase
the security from its holder. If an issuer exercises such a &#8220;call option&#8221; and redeems the security, the Trust may have to
replace such security with a lower-yielding security, resulting in a decreased return for investors. In addition, if the Trust experiences
net redemptions of its shares, it may be forced to sell its higher-rated securities, resulting in a decline in the overall credit quality
of its portfolio and increasing its exposure to the risks of non-investment grade securities.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Credit ratings issued by credit rating agencies are designed to evaluate
the safety of principal and interest payments of rated securities. They do not, however, evaluate the market value risk of non-investment
grade securities and, therefore, may not fully reflect the true risks of an investment. In addition, credit rating agencies may or may
not make timely changes in a rating to reflect changes in the economy or in the conditions of the issuer that affect the market value
of the security. Consequently, credit ratings are used only as a preliminary indicator of investment quality. Investments in non-investment
grade and comparable unrated obligations will be more dependent on the Investment Adviser&#8217;s credit analysis than would be the case
with investments in investment-grade debt obligations. The Investment Adviser employs its own credit research and analysis, which includes
a study of an issuer&#8217;s existing debt, capital structure, ability to service debt and to pay dividends, sensitivity to economic conditions,
operating history and current earnings trend. The Investment Adviser continually monitors the investments in the Trust&#8217;s portfolio
and evaluates whether to dispose of or to retain non-investment grade and comparable unrated securities whose credit ratings or credit
quality may have changed. If after its purchase, a portfolio security is assigned a lower rating or ceases to be rated, the Trust may
continue to hold the security if the Investment Adviser believes it is in the best interest of the Trust and its Shareholders.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">An economic downturn could severely affect the ability of highly leveraged
issuers of junk bond investments to service their debt obligations or to repay their obligations upon maturity. Factors having an adverse
impact on the market value of junk bonds will have an adverse effect on the Trust&#8217;s NAV to the extent it invests in such investments.
In addition, the Trust may incur additional expenses to the extent it is required to seek recovery upon a default in payment of principal
or interest on its portfolio holdings.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">18&#160;</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Loans of Portfolio Securities</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may lend its portfolio securities, subject to the limitation
that the Trust will not lend a security if, as a result of such loan, all securities then subject to loans would exceed 30% of the Trust&#8217;s
Managed Assets. Under applicable regulatory requirements (which are subject to change), the loan collateral must, on each business day,
be at least equal to the value of the loaned securities and must consist of cash, bank letters of credit or U.S. Government Securities.
To be acceptable as collateral, letters of credit must obligate a bank to pay amounts demanded by the Trust if the demand meets the terms
of the letter. Such terms and the issuing bank must be satisfactory to the Trust. When the Trust lends a security, it is entitled to receive
substitute payments in the amount of any dividends or interest on the loaned security and also receive one or more of: (1)&#160;a negotiated
loan fee; (2)&#160;interest on securities used as collateral for the loan; or (3)&#160;interest on short-term debt securities purchased
with the loan collateral. Either type of interest may be shared with the borrower of the security. The Trust may also pay reasonable finder&#8217;s,
custodian and administrative fees. The terms of the Trust&#8217;s loans of securities must meet certain requirements under the Internal
Revenue Code of 1986, as amended (the &#8220;Code&#8221;), such as providing that the Trust may terminate the loan upon no more than five
days&#8217; notice, and must permit the Trust to reacquire loaned securities in time to vote on any important matter. The Trust will make
such loans only to banks and dealers with which it may enter into repurchase agreements. If the borrower fails to return the loaned security,
the Trust&#8217;s risks include: (1)&#160;any costs in disposing of the collateral; (2)&#160;loss from a decline in value of the collateral
to an amount less than 100% of the securities loaned; (3)&#160;being unable to exercise its voting or consent rights with respect to the
security; (4)&#160;any loss arising from a delay in the Trust&#8217;s ability to recover such securities in a timely manner; (5)&#160;the
inability of the Trust to reacquire the loaned securities; and (6)&#160;counterparty risk.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>INVESTMENT
RESTRICTIONS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust has adopted certain fundamental restrictions, which may not
be changed without the affirmative vote of the holders of a majority of the Trust&#8217;s outstanding Shares. As used in this SAI, a &#8220;majority
of the Trust&#8217;s outstanding Shares&#8221; means the lesser of (1)&#160;67% of the Shares represented at a meeting at which more than
50% of the outstanding Shares are represented or (2)&#160;more than 50% of the outstanding Shares. For purposes of the following limitations
(except for the asset coverage requirement with respect to borrowings), all percentage limitations apply immediately after a purchase
and any subsequent change in any applicable percentage resulting from market conditions does not require any action. With respect to the
limitations on the issuance of senior securities and in the case of borrowings, the percentage limitations apply at the time of issuance
and on an ongoing basis. The Trust may not:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in">1.</td>
    <td>Invest 25% or more of its Managed Assets in the securities of one or more issuers conducting their principal business activities in the
        same industry (excluding the U.S. Government or any of its agencies or instrumentalities); except that the Trust will invest more than
        25% of its Managed Assets in companies conducting their principal business in healthcare industries.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in">2.</td>
    <td>Purchase or sell commodities or commodities contracts. The prohibition on the purchase or sale of commodities applies to the purchase
        or sale of &#8220;physical&#8221; commodities; the Trust may invest in currency and financial instruments and contracts in accordance
        with its investment objective and policies, including, without limitation, structured notes, futures contracts, swaps, options on commodities,
        currencies, swaps and futures, ETFs, ETNs, investment pools and other instruments, regardless of whether such instrument is considered
        to be a commodity.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in">3.</td>
    <td>Purchase or sell real estate; although the Trust may purchase and sell securities or instruments that are secured by real estate or interests
        therein or that reflect the return of an index of real estate values, securities of real estate investment trusts and mortgage-related
        securities, and may hold and sell real estate acquired by the Trust as a result of the ownership of securities.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in">4.</td>
    <td>Underwrite securities of other issuers, except to the extent that, in connection with the disposition of its portfolio securities, the
        Trust may be deemed an underwriter under federal or state securities law. See &#8220;Portfolio Transactions and Brokerage.&#8221;</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in">5.</td>
    <td>Issue senior securities to the extent such issuance would violate applicable law.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in">6.</td>
    <td>Borrow money, except as permitted by the Investment Company Act, or interpretations or modifications by the Commission, Commission staff
        or other authority with appropriate jurisdiction.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in">7.</td>
    <td>Mortgage, pledge, hypothecate or in any manner transfer, as security for indebtedness, any securities owned or held by the Trust, except
        as may be necessary in connection with permitted borrowings under 6 above.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">19&#160;</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in">8.</td>
    <td>Make loans of money, except (a)&#160;by the purchase of debt obligations in which the Trust may invest consistent with its investment
        objective and policies, or (b)&#160;as may otherwise be permitted by the Investment Company Act, as amended from time to time, the rules&#160;and
        regulation promulgated by the Commission under the Investment Company Act, as amended from time to time, or an exemption or other relief
        applicable to the Trust from the provisions of the Investment Company Act, as amended from time to time. The Trust reserves the authority
        to enter into repurchase agreements, reverse repurchase agreements and to make loans of its portfolio securities to qualified institutional
        investors, brokers, dealers, banks or other financial institutions, so long as the terms of the loans are not inconsistent with the requirements
        of the Investment Company Act.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">In addition, the Trust has adopted the following investment policies,
which may be changed by the action of the Board of Trustees (the &#8220;Board&#8221;) without Shareholder approval:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in">1.</td>
    <td>The Trust, under normal circumstances, will have at least 80% of its Managed Assets invested in Healthcare Companies. This investment
        policy may only be changed with 60 days&#8217; prior notice to Shareholders.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in">2.</td>
    <td>The Trust may invest up to 10% of the Trust&#8217;s Managed Assets in Restricted Securities.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Except as otherwise noted, all percentage limitations set forth above
apply immediately after a purchase and a subsequent change in the applicable percentage resulting from market fluctuations does not require
elimination of any security from the portfolio. Other than the restrictions identified above as fundamental, the Trust&#8217;s investment
objective, policies and restrictions may be changed without Shareholder approval.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>TRUSTEES
AND OFFICERS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Overall responsibility for general oversight of the Trust rests with the
Board. The Board is comprised of seven individuals, six of whom are not &#8220;interested persons&#8221; of the Trust (as that term is
defined in Section&#160;2(a)(19) of the Investment Company Act) (&#8220;Independent Trustee&#8221;). The Chairman of the Board is an Independent
Trustee. The Chairman presides at meetings of the Trustees, participates in the preparation of the agenda for meetings of the Board, and
acts as a liaison between the Independent Trustees and the Trust&#8217;s management between Board meetings. Except for any duties specified
herein, the designation as Chairman does not impose any obligations or standards greater than or different from other Trustees.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Board holds regular quarterly meetings each year to consider and address
matters involving the Trust. The Board also may hold special meetings to address matters arising between regular meetings. The Independent
Trustees also meet outside the presence of management in executive session at least quarterly and have engaged independent legal counsel
to assist them in performing their oversight responsibilities.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Board has established Audit, Governance and Nominating, Valuation
and Qualified Legal Compliance Committees to assist the Board in the oversight of the management and affairs of the Trust. All of the
members of these Committees are Independent Trustees, except for Dr.&#160;Omstead, who serves on the Valuation Committee. From time to
time the Board may establish additional committees or informal working groups to deal with specific matters.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust is subject to a number of risks including investment, compliance,
operational and valuation risks. Although the Investment Adviser and the officers of the Trust are responsible for managing these risks
on a day-to-day basis, the Board has adopted, and periodically reviews, policies and procedures designed to address these risks. As part
of its regular oversight of the Trust, the Board, directly or through a Committee, interacts with the Trust&#8217;s Chief Compliance Officer,
the Trust&#8217;s independent public accounting firm, and legal counsel to the Trust. These interactions include discussing the Trust&#8217;s
risk management and controls with the independent registered public accounting firm engaged by the Trust, reviewing valuation policies
and procedures and the valuations of specific restricted securities, and receiving periodic reports from the Trust&#8217;s Chief Compliance
Officer regarding compliance matters relating to the Trust and its major service providers, including results of the implementation and
testing of the Trust&#8217;s and such providers&#8217; compliance programs. The Board&#8217;s oversight function is facilitated by management
reporting processes designed to provide information to the Board regarding the identification, assessment, and management of critical
risks and the controls and policies and procedures used to mitigate those risks. The Board reviews its role in supervising the Trust&#8217;s
risk management from time to time and may change the manner in which it fulfills its oversight responsibilities at its discretion at any
time.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">20&#160;</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Board has determined that its leadership structure is appropriate
for the Trust because it enables the Board to exercise informed and independent judgment over matters under its purview, allocates responsibility
among committees in a manner that fosters effective oversight and allows the Board to devote appropriate resources to specific issues
in a flexible manner as they arise. The Board periodically reviews its leadership structure as well as its overall structure, composition,
and functioning, and may make changes at its discretion at any time.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s Declaration of Trust provides that the Trust will indemnify
Trustees and officers and may indemnify employees and agents of the Trust against liabilities and expenses incurred in connection with
claims or litigation in which they may be involved because of their offices with the Trust. However, nothing in the Declaration of Trust
or the By-laws of the Trust protects or indemnifies a Trustee, officer, employee or agent against any liability to which he or she would
otherwise be subject by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the
conduct of his or her office.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The names of the Trustees and officers of the Trust, their addresses,
ages and principal occupations during the past five years, and, in the case of the Trustees, their positions with certain other organizations
and publicly-held companies, are provided in the tables below. Trustees that are deemed &#8220;interested persons&#8221; (as that term
is defined in Section&#160;2(a)(19) of the Investment Company Act) of the Trust or the Investment Adviser are included in the table titled
&#8220;Interested Trustees.&#8221; Trustees who are not interested persons as described above are referred to as Independent Trustees.
The Trust and Tekla Healthcare Investors (&#8220;HQH&#8221;), Tekla Life Sciences Investors (&#8220;HQL&#8221;), and Tekla Healthcare
Opportunities Fund (&#8220;THQ&#8221;), other closed-end investment companies advised by the Investment Adviser, are the only four portfolios
in the &#8220;Fund Complex.&#8221; Each Trustee also serves as a trustee for HQL, HQH and THQ.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Trustees</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="border-bottom:Black 1pt solid;width:27%">
        <p style="font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NAMES, ADDRESSES<sup>(1)</sup>&#160;AND<br />DATES OF BIRTH</strong></p></td>
    <td style="padding-bottom:1pt;width:1%">&#160;</td>
    <td style="border-bottom:Black 1pt solid;width:20%">
        <p style="font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>POSITION WITH THE<br />TRUST, TERM OF<br />OFFICE<sup>(2)</sup>&#160;AND
        LENGTH<br />OF TIME SERVED</strong></p></td>
    <td style="padding-bottom:1pt;width:1%">&#160;</td>
    <td style="border-bottom:Black 1pt solid;width:35%">
        <p style="font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>PRINCIPAL OCCUPATION(S)&#160;AND OTHER </strong></p>
        <p style="font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>DIRECTORSHS HELD DURING PAST 5 YEARS</strong></p></td>
    <td style="padding-bottom:1pt;width:1%">&#160;</td>
    <td style="border-bottom:Black 1pt solid;width:15%">
        <p style="font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NUMBER OF<br />PORTFOLIOS IN<br />TRUST<br />COMPLEX<br />OVERSEEN
        BY<br />TRUSTEE</strong></p></td></tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td>&#160;</td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td>&#160;</td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td><strong>INDEPENDENT TRUSTEES:</strong></td>
    <td>&#160;</td>
    <td style="vertical-align:top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align:top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align:top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align:top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align:top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align:top">&#160;</td></tr>
  <tr style="vertical-align:top">
    <td>Jeffrey A. Bailey<br />4/1962</td>
    <td>&#160;</td>
    <td>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Trustee since 2020</p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Chairman since 2022</p></td>
    <td>&#160;</td>
    <td>CEO,&#160;IlluminOss Inc. (2018-2020); Vice President, Janssen Pharmaceutica (Johnson&#160;&#38; Johnson) (1984-2006); Board Chairperson,
        Aileron Therapeutics Inc. (since 2018); Director, Madison Vaccines,&#160;Inc. (since 2018); Director and CEO, BioDelivery Systems,&#160;Inc.
        (2020-2022).</td>
    <td>&#160;</td>
    <td style="padding-left:6.75pt">4</td></tr>
  <tr style="vertical-align:top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left:6.75pt">&#160;</td></tr>
  <tr style="vertical-align:top">
    <td>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Kathleen L. Goetz</p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">4/1966</p></td>
    <td>&#160;</td>
    <td>Trustee since 2021</td>
    <td>&#160;</td>
    <td>Independent Consultant (Since 2020); Vice President and Head of Sales, Novartis Pharmaceuticals (2017-2019); Executive Director of Strategic
        Account Management, Novartis Pharmaceuticals (2015-2016).</td>
    <td>&#160;</td>
    <td style="padding-left:6.75pt">4</td></tr>
  <tr style="vertical-align:top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left:6.75pt">&#160;</td></tr>
  <tr style="vertical-align:top">
    <td>Rakesh K. Jain, Ph.D.<br />12/1950</td>
    <td>&#160;</td>
    <td>Trustee since 2015</td>
    <td>&#160;</td>
    <td>Director, Steele Lab of Tumor Biology at Massachusetts General Hospital (since 1991); A.W. Cook Professor of Tumor Biology (Radiation
        Oncology) at Harvard Medical School (since 1991); Ad hoc Consultant/Scientific Advisory Board Member for pharmaceutical/biotech companies
        (various times since 2002); Ad hoc Consultant, Gershon Lehman Group (since 2004); Director, Co-Founder, XTuit Pharmaceuticals,&#160;Inc.
        (2012-2018).</td>
    <td>&#160;</td>
    <td style="padding-left:6.75pt">4</td></tr>
  </table>

<p style="margin:0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">21&#160;</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="margin:0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:27%">Thomas M. Kent, CPA<br />6/1953</td>
    <td style="width:1%">&#160;</td>
    <td style="width:20%">Trustee since 2017</td>
    <td style="width:1%">&#160;</td>
    <td style="width:35%">Director, Principal Global Investors Trust Co. (since 2014); Trustee, Thayer Academy (2009-2018); Director, New England
        Canada Business Council (since 2017).</td>
    <td style="width:1%">&#160;</td>
    <td style="padding-left:6.75pt;width:15%">4</td></tr>
  <tr style="vertical-align:top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left:6.75pt">&#160;</td></tr>
  <tr style="vertical-align:top">
    <td>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">W. Mark Watson, CPA</p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">7/1950</p></td>
    <td>&#160;</td>
    <td>Trustee since 2022</td>
    <td>&#160;</td>
    <td>Director, BioDelivery Sciences International,&#160;Inc. (2017-2022); Director,&#160;Inhibitor Therapeutics,&#160;Inc. (since 2014); Director,
        Global Health MCS, (since 2014); Director, Sykes Enterprises,&#160;Inc. (2018-2021); Director, The Moffitt Cancer Center (since 2009).</td>
    <td>&#160;</td>
    <td style="padding-left:6.75pt">4</td></tr>
  </table>

<p style="margin:0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="border-bottom:Black 1pt solid;width:27%">
        <p style="font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NAMES, ADDRESSES<sup>(1)</sup>&#160;AND<br />DATES OF BIRTH</strong></p></td>
    <td style="padding-bottom:1pt;width:1%">&#160;</td>
    <td style="border-bottom:Black 1pt solid;width:20%">
        <p style="font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>POSITION WITH THE<br />TRUST, TERM OF<br />OFFICE<sup>(2)</sup>&#160;AND
        LENGTH<br />OF TIME SERVED</strong></p></td>
    <td style="padding-bottom:1pt;width:1%">&#160;</td>
    <td style="border-bottom:Black 1pt solid;width:35%">
        <p style="font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>PRINCIPAL OCCUPATION(S)&#160;DURING PAST 5 </strong></p>
        <p style="font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>YEARS AND OTHER DIRECTORSHIPS HELD</strong></p></td>
    <td style="padding-bottom:1pt;width:1%">&#160;</td>
    <td style="border-bottom:Black 1pt solid;width:15%">
        <p style="font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NUMBER OF<br />PORTFOLIOS IN<br />TRUST<br />COMPLEX<br />OVERSEEN
        BY<br />TRUSTEE</strong></p></td></tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td><strong>INTERESTED TRUSTEES:</strong></td>
    <td>&#160;</td>
    <td style="vertical-align:top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align:top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align:top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align:top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align:top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align:top">&#160;</td></tr>
  <tr style="vertical-align:top">
    <td>
        <p style="margin-top:0;margin-bottom:0">Daniel R. Omstead, Ph.D.<sup>(3)</sup><br />7/1953</p></td>
    <td>&#160;</td>
    <td>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">President since 2015</p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Trustee since 2015</p></td>
    <td>&#160;</td>
    <td>President of the Fund (since 2015), Tekla Healthcare Investors (HQH) (since 2001), Tekla Life Sciences Investors (HQL) (since 2001), Tekla
        Healthcare Opportunities Fund (THQ) (since 2014); President, Chief Executive Officer and Managing Member of Tekla Capital Management LLC
        (since 2002); Director: Palyon Medical Corporation (2009-2015); Tibion Corporation (2011-2013); Celladon Corporation (2012-2014); IlluminOss
        Medical,&#160;Inc. (2011-2020); Magellan Diagnostics,&#160;Inc.(2006-2016); Dynex Corporation (2011-2017); Insightra Medical,&#160;Inc.
        (2015-2016); Neurovance,&#160;Inc. (2015-2017); EBI Life Sciences,&#160;Inc. (2015-2017); Euthymics Biosciences,&#160;Inc. (2015-2017);
        Veniti,&#160;Inc. (2015-2018);Joslin Diabetes Center (2016-2019); Decipher Biosciences,&#160;Inc. (2016-2018).</td>
    <td>&#160;</td>
    <td style="padding-left:6.75pt">4</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:3pt;margin-bottom:3pt;width:25%">

<div style="border-top:Black 1pt solid;font-size:1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0">&#160;</td>
    <td style="width:0.25in">(1)</td>
    <td>The address for each Trustee is: c/o Tekla World Healthcare, 100 Federal Street, 19<sup>th</sup> Floor, Boston, Massachusetts, 02110,
        617-7728500.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0">&#160;</td>
    <td style="width:0.25in">(2)</td>
    <td>Each Trustee currently is serving a three year term.</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0">&#160;</td>
    <td style="width:0.25in">(3)</td>
    <td>Trustee considered to be an &#8220;interested person&#8221; within the meaning of the Investment Company Act of 1940 through his position
        or affiliation with the Investment Adviser.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Board believes that each Trustee&#8217;s experience, qualifications,
attributes and skills on an individual basis and in combination with those of other Trustees lead to the conclusion that each Trustee
should serve in such capacity. Among the attributes or skills common to all Trustees are their ability to review critically and to evaluate,
question and discuss information provided to them, to interact effectively with the other Trustees, the Trust&#8217;s Investment Adviser,
the administrator and other service providers, counsel and independent registered public accounting firm, and to exercise effective and
independent business judgment in the performance of their duties as Trustees. Each Trustee&#8217;s ability to perform the duties of a
trustee effectively has been attained and enhanced through the Trustee&#8217;s education, professional training and other life experiences,
such as business, consulting or public service positions and through experience from service as a member of this Trust&#8217;s Board and
that of HQH, HQL and THW, public companies, or non-profit entities or other organizations.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Jeffrey A. Bailey: </i>Mr.&#160;Bailey is a seasoned operational healthcare
executive with over 30 years of leadership experience within the healthcare industry. Mr.&#160;Bailey serves as Chairman of the Board
of Trustees of the Trust and also serves as Chairman of the Trust&#8217;s</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">22&#160;</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Valuation Committee and serves on the Trust&#8217;s Governance and Nominating
Committee. Mr.&#160;Bailey has extensive business development and transactional expertise, with diverse leadership experiences in commercial
and supply chain management, finance, business development and product development for various pharmaceutical medical device companies.
Most recently, Mr.&#160;Bailey served as <span style="color:#202529">chief executive officer and director of IlluminOss Medical,&#160;Inc.,
a medical device company, from 2018 to 2020. From December&#160;2015 until March&#160;2017, Mr.&#160;Bailey served as chief executive
officer of Neurovance,&#160;Inc., a biotechnology company. Previously, from January&#160;2013 through June&#160;2015, Mr.&#160;Bailey
served as president and chief executive officer and as a director of Lantheus Medical Imaging,&#160;Inc., a public medical diagnostic
company. Prior to 2013, Mr.&#160;Bailey held various leadership positions with several public and private pharmaceutical and medical device
companies, including president and general manager at Novartis Pharmaceuticals, a multinational pharmaceutical company, and a 22-year
career with Johnson&#160;&#38; Johnson, multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company.
Mr.</span>&#160;Bailey also has extensive board member experience, having previously served on boards of directors for eight companies.
Mr.&#160;Bailey currently serves as a director for Aileron Therapeutics Inc. and Madison Vaccines,&#160;Inc. Mr.&#160;Bailey holds a BA
in business administration from Rutgers University.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Kathleen Goetz: </i>Ms.&#160;Goetz was Vice President Head of Sales
at Novartis Pharmaceuticals, a global healthcare company until 2019. Ms.&#160;Goetz serves on the Audit Committee and Valuation Committee
of the Trust. Ms.&#160;Goetz brings over 30 years of healthcare business and leadership experience, including experience working within
a spectrum of diverse healthcare stakeholders and ecosystems. She brings extensive knowledge of the healthcare provider, a deep understanding
of payor interests and the needs of the patient. During her 28 years with Novartis, Ms.&#160;Goetz held positions of increasing responsibility,
leading marketing, sales and reimbursement teams through various stages of commercialization from pre-launch planning through to loss
of exclusivity across diverse therapeutic areas. Other key roles during her time at Novartis also include National Executive Director
of Strategic Accounts,&#160;Integrated Market Planning and Marketing Director, providing her with valuable experience leading organizational
transformation, resourcing, forecasting, and analytics. Early in her career Ms.&#160;Goetz spent time working at Centocor Biologics. She
continues to act as a mentor to future leaders and as a champion for diversity through her past work as an Executive Leadership Development
mentor and a former Novartis Pharmaceuticals Women in Leadership Chair. Ms.&#160;Goetz has won numerous healthcare and business leadership
awards and recognition throughout her career, including being recognized with the Healthcare Women's Business Association Rising Star
Award. She continues to act as an independent consultant within the pharmaceutical and biotech industry. Ms.&#160;Goetz holds a Business
Finance degree from Iowa State University.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Rakesh K. Jain, Ph.D.: </i>Dr.&#160;Rakesh Jain is the A. W. Cook Professor
of Radiation Oncology (Tumor Biology) at Harvard Medical School and the Director of the E. L. Steele Laboratories of Tumor Biology at
Massachusetts General Hospital, providing the Trust with a valuable perspective on emerging life sciences technologies. Dr.&#160;Jain
is Chairperson of the Governance and Nominating Committee of the Trust. Dr.&#160;Jain co-founded XTuit Pharmaceuticals,&#160;Inc. in 2012,
where he also served as a board member until 2018. He serves <span style="color:#202529">as Chairman of</span> the Trust&#8217;s Governance
and Nominating Committee. Prior to joining Harvard, he was professor of chemical engineering at Columbia University and Carnegie Mellon
University. Dr.&#160;Jain is regarded as a pioneer in the fields of tumor biology, drug delivery, in vivo imaging and bioengineering.
Dr.&#160;Jain has authored more than 750 publications. He serves on advisory panels to government, industry and academia, and has served
or continues to serve on editorial advisory boards of twenty journals, including Journal of Clinical Oncology and Nature Reviews Clinical
Oncology. He has received more than 90 major awards and lectureships, including the United States National Medal of Science, a Guggenheim
Fellowship, the Humboldt Senior Scientist Award, the National Cancer Institute&#8217;s Research Career Development Award and Outstanding
Investigator Grant, the Academic Scientist of the Year Award from the Pharmaceutical Achievements Awards, the Distinguished Service Award
from Nature Biotechnology and the Innovator Award from the DoD Breast Cancer Program. He is a member of all three branches of U.S. National
Academies &#8211; the Institute of Medicine, the National Academy of Engineering and the National Academy of Sciences and is a member
of both the National Academy of Investors and the American Academy of Arts and Sciences. In May&#160;2016, Dr.&#160;Jain received the
National Medal of Science from President Obama at the White House.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Thomas M. Kent, CPA: </i>Mr.&#160;Kent was a Partner at PricewaterhouseCoopers,
LLP, where he served the Investment Management Industry for over 30 years, 24 years as a Partner. In so doing, he worked with and for
more than 20 different and distinct Investment Company Boards, and alongside several of those Boards&#8217; service providers, including
Advisors, Custodians, Accounting Agents, Transfer Agents, Security Pricing Providers, Tax advisors and others. His clients included both
large and small fund groups, with both open-end and closed-end fund structures. Therefore, he provides Trust with deep expertise in audit,
valuation, operational and governance matters. He serves as Chairman of the Trust&#8217;s Audit Committee <span style="color:#202529">and
serves </span>on the Trust&#8217;s Governance and Nominating Committee. Mr.&#160;Kent also serves as a Director of Principal Global Investors
Trust Co., and a Director of the New England Canada Business Council. Mr.&#160;Kent is a member of the American Institute of CPA&#8217;s
and the Massachusetts Society of CPA&#8217;s where he serves on the Registered Investment Company Committee. He received his AB cum laude
from Harvard College, where he majored in Economics and his MS in Accountancy from the Stern School of Business at New York University.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">23&#160;</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Daniel R. Omstead, Ph.D.: </i>Dr.&#160;Omstead is President and Chief
Executive Officer of Tekla Capital Management LLC, a registered investment adviser that serves as investment adviser to the Trust. Dr.&#160;Omstead
is also President of the Trust and serves on its Valuation Committee. Dr.&#160;Omstead is portfolio manager for the public and restricted/venture
portfolios within the Trust. As part of these responsibilities, Dr.&#160;Omstead is a member of the Board of Directors of a portfolio
company,&#160;IlluminOss Medical,&#160;Inc. Prior to joining the Adviser, Dr.&#160;Omstead was President and CEO of Reprogenesis,&#160;Inc.,
a private development stage biotech company which developed therapies in the field of tissue engineering and regenerative medicine. Before
joining Reprogenesis, Dr.&#160;Omstead was Senior Vice President, Research and Development, at Cytotherapeutics,&#160;Inc, a public biotech
company. Prior to entering the biotech industry, Dr.&#160;Omstead was employed for fourteen years in positions of increasing responsibility
within the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both
divisions of Johnson&#160;&#38; Johnson, and at Merck, Sharp and Dohme Research Laboratories, a division of Merck&#160;&#38; Co.,&#160;Inc.
Dr.&#160;Omstead provides the Trust with insights into both pharmaceutical and biotech companies. Dr.&#160;Omstead holds Ph.D. and Master&#8217;s
Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.
He is an emeritus member of the Board of Directors of a non-profit agency that provides emergency shelter, housing and supportive services
to homeless and low-income individuals and families in the Boston area. Dr.&#160;Omstead was also a member of the Board of Trustees at
the Joslin Diabetes Center.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>W. Mark Watson, CPA</i>: Mr.&#160;Watson is a Certified Public Accountant
with over 40 years of experience in public accounting and auditing, having spent his entire career from January&#160;1973 to June&#160;2013
at Deloitte Touche Tohmatsu, the multinational professional services network, and its predecessor, most recently as Central Florida Marketplace
Leader. Mr.&#160;Watson serves on the Valuation Committee and the Audit Committee of the Trust. Mr.&#160;Watson provides the Trust with
a particular expertise in the health and life sciences sector, having played a significant role in the development of Deloitte's audit
approach for health and life sciences companies and leading its national healthcare regulatory and compliance practice. He has served
as lead audit partner and advisory partner on the accounts of many public companies ranging from middle market firms to Fortune 500 enterprises.
Mr.&#160;Watson is a member of the American Institute of Certified Public Accountants and the Florida Institute of Certified Public Accountants.
Mr.&#160;Watson is a member of the Board of Directors of Inhibitor Therapeutics,&#160;Inc., Global Health MCS and the Moffitt Cancer Center.
He received his undergraduate degree in Accounting from Marquette University.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Officers</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="width:27%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NAME, ADDRESS<sup>(1)</sup>&#160;AND
        DATE<br />OF BIRTH</strong></p></td>
    <td style="width:1%">&#160;</td>
    <td style="width:28%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>POSITION(S)&#160;HELD
        WITH<br />THE TRUST, TERM OF<br />OFFICE<sup>(2)</sup> AND LENGTH OF<br />TIME SERVED</strong></p></td>
    <td style="width:1%">&#160;</td>
    <td style="width:43%">
        <p style="font:9pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>PRINCIPAL OCCUPATION(S)&#160;AND OTHER </strong></p>
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>DIRECTORSHIPS
        HELD DURING PAST 5 YEARS</strong></p></td></tr>
  <tr style="vertical-align:top">
    <td style="padding-top:5.4pt;padding-bottom:5.4pt">Daniel R. Omstead, Ph.D.<br />7/1953</td>
    <td style="padding-top:5.4pt;padding-bottom:5.4pt">&#160;</td>
    <td style="padding-top:5.4pt;padding-bottom:5.4pt">President since 2015</td>
    <td style="padding-top:5.4pt;padding-bottom:5.4pt">&#160;</td>
    <td style="padding-top:5.4pt;padding-bottom:5.4pt">President of the Fund, HQH (since 2001), HQL (since 2001), THQ (since 2014); President,
        Chief Executive Officer and Managing Member of Tekla Capital Management LLC (since 2002).</td></tr>
  <tr style="vertical-align:top">
    <td>Laura Woodward, CPA<br />11/1968</td>
    <td>&#160;</td>
    <td>Chief Compliance Officer, Secretary and Treasurer since 2015</td>
    <td>&#160;</td>
    <td>Chief Compliance Officer, Secretary and Treasurer of the Fund, HQH (since 2009), HQL (since 2009), THQ (since 2014); Chief Compliance
        Officer and Vice President of Fund Administration, Tekla Capital Management LLC (since 2009); Senior Manager, PricewaterhouseCoopers LLP
        (1990-2009).</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">____________________</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0">&#160;</td>
    <td style="width:0.25in">(1)</td>
    <td>The address for each Officer is: c/o Tekla World Healthcare Fund, 100 Federal Street, 19<sup>th</sup> Floor, Boston, Massachusetts, 02110,
        617-772-8500.</td></tr>
  <tr style="vertical-align:top">
    <td style="width:0">&#160;</td>
    <td style="width:0.25in">(2)</td>
    <td>Each Officer serves in such capacity for an indefinite period of time at the pleasure of the Trustees.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Ownership of Securities</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">As of September&#160;6, 2022, the Trust&#8217;s Trustees and executive
officers, as a group, beneficially owned less than 1% of the Trust&#8217;s outstanding Shares. The information as to beneficial ownership
of securities which appears below is based on statements furnished to the Trust by its Trustees and executive officers.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">24</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">To the knowledge of the Trust, as of September&#160;6, 2022, there were
no control persons of the Trust and no persons were known to own, either beneficially or of record, 5% or more of the Shares of the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">As of March&#160;31, 2022, the dollar range of equity securities owned
beneficially by each Trustee in the Trust and in any registered investment companies overseen by the Trustee within the same family of
investment companies as the Trust is as follows:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Independent Trustees</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="width:30%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Name of Trustee</strong></p></td>
    <td style="width:1%">&#160;</td>
    <td style="width:28%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Dollar Range
        of Equity Securities in<br />the Trust</strong></p></td>
    <td style="width:1%">&#160;</td>
    <td style="width:40%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Aggregate Dollar
        Range of Equity Securities in All<br />Registered Investment Companies Overseen by<br />Trustee in Family of Investment Companies*</strong></p></td></tr>
  <tr style="vertical-align:bottom">
    <td>Jeffrey A. Bailey</td>
    <td>&#160;</td>
    <td>$10,001-$50,000</td>
    <td>&#160;</td>
    <td>$50,001-$100,000</td></tr>
  <tr style="vertical-align:bottom">
    <td>Kathleen L. Goetz</td>
    <td>&#160;</td>
    <td>$10,001-$50,000</td>
    <td>&#160;</td>
    <td>$10,001-$50,000</td></tr>
  <tr style="vertical-align:bottom">
    <td>Rakesh K. Jain, Ph.D.</td>
    <td>&#160;</td>
    <td>None</td>
    <td>&#160;</td>
    <td>None</td></tr>
  <tr style="vertical-align:bottom">
    <td>Thomas M. Kent</td>
    <td>&#160;</td>
    <td>$10,001-$50,000</td>
    <td>&#160;</td>
    <td>Over $100,000</td></tr>
  <tr style="vertical-align:bottom">
    <td>W. Mark Watson, CPA</td>
    <td>&#160;</td>
    <td>None</td>
    <td>&#160;</td>
    <td>None</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Interested Trustees</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="width:30%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Name of Trustee</strong></p></td>
    <td style="width:1%">&#160;</td>
    <td style="width:28%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Dollar Range
        of Equity Securities in<br />the Trust</strong></p></td>
    <td style="width:1%">&#160;</td>
    <td style="width:40%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>Aggregate Dollar
        Range of Equity Securities in All<br />Registered Investment Companies Overseen by<br />Trustee in Family of Investment Companies*</strong></p></td></tr>
  <tr style="vertical-align:bottom">
    <td>Daniel R. Omstead, Ph.D.</td>
    <td>&#160;</td>
    <td>Over $100,000</td>
    <td>&#160;</td>
    <td>Over $100,000</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">_______________</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0">&#160;</td>
    <td style="width:0.25in">*</td>
    <td><i>The Family of Investment Companies includes the four funds that the Adviser serves as investment adviser. This includes the Trust,
        HQH, HQL and THQ.</i></td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Dr.&#160;Omstead and Ms.&#160;Woodward serve as officers of the Trust.
As of September&#160;7, 2022, the officers of the Trust beneficially owned 30,768 Shares of the Trust, or less than 1% of the Shares outstanding
on that date.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Independent Trustee Transactions/Relationships with Trust Affiliates</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">As of December&#160;31, 2021, neither the Independent Trustees nor members
of their immediate families owned securities, beneficially or of record, of the Advisor, or an affiliate or person directly or indirectly
controlling, controlled by, or under common control with the Advisor. In addition, over the past five years, neither Independent Trustees
nor members of their immediate families have had any direct or indirect interest, the value of which exceeds $120,000, in the Advisor
or any of its affiliates. Further, during each of the last two fiscal years, neither Independent Trustees nor members of their immediate
families have conducted any transactions (or series or transactions) or maintained any direct or indirect relationship in which the amount
involved exceeds $120,000 and to which the Advisor or any of its affiliates was a party.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Standing Committees</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Audit Committee. </i>The Trust has an Audit Committee comprised solely
of Independent Trustees who are &#8220;independent&#8221; as defined in the New York Stock Exchange (&#8220;NYSE&#8221;) Listing Standards.
The Board has adopted a written charter for the Audit Committee. The Audit Committee charter is available at <span style="text-decoration:underline">www.teklacap.com/funds/thw/info/literature</span>.
The principal purpose of the Trust&#8217;s Audit Committee is to assist the Board in fulfilling its responsibility to oversee management&#8217;s
conduct of the Trust&#8217;s financial reporting process, including reviewing the financial reports and other financial information provided
by the Trust, the Trust&#8217;s systems of internal accounting and financial controls and the annual independent audit process.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">For the Trust, the Audit Committee&#8217;s role is one of oversight, and
it is recognized that the Trust&#8217;s management is responsible for preparing the Trust&#8217;s financial statements and that the outside
auditor is responsible for auditing those financial statements. Although the Audit Committee member must be financially literate and one
member must have accounting or financial management expertise (as determined by the Board in its business judgment), Audit Committee members
are not professionally engaged in the practice of accounting or auditing and are not experts in the fields of accounting or auditing,
including with respect to auditor independence. Audit Committee members rely, without independent verification, on the information provided
to them and on the representations made by management and the Trust&#8217;s independent public accountants.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">25</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The members of the Trust&#8217;s Audit Committee are Mr.&#160;Kent, Ms.&#160;Goetz,
and Mr.&#160;Watson. Mr.&#160;Kent is the Chairman of the Trust&#8217;s Audit Committee. The Trust&#8217;s Audit Committee held four meetings
during the fiscal year ended September&#160;30, 2021.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Governance and Nominating Committee. </i>The Trust has a Governance
and Nominating Committee comprised solely of Independent Trustees who are &#8220;independent&#8221; as defined in the NYSE Listing Standards.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The principal missions of the Committee are to (i)&#160;review, evaluate,
and enhance the effectiveness of the Board in its role in governing the Trust and overseeing the management of the Trust and (ii)&#160;promote
the effective participation of qualified individuals on the Board, on committees of the Board, and as executive officers of the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Committee reviews, discusses and makes recommendations to the Board
relating to those issues that pertain to the effectiveness of the Board in carrying out its responsibilities in governing the Trust and
overseeing the Trust&#8217;s management. The Committee makes nominations for trustees and officers of the Trust and for membership on
all committees of the Board and submits such nominations to the full Board for consideration.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s By-Laws require that each prospective trustee candidate
have a college degree or equivalent business experience and provide a list of minimum qualifications for trustees, which include expertise,
experience or relationships relevant to the business of the Trust. The Trust&#8217;s By-Laws also require that a candidate is not serving
in any of various positions with another investment company (as defined in the Investment Company Act) that focuses its investments in
the healthcare and/or life sciences industries, unless such investment company is managed by the Trust&#8217;s Investment Adviser or an
affiliate, or in various positions with the investment adviser, sponsor or equivalent of such an investment company. The Committee may
also take into account other factors when considering and evaluating potential trustee candidates, including but not limited to: (i)&#160;availability
and commitment to attend meetings and perform responsibilities of the Board; (ii)&#160;relevant industry and related experience; (iii)&#160;educational
background; (iv)&#160;financial expertise; (v)&#160;the candidate&#8217;s ability, judgment and expertise; and (vi)&#160;the overall diversity
of the Board&#8217;s composition.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Committee may identify prospective trustees from any reasonable source,
including, but not limited to, the consultation of third-party trustee search services. The Committee will consider potential trustee
candidates recommended by Shareholders, provided that the proposed candidates (i)&#160;satisfy any minimum qualifications of the Trust
for its trustees; (ii)&#160;are not &#8220;interested persons&#8221; (as that term is defined in Section&#160;2(a)(19) of the Investment
Company Act) of the Trust or the Investment Adviser; and (iii)&#160;are &#8220;independent&#8221; as defined in the NYSE Listing Standards.
In order to be evaluated by the Committee, trustee candidates recommended by Shareholders must also meet certain eligibility requirements
as set out in the Committee&#8217;s Charter. Other than those eligibility requirements, the Committee shall not evaluate Shareholder trustee
nominees in a different manner than other nominees. The standard of the Committee is to treat all equally qualified nominees in the same
manner.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">All recommendations by Shareholders must be received by the Trust by the
deadline for submission of any Shareholder proposals which would be included in the Trust&#8217;s proxy statement for the next annual
meeting of the Trust. Each Shareholder or Shareholder group must meet the requirements stated in the Committee&#8217;s charter in order
to recommend a candidate. A Shareholder or Shareholder group may not submit more than one candidate per year. When recommending a trustee
candidate, Shareholders must include in their notice to the Trust&#8217;s Secretary: (i)&#160;the Shareholder&#8217;s contact information;
(ii)&#160;the trustee candidate&#8217;s contact information and the number of Trust shares owned by the proposed candidate; (iii)&#160;all
information regarding the candidate that would be required to be disclosed in solicitations of proxies for elections of trustees required
by Regulation 14A of the Securities Act of 1934, as amended; and (iv)&#160;a notarized letter executed by the trustee candidate, stating
his or her intention to serve as a nominee and be named in the Trust&#8217;s proxy statement, if nominated by the Board, and to serve
as a trustee, if so elected. Once a recommendation has been timely received in proper form, the candidate will be asked to complete an
eligibility questionnaire to assist the Trust in assessing the candidate&#8217;s qualifications as a potential Independent Trustee and
as someone who is &#8220;independent&#8221; under the NYSE Listing Standards. The Committee will make such determinations in its sole
discretion and such determinations shall be final.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The members of the Committee are Mr.&#160;Bailey, Dr.&#160;Jain, and Mr.&#160;Kent.
Dr.&#160;Jain is the Chairman of the Committee. During the fiscal year ended September&#160;30, 2021, the governance and nominating committee
held four meetings.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Valuation Committee. </i>The Board has delegated to the Trust&#8217;s
Valuation Committee general responsibility for determining, subject to final Board ratification, in accordance with the Trust&#8217;s
valuation procedures, the value of assets held by the Trust on any day on which the net asset value per share is determined. The Valuation
Committee may appoint, and has appointed, a Sub-Committee made up of employees and officers of the Investment Adviser, to deal in the
first instance with day to day valuation decisions, subject to oversight by the Valuation Committee. The Valuation Committee shall meet
as often as necessary to ensure that each action taken by the Sub-Committee is reviewed within a calendar quarter of the occurrence. In
connection with its review, the Valuation Committee shall</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">26</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">ratify or revise the pricing methodologies authorized by the Sub-Committee
since the last meeting of the Valuation Committee. The Valuation Committee is charged with the responsibility of determining the fair
value of the Trust&#8217;s securities or other assets in situations set forth in the Trust&#8217;s valuation procedures.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The members of the Trust&#8217;s Valuation Committee are Mr.&#160;Bailey,
Ms.&#160;Goetz, Mr.&#160;Watson, and Dr.&#160;Omstead. Mr.&#160;Bailey is the Chairman of the Trust&#8217;s Valuation Committee. The Trust&#8217;s
Valuation Committee held four meetings during the fiscal year ended September&#160;30, 2021.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Qualified Legal Compliance Committee. </i>The Trust has a Qualified
Legal Compliance Committee (&#8220;QLCC&#8221;) comprised solely of Independent Trustees. The Board has adopted a written charter for
the QLCC. The principal purpose of the Trust&#8217;s QLCC is to review and respond to reports of Evidence of a Material Violation (as
defined in the QLCC charter). Reporting Evidence of a Material Violation is required under the Standards of Professional Conduct for Attorneys
adopted by the Commission under the Sarbanes-Oxley Act of 2002 (the &#8220;Standards&#8221;). Under the Standards, if an attorney appearing
and practicing before the Commission in the representation of an issuer, such as the Trust, becomes aware of Evidence of a Material Violation
by the issuer or by any officer, trustee, employee or agent of the issuer, the Standards provide for the attorney to report such evidence
to the issuer&#8217;s QLCC forthwith. In discharging its role, the QLCC is granted the power to investigate any Evidence of a Material
Violation brought to its attention with full access to all books, records, facilities and personnel of the Trust and the power to retain
outside counsel, auditors or other experts for this purpose.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The members of the Trust&#8217;s QLCC are Dr.&#160;Jain and Mr.&#160;Kent.
Mr.&#160;Kent is the Chairman of the Trust&#8217;s QLCC. The Trust&#8217;s QLCC had no cause to meet during the fiscal year ended September&#160;30,
2021.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Compensation of Trustees and Officers</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust pays each of the Trustees not affiliated with the Investment
Adviser an annual fee of $17,500. Independent Trustees are also paid $1,000 for each Board meeting attended in person and $750 for each
Committee meeting. The Chairman of the Board receives an additional annual fee of $5,000, the Chairmen of the Audit and Valuation Committees
receive an additional annual fee of $2,000, and the Chairman of the Governance and Nominating Committee receives an additional annual
fee of $2,000. Independent Trustees are also reimbursed for travel expenses incurred in connection with attending such meetings. Trustees
and officers of the Trust who hold positions with the Investment Adviser receive indirect compensation from the Trust in the form of the
investment advisory fee paid to the Investment Adviser.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust has entered into a Services Agreement with the Investment Adviser.
Pursuant to the terms of the Services Agreement, the Trust reimburses the Investment Adviser for a portion of the payment of salary and
provision of benefits to the Trust's Chief Compliance Officer. Trustees and officers of the Trust who hold positions with the Investment
Adviser receive indirect compensation from the investment advisory fee paid to the Investment Adviser by the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The following table sets forth information regarding the estimated compensation
of Trustees by the Trust and other funds managed by the Investment Adviser for the fiscal year ending September&#160;30, 2021, but does
not include expenses. As of the date of this SAI, the Fund Complex was comprised of the Trust, HQH, HQL, and THQ (the &#8220;Funds&#8221;).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">COMPENSATION TABLE</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2021</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td>
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NAME OF TRUSTEE</strong></p></td>
    <td>&#160;</td>
    <td colspan="2">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>AGGREGATE COMPENSATION<br />FROM
        TRUST</strong></p></td>
    <td>&#160;</td>
    <td>
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>PENSION OR RETIREMENT BENEFITS
        ACCRUED AS PART&#160;OF TRUST EXPENSES</strong></p></td>
    <td>&#160;</td>
    <td>
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>ESTIMATED ANNUAL<br />BENEFITS
        UPON RETIREMENT</strong></p></td>
    <td>&#160;</td>
    <td colspan="2">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>TOTAL COMPENSATION<br />FROM TRUST
        AND FUND COMPLEX<br />PAID TO<br />TRUSTEES<sup>(1)</sup></strong></p></td></tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:5.4pt">INDEPENDENT TRUSTEES<sup>(2)</sup></td>
    <td style="padding-top:5.4pt">&#160;</td>
    <td colspan="2" style="padding-top:5.4pt">&#160;</td>
    <td style="padding-top:5.4pt">&#160;</td>
    <td style="padding-top:5.4pt">&#160;</td>
    <td style="padding-top:5.4pt">&#160;</td>
    <td style="padding-top:5.4pt">&#160;</td>
    <td style="padding-top:5.4pt">&#160;</td>
    <td colspan="2" style="padding-top:5.4pt">&#160;</td></tr>
  <tr style="vertical-align:bottom">
    <td style="width:38%">Jeffrey A. Bailey</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:right;width:1%">$</td>
    <td style="padding-right:0.2in;text-align:right;width:15%">26,438</td>
    <td style="width:1%">&#160;</td>
    <td style="width:13%">N/A</td>
    <td style="width:1%">&#160;</td>
    <td style="width:13%">N/A</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:right;width:1%">$</td>
    <td style="padding-right:0.2in;text-align:right;width:15%">104,250</td></tr>
  <tr style="vertical-align:bottom">
    <td>Rakesh K. Jain, Ph.D.</td>
    <td>&#160;</td>
    <td style="text-align:right">$</td>
    <td style="padding-right:0.2in;text-align:right">23,438</td>
    <td>&#160;</td>
    <td>N/A</td>
    <td>&#160;</td>
    <td>N/A</td>
    <td>&#160;</td>
    <td style="text-align:right">$</td>
    <td style="padding-right:0.2in;text-align:right">92,250</td></tr>
  <tr style="vertical-align:bottom">
    <td>Thomas M. Kent, CPA</td>
    <td>&#160;</td>
    <td style="text-align:right">$</td>
    <td style="padding-right:0.2in;text-align:right">26,438</td>
    <td>&#160;</td>
    <td>N/A</td>
    <td>&#160;</td>
    <td>N/A</td>
    <td>&#160;</td>
    <td style="text-align:right">$</td>
    <td style="padding-right:0.2in;text-align:right">104,250</td></tr>
  </table>

<p style="margin:0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">27</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="margin:0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="width:38%">Oleg M. Pohotsky, M.B.A., J.D.<sup>(3)</sup></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:right;width:1%">$</td>
    <td style="padding-right:0.2in;text-align:right;width:15%">31,688</td>
    <td style="width:1%">&#160;</td>
    <td style="width:13%">N/A</td>
    <td style="width:1%">&#160;</td>
    <td style="width:13%">N/A</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:right;width:1%">$</td>
    <td style="padding-right:0.2in;text-align:right;width:15%">126,000</td></tr>
  <tr style="vertical-align:bottom">
    <td>William S. Reardon, M.B.A.<sup>(4)</sup></td>
    <td>&#160;</td>
    <td style="text-align:right">$</td>
    <td style="padding-right:0.2in;text-align:right">28,438</td>
    <td>&#160;</td>
    <td>N/A</td>
    <td>&#160;</td>
    <td>N/A</td>
    <td>&#160;</td>
    <td style="text-align:right">$</td>
    <td style="padding-right:0.2in;text-align:right">112,250</td></tr>
  <tr style="vertical-align:bottom">
    <td>Lucinda H. Stebbins, M.B.A., CPA<sup>(5)</sup></td>
    <td>&#160;</td>
    <td style="text-align:right">$</td>
    <td style="padding-right:0.2in;text-align:right">21,875</td>
    <td>&#160;</td>
    <td>N/A</td>
    <td>&#160;</td>
    <td>N/A</td>
    <td>&#160;</td>
    <td style="text-align:right">$</td>
    <td style="padding-right:0.2in;text-align:right">86,000</td></tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align:bottom">
    <td>INTERESTED TRUSTEES</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align:bottom">
    <td>Daniel R. Omstead, Ph.D.</td>
    <td>&#160;</td>
    <td style="text-align:right">$</td>
    <td style="padding-right:0.2in;text-align:right">0</td>
    <td>&#160;</td>
    <td>N/A</td>
    <td>&#160;</td>
    <td>N/A</td>
    <td>&#160;</td>
    <td style="text-align:right">$</td>
    <td style="padding-right:0.2in;text-align:right">0</td></tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align:bottom">
    <td>EXECUTIVE OFFICER</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align:bottom">
    <td>Laura Woodward.</td>
    <td>&#160;</td>
    <td style="text-align:right">$</td>
    <td style="padding-right:0.2in;text-align:right">50,900</td>
    <td>&#160;</td>
    <td>N/A</td>
    <td>&#160;</td>
    <td>N/A</td>
    <td>&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="padding-right:0.2in;text-align:right">N/A</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">_____________</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0">&#160;</td>
    <td style="width:0.25in">(1)</td>
    <td>The Fund Complex consists of four funds: the Trust, HQH, HQL and THQ.</td></tr>
  <tr style="vertical-align:top">
    <td style="width:0">&#160;</td>
    <td style="width:0.25in">(2)</td>
    <td>Kathleen L. Goetz was appointed as a Trustee effective December&#160;9, 2021. W. Mark Watson was appointed as a Trustee effective June&#160;9,
        2022.</td></tr>
  <tr style="vertical-align:top">
    <td style="width:0">&#160;</td>
    <td style="width:0.25in">(3)</td>
    <td>Mr.&#160;Pohotsky served as an Independent Trustee until he passed away on July&#160;14, 2022.</td></tr>
  <tr style="vertical-align:top">
    <td style="width:0">&#160;</td>
    <td style="width:0.25in">(4)</td>
    <td>Mr.&#160;Reardon served as an Independent Trustee until he retired on June&#160;9, 2022.</td></tr>
  <tr style="vertical-align:top">
    <td style="width:0">&#160;</td>
    <td style="width:0.25in">(5)</td>
    <td>Ms.&#160;Stebbins served as an Independent Trustee until she retired on June&#160;10, 2021.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>THE TRUST</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s capitalization consists of an unlimited number of Shares,
$0.01 par value. Each Share represents an equal proportionate beneficial interest in the Trust and, when issued and outstanding, will
be fully paid and non-assessable by the Trust. Upon any liquidation of the Trust, Shareholders will be entitled to share pro rata in the
net assets of the Trust available for distribution after paying or adequately providing for the payment of all liabilities. The Trust
will send annual and semi-annual financial statements to Shareholders and may also issue more abbreviated interim reports to update Shareholders
on a quarterly basis. The Trust will hold annual meetings of its Shareholders in accordance with the provisions of the Trust&#8217;s By-laws
and the rules&#160;of the NYSE.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Shareholders are entitled to one vote for each whole Share held and a
proportionate fractional vote for each fractional Share held. The Trust&#8217;s Shares do not have cumulative voting rights, which means
that the holders of more than 50% of the Shares of the Trust voting for the election of Trustees can elect all of the Trustees, and, in
such event, the holders of the remaining Shares will not be able to elect any Trustees. The Trust has a staggered Board, whereby one class
of Trustees is elected each year.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust is an entity of the type commonly known as a &#8220;Massachusetts
business trust.&#8221; Under Massachusetts law, shareholders of such a trust under certain circumstances may be determined to be personally
liable as partners for the Trust&#8217;s obligations. However, the Trust&#8217;s Declaration of Trust contains an express disclaimer of
shareholder liability for the acts or obligations of the Trust and provides for indemnification and reimbursement of expenses out of the
Trust&#8217;s property for any shareholder held personally liable for the obligations of the Trust. Thus, the risk of a shareholder incurring
financial loss on account of a Trust liability is limited to circumstances in which the Trust is unable to meet its obligations from the
liquidation of its portfolio investments.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The overall management of the Trust is vested in the Board. The Board
approves all significant agreements between the Trust and persons or companies furnishing services to it, including the Trust&#8217;s
agreements with its Investment Adviser, Custodian, any foreign sub-custodians, Registrar and Transfer Agent. The management of the day-to-day
operations of the Trust is delegated to its officers and to the Investment Adviser, subject always to the investment objective and policies
of the Trust and to general supervision by the Board.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">In addition, the Declaration of Trust requires the affirmative vote or
consent of the holders of 75% of the Shares of the Trust to authorize certain transactions with a person or entity that is directly, or
indirectly through affiliates, the beneficial owner of 5% or more of the outstanding Shares of the Trust unless the Board takes certain
actions to approve such a transaction. These provisions could make it more difficult to change the management of the Trust and could have
the effect of depriving Shareholders of an opportunity to sell their Shares at a premium over prevailing market prices by discouraging
a third party from seeking to obtain control of the Trust in a tender offer or similar transaction.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">28</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Preferred Shares</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Declaration of Trust provides that the Trust has the power to issue
additional Shares by action of the Board without the approval of the holders of the Trust&#8217;s common Shareholders. This power may
be deemed to include the issuance of Preferred Shares with such rights and privileges as may be determined by the Board.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may elect to issue Preferred Shares as part of its leverage
strategy though it does not currently intend to do so. The Trust has the ability to issue Preferred Shares representing up to 50% of the
Trust&#8217;s total assets (less the Trust&#8217;s obligations under senior securities representing indebtedness). The Investment Company
Act permits the issuance of Preferred Shares if, immediately after such issuance, the liquidation value of the Trust&#8217;s outstanding
Preferred Shares exceeds 50% of its assets (including the proceeds from the issuance) less liabilities other than borrowings (i.e., the
value of the Trust&#8217;s assets must be at least 200% of the liquidation value of its outstanding Preferred Shares). In addition, the
Trust would not be permitted to declare any cash dividend or other distribution on its Shares unless, at the time of such declaration,
the value of the Trust&#8217;s assets less liabilities other than borrowings is at least 200% of such liquidation value. Notwithstanding
the Investment Company Act requirement listed above with respect to asset coverage of any Preferred Shares, if Preferred Shares are issued,
the Trust intends to maintain an asset coverage ratio of at least 300%. Although the terms of any Preferred Shares, including dividend
rate, liquidation preference and redemption provisions, would be determined by the Board, subject to applicable law and the Declaration
of Trust, it is likely that the Preferred Shares would be structured to carry a relatively short-term dividend rate reflecting interest
rates on short-term bonds, by providing for the periodic redetermination of the dividend rate at relatively short intervals through an
auction, remarketing or other procedure. The Trust also believes that it is likely that the liquidation preference, voting rights and
redemption provisions of any Preferred Shares would be similar to those stated below.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="text-decoration:underline">Liquidation Preference</span>.
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Trust, the holders of Preferred Shares would
be entitled to receive a preferential liquidating distribution, which would be expected to equal the original purchase price per Preferred
Share plus accrued and unpaid dividends, whether or not declared, before any distribution of assets is made to common shareholders. After
payment of the full amount of the liquidating distribution to which they are entitled, the holders of Preferred Shares would not be entitled
to any further participation in any distribution of assets by the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="text-decoration:underline">Votin</span>g <span style="text-decoration:underline">Ri</span>g<span style="text-decoration:underline">hts</span>.
The Investment Company Act requires that the holders of any Preferred Shares, voting separately as a single class, have the right to elect
at least two Trustees at all times. The remaining Trustees would be elected by holders of Shares and Preferred Shares, voting together
as a single class. In addition, subject to the prior rights, if any, of the holders of any other class of senior securities outstanding,
the holders of any Preferred Shares have the right to elect a majority of the Trustees of the Trust at any time in the event that two
years of dividends on any Preferred Shares are unpaid. The Investment Company Act also requires that, in addition to any approval by shareholders
that might otherwise be required, the approval of the holders of a majority of any outstanding</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Preferred Shares, voting separately as a class, would be required to:
(i)&#160;adopt any plan of reorganization that would adversely affect the Preferred Shares; and (ii)&#160;take any action requiring a
vote of security holders under Section&#160;13(a)&#160;of the Investment Company Act, including, among other things, changes in the Trust&#8217;s
subclassification as a closed-end investment company or changes in its fundamental investment restrictions. As a result of these voting
rights, the Trust&#8217;s ability to take any such actions may be impeded to the extent that there are any Preferred Shares outstanding.
The Board presently intends that, except as otherwise indicated in the Prospectus or the SAI and except as otherwise required by applicable
law or the Declaration of Trust, if Preferred Shares were issued, holders of Preferred Shares would have equal voting rights with common
shareholders (one vote per share, unless otherwise required by the Investment Company Act) and would vote together with common shareholders
as a single class.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The affirmative vote of the holders of a majority of the outstanding Preferred
Shares, voting as a separate class, would be required to amend, alter or repeal any of the preferences, rights or powers of holders of
Preferred Shares so as to affect materially and adversely such preferences, rights or powers, or to increase or decrease the authorized
number of Preferred Shares. The class vote of holders of Preferred Shares described above would in each case be in addition to any other
vote required to authorize the action in question.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="text-decoration:underline">Redemption</span>, <span style="text-decoration:underline">Purchase
and Sale of Preferred Shares b</span>y <span style="text-decoration:underline">the Trust</span>. The terms of any Preferred Shares issued
would be expected to provide that: (i)&#160;they are redeemable by the Trust in whole or in part at the original purchase price per share
plus accrued dividends per share; (ii)&#160;the Trust may tender for or purchase Preferred Shares; and (iii)&#160;the Trust may subsequently
resell any shares so tendered for or purchased. Any redemption or purchase of Preferred Shares by the Trust would reduce any leverage
applicable to the Shares, while any resale of shares by the Trust would increase that leverage.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">29</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The discussion above describes the possible offering of Preferred Shares
by the Trust. If the Board determines to proceed with such an offering, the terms of the Preferred Shares may be the same as, or different
from, the terms described above, subject to applicable law and the Trust&#8217;s Declaration of Trust. The Board, without the approval
of the common shareholders, may authorize an offering of Preferred Shares or may determine not to authorize such an offering, and may
fix the terms of the Preferred Shares to be offered. Shareholders will bear all expenses in connection with the offering and issuance
of Preferred Shares.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Repurchases of Shares and Tender Offers</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust is a closed-end management investment company and as such its
Shareholders do not, and will not, have the right to redeem their Shares of the Trust. The Trustees, however, intend to consider, from
time to time, but not less frequently than annually, the desirability of open market purchases or tender offers. Any such repurchases
will be made in accordance with the applicable provisions of the Investment Company Act and Massachusetts law in open market transactions.
Shares repurchased by the Trust will be held in its treasury. The share repurchase program is intended to enhance shareholder value and
potentially reduce the discount between the market price of the Trust&#8217;s shares and the Trust&#8217;s NAV. There is no assurance
that any action undertaken to repurchase Shares will result in the Shares trading at a price which approximates net asset value. Although
the Trust has no present intention of doing so, it reserves the right to incur debt to finance such repurchases or tender offers. Interest
on any borrowings to finance Share repurchase transactions will increase the Trust&#8217;s expenses and will reduce the Trust&#8217;s
net income. There can be no assurance that Share repurchases, if any, will cause the Shares to trade at a price equal to or in excess
of their net asset value. Nevertheless, the possibility that a portion of the Trust&#8217;s outstanding Shares may be the subject of repurchases
may reduce the spread between market price and net asset value that might otherwise exist. The Trust may not repurchase Shares except
(1)&#160;on a securities exchange and after notification to Shareholders of its intent to purchase Shares within the six months preceding
the purchase, (2)&#160;pursuant to a tender offer to all Shareholders, or (3)&#160;as otherwise permitted by the Commission.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Shares of the Trust will trade in the open market at a price which
will be a function of several factors, including their supply, demand, investment performance and yield. The shares of closed-end investment
companies generally sell at market prices varying from their NAV and such shares frequently trade at a discount to NAV, but in some cases
trade at a premium. The market price of the Shares will be determined by factors including trading volume of</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">such Shares, general market and economic conditions and other factors
beyond the control of the Trust. Therefore, the Trust cannot predict whether its Shares will trade at, below or above NAV. When the Trust
repurchases its Shares for a price below their NAV, the NAV of those Shares that remain outstanding will increase, but this does not necessarily
mean that the market price of those outstanding Shares will be affected, either positively or negatively.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Conversion to Open-End Investment Company</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Under the Declaration of Trust, the conversion of the Trust from a closed-end
to an open-end investment company would require (1)&#160;the approval of the Board, and (2)&#160;the affirmative vote or consent of the
holders of 75% of the Shares outstanding and entitled to vote. Such a vote would be in addition to any vote or consent required in addition
to the vote or consent of Shareholders otherwise required by law or any agreement between the Trust and the NYSE. The Investment Company
Act requires that the Trust receive a vote of a majority of its outstanding voting Shares in order to convert the Trust from a closed-end
to an open-end investment company.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The conversion of the Trust from a closed-end to an open-end investment
company would have to be approved by the Board prior to its submission to Shareholders. A proposal to convert the Trust to an open-end
company might be supported or opposed by the Board depending on the Board&#8217;s judgment as to its advisability in light of circumstances
prevailing at the time.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Shareholders of an open-end investment company may require the company
to redeem their shares at any time (except in certain circumstances as authorized by or under the Investment Company Act) at their NAV,
less such redemption charge, if any, as might be in effect at the time of a redemption. Conversion to an open-end investment company could
require the disposal of illiquid investments to meet current requirements of the Commission that no more than 15% of an open-end investment
company&#8217;s assets consist of illiquid securities, and would likely require involuntary liquidation of portfolio securities, and the
inherent realization of net long-term capital gains in connection therewith, to meet periodic requests for redemption. Moreover, Shares
of the Trust would no longer be listed on the NYSE.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">30</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="text-transform:uppercase"><strong>INVESTMENT
ADVISER AND INVESTMENT ADVISORY AGREEMENT</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Tekla Capital Management LLC, a limited liability company formed under
the laws of the State of Delaware, serves as the Investment Adviser to the Trust. The Investment Adviser is an investment adviser registered
under the Investment Advisers Act of 1940, as amended.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Investment Adviser is located at 100 Federal Street, 19<sup>th </sup>Floor,
Boston, MA 02110.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Investment Adviser is owned by Daniel R. Omstead and Mary N. Omstead.
Dr.&#160;Omstead is currently the President and Chief Executive Officer of the Investment Adviser. Mary N. Omstead is Dr.&#160;Omstead&#8217;s
wife.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Investment Advisory Agreement between the Investment Adviser and the
Trust (the &#8220;Advisory Agreement&#8221;) provides that, subject to the supervision and direction of the Board, the Investment Adviser
is responsible for the actual management of the Trust&#8217;s portfolio. The Investment Adviser is also obligated to supervise or perform
certain administrative and management services for the Trust and is obligated to provide the office space, facilities, equipment and personnel
necessary to perform its duties under the Advisory Agreement. The responsibility for making decisions to buy, sell or hold a particular
security rests with the Investment Adviser. However, the Investment Adviser may consider investment analysis from various sources, including
broker-dealers with which the Trust does business. See &#8220;Portfolio Transactions and Brokerage.&#8221;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Subject to the supervision and direction of the Board, the Investment
Adviser manages the Trust&#8217;s portfolio in accordance with the Trust&#8217;s investment objective and policies as stated in the Prospectus;
makes investment decisions for the Trust; places purchase and sale orders for portfolio transactions for the Trust; supplies the Trust
with office facilities (which may be in the Investment Adviser&#8217;s own offices), statistical and research data, data processing services,
clerical, internal executive and administrative services, and stationery and office supplies; supplies or directs and supervises a third
party administrator or custodian in the provision to the Trust of accounting and bookkeeping services, the calculation of the net asset
value of shares of the Trust, internal auditing services, and other clerical services in connection therewith; and prepares or supervises
and directs a third party administrator or custodian in the preparation of reports to Shareholders of the Trust, tax returns and reports
to and filings with the Commission and state securities authorities. In providing these services, the Investment Adviser provides investment
research and supervision of the Trust&#8217;s investments and conducts a continual program of investment, evaluation and, if appropriate,
sale and reinvestment of the Trust&#8217;s assets. In addition, the Investment Adviser furnishes the Trust with whatever statistical information
the Trust may reasonably request with respect to the securities that the Trust may hold or contemplate purchasing.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">For the services provided by the Investment Adviser under the Advisory
Agreement, the Trust will pay a fee, computed and payable monthly, equal when annualized to (1)&#160;1.00% of the average daily value
of the Trust&#8217;s Managed Assets. &#8220;Managed Assets&#8221; means the total assets of the Trust (including any assets attributable
to borrowings for investment purposes) minus the sum of the Trust&#8217;s accrued liabilities (other than liabilities representing borrowings
for investment purposes).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Advisory Agreement provides that the Investment Adviser shall not
be liable for any loss incurred by any act or omission of any broker. The Advisory Agreement also provides that the Investment Adviser
shall not be liable to the Trust or to any Shareholder of the Trust for any error or judgment or for any loss suffered by the Trust in
connection with rendering services under the Advisory Agreement except (1)&#160;a loss resulting from a breach of fiduciary duty with
respect to the receipt of compensation for services (in which case any award of damages shall be limited to the period and the amount
set forth in Section&#160;36(b)(3)&#160;of the Investment Company Act) or (2)&#160;a loss resulting from willful misfeasance, bad faith
or gross negligence on the part of the Investment Adviser, or reckless disregard of its obligations and duties under the Advisory Agreement.
Subject to the foregoing, the Advisory Agreement also provides that the Trust shall indemnify the Investment Adviser, and any officer,
director and employee of the Investment Adviser to the maximum extent permitted by Article&#160;V of the Trust&#8217;s Declaration of
Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">For the fiscal years ended September&#160;30, 2021, September&#160;30,
2020 and September&#160;30, 2019, the Trust paid the Adviser $6,283,994, $5,475,071 and $5,382,722, respectively, in advisory fees.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The services of the Investment Adviser to the Trust are not deemed to
be exclusive, and nothing in the Advisory Agreement prevents the Investment Adviser, or any affiliate thereof, from providing similar
services to other companies and other clients or from engaging in other activities.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Under the Advisory Agreement, the Investment Adviser has agreed to bear
all expenses in connection with the performance of its services under the Advisory Agreement, including compensation of and office space
for officers and employees of the Trust connected with investment and economic research, trading and investment management of the Trust,
as well as the fees of all Trustees of the</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">31</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Trust who are &#8220;affiliated persons&#8221; of the Investment Adviser,
as that term is defined in the Investment Company Act, or any of its &#8220;affiliated persons.&#8221;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Under the Advisory Agreement, the Trust must pay (or, in the event that
such expenses are paid by the Investment Adviser, shall reimburse the Investment Adviser for) all other expenses incurred in the operation
of the Trust including, among other things, expenses for legal and auditing services, costs of printing proxy statements, prospectuses,
stock certificates and shareholder reports, charges of the custodian, any sub-custodian and transfer agent, expenses in connection with
the Dividend Reinvestment and Stock Purchase Plan, the Commission, and the Financial Regulatory Authority (&#8220;FINRA&#8221;) fees,
fees and expenses of the Trustees who are not &#8220;affiliated persons&#8221; of the Investment Adviser or any of its &#8220;affiliated
persons,&#8221; accounting and valuation costs, administrator&#8217;s fees, membership fees in trade associations, fidelity bond coverage
for the Trust&#8217;s officers and employees, errors and omissions insurance coverage for Trustees and officers, interest, brokerage costs,
taxes, stock exchange listing fees and expenses, expenses of qualifying the Trust&#8217;s Shares for sale in various states, expenses
associated with personnel performing exclusively shareholder servicing functions, litigation and other extraordinary or non-recurring
expenses, and other expenses properly payable by the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Unless earlier terminated as described below, the Advisory Agreement will
remain in effect from year to year if approved annually (1)&#160;by the Board or by the holders of a majority of the Trust&#8217;s outstanding
Shares and (2)&#160;by the majority of the Trustees who are not parties to the Advisory Agreement or interested persons of any such party.
The Advisory Agreement may be terminated without penalty by (1)&#160;the Trust or the Investment Adviser at any time without penalty upon
not less than 30 and no more than 60 days&#8217; written notice or (2)&#160;a vote of the holders of a majority of the Trust&#8217;s outstanding
Shares, and will automatically terminate in the event of its assignment. Action by the Trust under (1)&#160;above may be taken either
by (i)&#160;vote of a majority of its Trustees, or (ii)&#160;the affirmative vote of a majority of the outstanding shares of the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Portfolio Management</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Daniel R. Omstead, Ph.D., Jason C. Akus, M.D./M.B.A., Timothy Gasperoni,
M.B.A., Ph.D., Ashton L. Wilson, Christopher Abbott, Robert Benson, Richard Goss, Loretta Tse, Ph.D., Jack Liu, M.B.A., Ph.D., Christopher
Seitz, M.B.A., Graham Attipoe, M.B.A., M.D. and Kelly Girskis, Ph.D. are members of a team that analyzes investments on behalf of the
Trust. Dr.&#160;Omstead exercises ultimate decision making authority with respect to investments.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Other Accounts Managed</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The information below lists other accounts for which the portfolio management
team was primarily responsible for the day to day management as of September&#160;30, 2021.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td>
        <p style="border-bottom:Black 0.5pt solid;font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Portfolio Managers Name</strong></p></td>
    <td>&#160;</td>
    <td colspan="2">
        <p style="border-bottom:Black 0.5pt solid;font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Registered<br />Investment Companies(1)</strong></p></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom:Black 1pt solid">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.25in"><strong>Other Pooled Investment<br />Vehicles(1)</strong></p></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom:Black 1pt solid">
        <p style="font:10pt Times New Roman, Times, Serif;margin-left:0.25in;text-align:justify;margin-top:0pt;margin-bottom:0pt"><strong>Other<br />Accounts(1)</strong></p></td></tr>
  <tr>
    <td style="width:54%">Daniel R. Omstead, Ph.D.</td>
    <td style="width:1%">&#160;</td>
    <td style="vertical-align:bottom;width:3%;text-align:center">3</td>
    <td style="vertical-align:bottom;width:13%;text-align:right">$2,657,706,608</td>
    <td style="width:2%">&#160;</td>
    <td style="text-align:center;width:2%">0</td>
    <td style="vertical-align:bottom;width:10%;text-align:right">$0</td>
    <td style="width:2%">&#160;</td>
    <td style="text-align:center;width:3%">0</td>
    <td style="vertical-align:bottom;width:10%;text-align:right">$0</td></tr>
  <tr>
    <td>Jason C. Akus, M.D./M.B.A</td>
    <td>&#160;</td>
    <td style="vertical-align:bottom;text-align:center">3</td>
    <td style="vertical-align:bottom;text-align:right">$2,657,706,608</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td></tr>
  <tr>
    <td>Timothy Gasperoni, M.B.A., Ph.D.</td>
    <td>&#160;</td>
    <td style="vertical-align:bottom;text-align:center">3</td>
    <td style="vertical-align:bottom;text-align:right">$2,657,706,608</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td></tr>
  <tr>
    <td>Ashton L. Wilson</td>
    <td>&#160;</td>
    <td style="vertical-align:bottom;text-align:center">3</td>
    <td style="vertical-align:bottom;text-align:right">$2,657,706,608</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td></tr>
  <tr>
    <td>Christopher Abbott</td>
    <td>&#160;</td>
    <td style="vertical-align:bottom;text-align:center">3</td>
    <td style="vertical-align:bottom;text-align:right">$2,657,706,608</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td></tr>
  <tr>
    <td>Robert Benson</td>
    <td>&#160;</td>
    <td style="vertical-align:bottom;text-align:center">3</td>
    <td style="vertical-align:bottom;text-align:right">$2,657,706,608</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td></tr>
  <tr>
    <td>Richard Goss</td>
    <td>&#160;</td>
    <td style="vertical-align:bottom;text-align:center">3</td>
    <td style="vertical-align:bottom;text-align:right">$2,657,706,608</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td></tr>
  <tr>
    <td>Loretta Tse, Ph.D.</td>
    <td>&#160;</td>
    <td style="vertical-align:bottom;text-align:center">3</td>
    <td style="vertical-align:bottom;text-align:right">$2,657,706,608</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td></tr>
  <tr>
    <td>Jack Liu, M.B.A., Ph.D.</td>
    <td>&#160;</td>
    <td style="vertical-align:bottom;text-align:center">3</td>
    <td style="vertical-align:bottom;text-align:right">$2,657,706,608</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td></tr>
  <tr>
    <td>Christopher Seitz, M.B.A.</td>
    <td>&#160;</td>
    <td style="vertical-align:bottom;text-align:center">3</td>
    <td style="vertical-align:bottom;text-align:right">$2,657,706,608</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td></tr>
  <tr>
    <td>Graham Attipoe, M.B.A., M.D.</td>
    <td>&#160;</td>
    <td style="vertical-align:bottom;text-align:center">3</td>
    <td style="vertical-align:bottom;text-align:right">$2,657,706,608</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td></tr>
  <tr>
    <td>Kelly Girskis, Ph.D.</td>
    <td>&#160;</td>
    <td style="vertical-align:bottom;text-align:center">3</td>
    <td style="vertical-align:bottom;text-align:right">$2,657,706,608</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td>
    <td>&#160;</td>
    <td style="text-align:center">0</td>
    <td style="vertical-align:bottom;text-align:right">$0</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">__________</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0">&#160;</td>
    <td style="width:0.25in">(1)</td>
    <td>None of the accounts managed by the portfolio managers are subject to a performance fee.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">32</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Security Ownership of Portfolio Managers</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">As of September&#160;30, 2021, the dollar range of Trust securities beneficially
owned by Dr.&#160;Omstead was over $100,000 and the dollar range of Trust securities beneficially owned by Dr.&#160;Gasperoni was $10,001
- $50,000. As of September&#160;30, 2021, none of the other members of the team owned securities of the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Portfolio Manager Compensation Structure</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Investment Adviser offers employees what it believes are competitive
salaries and benefits in order to attract and retain adequate staff to provide services to the Trusts. The Investment Adviser feels the
current staff level is adequate in size, experience and qualifications to effectively manage both the public and restricted portfolios
of the Trust, HQH, HQL and THQ. The Investment Adviser further believes that the staff has the unique qualifications and experience to
be effective in making purchase and sale decisions.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Dr.&#160;Omstead is an owner of the Investment Adviser. He receives compensation
for his contribution to the portfolio management team and for his contribution to the general management of the Investment Adviser. As
a member of the Investment Adviser, Dr.&#160;Omstead also receives distributions made to members. Currently, such distributions are principally
the result of the investment advisory fees paid to the Investment Adviser by the Trust, HQH, HQL and THQ.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Conflicts of Interest</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Actual or apparent conflicts of interest may arise when a portfolio manager
has day-to-day management responsibilities with respect to more than one fund or other accounts. More specifically, portfolio managers
who manage multiple funds are presented with the potential conflicts discussed below.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The management of multiple accounts may result in a portfolio manager
devoting unequal time and attention to the management of each account. The management of multiple funds and accounts also may give rise
to potential conflicts of interest if the funds and accounts have different objectives, benchmarks, time horizons, and fees as the portfolio
manager must allocate his time and investment ideas across multiple funds and accounts. Another potential conflict of interest may arise
where another account has the same investment objective as the Trust, whereby the portfolio manager could favor one account over another.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">With respect to securities transactions for the Trust, the Adviser determines
which broker to use to execute each order, consistent with the duty to seek best execution of the transaction. A portfolio manager may
execute transactions for another fund or account that may adversely impact the value of securities held by the Trust. Securities selected
for funds or accounts other than the Trust may outperform the securities selected for the Trust. Further, a potential conflict could include
the portfolio managers&#8217; knowledge about the size, timing and possible market impact of Trust trades, whereby they could use this
information to the advantage of other accounts and to the disadvantage of the Trust. These potential conflicts of interest could create
the appearance that a portfolio manager is favoring one investment vehicle over another.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The appearance of a conflict of interest may arise where the Adviser has
an incentive, such as a performance-based management fee. The management of personal accounts may give rise to potential conflicts of
interest; there is no assurance that the Trust&#8217;s Code of Ethics will adequately address such conflicts.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Adviser and the Trust have each adopted a code of ethics that, among
other things, permits personal trading by employees (including trading in securities that can be purchased, sold or held by the Trust)
under conditions where it has been determined that such trades would not adversely impact client accounts. Nevertheless, the management
of personal accounts may give rise to potential conflicts of interest, and there is no assurance that these codes of ethics will adequately
address such conflicts. <i>See &#8220;Code of Ethics&#8221; for more information</i>.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>PROXY
VOTING POLICY AND PROCEDURES</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Board has adopted a proxy voting policy and procedure (the &#8220;Proxy
Voting Policy&#8221;), pursuant to which the Trustees have delegated proxy voting responsibility to the Investment Adviser. A copy of
the Proxy Voting Policy is attached as Appendix A to this SAI.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">33</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A description of the Trust&#8217;s proxy voting policies and procedures
and information on how the Trust voted proxies relating to portfolio securities during the most recent 12-month period ended June&#160;30
is available (1)&#160;without charge, upon request, by calling the Trust at (617) 772-8500, and (2)&#160;on the Securities and Exchange
Commission&#8217;s website at <span style="text-decoration:underline">http://www.sec.gov</span>.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>CODE
OF ETHICS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Board has approved a joint Code of Ethics under Rule&#160;17j-1 of
the Investment Company Act that covers certain personnel of the Trust and the Investment Adviser. The joint Code of Ethics establishes
procedures for personal investing and restricts certain transactions by certain personnel covered by the joint Code of Ethics. Employees
subject to the joint Code of Ethics may invest in securities for their personal investment accounts, including, in certain cases, securities
that may be purchased or held by the Trust. The joint Code of Ethics applies to investments by covered persons in their personal accounts,
the accounts of family members living in the same household, and accounts in which the covered person has a beneficial interest (i.e.,
ownership, voting or investment control). Some of the restrictions set forth in the joint Code of Ethics do not apply to the Trust&#8217;s
Independent Trustees. In general terms, the joint Code of Ethics is designed to ensure that the investing activities of covered personnel
are conducted in a manner that avoids potential or actual conflicts of interest with the Trust and its Shareholders and that covered personnel
conduct their personal investing in a manner consistent with their fiduciary duty towards the Trust and its Shareholders.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The joint Code of Ethics requires pre-clearance for certain investments
in equities (not including mutual funds), imposes reporting requirements, and imposes sanctions for violations. Specifically, among other
things, the joint Code of Ethics prohibits sales of securities to or purchases of securities from the Trust and prohibits the purchase
or sale of any security under consideration for trading by the Trust within seven days before or after the Trust trades in the security</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The joint Code of Ethics is available on the EDGAR Database on the Commission
Internet site at <span style="text-decoration:underline">www.sec.gov.</span> You may obtain copies of the joint Code of Ethics, after
paying a duplicating fee, by electronic request at the following email address: <span style="text-decoration:underline">publicinfo@sec.gov.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>NET ASSET
VALUE</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The NAV of the Trust&#8217;s Shares is calculated at the close of regular
trading on the NYSE (generally 4:00 p.m., Eastern time) every day that the NYSE is open. The Trust makes this information available daily
by telephone (800) 451-2597, via its web site <span style="text-decoration:underline">www.teklacap.com).</span> and through electronic
distribution for media publication, including major internet-based financial services web sites and portals (<i>e.g.</i>, <span style="text-decoration:underline">bloomberg.com,
yahoo.com, cbsmarketwatch.com</span>,&#160;etc.). Currently, The Wall Street Journal, The New York Times and Barron&#8217;s publish NAVs
for closed-end investment companies periodically.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">NAV is calculated by dividing the Trust&#8217;s total assets (the value
of the securities held by the Trust plus any cash or other assets, including interest and dividends earned but not yet received) minus
all liabilities (including accrued expenses, dividends payable and any borrowings of the Trust) by the total number of Shares outstanding
at such time. If any preferred shares are outstanding, net assets available for common shareholders are determined by deducting from net
assets the liquidation preference and any accrued dividends on the preferred shares.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Securities for which market quotations are readily available are valued
at market price. Portfolio securities that are traded on one or more U.S. national securities exchanges or in the over-the-counter market
that are National Market System securities are valued at the last sale price or, lacking any sales, at the mean between last bid and asked
prices or at the last sale price. Other over-the-counter securities are valued at the most recent bid prices as obtained from one or more
dealers that make markets in the securities. Redeemable securities issued by a registered open-end investment company are valued at net
asset value per share. Other securities are valued at the mean between the closing bid and asked prices. Short- term investments that
mature in 60 days or less are valued at amortized cost, unless the Board determines that such valuation does not constitute fair value.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Bonds, other than convertible bonds, are valued using a third-party pricing
system when such valuations are available. Convertible bonds are generally valued using this pricing system only on days when there is
no sale reported. Temporary cash investments with maturity of 60 days or less are valued at amortized cost. Puts and calls generally are
valued at the close of regular trading on the securities or commodities exchange on which they are primarily traded. Options on securities
generally are valued at their last bid price in the case of exchange-traded options or, in the case of OTC-traded options, the average
of the last bid price as obtained from two or more dealers unless there is only one dealer, in which case that dealer&#8217;s price is
used. Forward foreign currency contracts are generally valued on the basis of the value of the underlying currencies at the prevailing
currency exchange rates. The prevailing</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">34</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin-top:0pt;margin-bottom:0pt">currency exchange rate shall generally
be determined within one hour of when the most recently available exchange rate information has been received based on information obtained
from a bank or banks.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Securities that are primarily traded on foreign securities exchanges are
generally valued at the last sale price on the exchange on which they are primarily traded. Foreign securities that are primarily traded
on the foreign over-the-counter market are generally valued at the last sale quotation, if market quotations are available, or the last
reported bid price if there is no active trading in a particular security on a given day. However, if intervening events result in market
volatility that significantly affects the value of any such foreign securities after the close of trading on the relevant foreign market,
but before the Trust values its Shares on any particular day on which the Trust is required to value its Shares, the Trust may, but is
not required to, determine the value of such securities at &#8220;fair value,&#8221; as determined in good faith by or under the direction
of the Board.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Quotations of foreign securities in foreign currencies are converted,
at current exchange rates, to their U.S. dollar equivalents in order to determine their current value. In addition, to the extent that
the Trust values its foreign securities (other than ADR and American Depositary Shares (&#8220;ADS&#8221;)) as of the close of trading
on various exchanges and over-the-counter markets throughout the world, the calculation of the Trust&#8217;s net asset value may not take
place contemporaneously with the valuation of foreign securities held by the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The value of any security or other asset for which market quotations are
not readily available shall be determined in a manner that most fairly reflects the security&#8217;s (or asset&#8217;s) &#8220;fair value,&#8221;
which is the amount that the Trust might reasonably expect to receive for the security (or asset) upon its current sale. Each such determination
is based on a consideration of all relevant factors, which are likely to vary from one pricing context to another. Examples of such factors
may include, but are not limited to: (1)&#160;the type of the security; (2)&#160;the size of the holding (including percent of outstanding
securities of issuer held by the Trust); (3)&#160;the initial cost of the security; (4)&#160;the existence of any contractual restrictions
on the security&#8217;s disposition and the time to freedom from such restrictions; (5)&#160;the price and extent of public trading in
similar securities of the issuer or of comparable companies; (6)&#160;quotations or prices from broker-dealers and/or pricing services;
(7)&#160;information obtained from the issuer, analysts, and/or the appropriate stock exchange (for exchange-traded securities); (8)&#160;an
analysis of the company&#8217;s financial statements; (9)&#160;an evaluation of the forces that influence the issuer and the market(s)&#160;in
which the security is purchased and sold (e.g., the existence of pending merger activity, public offerings or tender offers that might
affect the value of the security); and (10)&#160;the price of securities in a subsequent round of financing of an issuer in an arm&#8217;s-length
transaction, if the round includes a new third party investor.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Sometimes a &#8220;significant valuation event&#8221; may cause the market
value of a security to differ from the fair market value of that security. A &#8220;significant valuation event&#8221; is an event that
causes or is likely to cause a market quotation to be unavailable or unreliable, and may include: situations relating to a single issue
in a market sector; significant fluctuations in U.S. or foreign markets; market disruptions or closings caused by human error, equipment
failures, natural disasters, armed conflicts, acts of God, governmental actions or other developments, as well as the same or similar
events which may affect specific issues or the securities markets even though not tied directly to the securities markets. A significant
valuation event occurring after the close of trading but before the time of valuation may mean that the closing price for the security
does not constitute a readily available market quotation. If a significant valuation event has occurred, the security will be valued at
fair value as determined in good faith by the Board in accordance with the procedures described above. Such valuations and procedures
will be reviewed periodically by the Board.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust shall value an investment in a private placement or in a private
company at cost. The valuation of an investment in a private placement or in a private company will be adjusted to reflect its fair valuation,
as internal and external events are deemed to have a known or likely impact on the financial condition or market value of the investment.
Internal or external factors affecting the fair valuation may include items such as a subsequent financing round, a material deviation
from the business plan, or a change in market conditions that may impair the company&#8217;s ability to meet its capital requirements.
If a subsequent round of financing includes a new third-party investor in an arms-length transaction, then the securities shall be marked
up or down to the value used in that financing round. Equity investments in exchange for marketing or development rights do not constitute
arms-length transactions. Venture investments that have an initial public offering shall be generally valued at a discount to the public
market value of the securities. The discount in each case is determined by appraisal, considering such factors as market liquidity, time
to freedom from restrictions, fundamental outlook for the company and such other factors as are enumerated above that are deemed to be
relevant. Private placements in public companies are similarly priced at a discount to the public market generally until the restrictions
on sale of the security expire.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Other assets, which include cash, prepaid and accrued items, accounts
receivable and income on investments and from the sale of portfolio securities, are carried in accordance with generally accepted accounting
principles, as are all liabilities. Liabilities primarily include accrued expenses, sums owed for securities purchased and dividends payable.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">35</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>PORTFOLIO
TRANSACTIONS AND BROKERAGE</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Subject to policies established by the Board, the Investment Adviser is
primarily responsible for the execution of the Trust&#8217;s portfolio transactions and the allocation of brokerage. In executing transactions
for the portfolio and selecting brokers or dealers (which brokers or dealers may include any affiliate of the Investment Adviser to the
extent permitted by the Investment Company Act), the Investment Adviser will use its best efforts to obtain the best price and execution
for the Trust. In assessing the best price and execution available for any portfolio transaction, the Investment Adviser will consider
all factors it deems relevant including, but not limited to, price (including any applicable brokerage commission or dealer spread), size
of order, difficulty of execution, and operational facilities of the firm involved and the firm&#8217;s risk in positioning a block of
securities. The Investment Adviser may cause the Trust to pay a broker-dealer that furnishes brokerage and research services a higher
commission than that which might be charged by another broker-dealer for effecting the same transaction, provided that the Investment
Adviser determines in good faith that such commission is reasonable in relation to the value of the brokerage and research services provided
by such broker-dealer, viewed in terms of either the particular transaction or the overall responsibilities of the Investment Adviser
to the Trust. In selecting brokers or dealers to execute a particular transaction and in evaluating the best price and execution available,
the Investment Adviser may consider the brokerage and research services (as those terms are defined in Section&#160;28(e)&#160;of the
Securities Exchange Act of 1934, as amended) provided to the Trust and/or other accounts over which the Investment Adviser exercises investment
discretion. Such brokerage and research services might consist of reports and statistics on specific companies or industries, general
summaries of groups of bonds and their comparative earnings and yields, or broad overviews of the securities markets and the economy.
It is further understood that such services may be useful to the Investment Adviser in connection with its services to other clients.
While the Investment Adviser generally seeks reasonably competitive commission rates, the Trust will not necessarily pay the lowest commission
available.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust has no obligation to deal with any broker or group of brokers
in executing transactions in portfolio securities. Brokers who provide supplemental research, market and statistical information to the
Investment Adviser may receive orders for transactions by the Trust. The term &#8220;research, market and statistical information&#8221;
includes advice as to the value of securities, the advisability of purchasing or selling securities and the availability of securities
or purchasers or sellers of securities, and furnishing analyses and reports concerning issuers, industries, securities, economic factors
and trends, portfolio strategy and the performance of accounts. Information so received will be in addition to and not in lieu of the
services required to be performed by the Investment Adviser under the Advisory Agreement and the expenses of the Investment Adviser will
not necessarily be reduced as a result of the receipt of such supplemental information. Such information may be useful to the Investment
Adviser in providing services to clients other than the Trust, and not all such information may be used by the Investment Adviser in connection
with the Trust. Conversely, such information provided to the Investment Adviser by brokers and dealers through whom other clients of the
Investment Adviser in the future may effect securities transactions may be useful to the Investment Adviser in providing services to the
Trust. To the extent the Investment Adviser receives valuable research, market and statistical information from a broker-dealer, the Investment
Adviser intends to direct orders for Trust transactions to that broker-dealer, subject to the foregoing policies, regulatory constraints
and the ability of broker dealers to provide competitive prices and commission rates.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Investment Company Act restricts transactions involving the Trust
and its &#8220;affiliates,&#8221; including among others, the Trust&#8217;s Trustees, officers and employees, the Investment Adviser and
any &#8220;affiliates&#8221; of such affiliates. Subject to any such restrictions, investment companies advised by the Investment Adviser
may concurrently invest with the Trust in Restricted Securities, and the Trust may also invest in companies in which directors of the
Investment Adviser or Trustees of the Trust have invested or for which they serve as directors or executive officers. A substantial portion
of the securities in which the Trust may invest are traded in the over-the-counter markets, and the Trust intends to deal directly with
the dealers who make markets in the securities involved, except as limited by applicable law and in those circumstances where better prices
and execution are available elsewhere. Under the Investment Company Act, persons affiliated with the Trust are generally prohibited from
dealing as principal with the Trust in the purchase and sale of securities. Under certain circumstances, affiliated persons of the Trust
are permitted to serve as its broker in over-the-counter transactions conducted on an agency basis.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">It is likely that, subject to applicable law, the Trust may invest in
securities concurrently being purchased by other investment companies advised by the Investment Adviser. Such purchases would be made
on terms no less favorable than those under which such investment companies would be acquiring the securities. In the case of concurrent
purchases by the Trust and another investment company or companies managed by the Investment Adviser, such purchases would be made where
the Investment Adviser has made an independent decision on behalf of the Trust and such other company that the purchase is appropriate
in light of the investment objectives, policies, restrictions, current holdings, available cash and portfolio structure of and other factors
affecting each. Such investments will be allocated among clients in a manner believed by the Investment Adviser to be equitable to each.
The Trust may</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">36</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">also from time to time invest in securities of companies in which affiliated
persons of the Trust have invested, subject to the provisions of the Investment Company Act and the rules&#160;and regulations promulgated
thereunder.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s portfolio transactions in Restricted Securities are
generally subject to Rule&#160;144 under the Securities Act. In general, under Rule&#160;144 as currently in effect, if the Trust has
beneficially owned Restricted Securities of a publicly held issuer for a minimum of six months, it will be entitled to sell in any three-month
period that number of such securities that will not exceed the greater of 1% of the then outstanding securities of that class or the average
weekly trading volume in securities of that class in any national securities exchange and/or in the over-the-counter market during the
four calendar weeks immediately preceding the date on which notice of the sale is filed with the Commission. These volume limitations
also apply to sales by the Trust of the securities of any issuer as to which it is deemed an affiliate, regardless of whether securities
of such issuer are publicly traded. The above-described sales under Rule&#160;144 are subject to certain requirements relating to manner
of sale, notice and availability of current public information about the issuer. If the Trust is not deemed to have been an affiliate
of the issuer at any time during the 90 days immediately preceding the sale and has beneficially owned Restricted Securities for at least
one year, it is entitled to sell such securities under Rule&#160;144(k)&#160;without regard to whether the issuer is publicly-held or
to the volume limitations or other requirements described above. When Restricted Securities are sold to the public other than pursuant
to Rule&#160;144 or 144A, the Trust may be deemed an &#8220;underwriter&#8221; with respect thereto for purposes of the Securities Act
and subject to liability as such thereunder.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">On occasions when the Investment Adviser deems the purchase or sale of
a security to be in the best interest of the Trust as well as other clients, the Investment Adviser, to the extent permitted by applicable
laws and regulations, may, but shall be under no obligation to, aggregate the securities to be sold or purchased in order to obtain the
most favorable price or lower brokerage commissions and efficient execution. In such event, allocation of the securities so purchased
or sold, as well as the expenses incurred in the transaction, will be made by the Investment Adviser in the manner it considers to be
the most equitable and consistent with its fiduciary obligations to the Trust and to such other clients.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Allocation of transactions, including their frequency, to various broker-dealers
is determined by the Investment Adviser with respect to the Trust, based on their best judgment and in a manner deemed fair and reasonable
to Shareholders. The primary consideration is prompt execution of orders in an effective manner at the most favorable price. Certain investments
may be appropriate for the Trust and also for other clients advised by the Investment Adviser. Investment decisions for the Trust and
for other investment accounts managed by the Investment Adviser are made independently of each other in the light of differing conditions.
However, the same investment decision may be made for two or more of such accounts. When a purchase or sale of the same security is made
at substantially the same time on behalf of the Trust and one or more other accounts, the transaction will be averaged as to price, and
available investments allocated as to amount, in a manner the Investment Adviser believes to be equitable to each such account. Although
the Investment Adviser seeks the most favorable overall net results for all of the accounts in any aggregated transaction, in some cases,
this practice may adversely affect the price paid or received by the Trust or the size of the position obtained or sold by the Trust.
To the extent permitted by law, the Investment Adviser may aggregate the securities to be sold or purchase for the Trust with those to
be sold or purchased for other investment companies or accounts in order to obtain best execution.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">For the fiscal years ended September&#160;30, 2021, September&#160;30,
2020 and September&#160;30, 2019, the Trust paid $251,449, $220,597 and $300,459, respectively, of brokerage commissions.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">As stated in the Prospectus, the Trust&#8217;s portfolio turnover rate
for the fiscal years ended September&#160;30, 2021, September&#160;30, 2020 and September&#160;30, 2019 was 69.37%, 48.11% and 55.17%,
respectively. For a description of the Trust&#8217;s portfolio turnover policies, see &#8220;Portfolio Transactions and Brokerage&#8221;
in the Prospectus.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>TAX MATTERS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The following is only a summary of certain U.S. federal income tax considerations
generally affecting the Trust and its Shareholders. The discussion is based on laws, regulations, rulings and decisions currently in effect,
all of which are subject to change (possibly with retroactive effect) or different interpretations. No attempt is made to present a detailed
explanation of the tax treatment of the Trust or its Shareholders, and the following discussion is not intended as a substitute for careful
tax planning. Shareholders should consult with their own tax advisers regarding the specific federal, state, local, foreign and other
tax consequences of investing in the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">37</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Taxation of the Trust</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust intends to qualify and has elected to be treated in each of
its taxable years as a regulated investment company (&#8220;RIC&#8221;) under the Code. As a RIC, the Trust generally will not be required
to pay U.S. federal income taxes on any ordinary income or capital gains that the Trust distributes to its Shareholders. To qualify as
a RIC and maintain RIC status, the Trust must meet specific source-of-income and asset diversification requirements and must generally
distribute an amount at least equal to the sum of 90% of its investment company taxable income (which includes, among other items, dividends,
interest and net short-term capital gains in excess of net long-term capital losses), but determined without regard to the deduction for
dividends paid) plus 90% of any net tax-exempt income for the Trust&#8217;s taxable year. If, in any year, the Trust fails to qualify
as a RIC under U.S. federal income tax laws, the Trust would be taxed as an ordinary corporation. In such circumstances, the Trust could
be required to recognize unrealized gains, pay substantial taxes and make substantial distributions before re-qualifying as a RIC that
is accorded special tax treatment.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">To qualify as a RIC, the Trust must, among other things, (a)&#160;derive
in each taxable year at least 90% of its gross income from dividends, interest, payments with respect to securities loans, gains from
the sale or other disposition of stock, securities or foreign currencies, net income derived from an interest in a qualified publicly
traded partnership and other income derived with respect to its business of investing in such stock, securities or currencies (the &#8220;Qualifying
Income Requirement&#8221;); (b)&#160;diversify its holdings so that, at the end of each quarter of the taxable year, (1)&#160;at least
50% of the market value of the Trust&#8217;s assets is represented by cash and cash items, U.S. Government Securities, the securities
of other RICs and other securities, with such other securities of any one issuer limited for the purposes of this calculation to an amount
not greater than 5% of the value of the Trust&#8217;s total assets and not greater than 10% of the outstanding voting securities of such
issuer, and (2)&#160;not more than 25% of the value of its total assets is invested in the securities of any one issuer (other than U.S.
Government Securities or the securities of other RICs); and (c)&#160;distribute at least 90% of its investment company taxable income
(which includes, among other items, dividends, interest and net short-term capital gains in excess of net long-term capital losses) each
taxable year. The U.S. Treasury Department has authority to promulgate regulations pursuant to which gains from foreign currency (and
options, futures and forward contracts on foreign currency) not directly related to a RIC&#8217;s business of investing in stocks and
securities would not be treated as qualifying income for purposes of the Qualifying Income Requirement. To date, such regulations have
not been promulgated.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">If for any taxable year the Trust were to fail to qualify as a RIC, all
of the Trust&#8217;s taxable income would be subject to federal income tax at the rates applicable to corporations (with no deduction
for distributions to Shareholders), and Trust distributions would be taxable to Shareholders as dividends to the extent of the Trust&#8217;s
earnings and profits.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Amounts not distributed on a timely basis in accordance with a calendar
year distribution requirement are subject to a nondeductible 4% excise tax. To avoid the excise tax, the Trust must generally distribute
during each calendar year an amount at least equal to the sum of (1)&#160;98% of its ordinary income (taking into account certain deferrals
and elections) for the calendar year, (2)&#160;98.2% of its capital gains in excess of its capital losses (adjusted for certain ordinary
losses) for the one-year period ending on October&#160;31 of the calendar year, and (3)&#160;all ordinary income and capital gains for
previous years that were not distributed during such years. To avoid application of the excise tax, the Trust intends to make its distributions
in accordance with the calendar year distribution requirement. A dividend will be treated as paid on December&#160;31 of the calendar
year if it is declared by the Trust in October, November&#160;or December&#160;of the year, payable to Shareholders of record on a date
in such a month and paid by the Trust during January&#160;of the following year. Such dividends will be taxable to Shareholders as of
December&#160;31 of the calendar year in which the dividends are declared, rather than during the calendar year in which the dividends
are received. If the Trust elects to retain net capital gains and treat such gains as having been distributed, all or a portion of such
gains may not be treated as having been timely distributed for purposes of satisfying the excise tax calendar year distribution requirement.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">If the Trust utilizes leverage through the issuance of Preferred Shares
or borrowings, it will be prohibited from declaring a distribution or dividend if it would fail the applicable asset coverage test(s)&#160;under
the 1940 Act after the payment of such distribution or dividend. In addition, certain covenants in credit facilities or indentures may
impose greater restrictions on the Trust&#8217;s ability to declare and pay dividends on Shares. Limits on the Trust&#8217;s ability to
pay dividends on Shares may prevent the Trust from meeting the distribution requirements described above and, as a result, may affect
the Trust&#8217;s ability to be subject to tax as a RIC or subject the Trust to the 4% excise tax. If the Trust is precluded from making
distributions on Shares because of any applicable asset coverage requirements, the terms of Preferred Shares (if any) may provide that
any amounts so precluded from being distributed, but required to be distributed by the Trust to enable the Trust to satisfy the distribution
requirements that would enable the Trust to be subject to tax as a RIC, will be paid to the holders of Preferred Shares as a special distribution.
This distribution can be expected to decrease the amount that holders of Preferred Shares would be entitled to receive upon redemption
or liquidation of such Preferred Shares.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">38</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Distributions</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Dividends paid from investment company taxable income as calculated for
federal income tax purposes generally will be taxable to Shareholders as ordinary income whether paid in cash or reinvested in the Trust&#8217;s
Shares. The Trust intends to distribute to its Shareholders substantially all of its investment company taxable income, if any, for each
year. It is anticipated that the Trust&#8217;s income distributions will be paid monthly in cash.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A portion of the dividends received by non-corporate Shareholders may
be treated as &#8220;qualified dividend income&#8221; which is taxable to individuals at the same rates that are applicable to long-term
capital gains. A Trust distribution is treated as qualified dividend income to the extent that the Trust receives dividend income from
taxable domestic corporations and certain qualified foreign corporations, provided that certain holding period and other requirements
are met. Holding periods may be affected by certain of the Trust&#8217;s transactions in options (including covered call options) and
other derivatives. Trust distributions generally will not qualify as qualified dividend income to the extent attributable to interest,
capital gains, REITs distributions and distributions from certain non-U.S. corporations.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Distributions of the excess, if any, of net long-term capital gains over
net short-term capital losses (&#8220;net capital gains&#8221;) reported by the Trust as capital gain dividends will be taxable to Shareholders
as long-term capital gains, whether paid in cash or reinvested in the Trust&#8217;s Shares, regardless of how long the Shareholders have
held the Trust&#8217;s Shares, and will not be eligible for the dividends received deduction for corporations. The Trust may elect to
retain net capital gains. In such event, the Trust will be required to pay federal income taxes on the undistributed net capital gains,
but intends to elect to treat such capital gains as having been distributed to Shareholders. As a result, such amounts will be included
in the gross income of the Shareholders as long-term capital gains and Shareholders will be able to claim their proportionate share of
federal income taxes paid by the Trust on such gains as a credit against their own federal income tax liabilities, and will be entitled
to increase the adjusted tax basis of their Shares of the Trust by an amount equal to 65% of the amount of the undistributed capital gains
included in their gross income. Organizations or persons not subject to federal income tax on such capital gains (such as, generally,
qualified pension and profit-sharing funds, including Individual Retirement Accounts and Keogh plans, and certain trusts, nonresident
aliens and foreign corporations) will be entitled to a refund of their pro rata share of such taxes paid by the Trust upon filing appropriate
returns or claims for refund with the IRS. Even if the Trust makes such an election, it is possible that the Trust may incur an excise
tax as a result of not having distributed sufficient net capital gains.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A distribution of an amount in excess of the Trust&#8217;s current and
accumulated earnings and profits will be treated by a Shareholder as a return of capital which is applied against and reduces the Shareholder&#8217;s
basis in his or her Shares. To the extent that the amount of any such distribution exceeds the Shareholder&#8217;s basis in his or her
Shares, the excess will be treated by the Shareholder as gain from a sale or exchange of the Shares. The Trust has returned investor capital
over each of the past three years.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The price of Shares purchased at this time may reflect the amount of the
forthcoming distribution. Those purchasing just prior to a distribution of investment company taxable income or net capital gains will
receive a distribution which will nevertheless be taxable to them.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Dividends (not including capital gain dividends) received by corporate
Shareholders from the Trust qualify for the dividends received deduction for corporate Shareholders to the extent the Trust reports the
amount distributed as eligible for the deduction. The aggregate amount reported by the Trust cannot exceed the aggregate amount of dividends
received by the Trust from domestic corporations for the taxable year, and the reporting of dividend income must generally be the same
for all Shares. Thus, unless 100% of the Trust&#8217;s gross income constitutes qualified dividends, a portion of the dividends paid to
corporate Shareholders will not qualify for the dividends received deduction. The dividends received deduction for corporate Shareholders
may be further reduced if the Shares with respect to which dividends are received are treated as debt-financed or if either those Shares
or the Shares of the Trust are deemed to have been held by the Trust or its Shareholders, respectively, for less than 46 days.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Certain distributions reported by the Trust as Section&#160;163(j)&#160;interest
dividends may be treated as interest income by Shareholders for purposes of the tax rules&#160;applicable to interest expense limitations
under Section&#160;163(j)&#160;of the Code. Such treatment by Shareholders is generally subject to holding period requirements and other
potential limitations, although the holding period requirements are generally not applicable to dividends declared by money market funds
and certain other funds that declare dividends daily and pay such dividends on a monthly or more frequent basis. The amount that the Trust
is eligible to report as a Section&#160;163(j)&#160;dividend for a tax year is generally limited to the excess of the Trust&#8217;s business
interest income over the sum of the Trust&#8217;s (i)&#160;business interest expense and (ii)&#160;other deductions properly allocable
to the Trust&#8217;s business interest income.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">39</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The IRS currently requires that a RIC that has two or more classes of
stock allocate to each such class proportionate amounts of each type of its income (such as ordinary income and capital gains) based upon
the percentage of total dividends paid to each class for the tax year. Accordingly, if the Trust issues Preferred Shares, the Trust intends
each year to allocate capital gain dividends, if any, between its Common Shares and Preferred Shares in proportion to the total dividends
paid to each class with respect to such tax year.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">In addition to furnishing any other required tax statements, the Trust
intends to report in written notices to Shareholders regarding the tax status of all distributions made during such taxable year, the
amount qualifying for the dividends received deduction for corporations and the amount, if any, of undistributed net capital gains and
related tax credits.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Sale or Exchange of Shares</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Generally, gain or loss realized upon the sale or exchange of Shares will
be capital gain or loss if the Shares are capital assets in the shareholder&#8217;s hands and generally will be long-term or short-term,
depending upon the Shareholder&#8217;s holding period for the Shares. Investors should be aware that any loss realized upon the sale or
exchange of Shares held for six months or less will be treated as a long-term capital loss to the extent of any distributions or deemed
distributions of long-term capital gain to the Shareholder with respect to such Shares. In addition, any loss realized on a sale or exchange
of Shares will be disallowed to the extent the Shares disposed of are replaced within a period of 61 days beginning 30 days before and
ending 30 days after the Shares are disposed of, such as pursuant to the Plan. In such case, the basis of Shares acquired will be adjusted
to reflect the disallowed loss.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Reporting of adjusted cost basis information is required for covered securities,
which generally include shares of a regulated investment company, to the IRS and to taxpayers. Shareholders should contact their financial
intermediaries with respect to reporting of cost basis and available elections for their accounts.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Investments of the Trust &#8212; General</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The application of certain requirements for qualification as a RIC and
the application of certain other federal income tax rules&#160;may be unclear in some respects in connection with certain investments.
As a result, the Trust may be required to limit the extent to which it invests in such investments, and it is also possible that the IRS
may not agree with the Trust&#8217;s treatment of such investments. In addition, the tax treatment of certain investments may be affected
by future legislation, Treasury regulations and guidance issued by the IRS (which could apply retroactively) that could affect the timing,
character and amount of the Trust&#8217;s income and gains and distributions to shareholders, affect whether the Trust has made sufficient
distributions&#160; and&#160; otherwise &#160;satisfied&#160; the requirements to maintain its qualification as a RIC and avoid federal
income and excise taxes or limit the extent to which the Trust may invest in certain investments in the future.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Certain of the Trust&#8217;s investment practices are subject to special
and complex federal income tax provisions that may, among other things, (1)&#160;convert distributions that would otherwise constitute
qualified dividend income into ordinary income taxed at the higher rate applicable to ordinary income; (2)&#160;treat distributions that
would otherwise be eligible for the corporate dividends received deduction as ineligible for such treatment; (3)&#160;disallow, suspend
or otherwise limit the allowance of certain losses or deductions; (4)&#160;convert long-term capital gain into short-term capital gain
or ordinary income; (5)&#160;convert an ordinary loss or deduction into a capital loss (the deductibility of which is more limited); (6)&#160;cause
the Trust to recognize income or gain without a corresponding receipt of cash; (7)&#160;adversely affect the time as to when a purchase
or sale of stock or securities is deemed to occur; (8)&#160;adversely alter the characterization of certain complex financial transactions;
and (9)&#160;produce income that will not be included in the sources of income from which a RIC must derive at least 90% of its gross
income each year. While it may not always be successful in doing so, the Trust will seek to avoid or minimize any adverse tax consequences
of its investment practices.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Passive Foreign Investment Companies</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest in shares of foreign corporations which may be classified
under the Code as passive foreign investment companies (&#8220;PFICs&#8221;). In general, a foreign corporation is classified as a PFIC
if at least one-half of its assets produce passive income, or 75% or more of its gross income is passive income. If the Trust receives
a so-called &#8220;excess distribution&#8221; with respect to PFIC stock, the Trust itself may be subject to a tax on a portion of the
excess distribution, whether or not the corresponding income is distributed by the Trust to Shareholders. In general, under the PFIC rules,
an excess distribution is treated as having been realized ratably over the period during which the Trust held the PFIC shares. The Trust
itself will be subject to tax on the portion, if any, of an excess distribution that is so allocated to prior Trust taxable years and
an interest factor will be added to the tax, as if the tax had been payable in such prior taxable years. Gain from the sale of PFIC shares
is treated in the same manner as an excess distribution. Excess</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">40</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">distributions and gain from the sale of PFIC shares are characterized
as ordinary income even though, absent application of the PFIC rules, such gains and certain excess distributions might have been classified
as capital gain.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may elect to mark to market any PFIC shares in lieu of being
subject to U.S. federal income taxation. At the end of each taxable year to which the election relates, the Trust would report as ordinary
income the amount by which the fair market value of the PFIC stock exceeds the Trust&#8217;s adjusted basis in the stock. Any mark-to-market
losses and any loss from an actual disposition of shares would be deductible as ordinary losses to the extent of any net mark-to-market
gains included in income in prior years. The effect of the election would be to treat excess distributions and gain on dispositions as
ordinary income which is not subject to a Trust-level tax when distributed to Shareholders as a dividend. Alternatively, the Trust may
elect to include as income and gain its share of the ordinary earnings and net capital gain of certain PFICs in lieu of being taxed in
the manner described above.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Currency Fluctuations &#8212; &#8220;Section&#160;988&#8221; Gains
or Losses</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Under the Code, the gains or losses attributable to fluctuations in exchange
rates which occur between the time the Trust accrues receivables or liabilities denominated in a foreign currency and the time the Trust
actually collects such receivables or pays such liabilities generally are treated as ordinary income or ordinary loss. Similarly, on disposition
of foreign currency or debt securities denominated in a foreign currency and on disposition of certain futures and forward contracts,
gains or losses attributable to fluctuations in the value of foreign currency between the date of acquisition of the currency, security
or contract and the date of disposition also are treated as ordinary gain or loss. These gains or losses, referred to under the Code as
&#8220;Section&#160;988&#8221; gains or losses, may increase or decrease the amount of the Trust&#8217;s investment company taxable income
to be distributed to its Shareholders as ordinary income.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Hedging Transactions</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Certain futures, foreign currency contracts and options in which the Trust
may invest are &#8220;section 1256 contracts.&#8221; While gains or losses on section 1256 contracts are considered 60% long-term and
40% short-term capital gains or losses, certain foreign currency futures and foreign currency contracts may give rise to ordinary income
or loss, as described above. Also, section 1256 contracts held by the Trust at the end of each taxable year (and, generally, for purposes
of the 4% excise tax, on October&#160;31 of each year) are &#8220;marked-to-market&#8221; with the result that unrealized gains or losses
are treated as though they were realized.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Generally, the hedging transactions undertaken by the Trust (including
certain covered call options) may result in &#8220;straddles&#8221; for U.S. federal income tax purposes. The straddle rules&#160;may
affect the character of gains (or losses) realized by the Trust. In addition, losses realized by the Trust on positions that are part
of a straddle may be deferred under the straddle rules, rather than being taken into account in calculating the taxable income for the
taxable year in which the losses are realized. Because only a few regulations implementing the straddle rules&#160;have been promulgated,
the tax consequences to the Trust of engaging in hedging transactions are not entirely clear.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may make one or more of the elections available under the Code
which are applicable to straddles. If the Trust makes any of the elections, the amount, character and timing of the recognition of gains
or losses from the affected straddle positions will be determined under the rules&#160;that vary according to the election(s)&#160;made.
The rules&#160;applicable under certain of the elections may operate to accelerate the recognition of gains or losses from the affected
straddle positions.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Notwithstanding any of the foregoing, the Trust may recognize gain (but
not loss) from a constructive sale of certain &#8220;appreciated financial positions&#8221; if the Trust enters into a short sale, offsetting
notional principal contract, futures or forward contract transaction with respect to the appreciated position or substantially identical
property. Appreciated financial positions subject to this constructive sale treatment are interests (including options, futures and forward
contracts and short sales) in stock, partnership interests, certain actively traded trust instruments and certain debt instruments. Constructive
sale treatment does not apply to certain transactions closed before the end of the thirtieth day after the close of the taxable year,
if certain conditions are met.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>High Yield Debt Investments</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Investments in debt obligations that are at risk of or in default present
tax issues for the Trust. Tax rules&#160;are not entirely clear about issues such as whether and to what extent the Trust should recognize
market discount on a debt obligation, when the Trust may cease to accrue interest, original issue discount or market discount, when and
to what extent the Trust may take deductions for bad debts or worthless securities and how the Trust should allocate payments received
on obligations in default between principal and income.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">41</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">These and other related issues will be addressed by the Trust in order
to ensure that it distributes sufficient income to preserve its status as a RIC.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>REITs</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust may invest in REITs. Investments in REIT equity securities may
require the Trust to accrue and distribute income not yet received. In order to generate sufficient cash to make the requisite distributions,
the Trust may be required to sell securities in its portfolio (including when it is not advantageous to do so) that it otherwise would
have continued to hold. The Trust&#8217;s investments in REIT equity securities may at other times result in the Trust&#8217;s receipt
of cash in excess of the REIT&#8217;s earnings; if the Trust distributes such amounts, such distribution could constitute a return of
capital to Trust shareholders for federal income tax purposes. Dividends received by the Trust from a REIT generally will not constitute
qualified dividend income.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Under applicable Treasury regulations, properly reported dividends paid
by the Trust that are attributable to the Trust&#8217;s &#8220;qualified REIT dividends&#8221; (generally, ordinary income dividends paid
by a REIT, not including capital gain dividends or dividends treated as qualified dividend income) may be eligible for the 20% deduction
described in Section&#160;199A of the Code in the case of non-corporate U.S. Shareholders, provided that certain holding period and other
requirements are met by the Shareholder and the Trust. There can be no assurance as to what portion of the Trust&#8217;s distributions
will qualify for such deduction.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Foreign Withholding Taxes</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Income received by the Trust from non-U.S. sources may be subject to withholding
and other taxes imposed by other countries. Because it is not expected that more than 50% of the value of the Trust&#8217;s total assets
at the close of its taxable year will consist of stock and securities of non-U.S. corporations, it is not expected that the Trust will
be eligible to elect to &#8220;pass-through&#8221; to the Trust&#8217;s Shareholders the amount of foreign income and similar taxes paid
by the Trust. In the absence of such an election, the foreign taxes paid by the Trust will reduce its investment company taxable income,
and distributions of investment company taxable income received by the Trust from non-U.S. sources will be treated as U.S. source income.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Medicare Tax</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A Shareholder that is an individual or estate, or a trust that does not
fall into a special class of trusts that is exempt from such tax, will generally be subject to a 3.8% tax on the lesser of (i)&#160;the
Shareholder&#8217;s &#8220;net investment income&#8221; (or &#8220;undistributed net investment income&#8221; for an estate or trust)
for a taxable year and (ii)&#160;the excess of the Shareholder&#8217;s modified adjusted gross income for such taxable year, over a certain
threshold, which for individuals is $200,000 in the case of single filers ($250,000 in the case of joint filers). For these purposes,
&#8220;net investment income&#8221; will generally include taxable distributions and deemed distributions paid with respect to Shares
and net gain attributable to the disposition of Shares (in each case, unless such Shares are held in connection with certain trades or
businesses), but will be reduced by any deductions properly allocable to such distributions or net gain.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Tax Shelter Reporting Regulations</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Under applicable Treasury regulations, if a Shareholder recognizes a loss
with respect to Shares of $2 million or more for a non-corporate Shareholder or $10 million or more for a corporate Shareholder in any
single taxable year (or a greater loss over a combination of years), the Shareholder must file with the IRS a disclosure statement on
Form&#160;8886. Direct shareholders of portfolio securities are in many cases excepted from this reporting requirement, but, under current
guidance, shareholders of a RIC are not excepted. Future guidance may extend the current exception from this reporting requirement to
shareholders of most or all RICs. The fact that a loss is reportable under these regulations does not affect the legal determination of
whether the taxpayer&#8217;s treatment of the loss is proper. Significant monetary penalties apply to a failure to comply with this reporting
requirement. States may also have a similar reporting requirement. Shareholder should consult their own tax advisers to determine the
applicability of these Treasury regulations in light of their individual circumstances.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Backup Withholding</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust (or applicable withholding agent) may be required to withhold
U.S. federal income tax at the rate of 24% of all taxable distributions payable to Shareholders who fail to provide the Trust with their
correct taxpayer identification number or to make required certifications, or who have been notified by the IRS that they are subject
to backup withholding. Backup withholding is not</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">42</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">an additional tax. Any amounts withheld may be credited against a shareholder&#8217;s
U.S. federal income tax liability. Certain persons are exempt from the backup withholding requirements. Questions relating to backup withholding
should be directed to your tax adviser.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Foreign Shareholders</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">U.S. taxation of a shareholder who, as to the U.S., is a non-resident
alien individual, a foreign trust or estate, a foreign corporation or foreign partnership (&#8220;Foreign Shareholder&#8221;) depends
on whether the income from the Trust is &#8220;effectively connected&#8221; with a U.S. trade or business carried on by such shareholder.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">As a RIC is a corporation for U.S. federal income tax purposes, its business
activities generally will not be attributed to its shareholders for purposes of determining their treatment under current law. Therefore,
a foreign shareholder should not be considered to earn income &#8220;effectively connected&#8221; with a U.S. trade or business solely
as a result of activities conducted by the Fund.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">If the income from the Trust is not &#8220;effectively connected&#8221;
with a U.S. trade or business carried on by the Foreign Shareholder, distributions of investment company taxable income will be subject
to a U.S. tax of 30% (or lower treaty rate), which tax is generally withheld from such distributions.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Distributions of capital gain dividends and amounts retained by the Trust
which are designated as undistributed capital gains will not be subject to U.S. tax at the rate of 30% (or lower treaty rate) unless the
Foreign Shareholder is a non-resident alien individual and is physically present in the U.S. for more than 182 days during the taxable
year and meets certain other requirements. However, this 30% tax on capital gains of non-resident alien individuals who are physically
present in the U.S. for more than the 182-day period only applies in exceptional cases, because any individual present in the U.S. for
more than 182 days during the taxable year is generally treated as a resident for U.S. federal income tax purposes; in that case, he or
she would be subject to U.S. federal income tax on his or her worldwide income at the graduated rates applicable to U.S. citizens, rather
than the 30% U.S. tax. In the case of a Foreign Shareholder who is a nonresident alien individual, the Trust may be required to withhold
U.S. federal income tax at a rate of 24% of distributions of net capital gains unless the Foreign Shareholder certifies his or her non-U.S.
status under penalties of perjury or otherwise establishes an exemption. See &#8220;Backup Withholding&#8221; above. If a Foreign Shareholder
is a non-resident alien individual, any gain such shareholder realizes upon the sale or exchange of such shareholder&#8217;s Shares of
the Trust in the U.S. will ordinarily be exempt from U.S. tax unless such shareholder is physically present in the U.S. for more than
182 days during the taxable year and meets certain other requirements.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Two categories of dividends, however, &#8220;short-term capital gain dividends&#8221;
and &#8220;interest-related dividends,&#8221; if reported by the Trust in writing to its shareholders, will be exempt from that tax. &#8220;Short-term
capital gain dividends&#8221; are dividends that are attributable to net short-term capital gain, computed with certain adjustments. &#8220;Interest-related
dividends&#8221; are dividends that are attributable to &#8220;qualified net interest income&#8221; (i.e., &#8220;qualified interest income,&#8221;
which generally consists of certain original issue discount, interest on obligations &#8220;in registered form,&#8221; and interest on
deposits, less allocable deductions) from sources within the United States. Depending on the circumstances, the Trust may report all,
some or none of the Trust&#8217;s potentially eligible dividends as eligible for exemption from withholding tax, and a portion of the
Trust&#8217;s distributions (e.g. interest and dividends from non-U.S. sources or any non-U.S. currency gains) would be ineligible for
such exemption. In the case of shares held through an intermediary, the intermediary may withhold on a payment even if the Trust reports
the payment as eligible for the exemption from withholding. In order to qualify for this exemption from withholding, a non-U.S. shareholder
must have provided appropriate withholding certificates (e.g., an executed W-8BEN,&#160;etc.) certifying foreign status.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">If the income from the Trust is &#8220;effectively connected&#8221; with
a U.S. trade or business carried on by a Foreign Shareholder, then distributions of investment company taxable income and capital gain
dividends, amounts retained by the Trust which are designated as undistributed capital gains and any gains realized upon the sale or exchange
of Shares of the Trust will be subject to U.S. federal income tax at the graduated rates applicable to U.S. citizens, residents and domestic
corporations. Such Foreign Shareholders that are corporations may also be subject to the branch profits tax imposed by the Code.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Withholding of U.S. tax is required (at a 30% rate) on payments of taxable
dividends paid to certain non-U.S. entities that fail to comply (or be deemed compliant) with extensive reporting and withholding requirements
designed to inform the U.S. Department of the Treasury of U.S.-owned foreign investment accounts. Shareholders may be requested to provide
additional information to enable the applicable withholding agent to determine whether withholding is required.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">43</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The tax consequences to a Foreign Shareholder entitled to claim the benefits
of an applicable tax treaty may be different from those described herein. Foreign Shareholders may also be subject to U.S. estate tax
with respect to their Trust shares. Foreign Shareholders are advised to consult their own tax advisers with respect to the particular
tax consequences to them of an investment in the Trust.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Other Taxes</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Distributions may also be subject to state, local and foreign taxes and/or
the alternative minimum tax depending on each Shareholder&#8217;s particular situation. Shareholders should consult their own tax advisers
with respect to their particular situation.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>ADMINISTRATOR,
CUSTODIAN, TRANSFER AGENT, DIVIDEND DISBURSING AGENT AND REGISTRAR</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s securities and cash are held under a custodian contract
by State Street Bank and Trust Company (the &#8220;Custodian&#8221;), whose principal business address is One Lincoln Street, Boston,
MA 02111. Rules&#160;adopted under the Investment Company Act permit the Trust to maintain its securities and cash in the custody of certain
eligible banks and securities depositories. Pursuant to those Rules, the Trust&#8217;s portfolio of securities and cash, when invested
in</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Foreign Securities, will be held by sub-custodians who have been approved
by the Board in accordance with the rules&#160;and regulations of the Commission following consideration of a number of factors, including,
but not limited to, the relationship of the institution with the Custodian, the reliability and financial stability of the institution,
the ability of the institution to perform capably custodial services for the Trust, the reputation of the institution in its national
market, the political and economic stability of the countries in which the sub-custodians will be located and the risks of potential nationalization
or expropriation of Trust assets. The Custodian also performs certain accounting related functions for the Trust, including calculation
of NAV and net income.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">State Street Bank and Trust Company (the &#8220;Administrator&#8221;)
also serves as administrator to the Trust pursuant to an Administration Agreement. Under the Administration Agreement the Trust&#8217;s
assets are combined with assets of HQH, HQL and THW. The combined assets are charged a fee computed and payable monthly at an annual rate
of (i)&#160;3.4% of the first $150 million; (ii)&#160;2.4% of the next $150 million; and (iii)&#160;1.4% on assets in excess of $300 million,
subject to annual minimum fee of $77,500. The Administrative Agreement covers administrative costs, including out-of-pocket expenses incurred
in the ordinary course of providing services under the Administration Agreement.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Computershare Inc. serves as Dividend Disbursing Agent for the Trust.
Computershare Trust Company, N.A., a fully owned subsidiary of Computershare Inc., serves as (1)&#160;the Plan Agent for the Trust&#8217;s
Dividend Reinvestment Plan and (2)&#160;the Transfer Agent and Registrar for Shares of the Trust. Computershare Trust Company, N.A. and
Computershare Inc. have their principal business at 150 Royall Street, Canton, MA 02021.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>INCORPORATION
BY REFERENCE</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">This SAI is part of a registration statement filed with the SEC. Pursuant
to the final rule&#160;and form amendments adopted by the SEC on April&#160;8, 2020 to implement certain provisions of the Economic Growth,
Regulatory Relief, and Consumer Protection Act, the Trust may &#8220;incorporate by reference&#8221; the information that it files with
the SEC, which means that the Trust can disclose important information by referring to those documents. The information incorporated by
reference is considered to be part of this SAI, and later information that the Trust files with the SEC will automatically update and
supersede this information.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The documents listed below, and any reports and other documents subsequently
filed with the SEC pursuant to Rule&#160;30(b)(2)&#160;under the 1940 Act and Sections 13(a), 13(c), 14 or 15(d)&#160;of the Exchange
Act, prior to the termination of this offering, are incorporated by reference into this Prospectus and deemed to be part of this registration
statement from the date of the filing of such reports and documents:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td>the Trust&#8217;s Prospectus, dated December 6, 2022, filed with this SAI;</td></tr>
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/805267/000110465922045016/tm222535d1_def14a.htm" style="-sec-extract:exhibit">the Trust&#8217;s
        definitive Proxy Statement, dated April&#160;18, 2022, filed on April&#160;12, 2022</a>;</td></tr>
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001635977/000110465922125461/tm2225215d1_ncsr.htm" style="-sec-extract:exhibit">the
        Trust&#8217;s annual report on Form&#160;N-CSR for the fiscal year ended September&#160;30, 2022, filed with the SEC on December&#160;8,
        2022</a>;</td></tr>
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1635977/000110465922068028/tm228078d1_ncsrs.htm">the Trust&#8217;s semi-annual report
        on Form&#160;N-CSR for the fiscal period ended March&#160;31, 2022, filed with the SEC on June&#160;3, 2022</a>;</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">44</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1635977/000110465915046396/a15-14451_18a12b.htm" style="-sec-extract:exhibit">the Trust&#8217;s
        description of Common Shares on Form&#160;8-A, filed on June&#160;19, 2015</a></td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust will provide without charge to each person, including any beneficial
owner, to whom this SAI is delivered, upon written or oral request, a copy of any and all of the documents that have been or may be incorporated
by reference in this SAI.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">You should direct requests for documents by calling the Investment Adviser
at (617) 772-8500 or by writing to the Trust at c/o Tekla Capital Management LLC, 100 Federal Street, 19th Floor Boston, MA 02110. The
Trust makes available this SAI, Prospectus and the Trust&#8217;s annual and semi-annual reports, free of charge, on the Trust&#8217;s
website (www.teklacap.com). You may also obtain this SAI, the Prospectus, other documents incorporated by reference and other information
the Trust files electronically, including reports and proxy statements, on the SEC website (http://www.sec.gov) or with the payment of
a duplication fee, by electronic request at publicinfo@sec.gov. Information contained in, or that can be accessed through, the Trust&#8217;s
website is not incorporated by reference into this SAI and should not be considered to be part of this SAI.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>FINANCIAL
STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s audited financial statements as of and for the fiscal
year ended September&#160;30, 2021, together with the report thereon of Deloitte &#38; Touche LLP, an independent registered public accounting
firm, given on the authority of such firm as experts in auditing and accounting, are incorporated in this SAI by reference to the Trust&#8217;s
September&#160;30, 2021 Annual Report to Shareholders, including the Schedule of Investments, the Statement of Assets and Liabilities,
the Statement of Operations, the Statement of Changes in Net Assets, the Statement of Cash Flows and the five-year Financial Highlights.
The Trust&#8217;s unaudited financial statements as of and for the six-month period ended March&#160;31, 2022 are also incorporated in
this SAI by reference to the Trust&#8217;s March&#160;31, 2022 Semi-Annual Report to Shareholders. A copy of the Trust&#8217;s 2021 Annual
Report to Shareholders and the Trust&#8217;s 2022 Semi-Annual Report to Shareholders are available at the SEC&#8217;s website (<span style="text-decoration:underline">www.sec.gov</span>).
Copies may also be obtained free of charge upon request from the Trust at (617) 772-8500.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">45</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>APPENDIX
A</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>PROXY
VOTING POLICIES AND PROCEDURES</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong><span style="text-decoration:underline">Policy</span></strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The following are the policies and procedures adopted and implemented
by Tekla Capital Management LLC (&#8220;TCM&#8221;) for voting proxies with respect to portfolio securities held by Tekla Healthcare Investors,
Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, and Tekla World Healthcare Fund (each a &#8220;Fund&#8221; and together
the &#8220;Funds&#8221;). The policies and procedures are reasonably designed to ensure that proxies are voted in the best interest of
the Funds and the Funds&#8217; shareholders, in accordance with TCM&#8217;s fiduciary duties and Rule&#160;206(4)-6 under the Investment
Advisers Act of 1940 (the &#8220;Investment Advisers Act&#8221;). TCM considers the &#8220;best interests&#8221; of the Funds and their
shareholders to mean their best long-term economic interests.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">TCM shall vote proxies for the exclusive benefit, and in the best economic
interest, of the Funds and their shareholders. Such exercise of voting rights shall be subject to the same standard of care as is generally
applicable to TCM&#8217;s performance of its duties, as set forth in the advisory agreements with the Funds. The policies and procedures
contained herein are designed to be guidelines, however each vote is ultimately cast on a case-by-case basis, taking into consideration
the relevant facts and circumstances at the time of the vote. Any material conflicts that may arise will be resolved in the best interests
of the Funds and their shareholders.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A proxy committee has been designated and is responsible for administering
and overseeing the proxy voting process. The committee consists of the President of TCM, TCM&#8217;s Chief Compliance Officer (&#8220;CCO&#8221;),
and the analyst responsible for oversight of the company that is the subject of the proxy. The committee considers proxy questions and
determines the vote on behalf of the Funds.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong><span style="text-decoration:underline">Procedures</span></strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Logistics</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">TCM&#8217;s CCO shall be responsible for maintaining the proxy log, monitoring
corporate actions and confirming the timely voting of proxies. The proxy log shall contain the following information, in accordance with
Form&#160;N-PX:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td style="text-align:justify">the name of the issuer;</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td style="text-align:justify">the exchange ticker symbol, if available;</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td style="text-align:justify">the CUSIP number, if available;</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td style="text-align:justify">the shareholder meeting date;</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td style="text-align:justify">a brief identification of the matter voted on;</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td style="text-align:justify">whether the matter was proposed by the issuer or a security holder;</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td style="text-align:justify">whether TCM cast its vote on the matter;</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td style="text-align:justify">how TCM cast its vote on the matter (for, against, abstain; for or withhold regarding the election of directors);
        and</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td style="text-align:justify">whether TCM cast its vote for or against management.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">TCM&#8217;s CCO shall also record whether any conflicts of interest have
been identified and, if so, what action was taken to resolve the conflict with respect to each vote cast and each abstention.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">A-1</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Substantive Voting Decisions</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">TCM&#8217;s substantive voting decisions turn on the particular facts
and circumstances of each proxy vote. The following is a list of common proxy vote issues and TCM&#8217;s standard considerations when
determining how to vote such proxies.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Routine Matters/Corporate Administrative Items</i>. After an initial
review, TCM generally votes with management on routine matters related to the operation of the issuer that are not expected to have a
significant economic impact on the issuer and/or its shareholders.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Potential for Major Economic Impact</i>. TCM may review and analyze
on a case-by-case basis, non-routine proposals that are more likely to affect the structure and operation of the issuer and to have a
greater impact on the value of the investment.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Corporate Governance</i>. TCM may review and consider corporate governance
issues related to proxy matters and generally supports proposals that foster good corporate governance practices.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Special Interest Issues</i>. TCM may consider: (i)&#160;the long-term
benefit to shareholders of promoting corporate accountability and responsibility on social issues; (ii)&#160;management&#8217;s responsibility
with respect to special interest issues; (iii)&#160;any economic costs and restrictions on management; and (iv)&#160;the responsibility
of TCM to vote proxies for the greatest long-term shareholder value.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Limitations on Director Tenure and Retirement</i>. TCM may consider:
(i)&#160;a reasonable retirement age for directors, <i>e.g. </i>70 or 72; (ii)&#160;the introduction of new perspectives on the board;
and (iii)&#160;the arbitrary nature of such limitations and the possibility of detracting from the board&#8217;s stability and continuity.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Directors&#8217; Minimum Stock Ownership</i>. TCM may consider: (i)&#160;the
benefits of additional vested interest; (ii)&#160;the ability of a director to serve a company well regardless of the extent of his or
her share ownership; and (iii)&#160;the impact of limiting the number of persons qualified to be directors.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>D&#38;O Indemnification and Liability Protection</i>. TCM may consider:
(i)&#160;indemnifying directors for acts conducted in the normal course of business; (ii)&#160;limiting liability for monetary damages
for violating the duty of care; (iii)&#160;expanding coverage beyond legal expenses to acts that represent more serious violations of
fiduciary obligation than carelessness (<i>e.g. </i>negligence); and (iv)&#160;providing expanded coverage in cases when a director&#8217;s
legal defense was unsuccessful if the director was found to have acted in good faith and in a manner that he or she reasonably believed
was in the best interests of the issuer.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Director Nominations in Contested Elections</i>. TCM may consider:
(i)&#160;long-term financial performance of the issuer relative to its industry; (ii)&#160;management&#8217;s track record; (iii)&#160;background
to proxy contest; (iv)&#160;qualifications of both slates of nominees; (v)&#160;evaluations of what each side is offering shareholders
as well as the likelihood that the proposed objectives and goals can be met; and (vi)&#160;stock ownership positions.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Cumulative Voting</i>. TCM may consider: (i)&#160;the ability of significant
stockholders to elect a director of their choosing; (ii)&#160;the ability of minority shareholders to concentrate their support in favor
of a director or directors of their choosing; and (iii)&#160;the potential to limit the ability of directors to work for all shareholders.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Classified Boards</i>. TCM may consider: (i)&#160;providing continuity;
(ii)&#160;promoting long-term planning; and (iii)&#160;guarding against unwanted takeovers.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Poison Pills</i>. TCM may consider: (i)&#160;TCM&#8217;s position on
supporting proposals to require a shareholder vote on other shareholder rights plans; (ii)&#160;ratifying or redeeming a poison pill in
the interest of protecting the value of the issuer; and (iii)&#160;other alternatives to prevent a takeover at a price demonstrably below
the true value of the issuer.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Fair Price Provisions</i>. TCM may consider: (i)&#160;the vote required
to approve the proposed acquisition; (ii)&#160;the vote required to repeal the fair price provision; (iii)&#160;the mechanism for determining
fair price; and (iv)&#160;whether these provisions are bundled with other antitakeover measures (<i>e.g.</i>, supermajority voting requirements)
that may entrench management and discourage attractive tender offers.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">A-2</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Equal Access</i>. TCM may consider: (i)&#160;the opportunity for significant
shareholders of the issuer to evaluate and propose voting recommendations on proxy proposals and director nominees, and to nominate candidates
to the board; and (ii)&#160;the added complexity and burden.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Charitable Contributions</i>. TCM may consider: (i)&#160;the potential
benefits to shareholders; (ii)&#160;the potential to detract the issuer&#8217;s resources from more direct uses of increasing shareholder
value; and (iii)&#160;the responsibility of shareholders to make individual contributions.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Stock Authorizations</i>: TCM may consider: (i)&#160;the need for the
increase; (ii)&#160;the percentage increase with respect to the existing authorization; (iii)&#160;voting rights of the stock; and (iv)&#160;overall
capitalization structures.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Preferred Stock</i>. TCM may consider: (i)&#160;whether the new class
of preferred stock has unspecified voting, conversion, dividend distribution, and other rights; (ii)&#160;whether the issuer expressly
states that the stock will not be used as a takeover defense or carry superior voting rights; (iii)&#160;whether the issuer specifies
the voting, dividend, conversion, and other rights of such stock and the terms of the preferred stock appear reasonable; and (iv)&#160;whether
the stated purpose is to raise capital or make acquisitions in the normal course of business.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Director Compensation</i>. TCM may consider: (i)&#160;whether director
shares are at the same market risk as those of the shareholders; and (ii)&#160;how option programs for outside directors compare with
the standards of internal programs.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Golden and Tin Parachutes</i>. TCM may consider: (i)&#160;whether they
will be submitted for shareholder approval; and (ii)&#160;the employees covered by the plan and the quality of management.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Compensation</i>. TCM may consider: (i)&#160;Whether the company has
an independent compensation committee; (ii)&#160;whether the compensation committee engaged independent consultants; (iii)&#160;whether
the compensation committee has lapsed or waived equity vesting restrictions; and (iv)&#160;whether the company has adopted or extended
a Golden Parachute without shareholder approval. TCM will generally support annual advisory votes on executive compensation.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Limitations</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">TCM may abstain from voting a proxy if it concludes that the effect on
shareholders&#8217; economic interests or the value of the portfolio holding is indeterminable or insignificant. TCM may abstain from
voting a proxy if it concludes that the cost of voting is disproportionate to the economic impact the vote would have on the portfolio
holdings. With respect to certain privately held companies, TCM may not have the opportunity to vote or may have a limitation on its ability
to vote. For example, in certain cases a company may be permitted by its charter or other governing documents to take action without a
shareholder meeting and with written consent of fewer than all shareholders.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Conflicts of Interest</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Proxy Committee identifies any potential conflicts of interest. Each
potential conflict must be addressed in a manner which will be in the best interest of the Funds and their shareholders. If any potential
conflict is identified the Proxy Committee consults with the Funds&#8217; counsel. Where conflicts of interest arise between clients and
TCM, TCM may convene an ad-hoc committee to debate the conflict and to give a ruling on a preferred course of action. If the ad-hoc committee
determines that TCM has a conflict of interest in any instance, TCM&#8217;s CCO shall disclose the conflict to the Board and seek voting
instructions.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">TCM may cause the proxies to be voted in accordance with the recommendations
of an independent third party service provider that TCM may use to assist in voting proxies.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Disclosure</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The following disclosure shall be provided in connection with these policies
and procedures:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td style="text-align:justify">TCM shall provide a description or a copy of these policies and procedures to the Boards of Trustees of the
        Funds annually and upon request.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="border-bottom:Black 1pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">A-3</p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td style="text-align:justify">TCM shall make available to the Funds its proxy voting records, for inclusion on the Funds&#8217; Form&#160;N-PX.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td style="text-align:justify">TCM shall include its proxy voting policies and procedures in its annual filing on Form&#160;N-CSR.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td style="text-align:justify">TCM shall cause the Funds&#8217; shareholder reports to include a statement that a copy of these policies and
        procedures is available upon request (i)&#160;by calling a toll-free number; (ii)&#160;on the Funds&#8217; website, (if the Funds choose);
        and (iii)&#160;on the SEC&#8217;s website.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in"><span style="font-size:8pt">&#9679;</span></td>
    <td style="text-align:justify">TCM shall cause the Funds&#8217; annual and semi-annual reports to include a statement that information is
        available regarding how the Funds voted proxies during the most recent twelve-month period (i)&#160;without charge, upon request, either
        by calling a toll-free number or on or through the Funds&#8217; website, or both; and (ii)&#160;on the SEC&#8217;s website.</td></tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Recordkeeping</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">TCM shall maintain records of proxies voted in accordance with Section&#160;204-2
of the Advisers Act, including proxy statements, a record of each vote cast, and a copy of any document created by TCM that was material
to making a decision of how to vote the proxy, or that memorializes the basis for TCM&#8217;s decision on how to vote the proxy. TCM shall
also maintain a copy of its policies and procedures and each written request from a client for proxy voting records and TCM&#8217;s written
response to any client request, either written or oral, for such records. Proxy statements that are filed on EDGAR shall be considered
maintained by TCM. All such records shall be maintained for a period of five years in an easily accessible place, the first two year in
the offices of TCM.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">A-4</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:left">&#160;</p></div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>ck0001635977-20221213.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:ck0001635977="http://www.teklacap.com/20221213" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:cef="http://xbrl.sec.gov/cef/2022" targetNamespace="http://www.teklacap.com/20221213" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/cef/2022" schemaLocation="https://xbrl.sec.gov/cef/2022/cef-2022.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.teklacap.com/role/Cover" id="Cover">
        <link:definition>0000 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.teklacap.com/role/OtherData" id="OtherData">
        <link:definition>0002 - Disclosure - Other data</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.teklacap.com/role/FINANCIALHIGHLIGHTSANDINVESTMENTPERFORMANCE" id="FINANCIALHIGHLIGHTSANDINVESTMENTPERFORMANCE">
        <link:definition>0004 - Disclosure - FINANCIAL HIGHLIGHTS AND INVESTMENT PERFORMANCE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.teklacap.com/role/LeverageOfPortfolio" id="LeverageOfPortfolio">
        <link:definition>0005 - Disclosure - Leverage of portfolio</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.teklacap.com/role/DESCRIPTIONOFOURCAPITALSTOCK" id="DESCRIPTIONOFOURCAPITALSTOCK">
        <link:definition>0006 - Disclosure - DESCRIPTION OF OUR CAPITAL STOCK</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ck0001635977-20221213_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ck0001635977-20221213_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ck0001635977-20221213_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="LoanFacilityMember" id="ck0001635977_LoanFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>ck0001635977-20221213_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <link:roleRef roleURI="http://xbrl.sec.gov/cef/role/RiskOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/cef/2022/cef-2022.xsd#RiskOnly"/>
  <link:roleRef roleURI="http://xbrl.sec.gov/cef/role/SecurityOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/cef/2022/cef-2022.xsd#SecurityOnly"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/SecurityOnly">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cef/2022/cef-2022.xsd#cef_AllSecuritiesMember" xlink:label="loc_cef_AllSecuritiesMember_0"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20221213.xsd#ck0001635977_LoanFacilityMember" xlink:label="loc_ck0001635977_LoanFacilityMember_1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cef_AllSecuritiesMember_0" xlink:to="loc_ck0001635977_LoanFacilityMember_1" order="1" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/RiskOnly">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cef/2022/cef-2022.xsd#cef_AllRisksMember" xlink:label="loc_cef_AllRisksMember_0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ck0001635977-20221213_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="ck0001635977-20221213.xsd#ck0001635977_LoanFacilityMember" xlink:label="loc_ck0001635977_LoanFacilityMember_1"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20221213.xsd#ck0001635977_LoanFacilityMember" xlink:label="loc_ck0001635977_LoanFacilityMember_2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001635977_LoanFacilityMember_0" xml:lang="en-US">It represents as a loan facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001635977_LoanFacilityMember_1" xml:lang="en-US">Loan Facility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacilityMember_1" xlink:to="lab_ck0001635977_LoanFacilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001635977_LoanFacilityMember_2" xlink:to="lab_ck0001635977_LoanFacilityMember_1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ck0001635977-20221213_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <link:roleRef roleURI="http://xbrl.sec.gov/cef/role/N2" xlink:type="simple" xlink:href="https://xbrl.sec.gov/cef/2022/cef-2022.xsd#N2"/>
  <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/N2">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cef/2022/cef-2022.xsd#cef_AllSecuritiesMember" xlink:label="loc_cef_AllSecuritiesMember_0"/>
    <loc xlink:type="locator" xlink:href="ck0001635977-20221213.xsd#ck0001635977_LoanFacilityMember" xlink:label="loc_ck0001635977_LoanFacilityMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cef/2022/cef-2022.xsd#cef_AllRisksMember" xlink:label="loc_cef_AllRisksMember_0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cef_AllSecuritiesMember_0" xlink:to="loc_ck0001635977_LoanFacilityMember_1" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140346704280928">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>N-2 - USD ($)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="11">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 13, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 06, 2022</div></th>
<th class="th"><div>Dec. 01, 2022</div></th>
<th class="th"><div>Sep. 06, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">0001635977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">424B5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">TEKLA
WORLD HEALTHCARE FUND<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_FeeTableAbstract', window );"><strong>Fee Table [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ShareholderTransactionExpensesTableTextBlock', window );">Shareholder Transaction Expenses [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;width:85%;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Fees
        and Expenses</strong></span></td>
    <td style="padding-top:2pt;width:15%;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:5pt;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Shareholder
        Transaction Expenses</strong></span></td>
    <td style="padding-top:5pt;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Sales
        Load<sup>(1)</sup> </span></td>
    <td style="padding-top:2pt;text-align:right;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">1.00%</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Expenses
        Borne by Shareholders of the Trust </span></td>
    <td style="padding-top:2pt;text-align:right;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#8212;%</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Dividend
        Reinvestment and Stock Repurchase Plan Fees </span></td>
    <td style="padding-top:2pt;text-align:right;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">None
        <sup>(2)</sup></span></td> </tr>
  </table> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">

<div>

<table style="font:13px Times New Roman, Times, serif;text-decoration-style:initial;text-decoration-color:initial;border-collapse:collapse;width:100%;border:0px">
  <tr>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px;font-weight:bold">Fees and Expenses</span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td>
    <td colspan="2" style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td> </tr>
  <tr>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px;font-weight:bold">Shareholder Transaction Expenses (</span> <span style="font-size:13px;font-weight:bold">as
        a percentage of Subscription Price</span><span style="font-size:13px;font-weight:bold">)</span> </td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td>
    <td colspan="2" style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td> </tr>
  <tr>
    <td style="padding-left:0.125in;padding-top:3px;padding-bottom:3px"><span style="font-size:13px">Sales Load</span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td>
    <td colspan="2" style="padding-top:3px;text-align:right;padding-bottom:3px"><span style="font-size:13px">&#8212;%</span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td> </tr>
  <tr>
    <td style="padding-left:0.125in;padding-top:3px;padding-bottom:3px"><span style="font-size:13px">Expenses Borne by Shareholders of the Trust</span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td>
    <td colspan="2" style="padding-top:3px;text-align:right;padding-bottom:3px"><span style="font-size:13px">&#8212;%</span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td> </tr>
  <tr>
    <td style="padding-left:0.125in;padding-top:3px;padding-bottom:3px"><span style="font-size:13px">Dividend Reinvestment and Stock Repurchase
        Plan Fees</span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td>
    <td colspan="2" style="padding-top:3px;text-align:right;padding-bottom:3px"><span style="font-size:13px">None&#160;<sup>(1)</sup></span></td>
    <td style="padding-top:3px;padding-bottom:3px"><span style="font-size:13px">&#160;</span></td> </tr>
  </table> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SalesLoadPercent', window );">Sales Load [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_DividendReinvestmentAndCashPurchaseFees', window );">Dividend Reinvestment and Cash Purchase Fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_OtherTransactionExpensesAbstract', window );"><strong>Other Transaction Expenses [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_OtherTransactionExpense1Percent', window );">Other Transaction Expense 1 [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_OtherTransactionExpensesPercent', window );">Other Transaction Expenses [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_AnnualExpensesTableTextBlock', window );">Annual Expenses [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;padding-bottom:2pt;width:85%"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Annual
        Expenses (as a percentage of average net assets attributable to Shares)<sup>(2)</sup></strong></span></td>
    <td style="padding-top:2pt;text-align:right;padding-bottom:2pt;width:15%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Management
        Fee<sup>(3)</sup> </span></td>
    <td style="padding-top:2pt;text-align:right;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">1.23%</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Interest
        Payments on Borrowed Funds </span></td>
    <td style="padding-top:2pt;text-align:right;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">0.38%</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Other
        Expenses<sup>(4)</sup> </span></td>
    <td style="padding-top:2pt;text-align:right;padding-bottom:2pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">0.30%</span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;padding-left:9pt;padding-bottom:2.5pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Total
        Annual Expenses </span></td>
    <td style="border-bottom:Black 2.5pt double;padding-top:2pt">
        <p style="border-top:Black 0.5pt solid;font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:right">1.91%</p>
        </td> </tr>
  </table> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="padding-top:2pt;font-size:10pt;font-weight:bold;text-align:left;padding-bottom:2pt"><strong>Annual Expenses (as a percentage of
        average net assets attributable to Shares) <sup>(1)</sup></strong></td>
    <td style="padding-top:2pt;font-size:10pt;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;font-size:10pt;text-align:right;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;width:83%;font-size:10pt;text-align:left;padding-left:9pt;padding-bottom:2pt">Management Fee <sup>(2)</sup></td>
    <td style="padding-top:2pt;width:2%;font-size:10pt;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;width:1%;font-size:10pt;text-align:left;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;width:13%;font-size:10pt;text-align:right;padding-bottom:2pt">1.23%</td>
    <td style="padding-top:2pt;width:1%;font-size:10pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="padding-top:2pt;font-size:10pt;text-align:left;padding-left:9pt;padding-bottom:2pt">Interest Payments on Borrowed Funds</td>
    <td style="padding-top:2pt;font-size:10pt;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt">&#160;</td>
    <td style="padding-top:2pt;font-size:10pt;text-align:right;padding-bottom:2pt">0.38%</td>
    <td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt;padding-left:9pt">Other Expenses <sup>(3)</sup></td>
    <td style="padding-top:2pt;font-size:10pt;padding-bottom:2pt">&#160;</td>
    <td style="border-bottom:Black 1pt solid;padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt">&#160;</td>
    <td style="border-bottom:Black 1pt solid;padding-top:2pt;font-size:10pt;text-align:right;padding-bottom:2pt">0.30%</td>
    <td style="padding-top:2pt;padding-bottom:2pt;font-size:10pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt;padding-left:9pt">Total Annual Expenses</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt">&#160;</td>
    <td style="border-bottom:Black 2.5pt double;padding-top:2pt;font:10pt Times New Roman, Times, Serif;text-align:left;padding-bottom:2pt">&#160;</td>
    <td style="border-bottom:Black 2.5pt double;padding-top:2pt;font:10pt Times New Roman, Times, Serif;text-align:right;padding-bottom:2pt">1.91%</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt;text-align:left">&#160;</td> </tr>
  </table> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ManagementFeesPercent', window );">Management Fees [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.23%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[4]</sup></td>
<td class="nump">1.23%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3],[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_InterestExpensesOnBorrowingsPercent', window );">Interest Expenses on Borrowings [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.38%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0.38%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_OtherAnnualExpensesAbstract', window );"><strong>Other Annual Expenses [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_OtherAnnualExpensesPercent', window );">Other Annual Expenses [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.30%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[6]</sup></td>
<td class="nump">0.30%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3],[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_TotalAnnualExpensesPercent', window );">Total Annual Expenses [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.91%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1.91%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ExpenseExampleTableTextBlock', window );">Expense Example [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td colspan="2" style="font:bold 10pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1pt solid">1 Year</td>
    <td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="font:bold 10pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1pt solid">3 Years</td>
    <td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="font:bold 10pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1pt solid">5 Years</td>
    <td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="font:bold 10pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1pt solid">10 Years</td>
    <td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td colspan="2" style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif;text-align:center">&#160;</td>
    <td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif;text-align:center">&#160;</td>
    <td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif;text-align:center">&#160;</td>
    <td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif;text-align:center">&#160;</td>
    <td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="font:10pt Times New Roman, Times, Serif;padding-left:-0.25in;width:22%;text-align:right">19&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="width:2%;font:10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="width:22%;font:10pt Times New Roman, Times, Serif;text-align:right">60&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="width:2%;font:10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="width:21%;font:10pt Times New Roman, Times, Serif;text-align:right">103&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left">&#160;</td>
    <td style="width:2%;font:10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left">$</td>
    <td style="width:21%;font:10pt Times New Roman, Times, Serif;text-align:right">223&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left">&#160;</td> </tr>
  </table> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">

<div>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td colspan="3" style="border-bottom:Black 1pt solid;font:bold 10pt Times New Roman, Times, Serif;text-align:center">1 Year</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="3" style="border-bottom:Black 1pt solid;font:bold 10pt Times New Roman, Times, Serif;text-align:center">3 Years</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="3" style="border-bottom:Black 1pt solid;font:bold 10pt Times New Roman, Times, Serif;text-align:center">5 Years</td>
    <td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td colspan="3" style="border-bottom:Black 1pt solid;font:bold 10pt Times New Roman, Times, Serif;text-align:center">10 Years</td> </tr>
  <tr style="vertical-align:bottom;background-color:transparent">
    <td style="width:1%;font-size:10pt;text-align:left">$</td>
    <td style="width:22%;font-size:10pt;text-align:right">19</td>
    <td style="width:1%;font-size:10pt;text-align:left">&#160;</td>
    <td style="width:2%;font-size:10pt">&#160;</td>
    <td style="width:1%;font-size:10pt;text-align:left">$</td>
    <td style="width:22%;font-size:10pt;text-align:right">60</td>
    <td style="width:1%;font-size:10pt;text-align:left">&#160;</td>
    <td style="width:2%;font-size:10pt">&#160;</td>
    <td style="width:1%;font-size:10pt;text-align:left">$</td>
    <td style="width:21%;font-size:10pt;text-align:right">103</td>
    <td style="width:1%;font-size:10pt;text-align:left">&#160;</td>
    <td style="width:2%;font-size:10pt">&#160;</td>
    <td style="width:1%;font-size:10pt;text-align:left">$</td>
    <td style="width:21%;font-size:10pt;text-align:right">223</td>
    <td style="width:1%;font-size:10pt;text-align:left">&#160;</td> </tr>
  </table> </div> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ExpenseExampleYear01', window );">Expense Example, Year 01</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ExpenseExampleYears1to3', window );">Expense Example, Years 1 to 3</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ExpenseExampleYears1to5', window );">Expense Example, Years 1 to 5</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">103<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">103<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ExpenseExampleYears1to10', window );">Expense Example, Years 1 to 10</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 223<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 223<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_PurposeOfFeeTableNoteTextBlock', window );">Purpose of Fee Table , Note [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The purpose of the table above is to assist you in understanding
the various cost and expenses that you will bear directly or indirectly as an investor in the Trust. For more information on the management
fees paid by the Trust, please refer to the section of the accompanying Prospectus entitled &#8220;The Trust&#8212;Compensation of Investment
Adviser.&#8221;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">The purpose of the table above is to assist you in understanding
the various costs and expenses that you will bear directly or indirectly as an investor in the Trust. For more information regarding the
management fees paid by the Trust, refer to the section of the accompanying Prospectus entitled &#8220;Management of the Trust&#8212;Investment
Adviser.&#8221;</p> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The purpose of the table above is to assist you in understanding the various
cost and expenses that you will bear directly or indirectly as an investor in the Trust. For more information on the management fees paid
by the Trust, see &#8220;The Trust&#8212;Compensation of Investment Adviser.&#8221;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The purpose of the table above is to assist you in understanding the various
costs and expenses that you will bear directly or indirectly as an investor in the Trust. For more information regarding the management
fees paid by the Trust, refer to the section of this Prospectus entitled &#8220;Management of the Trust&#8212;Investment Adviser.&#8221;</p>
</div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_BasisOfTransactionFeesNoteTextBlock', window );">Basis of Transaction Fees, Note [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"><span style="font-size:13px;font-weight:bold">as
        a percentage of Subscription Price</span><span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_OtherExpensesNoteTextBlock', window );">Other Expenses, Note [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#8220;Other
        Expenses&#8221; have been estimated for the current fiscal year.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#8220;Other
        Expenses&#8221; for the current fiscal year.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock', window );">Management Fee not based on Net Assets, Note [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">The
        management fee is charged as a percentage of the Trust&#8217;s average daily Managed Assets (as defined herein), as opposed to net assets.
        If leverage is used, Managed Assets will be greater in amount than net assets, because Managed Assets includes borrowings for investment
        purposes. &#8220;Managed Assets&#8221; means the total assets of the Trust (including any assets attributable to borrowings for investment
        purposes) minus the sum of the Trust&#8217;s accrued liabilities (other than liabilities representing borrowings for investment purposes).<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">The
        management fee is charged as a percentage of the Trust&#8217;s average daily Managed Assets, as opposed to net assets. If leverage is
        used, Managed Assets will be greater in amount than net assets, because Managed Assets includes borrowings for investment purposes.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesTableTextBlock', window );">Senior Securities [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="width:32%"><strong>Class&#160;and Year</strong></td>
    <td style="width:17%"><strong>Total Amount Outstanding<br/>Exclusive of Treasury Securities(1)</strong></td>
    <td style="width:17%"><strong>Asset Coverage Per<br/>$1,000 of Indebtedness</strong></td>
    <td style="width:17%"><strong>Involuntary<br/>Liquidating<br/>Preferences Per Unit</strong></td>
    <td style="width:17%"><strong>Average Market<br/>Value(2)</strong></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2021</td>
    <td>$120</td>
    <td>$5,714</td>
    <td>$&#8212;</td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173039070">N/A</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2020</td>
    <td>$120</td>
    <td>$4,554</td>
    <td>$&#8212;</td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173120190">N/A</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2019</td>
    <td>$120</td>
    <td>$4,396</td>
    <td>$&#8212;</td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173123789">N/A</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2018</td>
    <td>$120</td>
    <td>$4,861</td>
    <td>$&#8212;</td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173241279">N/A</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2017</td>
    <td>$120</td>
    <td>$4,999</td>
    <td>$&#8212;</td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173248397">N/A</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2016</td>
    <td>$120</td>
    <td>$5,160</td>
    <td>$&#8212;</td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173251957">N/A</span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">_______________</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;margin-top:0pt;margin-bottom:0pt">
  <tr style="vertical-align:top">
    <td style="width:0.25in">(1)</td>
    <td>Total amount in $ millions of each class of senior securities outstanding at the end of the period presented.</td> </tr>
  <tr style="vertical-align:top">
    <td>(2)</td>
    <td>Not applicable because the senior securities are not registered for public trading.</td> </tr>
  </table> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAmount', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesCoveragePerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,601<span></span>
</td>
<td class="nump">$ 5,714<span></span>
</td>
<td class="nump">$ 4,554<span></span>
</td>
<td class="nump">$ 4,396<span></span>
</td>
<td class="nump">$ 4,861<span></span>
</td>
<td class="nump">$ 4,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesNoteTextBlock', window );">Senior Securities, Note [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>SENIOR SECURITIES</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Information about our senior securities is shown in the following table
as of the end of the last 10 fiscal years. The information in this table for the fiscal years ended 2021, 2020, 2019, 2018 and 2017 has
been audited by Deloitte &amp; Touche LLP, independent registered public accounting firm. The Trust&#8217;s audited financial statements
appearing in the Trust&#8217;s Annual Report to Shareholders for the year ended September&#160;30, 2021, including the report of Deloitte
&amp; Touche LLP thereon, including accompanying notes thereto, are incorporated by reference in the SAI. The &#8220;--&#8221; indicates
information that the SEC expressly does not require to be disclosed for certain types of senior securities.</p>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="width:32%"><strong>Class&#160;and Year</strong></td>
    <td style="width:17%"><strong>Total Amount Outstanding<br/>Exclusive of Treasury Securities(1)</strong></td>
    <td style="width:17%"><strong>Asset Coverage Per<br/>$1,000 of Indebtedness</strong></td>
    <td style="width:17%"><strong>Involuntary<br/>Liquidating<br/>Preferences Per Unit</strong></td>
    <td style="width:17%"><strong>Average Market<br/>Value(2)</strong></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2021</td>
    <td>$120</td>
    <td>$5,714</td>
    <td>$&#8212;</td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173039070">N/A</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2020</td>
    <td>$120</td>
    <td>$4,554</td>
    <td>$&#8212;</td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173120190">N/A</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2019</td>
    <td>$120</td>
    <td>$4,396</td>
    <td>$&#8212;</td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173123789">N/A</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2018</td>
    <td>$120</td>
    <td>$4,861</td>
    <td>$&#8212;</td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173241279">N/A</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2017</td>
    <td>$120</td>
    <td>$4,999</td>
    <td>$&#8212;</td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173248397">N/A</span></td> </tr>
  <tr style="vertical-align:bottom">
    <td>Loan Facility 2016</td>
    <td>$120</td>
    <td>$5,160</td>
    <td>$&#8212;</td>
    <td><span style="-sec-ix-hidden:Fxbrl_20221209173251957">N/A</span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">_______________</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;margin-top:0pt;margin-bottom:0pt">
  <tr style="vertical-align:top">
    <td style="width:0.25in">(1)</td>
    <td>Total amount in $ millions of each class of senior securities outstanding at the end of the period presented.</td> </tr>
  <tr style="vertical-align:top">
    <td>(2)</td>
    <td>Not applicable because the senior securities are not registered for public trading.</td> </tr>
  </table> </div>  </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_InvestmentObjectivesAndPracticesTextBlock', window );">Investment Objectives and Practices [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">

<table style="font:13px Times New Roman, Times, serif;text-decoration-style:initial;text-decoration-color:initial;width:100%;border-collapse:collapse;border:0px">
  <tr>
    <td colspan="2" style="padding-right:7px;padding-left:7px">Please refer to&#160;<span style="color:#0070c0"><a href="https://www.sec.gov/Archives/edgar/data/1635977/000110465921146323/tm2129557d1_ncsr.htm"><span style="color:#0070c0">the
        section of the Trust&#8217;s most recent annual report on Form&#160;N-CSR entitled &#8220;Investment Objective, Policies, and Risk Factors&#8212;Investment
        Objective and Policies&#8221;</span></a></span><span style="text-decoration:underline"><span style="text-decoration:underline">,</span></span>&#160;which
        is incorporated by reference herein, for a discussion of the Trust&#8217;s investment objective and policies.</td> </tr>
  </table> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>INVESTMENT
OBJECTIVE AND POLICIES</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">Please
refer to&#160;</span><a href="https://www.sec.gov/Archives/edgar/data/1635977/000110465921146323/tm2129557d1_ncsr.htm"><span style="font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;font-weight:400;text-align:start;white-space:normal;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;color:#0070c0"><span style="text-decoration:underline">the&#160;</span></span><span style="color:#0070c0"><span style="text-decoration:underline">section
of the Trust&#8217;s most recent annual report on Form N-CSR entitled &#8220;Investment Objective, Policies and Risk Factors&#8212;Investment
Objective and Policies,&#8221;</span></span></a><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">&#160;which
is incorporated by reference herein, for discussion of the Trust&#8217;s investment objective and policies.</span></p> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_RiskFactorsTableTextBlock', window );">Risk Factors [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">

<table style="font:13px Times New Roman, Times, serif;text-decoration-style:initial;text-decoration-color:initial;width:100%;border-collapse:collapse;border:0px">
  <tr>
    <td style="vertical-align:top;padding-right:7px;padding-left:7px">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">See &#8220;Risks Factors&#8221; beginning
        on page&#160;15 of the accompanying Prospectus for a discussion of factors you should carefully consider before deciding to invest in
        the Trust&#8217;s Common Shares.</p> </td> </tr>
  </table> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="text-transform:uppercase"><strong>RISK
FACTORS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">An
investment in common shares of the Trust involves risk. Please refer&#160;</span><span style="color:#0070c0"><span style="text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1635977/000110465921146323/tm2129557d1_ncsr.htm"><span style="color:#0070c0"><span style="text-decoration:underline">to
the section of the Trust&#8217;s most recent annual report on Form N-CSR entitled &#8220;Investment Objectives, Policies and Risks&#8212;Risk
Factors,&#8221;</span></span></a></span></span><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">&#160;which
is incorporated by reference herein, for a discussion of the risks of investing in the Trust.</span></p> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_EffectsOfLeverageTextBlock', window );">Effects of Leverage [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><i>Effects of Leverage</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Assuming that leverage will represent approximately 20% of Managed Assets
and that the Trust will bear expenses relating to that leverage at an annual cost of 1.00%, Trust performance before leverage (net of
expenses) must exceed 0.2% in order to cover the expenses specifically related to the Trust&#8217;s use of leverage. Actual leverage expenses
will vary frequently and may be significantly higher or lower than the rate estimated above.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">As of September&#160;30, 2022 and the most recently signed line of credit
agreement, the Trust projects an annual leverage expense of 3.59%. The Trust had $120,000,000 of funds drawn on its line of credit which
was 18.9% of Managed Assets as of September&#160;30, 2022.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The following table is furnished in response to requirements of the SEC.
It is designed to illustrate the effects of leverage on total returns from an investment in the Trust assuming investment portfolio returns
before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage representing 20% of the Trust&#8217;s Managed
Assets and the Trust&#8217;s currently projected annual leverage expense of 1.00%.</p>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="border:black 1pt solid;width:50%">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Assumed Trust Return Before Leverage</p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">(Net of Expenses)</p> </td>
    <td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid">(10.00)%</td>
    <td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid">(5.00)%</td>
    <td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid">0.00%</td>
    <td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid">5.00%</td>
    <td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid">10.00%</td> </tr>
  <tr>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid;border-left:black 1pt solid">Assumed Trust Return Inclusive of Leverage</td>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid">(13.40)%</td>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid">(7.15)%</td>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid">(0.90)%</td>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid">5.35%</td>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid">11.60%</td>
        </tr>
  </table> </div>

<div/>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Assumed Trust performance before and inclusive of leverage are hypothetical
and are pro-vided to assist investors in understanding the effects of leverage. Actual performance experienced by the Trust may be lesser
or greater than that shown above.</p> </div>  </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_AnnualDividendPayment', window );">Annual Dividend Payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_EffectsOfLeverageTableTextBlock', window );">Effects of Leverage [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The following table is furnished in response to requirements of the SEC.
It is designed to illustrate the effects of leverage on total returns from an investment in the Trust assuming investment portfolio returns
before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage representing 20% of the Trust&#8217;s Managed
Assets and the Trust&#8217;s currently projected annual leverage expense of 1.00%.</p>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="border:black 1pt solid;width:50%">
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Assumed Trust Return Before Leverage</p>
        <p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">(Net of Expenses)</p> </td>
    <td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid">(10.00)%</td>
    <td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid">(5.00)%</td>
    <td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid">0.00%</td>
    <td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid">5.00%</td>
    <td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid">10.00%</td> </tr>
  <tr>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid;border-left:black 1pt solid">Assumed Trust Return Inclusive of Leverage</td>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid">(13.40)%</td>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid">(7.15)%</td>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid">(0.90)%</td>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid">5.35%</td>
    <td style="border-right:black 1pt solid;border-bottom:black 1pt solid">11.60%</td>
        </tr>
  </table> </div>

<div/>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Assumed Trust performance before and inclusive of leverage are hypothetical
and are pro-vided to assist investors in understanding the effects of leverage. Actual performance experienced by the Trust may be lesser
or greater than that shown above.</p> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ReturnAtMinusTenPercent', window );">Return at Minus Ten [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(13.40%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ReturnAtMinusFivePercent', window );">Return at Minus Five [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7.15%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ReturnAtZeroPercent', window );">Return at Zero [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ReturnAtPlusFivePercent', window );">Return at Plus Five [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5.35%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_ReturnAtPlusTenPercent', window );">Return at Plus Ten [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11.60%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_EffectsOfLeveragePurposeTextBlock', window );">Effects of Leverage, Purpose [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The following table is furnished in response to requirements of the SEC.
It is designed to illustrate the effects of leverage on total returns from an investment in the Trust assuming investment portfolio returns
before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage representing 20% of the Trust&#8217;s Managed
Assets and the Trust&#8217;s currently projected annual leverage expense of 1.00%.</p> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SharePriceTableTextBlock', window );">Share Price [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="width:12%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Quarter<br/>Ending</strong></p>
        </td>
    <td style="width:1%">&#160;</td>
    <td style="width:12%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Market<br/>Price(1)&#160;High</strong></p>
        </td>
    <td style="width:1%">&#160;</td>
    <td style="width:10%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Corresponding<br/>Net Asset<br/>Value(2)</strong></p>
        </td>
    <td style="width:1%">&#160;</td>
    <td style="width:11%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Market<br/>Premium/ (Discount)(2)</strong></p>
        </td>
    <td style="width:1%">&#160;</td>
    <td style="width:12%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Corresponding Price(1)&#160;Low</strong></p>
        </td>
    <td style="width:1%">&#160;</td>
    <td style="width:12%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Net Asset<br/>Value(2)</strong></p>
        </td>
    <td style="width:1%">&#160;</td>
    <td style="width:12%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Premium/ (Discount)(2)</strong></p>
        </td>
    <td style="width:1%">&#160;</td>
    <td style="width:12%">
        <p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Trading<br/>Volume(1)</strong></p>
        </td> </tr>
  <tr style="vertical-align:bottom">
    <td>Fiscal 2020</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:6pt">Dec.&#160;31</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$13.97</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$14.84</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">-5.86%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$13.00</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$13.32</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">-2.40%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">7,311,726</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:6pt">Mar.&#160;31</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$14.49</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$15.25</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">-4.98%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$8.89</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$10.50</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">-15.33%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">13,080,124</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:6pt">June&#160;30</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$14.76</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$14.58</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">1.24%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$10.83</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$12.29</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">-11.88%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">13,241,814</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:6pt">Sept. 30</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$14.99</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$14.67</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">2.18%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$13.82</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$13.76</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">0.436%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">6,999,269</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Fiscal 2021</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:6pt">Dec.&#160;31</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$16.07</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$14.68</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">9.47%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$13.43</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">$13.25</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">1.36%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">6,759,018</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-left:6pt">Mar.&#160;31</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$17.92</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$15.29</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">17.20%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$14.29</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$14.63</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">-2.32%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:bottom;text-align:right">12,830,000</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-left:6pt">June&#160;30</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$16.69</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$15.56</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">7.26%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$14.86</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$15.15</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">-1.91%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">12,500,000</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-left:6pt">Sept. 30</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$17.38</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$16.22</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">7.15%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$16.13</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$15.45</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">4.40%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">6,800,000</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Fiscal 2022</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;text-align:right">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-left:6pt">Dec.&#160;31</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$17.08</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$15.63</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:bottom;text-align:right">9.28%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$15.51</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$14.75</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">5.15%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">6,310,000</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-left:6pt">Mar.&#160;31</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$16.34</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$15.63</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:bottom;text-align:right">4.54%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$13.29</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$13.86</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">-4.11%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">8,990,000</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-left:6pt">June&#160;30</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$10.39</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$14.49</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:bottom;text-align:right">9.70%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$14.00</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">$12.40</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">12.90%</td>
    <td>&#160;</td>
    <td style="padding-right:0.2in;vertical-align:top;text-align:right">7,990,000</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">__________________</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.25in">(1)</td>
    <td>As reported by Bloomberg LLP.</td> </tr>
  <tr style="vertical-align:top">
    <td style="width:0.25in">(2)</td>
    <td>Based on the Trust&#8217;s computations, on the day that the high or low market price was recorded.</td> </tr>
  </table> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_LowestPriceOrBid', window );">Lowest Price or Bid</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 13.29<span></span>
</td>
<td class="nump">$ 15.51<span></span>
</td>
<td class="nump">$ 16.13<span></span>
</td>
<td class="nump">$ 14.86<span></span>
</td>
<td class="nump">$ 14.29<span></span>
</td>
<td class="nump">$ 13.43<span></span>
</td>
<td class="nump">$ 13.82<span></span>
</td>
<td class="nump">$ 10.83<span></span>
</td>
<td class="nump">$ 8.89<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_HighestPriceOrBid', window );">Highest Price or Bid</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.39<span></span>
</td>
<td class="nump">16.34<span></span>
</td>
<td class="nump">17.08<span></span>
</td>
<td class="nump">17.38<span></span>
</td>
<td class="nump">16.69<span></span>
</td>
<td class="nump">17.92<span></span>
</td>
<td class="nump">16.07<span></span>
</td>
<td class="nump">14.99<span></span>
</td>
<td class="nump">14.76<span></span>
</td>
<td class="nump">14.49<span></span>
</td>
<td class="nump">13.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_LowestPriceOrBidNav', window );">Lowest Price or Bid, NAV</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
<td class="nump">13.86<span></span>
</td>
<td class="nump">14.75<span></span>
</td>
<td class="nump">15.45<span></span>
</td>
<td class="nump">15.15<span></span>
</td>
<td class="nump">14.63<span></span>
</td>
<td class="nump">13.25<span></span>
</td>
<td class="nump">13.76<span></span>
</td>
<td class="nump">12.29<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">13.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_HighestPriceOrBidNav', window );">Highest Price or Bid, NAV</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.49<span></span>
</td>
<td class="nump">$ 15.63<span></span>
</td>
<td class="nump">$ 15.63<span></span>
</td>
<td class="nump">$ 16.22<span></span>
</td>
<td class="nump">$ 15.56<span></span>
</td>
<td class="nump">$ 15.29<span></span>
</td>
<td class="nump">$ 14.68<span></span>
</td>
<td class="nump">$ 14.67<span></span>
</td>
<td class="nump">$ 14.58<span></span>
</td>
<td class="nump">$ 15.25<span></span>
</td>
<td class="nump">$ 14.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_HighestPriceOrBidPremiumDiscountToNavPercent', window );">Highest Price or Bid, Premium (Discount) to NAV [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.70%<span></span>
</td>
<td class="nump">4.54%<span></span>
</td>
<td class="nump">9.28%<span></span>
</td>
<td class="nump">7.15%<span></span>
</td>
<td class="nump">7.26%<span></span>
</td>
<td class="nump">17.20%<span></span>
</td>
<td class="nump">9.47%<span></span>
</td>
<td class="nump">2.18%<span></span>
</td>
<td class="nump">1.24%<span></span>
</td>
<td class="num">(4.98%)<span></span>
</td>
<td class="num">(5.86%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_LowestPriceOrBidPremiumDiscountToNavPercent', window );">Lowest Price or Bid, Premium (Discount) to NAV [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.90%<span></span>
</td>
<td class="num">(4.11%)<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="num">(1.91%)<span></span>
</td>
<td class="num">(2.32%)<span></span>
</td>
<td class="nump">1.36%<span></span>
</td>
<td class="nump">0.436%<span></span>
</td>
<td class="num">(11.88%)<span></span>
</td>
<td class="num">(15.33%)<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_LatestSharePrice', window );">Latest Share Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 15.03<span></span>
</td>
<td class="nump">$ 14.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_LatestPremiumDiscountToNavPercent', window );">Latest Premium (Discount) to NAV [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10.60%<span></span>
</td>
<td class="nump">13.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_LatestNav', window );">Latest NAV</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 13.59<span></span>
</td>
<td class="nump">$ 12.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract', window );"><strong>Capital Stock, Long-Term Debt, and Other Securities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_CapitalStockTableTextBlock', window );">Capital Stock [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">The Trust&#8217;s capitalization consists of an unlimited number of Shares
of beneficial interest, $0.01 par value. Each Share represents an equal proportionate beneficial interest in the Trust and, when issued
and outstanding, will be fully paid and non-assessable by the Trust. Upon
any liquidation of the Trust, Shareholders will be entitled to share pro rata in the net assets of the Trust available for distribution
after paying or adequately providing for the payment of all liabilities. The Trust will send annual and semi-annual financial
statements to Shareholders and may also issue more abbreviated interim reports to update Shareholders on a quarterly basis. The Trust
will hold annual meetings of its Shareholders in accordance with the provisions of the Trust&#8217;s By-laws and the rules&#160;of the
NYSE.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Shareholders
are entitled to one vote for each whole Share held and a proportionate fractional vote for each fractional Share held. The Trust&#8217;s
Shares do not have cumulative voting rights, which means that the holders of more than 50% of the Shares of the Trust voting for the election
of Trustees can elect all of the Trustees, and, in such event, the holders of the remaining Shares will not be able to elect any Trustees.
The Trust has a classified Board of three classes, whereby one class of Trustees is elected each year.</p> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SecurityTitleTextBlock', window );">Security Title [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Common
        shares<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SecurityDividendsTextBlock', window );">Security Dividends [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>Distributions</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Dividends paid from investment company taxable income as calculated for
federal income tax purposes generally will be taxable to Shareholders as ordinary income whether paid in cash or reinvested in the Trust&#8217;s
Shares. The Trust intends to distribute to its Shareholders substantially all of its investment company taxable income(including distributions
of net short-term capital gains), if any, for each year. It is anticipated that the Trust&#8217;s income distributions will be paid annually
in additional Shares unless the Shareholder elects payment in cash.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A portion of the dividends paid by the Trust may be treated as &#8220;qualified
dividend income&#8221; which is taxable to individuals at the same rates that are applicable to long-term capital gains. A Trust distribution
is treated as qualified dividend income to the extent that the Trust receives dividend income from taxable domestic corporations and certain
qualified foreign corporations, provided that certain holding period and other requirements are met by both the Trust and the Shareholder.
Trust distributions generally will not qualify as qualified dividend income to the extent attributable to interest, capital gains, REIT
distributions and distributions from certain non-U.S. corporations.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">If a portion of the Trust&#8217;s income consists of dividends paid by
U.S. corporations, a portion of the dividends paid by the Trust may be eligible for the corporate dividends-received deduction provided
that certain holding period and other requirements are met by both the Trust and the corporate Shareholder.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Distributions of the excess, if any, of net long-term capital gains over
net short-term capital losses reported by the Trust as capital gain dividends will be taxable to Shareholders as long-term capital gains,
whether paid in cash or reinvested in the Trust&#8217;s Shares, regardless of how long the Shareholders have held the Trust&#8217;s Shares
and will not be eligible for the dividends received deduction for corporations.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Each year, Shareholders will be notified as to the amount and federal
tax status of all dividends and capital gains paid during the prior year. Such dividends and capital gains may also be subject to state
or local taxes. Dividends declared in October, November, or December&#160;with a record date in such month and paid during the following
January&#160;will be treated as having been paid by the Trust and received by Shareholders on December&#160;31 of the calendar year in
which declared, rather than the calendar year in which the dividends are actually received.</p>

<div/>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">Gain or loss realized upon the sale or exchange of Shares will be a capital
gain or loss if the Shares are capital assets in the Shareholder&#8217;s hands and generally will be long-term or short-term, depending
upon the Shareholder&#8217;s holding period for the Shares. You should be aware that any loss realized upon the sale or exchange of Shares
held for six months or less will be treated as a long-term capital loss to the extent of any distributions or deemed distributions of
long-term capital gain to the Shareholder with respect to such Shares. In addition, any loss realized on a sale or exchange of Shares
will be disallowed to the extent the Shares disposed of are replaced within a period of 61 days beginning 30 days before and ending 30
days after the Shares are disposed of, such as pursuant to the Plan. In such case, the basis of Shares acquired will be adjusted to reflect
the disallowed loss.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">An additional 3.8% Medicare tax is imposed on certain net investment income
(including ordinary dividends and capital gain distributions received from the Trust and net gains from redemptions or other taxabledispositions
of Trust Shares) of U.S. individuals, estates and trusts to the extent that such person&#8217;s &#8220;modified adjusted gross income&#8221;
(in the case of an individual) or &#8220;adjusted gross income&#8221; (in the case of an estate or trust) exceeds certain threshold amounts.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">If a Shareholder has not furnished a certified correct taxpayer identification
number (generally a Social Security number) and has not certified that withholding does not apply, or if the Internal Revenue Service
has notified the Trust that the taxpayer identification number listed on the account is incorrect according to their records or that the
Shareholder is subject to backup withholding, federal law generally requires the Trust to withhold 24% from any dividends and/or redemptions
(including exchange redemptions). Amounts withheld are applied to federal tax liability; a refund may be obtained from the Service if
withholding results in overpayment of taxes. Federal law also requires the Trust to withhold up to 30% or the applicable tax treaty rate
from ordinary dividends paid to certain nonresident alien and other non-U.S. Shareholder accounts.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">This is a brief summary of some of the tax laws that affect an investment
in the Trust. Moreover, the foregoing does not address the many factors that may determine whether an investor will be liable for the
federal alternative minimum tax. Please see the SAI and a tax adviser for further information.</p> </div> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SecurityVotingRightsTextBlock', window );">Security Voting Rights [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Shareholders
are entitled to one vote for each whole Share held and a proportionate fractional vote for each fractional Share held. The Trust&#8217;s
Shares do not have cumulative voting rights, which means that the holders of more than 50% of the Shares of the Trust voting for the election
of Trustees can elect all of the Trustees, and, in such event, the holders of the remaining Shares will not be able to elect any Trustees.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SecurityLiquidationRightsTextBlock', window );">Security Liquidation Rights [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Upon
any liquidation of the Trust, Shareholders will be entitled to share pro rata in the net assets of the Trust available for distribution
after paying or adequately providing for the payment of all liabilities.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_OutstandingSecurityHeldShares', window );">Outstanding Security, Held [Shares]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,500,309<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SecurityAxis=ck0001635977_LoanFacilityMember', window );">Loan Facility [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAmount', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[10]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesCoveragePerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,714<span></span>
</td>
<td class="nump">$ 4,554<span></span>
</td>
<td class="nump">$ 4,396<span></span>
</td>
<td class="nump">$ 4,861<span></span>
</td>
<td class="nump">$ 4,999<span></span>
</td>
<td class="nump">$ 5,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit', window );">Senior Securities Involuntary Liquidating Preference per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[11]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="25"></td></tr>
<tr><td colspan="25"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents the estimated commission with respect to the Common Shares being sold under this Prospectus Supplement and the accompanying Prospectus. There is no guarantee that there will be any sales of Common Shares under this Prospectus Supplement and the accompanying Prospectus. Actual sales of Common Shares under this Prospectus Supplement and the accompanying Prospectus, if any, may be less than as set forth under &#8220;Capitalization&#8221; below. In addition, the price per Common Share of any such sale may be greater or less than the price set forth under &#8220;Capitalization&#8221; below, depending on market price of the Common Shares at the time of any such sale.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The expenses of administering the Trust&#8217;s Dividend Reinvestment and Stock Purchase Plan are included in &#8220;Other Expenses.&#8221; You will pay brokerage charges if you direct your broker or the plan agent to sell your Common Shares that you acquired pursuant to the Trust&#8217;s Dividend Reinvestment and Stock Purchase Plan. You may also pay a pro rata share of brokerage commissions incurred in connection with open-market purchases pursuant to the Trust&#8217;s Dividend Reinvestment and Stock Purchase Plan.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The expenses of administering the Trust&#8217;s Dividend Reinvestment and Stock Purchase Plan are included in &#8220;Other Expenses.&#8221; You will pay brokerage charges if you direct your broker or the plan agent to sell your Shares that you acquired pursuant to the Trust&#8217;s Dividend Reinvestment and Stock Purchase Plan. You may also pay a pro rata share of brokerage commissions incurred in connection with open-market purchases pursuant to the Trust&#8217;s Dividend Reinvestment and Stock Purchase Plan. See &#8220;Dividend Reinvestment and Stock Purchase Plan.&#8221;</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">The management fee is charged as a percentage of the Trust&#8217;s average daily Managed Assets (as defined herein), as opposed to net assets. If leverage is used, Managed Assets will be greater in amount than net assets, because Managed Assets includes borrowings for investment purposes. &#8220;Managed Assets&#8221; means the total assets of the Trust (including any assets attributable to borrowings for investment purposes) minus the sum of the Trust&#8217;s accrued liabilities (other than liabilities representing borrowings for investment purposes).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">The management fee is charged as a percentage of the Trust&#8217;s average daily Managed Assets, as opposed to net assets. If leverage is used, Managed Assets will be greater in amount than net assets, because Managed Assets includes borrowings for investment purposes.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">&#8220;Other Expenses&#8221; have been estimated for the current fiscal year.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">&#8220;Other Expenses&#8221; for the current fiscal year.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">As reported by Bloomberg LLP.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top">Based on the Trust&#8217;s computations, on the day that the high or low market price was recorded.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[10]</td>
<td style="vertical-align: top;" valign="top">Total amount in $ millions of each class of senior securities outstanding at the end of the period presented.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[11]</td>
<td style="vertical-align: top;" valign="top">Not applicable because the senior securities are not registered for public trading.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_AnnualDividendPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br> -Subparagraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_AnnualDividendPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_AnnualExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_AnnualExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_BasisOfTransactionFeesNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_BasisOfTransactionFeesNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_CapitalStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 1<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_CapitalStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_DividendReinvestmentAndCashPurchaseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_DividendReinvestmentAndCashPurchaseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_EffectsOfLeveragePurposeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br> -Subparagraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_EffectsOfLeveragePurposeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_EffectsOfLeverageTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br> -Subparagraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_EffectsOfLeverageTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_EffectsOfLeverageTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_EffectsOfLeverageTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ExpenseExampleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ExpenseExampleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ExpenseExampleYear01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ExpenseExampleYear01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ExpenseExampleYears1to10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ExpenseExampleYears1to10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ExpenseExampleYears1to3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ExpenseExampleYears1to3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ExpenseExampleYears1to5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ExpenseExampleYears1to5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_FeeTableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_FeeTableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_FinancialHighlightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_FinancialHighlightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_GeneralDescriptionOfRegistrantAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_GeneralDescriptionOfRegistrantAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_HighestPriceOrBid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 5<br> -Paragraph b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_HighestPriceOrBid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_HighestPriceOrBidNav">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 5<br> -Paragraph b<br> -Subparagraph Instruction 4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_HighestPriceOrBidNav</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_HighestPriceOrBidPremiumDiscountToNavPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 5<br> -Paragraph b<br> -Subparagraph Instructions 4, 5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_HighestPriceOrBidPremiumDiscountToNavPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_InterestExpensesOnBorrowingsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_InterestExpensesOnBorrowingsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_InvestmentObjectivesAndPracticesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 2<br> -Paragraph b, d<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_InvestmentObjectivesAndPracticesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_LatestNav">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 5<br> -Paragraph c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_LatestNav</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_LatestPremiumDiscountToNavPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 5<br> -Paragraph c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_LatestPremiumDiscountToNavPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_LatestSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 5<br> -Paragraph c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_LatestSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_LowestPriceOrBid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 5<br> -Paragraph b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_LowestPriceOrBid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_LowestPriceOrBidNav">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 5<br> -Paragraph b<br> -Subparagraph Instruction 4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_LowestPriceOrBidNav</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_LowestPriceOrBidPremiumDiscountToNavPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 5<br> -Paragraph b<br> -Subparagraph Instructions 4, 5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_LowestPriceOrBidPremiumDiscountToNavPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 7<br> -Subparagraph b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ManagementFeesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 7<br> -Subparagraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ManagementFeesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OtherAnnualExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OtherAnnualExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OtherAnnualExpensesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OtherAnnualExpensesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OtherExpensesNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OtherExpensesNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OtherTransactionExpense1Percent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OtherTransactionExpense1Percent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OtherTransactionExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OtherTransactionExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OtherTransactionExpensesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OtherTransactionExpensesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OutstandingSecurityHeldShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 5<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OutstandingSecurityHeldShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_PurposeOfFeeTableNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_PurposeOfFeeTableNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ReturnAtMinusFivePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br> -Subparagraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ReturnAtMinusFivePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ReturnAtMinusTenPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br> -Subparagraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ReturnAtMinusTenPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ReturnAtPlusFivePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br> -Subparagraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ReturnAtPlusFivePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ReturnAtPlusTenPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br> -Subparagraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ReturnAtPlusTenPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ReturnAtZeroPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph b<br> -Subparagraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ReturnAtZeroPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskFactorsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskFactorsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SalesLoadPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SalesLoadPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SecurityDividendsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 1<br> -Paragraph a<br> -Subparagraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SecurityDividendsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SecurityLiquidationRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 1<br> -Paragraph a<br> -Subparagraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SecurityLiquidationRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SecurityTitleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 1<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SecurityTitleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SecurityVotingRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 1<br> -Paragraph a<br> -Subparagraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SecurityVotingRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesAverageMarketValuePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br> -Paragraph 5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesAverageMarketValuePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesCoveragePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br> -Paragraph 3<br> -Subparagraph Instruction 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesCoveragePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br> -Paragraph 4<br> -Subparagraph Instruction 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br> -Paragraph Instruction 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 1<br> -Paragraph Instruction 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SharePriceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 5<br> -Paragraph b<br> -Subparagraph 4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SharePriceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ShareholderTransactionExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ShareholderTransactionExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_TotalAnnualExpensesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_TotalAnnualExpensesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SecurityAxis=ck0001635977_LoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SecurityAxis=ck0001635977_LoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>tm2226039d6_424b5_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cef="http://xbrl.sec.gov/cef/2022"
  xmlns:ck0001635977="http://www.teklacap.com/20221213"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ck0001635977-20221213.xsd" xlink:type="simple"/>
    <context id="C_20221213to20221213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2022-12-13</startDate>
            <endDate>2022-12-13</endDate>
        </period>
    </context>
    <context id="C_20220906to20220906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2022-09-06</startDate>
            <endDate>2022-09-06</endDate>
        </period>
    </context>
    <context id="C_20221206to20221206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2022-12-06</startDate>
            <endDate>2022-12-06</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930_cefSecurityAxis_ck0001635977LoanFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:SecurityAxis">ck0001635977:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930_cefSecurityAxis_ck0001635977LoanFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:SecurityAxis">ck0001635977:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20181001to20190930_cefSecurityAxis_ck0001635977LoanFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:SecurityAxis">ck0001635977:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20171001to20180930_cefSecurityAxis_ck0001635977LoanFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:SecurityAxis">ck0001635977:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_20161001to20170930_cefSecurityAxis_ck0001635977LoanFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:SecurityAxis">ck0001635977:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="C_20151001to20160930_cefSecurityAxis_ck0001635977LoanFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:SecurityAxis">ck0001635977:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_20211001to20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_20201001to20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20181001to20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_20171001to20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_20161001to20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="C_20191001to20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_20200401to20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_20200701to20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20201001to20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_20210401to20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20210701to20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_20211001to20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_20220401to20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20221201to20221201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-01</endDate>
        </period>
    </context>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USD_Per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="C_20201001to20210930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      id="Fxbrl_20221209173039070"
      unitRef="USD_Per_Share"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="C_20191001to20200930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      id="Fxbrl_20221209173120190"
      unitRef="USD_Per_Share"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="C_20181001to20190930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      id="Fxbrl_20221209173123789"
      unitRef="USD_Per_Share"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="C_20171001to20180930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      id="Fxbrl_20221209173241279"
      unitRef="USD_Per_Share"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="C_20161001to20170930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      id="Fxbrl_20221209173248397"
      unitRef="USD_Per_Share"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="C_20151001to20160930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      id="Fxbrl_20221209173251957"
      unitRef="USD_Per_Share"
      xsi:nil="true"/>
    <dei:AmendmentFlag
      contextRef="C_20221213to20221213"
      id="Fdei_AmendmentFlag20221209134115862">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_20221213to20221213"
      id="Fdei_EntityCentralIndexKey20221209134133945">0001635977</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_20221213to20221213"
      id="Fxbrl_20221209140522624">424B5</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="C_20221213to20221213"
      id="Fxbrl_20221209051558120">TEKLA WORLD HEALTHCARE FUND</dei:EntityRegistrantName>
    <cef:LatestNav
      contextRef="C_20221201to20221201"
      decimals="2"
      id="Fxbrl_20221212124516544"
      unitRef="USD_Per_Share">13.59</cef:LatestNav>
    <cef:LatestSharePrice
      contextRef="C_20221201to20221201"
      decimals="2"
      id="Fxbrl_20221212124532792"
      unitRef="USD_Per_Share">15.03</cef:LatestSharePrice>
    <cef:LatestPremiumDiscountToNavPercent
      contextRef="C_20221201to20221201"
      decimals="4"
      id="Fxbrl_20221212121322467"
      unitRef="Pure">0.106</cef:LatestPremiumDiscountToNavPercent>
    <cef:ShareholderTransactionExpensesTableTextBlock
      contextRef="C_20221213to20221213"
      id="Fxbrl_20221209164044176">

&lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;border-collapse:collapse"&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="padding-top:2pt;width:85%;padding-bottom:2pt"&gt;&lt;span style="font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;&lt;strong&gt;Fees
        and Expenses&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:2pt;width:15%;padding-bottom:2pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="padding-top:5pt;padding-bottom:2pt"&gt;&lt;span style="font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;&lt;strong&gt;Shareholder
        Transaction Expenses&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:5pt;padding-bottom:2pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"&gt;&lt;span style="font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Sales
        Load&lt;sup&gt;(1)&lt;/sup&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:2pt;text-align:right;padding-bottom:2pt"&gt;&lt;span style="font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;1.00%&lt;/span&gt;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"&gt;&lt;span style="font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Expenses
        Borne by Shareholders of the Trust &lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:2pt;text-align:right;padding-bottom:2pt"&gt;&lt;span style="font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"&gt;&lt;span style="font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Dividend
        Reinvestment and Stock Repurchase Plan Fees &lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:2pt;text-align:right;padding-bottom:2pt"&gt;&lt;span style="font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;None
        &lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </cef:ShareholderTransactionExpensesTableTextBlock>
    <cef:SalesLoadPercent
      contextRef="C_20221213to20221213"
      decimals="4"
      id="Fxbrl_20221209055556812"
      unitRef="Pure">0.01</cef:SalesLoadPercent>
    <cef:OtherTransactionExpensesPercent
      contextRef="C_20221213to20221213"
      decimals="2"
      id="Fxbrl_20221209055602682"
      unitRef="Pure">0</cef:OtherTransactionExpensesPercent>
    <cef:DividendReinvestmentAndCashPurchaseFees
      contextRef="C_20221213to20221213"
      decimals="0"
      id="Fxbrl_20221209055609172"
      unitRef="USD">0</cef:DividendReinvestmentAndCashPurchaseFees>
    <cef:AnnualExpensesTableTextBlock
      contextRef="C_20221213to20221213"
      id="Fxbrl_20221209164101502">

&lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;border-collapse:collapse"&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="padding-top:2pt;padding-bottom:2pt;width:85%"&gt;&lt;span style="font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;&lt;strong&gt;Annual
        Expenses (as a percentage of average net assets attributable to Shares)&lt;sup&gt;(2)&lt;/sup&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:2pt;text-align:right;padding-bottom:2pt;width:15%"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"&gt;&lt;span style="font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Management
        Fee&lt;sup&gt;(3)&lt;/sup&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:2pt;text-align:right;padding-bottom:2pt"&gt;&lt;span style="font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;1.23%&lt;/span&gt;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"&gt;&lt;span style="font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Interest
        Payments on Borrowed Funds &lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:2pt;text-align:right;padding-bottom:2pt"&gt;&lt;span style="font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;0.38%&lt;/span&gt;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="padding-top:2pt;padding-left:9pt;padding-bottom:2pt"&gt;&lt;span style="font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Other
        Expenses&lt;sup&gt;(4)&lt;/sup&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:2pt;text-align:right;padding-bottom:2pt"&gt;&lt;span style="font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;0.30%&lt;/span&gt;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="padding-top:2pt;padding-left:9pt;padding-bottom:2.5pt"&gt;&lt;span style="font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Total
        Annual Expenses &lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2.5pt double;padding-top:2pt"&gt;
        &lt;p style="border-top:Black 0.5pt solid;font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:right"&gt;1.91%&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </cef:AnnualExpensesTableTextBlock>
    <cef:ManagementFeesPercent
      contextRef="C_20221213to20221213"
      decimals="4"
      id="Fxbrl_20221209055614851"
      unitRef="Pure">0.0123</cef:ManagementFeesPercent>
    <cef:InterestExpensesOnBorrowingsPercent
      contextRef="C_20221213to20221213"
      decimals="4"
      id="Fxbrl_20221209055621581"
      unitRef="Pure">0.0038</cef:InterestExpensesOnBorrowingsPercent>
    <cef:OtherAnnualExpensesPercent
      contextRef="C_20221213to20221213"
      decimals="4"
      id="Fxbrl_20221209055626506"
      unitRef="Pure">0.003</cef:OtherAnnualExpensesPercent>
    <cef:TotalAnnualExpensesPercent
      contextRef="C_20221213to20221213"
      decimals="4"
      id="Fxbrl_20221209055631106"
      unitRef="Pure">0.0191</cef:TotalAnnualExpensesPercent>
    <cef:ManagementFeeNotBasedOnNetAssetsNoteTextBlock
      contextRef="C_20221213to20221213"
      id="Fxbrl_20221209164954240">The
        management fee is charged as a percentage of the Trust&#x2019;s average daily Managed Assets (as defined herein), as opposed to net assets.
        If leverage is used, Managed Assets will be greater in amount than net assets, because Managed Assets includes borrowings for investment
        purposes. &#x201c;Managed Assets&#x201d; means the total assets of the Trust (including any assets attributable to borrowings for investment
        purposes) minus the sum of the Trust&#x2019;s accrued liabilities (other than liabilities representing borrowings for investment purposes).</cef:ManagementFeeNotBasedOnNetAssetsNoteTextBlock>
    <cef:OtherExpensesNoteTextBlock
      contextRef="C_20221213to20221213"
      id="Fxbrl_20221209173218788">&#x201c;Other
        Expenses&#x201d; have been estimated for the current fiscal year.</cef:OtherExpensesNoteTextBlock>
    <cef:ExpenseExampleTableTextBlock
      contextRef="C_20221213to20221213"
      id="Fxbrl_20221209172819743">

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td colspan="2" style="font:bold 10pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1pt solid"&gt;1 Year&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font:bold 10pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1pt solid"&gt;3 Years&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font:bold 10pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1pt solid"&gt;5 Years&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font:bold 10pt Times New Roman, Times, Serif;text-align:center;border-bottom:Black 1pt solid"&gt;10 Years&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td colspan="2" style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif;text-align:center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif;text-align:center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif;text-align:center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif;text-align:center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font:bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left"&gt;$&lt;/td&gt;
    &lt;td style="font:10pt Times New Roman, Times, Serif;padding-left:-0.25in;width:22%;text-align:right"&gt;19&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:2%;font:10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left"&gt;$&lt;/td&gt;
    &lt;td style="width:22%;font:10pt Times New Roman, Times, Serif;text-align:right"&gt;60&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:2%;font:10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left"&gt;$&lt;/td&gt;
    &lt;td style="width:21%;font:10pt Times New Roman, Times, Serif;text-align:right"&gt;103&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:2%;font:10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left"&gt;$&lt;/td&gt;
    &lt;td style="width:21%;font:10pt Times New Roman, Times, Serif;text-align:right"&gt;223&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font:10pt Times New Roman, Times, Serif;text-align:left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </cef:ExpenseExampleTableTextBlock>
    <cef:ExpenseExampleYear01
      contextRef="C_20221213to20221213"
      decimals="0"
      id="Fxbrl_20221209055649420_xbrl_20221209053046419"
      unitRef="USD">19</cef:ExpenseExampleYear01>
    <cef:ExpenseExampleYears1to3
      contextRef="C_20221213to20221213"
      decimals="0"
      id="Fxbrl_20221209055649420_xbrl_20221209053117548"
      unitRef="USD">60</cef:ExpenseExampleYears1to3>
    <cef:ExpenseExampleYears1to5
      contextRef="C_20221213to20221213"
      decimals="0"
      id="Fxbrl_20221209055649420_xbrl_20221209053127722"
      unitRef="USD">103</cef:ExpenseExampleYears1to5>
    <cef:ExpenseExampleYears1to10
      contextRef="C_20221213to20221213"
      decimals="0"
      id="Fxbrl_20221209055649420_xbrl_20221209053136666"
      unitRef="USD">223</cef:ExpenseExampleYears1to10>
    <cef:PurposeOfFeeTableNoteTextBlock
      contextRef="C_20221213to20221213"
      id="Fxbrl_20221209055714418">

&lt;div&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in"&gt;The purpose of the table above is to assist you in understanding
the various cost and expenses that you will bear directly or indirectly as an investor in the Trust. For more information on the management
fees paid by the Trust, please refer to the section of the accompanying Prospectus entitled &#x201c;The Trust&#x2014;Compensation of Investment
Adviser.&#x201d;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in"&gt;The purpose of the table above is to assist you in understanding
the various costs and expenses that you will bear directly or indirectly as an investor in the Trust. For more information regarding the
management fees paid by the Trust, refer to the section of the accompanying Prospectus entitled &#x201c;Management of the Trust&#x2014;Investment
Adviser.&#x201d;&lt;/p&gt; &lt;/div&gt; </cef:PurposeOfFeeTableNoteTextBlock>
    <cef:SecurityTitleTextBlock
      contextRef="C_20221213to20221213"
      id="Fxbrl_20221209122812359">Common
        shares</cef:SecurityTitleTextBlock>
    <cef:OutstandingSecurityHeldShares
      contextRef="C_20221213to20221213"
      decimals="0"
      id="Fxbrl_20221209122842507"
      unitRef="Shares">47500309</cef:OutstandingSecurityHeldShares>
    <cef:LatestNav
      contextRef="C_20220906to20220906"
      decimals="2"
      id="Fxbrl_20221212124716584"
      unitRef="USD_Per_Share">12.72</cef:LatestNav>
    <cef:LatestSharePrice
      contextRef="C_20220906to20220906"
      decimals="2"
      id="Fxbrl_20221212124703163"
      unitRef="USD_Per_Share">14.42</cef:LatestSharePrice>
    <cef:LatestPremiumDiscountToNavPercent
      contextRef="C_20220906to20220906"
      decimals="4"
      id="Fxbrl_20221212121450193"
      unitRef="Pure">0.1336</cef:LatestPremiumDiscountToNavPercent>
    <cef:ShareholderTransactionExpensesTableTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221212110108013">

&lt;div&gt;

&lt;table style="font:13px Times New Roman, Times, serif;text-decoration-style:initial;text-decoration-color:initial;border-collapse:collapse;width:100%;border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="padding-top:3px;padding-bottom:3px"&gt;&lt;span style="font-size:13px;font-weight:bold"&gt;Fees and Expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:3px;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="padding-top:3px;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:3px;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="padding-top:3px;padding-bottom:3px"&gt;&lt;span style="font-size:13px;font-weight:bold"&gt;Shareholder Transaction Expenses (&lt;/span&gt; &lt;span style="font-size:13px;font-weight:bold"&gt;as
        a percentage of Subscription Price&lt;/span&gt;&lt;span style="font-size:13px;font-weight:bold"&gt;)&lt;/span&gt; &lt;/td&gt;
    &lt;td style="padding-top:3px;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="padding-top:3px;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:3px;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="padding-left:0.125in;padding-top:3px;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;Sales Load&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:3px;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="padding-top:3px;text-align:right;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:3px;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="padding-left:0.125in;padding-top:3px;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;Expenses Borne by Shareholders of the Trust&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:3px;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="padding-top:3px;text-align:right;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:3px;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="padding-left:0.125in;padding-top:3px;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;Dividend Reinvestment and Stock Repurchase
        Plan Fees&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:3px;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="padding-top:3px;text-align:right;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;None&#160;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-top:3px;padding-bottom:3px"&gt;&lt;span style="font-size:13px"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; </cef:ShareholderTransactionExpensesTableTextBlock>
    <cef:BasisOfTransactionFeesNoteTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221212171636665">&lt;span style="font-size:13px;font-weight:bold"&gt;as
        a percentage of Subscription Price&lt;/span&gt;</cef:BasisOfTransactionFeesNoteTextBlock>
    <cef:SalesLoadPercent
      contextRef="C_20221206to20221206"
      decimals="2"
      id="Fxbrl_20221212110831436"
      unitRef="Pure">0</cef:SalesLoadPercent>
    <cef:OtherTransactionExpense1Percent
      contextRef="C_20221206to20221206"
      decimals="2"
      id="Fxbrl_20221212110825428"
      unitRef="Pure">0</cef:OtherTransactionExpense1Percent>
    <cef:DividendReinvestmentAndCashPurchaseFees
      contextRef="C_20221206to20221206"
      decimals="0"
      id="Fxbrl_20221212110818655"
      unitRef="USD">0</cef:DividendReinvestmentAndCashPurchaseFees>
    <cef:AnnualExpensesTableTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221212110124846">

&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%"&gt;
  &lt;tr style="vertical-align:bottom;background-color:transparent"&gt;
    &lt;td style="padding-top:2pt;font-size:10pt;font-weight:bold;text-align:left;padding-bottom:2pt"&gt;&lt;strong&gt;Annual Expenses (as a percentage of
        average net assets attributable to Shares) &lt;sup&gt;(1)&lt;/sup&gt;&lt;/strong&gt;&lt;/td&gt;
    &lt;td style="padding-top:2pt;font-size:10pt;padding-bottom:2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-top:2pt;font-size:10pt;text-align:right;padding-bottom:2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="padding-top:2pt;width:83%;font-size:10pt;text-align:left;padding-left:9pt;padding-bottom:2pt"&gt;Management Fee &lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="padding-top:2pt;width:2%;font-size:10pt;padding-bottom:2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-top:2pt;width:1%;font-size:10pt;text-align:left;padding-bottom:2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-top:2pt;width:13%;font-size:10pt;text-align:right;padding-bottom:2pt"&gt;1.23%&lt;/td&gt;
    &lt;td style="padding-top:2pt;width:1%;font-size:10pt;text-align:left;padding-bottom:2pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom;background-color:transparent"&gt;
    &lt;td style="padding-top:2pt;font-size:10pt;text-align:left;padding-left:9pt;padding-bottom:2pt"&gt;Interest Payments on Borrowed Funds&lt;/td&gt;
    &lt;td style="padding-top:2pt;font-size:10pt;padding-bottom:2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-top:2pt;font-size:10pt;text-align:right;padding-bottom:2pt"&gt;0.38%&lt;/td&gt;
    &lt;td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt;padding-left:9pt"&gt;Other Expenses &lt;sup&gt;(3)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="padding-top:2pt;font-size:10pt;padding-bottom:2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;padding-top:2pt;font-size:10pt;text-align:right;padding-bottom:2pt"&gt;0.30%&lt;/td&gt;
    &lt;td style="padding-top:2pt;padding-bottom:2pt;font-size:10pt;text-align:left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom;background-color:transparent"&gt;
    &lt;td style="padding-top:2pt;font-size:10pt;text-align:left;padding-bottom:2pt;padding-left:9pt"&gt;Total Annual Expenses&lt;/td&gt;
    &lt;td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2.5pt double;padding-top:2pt;font:10pt Times New Roman, Times, Serif;text-align:left;padding-bottom:2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2.5pt double;padding-top:2pt;font:10pt Times New Roman, Times, Serif;text-align:right;padding-bottom:2pt"&gt;1.91%&lt;/td&gt;
    &lt;td style="font:10pt Times New Roman, Times, Serif;padding-top:2pt;padding-bottom:2pt;text-align:left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; </cef:AnnualExpensesTableTextBlock>
    <cef:ManagementFeesPercent
      contextRef="C_20221206to20221206"
      decimals="4"
      id="Fxbrl_20221212110810366"
      unitRef="Pure">0.0123</cef:ManagementFeesPercent>
    <cef:InterestExpensesOnBorrowingsPercent
      contextRef="C_20221206to20221206"
      decimals="4"
      id="Fxbrl_20221212110803558"
      unitRef="Pure">0.0038</cef:InterestExpensesOnBorrowingsPercent>
    <cef:OtherAnnualExpensesPercent
      contextRef="C_20221206to20221206"
      decimals="4"
      id="Fxbrl_20221212110756531"
      unitRef="Pure">0.003</cef:OtherAnnualExpensesPercent>
    <cef:TotalAnnualExpensesPercent
      contextRef="C_20221206to20221206"
      decimals="4"
      id="Fxbrl_20221212110750235"
      unitRef="Pure">0.0191</cef:TotalAnnualExpensesPercent>
    <cef:ManagementFeeNotBasedOnNetAssetsNoteTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221212110159011">The
        management fee is charged as a percentage of the Trust&#x2019;s average daily Managed Assets, as opposed to net assets. If leverage is
        used, Managed Assets will be greater in amount than net assets, because Managed Assets includes borrowings for investment purposes.</cef:ManagementFeeNotBasedOnNetAssetsNoteTextBlock>
    <cef:OtherExpensesNoteTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221212110239300">&#x201c;Other
        Expenses&#x201d; for the current fiscal year.</cef:OtherExpensesNoteTextBlock>
    <cef:ExpenseExampleTableTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221212110921823">

&lt;div&gt;

&lt;div&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%"&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td colspan="3" style="border-bottom:Black 1pt solid;font:bold 10pt Times New Roman, Times, Serif;text-align:center"&gt;1 Year&lt;/td&gt;
    &lt;td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom:Black 1pt solid;font:bold 10pt Times New Roman, Times, Serif;text-align:center"&gt;3 Years&lt;/td&gt;
    &lt;td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom:Black 1pt solid;font:bold 10pt Times New Roman, Times, Serif;text-align:center"&gt;5 Years&lt;/td&gt;
    &lt;td style="font:bold 10pt Times New Roman, Times, Serif;padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom:Black 1pt solid;font:bold 10pt Times New Roman, Times, Serif;text-align:center"&gt;10 Years&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom;background-color:transparent"&gt;
    &lt;td style="width:1%;font-size:10pt;text-align:left"&gt;$&lt;/td&gt;
    &lt;td style="width:22%;font-size:10pt;text-align:right"&gt;19&lt;/td&gt;
    &lt;td style="width:1%;font-size:10pt;text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:2%;font-size:10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-size:10pt;text-align:left"&gt;$&lt;/td&gt;
    &lt;td style="width:22%;font-size:10pt;text-align:right"&gt;60&lt;/td&gt;
    &lt;td style="width:1%;font-size:10pt;text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:2%;font-size:10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-size:10pt;text-align:left"&gt;$&lt;/td&gt;
    &lt;td style="width:21%;font-size:10pt;text-align:right"&gt;103&lt;/td&gt;
    &lt;td style="width:1%;font-size:10pt;text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:2%;font-size:10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-size:10pt;text-align:left"&gt;$&lt;/td&gt;
    &lt;td style="width:21%;font-size:10pt;text-align:right"&gt;223&lt;/td&gt;
    &lt;td style="width:1%;font-size:10pt;text-align:left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; </cef:ExpenseExampleTableTextBlock>
    <cef:ExpenseExampleYear01
      contextRef="C_20221206to20221206"
      decimals="0"
      id="Fxbrl_20221212110726974"
      unitRef="USD">19</cef:ExpenseExampleYear01>
    <cef:ExpenseExampleYears1to3
      contextRef="C_20221206to20221206"
      decimals="0"
      id="Fxbrl_20221212110716631"
      unitRef="USD">60</cef:ExpenseExampleYears1to3>
    <cef:ExpenseExampleYears1to5
      contextRef="C_20221206to20221206"
      decimals="0"
      id="Fxbrl_20221212110707826"
      unitRef="USD">103</cef:ExpenseExampleYears1to5>
    <cef:ExpenseExampleYears1to10
      contextRef="C_20221206to20221206"
      decimals="0"
      id="Fxbrl_20221212110700589"
      unitRef="USD">223</cef:ExpenseExampleYears1to10>
    <cef:PurposeOfFeeTableNoteTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221212110944247">

&lt;div&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;The purpose of the table above is to assist you in understanding the various
cost and expenses that you will bear directly or indirectly as an investor in the Trust. For more information on the management fees paid
by the Trust, see &#x201c;The Trust&#x2014;Compensation of Investment Adviser.&#x201d;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;The purpose of the table above is to assist you in understanding the various
costs and expenses that you will bear directly or indirectly as an investor in the Trust. For more information regarding the management
fees paid by the Trust, refer to the section of this Prospectus entitled &#x201c;Management of the Trust&#x2014;Investment Adviser.&#x201d;&lt;/p&gt;
&lt;/div&gt; </cef:PurposeOfFeeTableNoteTextBlock>
    <cef:AnnualDividendPayment
      contextRef="C_20211001to20220331"
      decimals="2"
      id="Fxbrl_20221209165819673"
      unitRef="USD_Per_Share">0.7</cef:AnnualDividendPayment>
    <cef:AnnualDividendPayment
      contextRef="C_20201001to20210930"
      decimals="2"
      id="Fxbrl_20221212174428329"
      unitRef="USD_Per_Share">1.4</cef:AnnualDividendPayment>
    <cef:AnnualDividendPayment
      contextRef="C_20191001to20200930"
      decimals="2"
      id="Fxbrl_20221212174546307"
      unitRef="USD_Per_Share">1.4</cef:AnnualDividendPayment>
    <cef:AnnualDividendPayment
      contextRef="C_20181001to20190930"
      decimals="2"
      id="Fxbrl_20221212174607715"
      unitRef="USD_Per_Share">1.4</cef:AnnualDividendPayment>
    <cef:AnnualDividendPayment
      contextRef="C_20171001to20180930"
      decimals="2"
      id="Fxbrl_20221212174623688"
      unitRef="USD_Per_Share">1.4</cef:AnnualDividendPayment>
    <cef:AnnualDividendPayment
      contextRef="C_20161001to20170930"
      decimals="2"
      id="Fxbrl_20221212174641868"
      unitRef="USD_Per_Share">1.4</cef:AnnualDividendPayment>
    <cef:SeniorSecuritiesAmount
      contextRef="C_20211001to20220331"
      decimals="-6"
      id="Fxbrl_20221209102707857"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmount>
    <cef:SeniorSecuritiesAmount
      contextRef="C_20201001to20210930"
      decimals="-6"
      id="Fxbrl_20221209103219200"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmount>
    <cef:SeniorSecuritiesAmount
      contextRef="C_20191001to20200930"
      decimals="-6"
      id="Fxbrl_20221209103224493"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmount>
    <cef:SeniorSecuritiesAmount
      contextRef="C_20181001to20190930"
      decimals="-6"
      id="Fxbrl_20221209103228580"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmount>
    <cef:SeniorSecuritiesAmount
      contextRef="C_20171001to20180930"
      decimals="-6"
      id="Fxbrl_20221209103232259"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmount>
    <cef:SeniorSecuritiesAmount
      contextRef="C_20161001to20170930"
      decimals="-6"
      id="Fxbrl_20221209103235704"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmount>
    <cef:SeniorSecuritiesCoveragePerUnit
      contextRef="C_20211001to20220331"
      decimals="0"
      id="Fxbrl_20221209105043194_xbrl_20221209102707857"
      unitRef="USD_Per_Share">5601</cef:SeniorSecuritiesCoveragePerUnit>
    <cef:SeniorSecuritiesCoveragePerUnit
      contextRef="C_20201001to20210930"
      decimals="0"
      id="Fxbrl_20221209105043194_xbrl_20221209103219200"
      unitRef="USD_Per_Share">5714</cef:SeniorSecuritiesCoveragePerUnit>
    <cef:SeniorSecuritiesCoveragePerUnit
      contextRef="C_20191001to20200930"
      decimals="0"
      id="Fxbrl_20221209105043194_xbrl_20221209103224493"
      unitRef="USD_Per_Share">4554</cef:SeniorSecuritiesCoveragePerUnit>
    <cef:SeniorSecuritiesCoveragePerUnit
      contextRef="C_20181001to20190930"
      decimals="0"
      id="Fxbrl_20221209105043194_xbrl_20221209103228580"
      unitRef="USD_Per_Share">4396</cef:SeniorSecuritiesCoveragePerUnit>
    <cef:SeniorSecuritiesCoveragePerUnit
      contextRef="C_20171001to20180930"
      decimals="0"
      id="Fxbrl_20221209105043194_xbrl_20221209103232259"
      unitRef="USD_Per_Share">4861</cef:SeniorSecuritiesCoveragePerUnit>
    <cef:SeniorSecuritiesCoveragePerUnit
      contextRef="C_20161001to20170930"
      decimals="0"
      id="Fxbrl_20221209105043194_xbrl_20221209103235704"
      unitRef="USD_Per_Share">4999</cef:SeniorSecuritiesCoveragePerUnit>
    <cef:LatestNav
      contextRef="C_20220906to20220906"
      decimals="2"
      id="Fxbrl_20221209120159437"
      unitRef="USD_Per_Share">12.72</cef:LatestNav>
    <cef:LatestSharePrice
      contextRef="C_20220906to20220906"
      decimals="2"
      id="Fxbrl_20221209120206515"
      unitRef="USD_Per_Share">14.42</cef:LatestSharePrice>
    <cef:SharePriceTableTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221209115709953">

&lt;div&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse"&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="width:12%"&gt;
        &lt;p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&lt;strong&gt;Quarter&lt;br/&gt;Ending&lt;/strong&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%"&gt;
        &lt;p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&lt;strong&gt;Market&lt;br/&gt;Price(1)&#160;High&lt;/strong&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:10%"&gt;
        &lt;p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&lt;strong&gt;Corresponding&lt;br/&gt;Net Asset&lt;br/&gt;Value(2)&lt;/strong&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:11%"&gt;
        &lt;p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&lt;strong&gt;Market&lt;br/&gt;Premium/ (Discount)(2)&lt;/strong&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%"&gt;
        &lt;p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&lt;strong&gt;Corresponding Price(1)&#160;Low&lt;/strong&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%"&gt;
        &lt;p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&lt;strong&gt;Net Asset&lt;br/&gt;Value(2)&lt;/strong&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%"&gt;
        &lt;p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&lt;strong&gt;Premium/ (Discount)(2)&lt;/strong&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%"&gt;
        &lt;p style="border-bottom:Black 0.5pt solid;font:9pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&lt;strong&gt;Trading&lt;br/&gt;Volume(1)&lt;/strong&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td&gt;Fiscal 2020&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="padding-left:6pt"&gt;Dec.&#160;31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$13.97&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$14.84&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;-5.86%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$13.00&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$13.32&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;-2.40%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;7,311,726&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="padding-left:6pt"&gt;Mar.&#160;31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$14.49&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$15.25&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;-4.98%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$8.89&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$10.50&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;-15.33%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;13,080,124&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="padding-left:6pt"&gt;June&#160;30&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$14.76&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$14.58&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;1.24%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$10.83&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$12.29&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;-11.88%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;13,241,814&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="padding-left:6pt"&gt;Sept. 30&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$14.99&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$14.67&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;2.18%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$13.82&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$13.76&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;0.436%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;6,999,269&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td&gt;Fiscal 2021&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="padding-left:6pt"&gt;Dec.&#160;31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$16.07&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$14.68&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;9.47%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$13.43&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;$13.25&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;1.36%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;6,759,018&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;padding-left:6pt"&gt;Mar.&#160;31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$17.92&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$15.29&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;17.20%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$14.29&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$14.63&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;-2.32%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:bottom;text-align:right"&gt;12,830,000&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;padding-left:6pt"&gt;June&#160;30&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$16.69&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$15.56&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;7.26%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$14.86&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$15.15&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;-1.91%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;12,500,000&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;padding-left:6pt"&gt;Sept. 30&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$17.38&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$16.22&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;7.15%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$16.13&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$15.45&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;4.40%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;6,800,000&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td&gt;Fiscal 2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;text-align:right"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;padding-left:6pt"&gt;Dec.&#160;31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$17.08&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$15.63&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:bottom;text-align:right"&gt;9.28%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$15.51&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$14.75&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;5.15%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;6,310,000&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;padding-left:6pt"&gt;Mar.&#160;31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$16.34&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$15.63&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:bottom;text-align:right"&gt;4.54%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$13.29&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$13.86&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;-4.11%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;8,990,000&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;padding-left:6pt"&gt;June&#160;30&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$10.39&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$14.49&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:bottom;text-align:right"&gt;9.70%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$14.00&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;$12.40&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;12.90%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-right:0.2in;vertical-align:top;text-align:right"&gt;7,990,000&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;__________________&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%"&gt;
  &lt;tr style="vertical-align:top"&gt;
    &lt;td style="width:0.25in"&gt;(1)&lt;/td&gt;
    &lt;td&gt;As reported by Bloomberg LLP.&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:top"&gt;
    &lt;td style="width:0.25in"&gt;(2)&lt;/td&gt;
    &lt;td&gt;Based on the Trust&#x2019;s computations, on the day that the high or low market price was recorded.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; </cef:SharePriceTableTextBlock>
    <cef:HighestPriceOrBid
      contextRef="C_20191001to20191231"
      decimals="2"
      id="Fxbrl_20221209105303397"
      unitRef="USD_Per_Share">13.97</cef:HighestPriceOrBid>
    <cef:HighestPriceOrBidNav
      contextRef="C_20191001to20191231"
      decimals="2"
      id="Fxbrl_20221209105328471"
      unitRef="USD_Per_Share">14.84</cef:HighestPriceOrBidNav>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20191001to20191231"
      decimals="4"
      id="Fxbrl_20221209105410129"
      unitRef="Pure">-0.0586</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBid
      contextRef="C_20191001to20191231"
      decimals="2"
      id="Fxbrl_20221209105432641"
      unitRef="USD_Per_Share">13</cef:LowestPriceOrBid>
    <cef:LowestPriceOrBidNav
      contextRef="C_20191001to20191231"
      decimals="2"
      id="Fxbrl_20221209105451232"
      unitRef="USD_Per_Share">13.32</cef:LowestPriceOrBidNav>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20191001to20191231"
      decimals="4"
      id="Fxbrl_20221209105504591"
      unitRef="Pure">-0.024</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="C_20200101to20200331"
      decimals="2"
      id="Fxbrl_20221209105735391_xbrl_20221209105303397"
      unitRef="USD_Per_Share">14.49</cef:HighestPriceOrBid>
    <cef:HighestPriceOrBidNav
      contextRef="C_20200101to20200331"
      decimals="2"
      id="Fxbrl_20221209105735391_xbrl_20221209105328471"
      unitRef="USD_Per_Share">15.25</cef:HighestPriceOrBidNav>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20200101to20200331"
      decimals="4"
      id="Fxbrl_20221209114948366"
      unitRef="Pure">-0.0498</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBid
      contextRef="C_20200101to20200331"
      decimals="2"
      id="Fxbrl_20221209105735391_xbrl_20221209105432641"
      unitRef="USD_Per_Share">8.89</cef:LowestPriceOrBid>
    <cef:LowestPriceOrBidNav
      contextRef="C_20200101to20200331"
      decimals="2"
      id="Fxbrl_20221209105735391_xbrl_20221209105451232"
      unitRef="USD_Per_Share">10.5</cef:LowestPriceOrBidNav>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20200101to20200331"
      decimals="4"
      id="Fxbrl_20221209115004831"
      unitRef="Pure">-0.1533</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="C_20200401to20200630"
      decimals="2"
      id="Fxbrl_20221209105737683_xbrl_20221209105303397"
      unitRef="USD_Per_Share">14.76</cef:HighestPriceOrBid>
    <cef:HighestPriceOrBidNav
      contextRef="C_20200401to20200630"
      decimals="2"
      id="Fxbrl_20221209105737683_xbrl_20221209105328471"
      unitRef="USD_Per_Share">14.58</cef:HighestPriceOrBidNav>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20200401to20200630"
      decimals="4"
      id="Fxbrl_20221209105737683_xbrl_20221209105410129"
      unitRef="Pure">0.0124</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBid
      contextRef="C_20200401to20200630"
      decimals="2"
      id="Fxbrl_20221209105737683_xbrl_20221209105432641"
      unitRef="USD_Per_Share">10.83</cef:LowestPriceOrBid>
    <cef:LowestPriceOrBidNav
      contextRef="C_20200401to20200630"
      decimals="2"
      id="Fxbrl_20221209105737683_xbrl_20221209105451232"
      unitRef="USD_Per_Share">12.29</cef:LowestPriceOrBidNav>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20200401to20200630"
      decimals="4"
      id="Fxbrl_20221209115026176"
      unitRef="Pure">-0.1188</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="C_20200701to20200930"
      decimals="2"
      id="Fxbrl_20221209105739625_xbrl_20221209105303397"
      unitRef="USD_Per_Share">14.99</cef:HighestPriceOrBid>
    <cef:HighestPriceOrBidNav
      contextRef="C_20200701to20200930"
      decimals="2"
      id="Fxbrl_20221209105739625_xbrl_20221209105328471"
      unitRef="USD_Per_Share">14.67</cef:HighestPriceOrBidNav>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20200701to20200930"
      decimals="4"
      id="Fxbrl_20221209105739625_xbrl_20221209105410129"
      unitRef="Pure">0.0218</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBid
      contextRef="C_20200701to20200930"
      decimals="2"
      id="Fxbrl_20221209105739625_xbrl_20221209105432641"
      unitRef="USD_Per_Share">13.82</cef:LowestPriceOrBid>
    <cef:LowestPriceOrBidNav
      contextRef="C_20200701to20200930"
      decimals="2"
      id="Fxbrl_20221209105739625_xbrl_20221209105451232"
      unitRef="USD_Per_Share">13.76</cef:LowestPriceOrBidNav>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20200701to20200930"
      decimals="5"
      id="Fxbrl_20221209105739625_xbrl_20221209105504591"
      unitRef="Pure">0.00436</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="C_20201001to20201231"
      decimals="2"
      id="Fxbrl_20221209105741931_xbrl_20221209105303397"
      unitRef="USD_Per_Share">16.07</cef:HighestPriceOrBid>
    <cef:HighestPriceOrBidNav
      contextRef="C_20201001to20201231"
      decimals="2"
      id="Fxbrl_20221209105741931_xbrl_20221209105328471"
      unitRef="USD_Per_Share">14.68</cef:HighestPriceOrBidNav>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20201001to20201231"
      decimals="4"
      id="Fxbrl_20221209105741931_xbrl_20221209105410129"
      unitRef="Pure">0.0947</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBid
      contextRef="C_20201001to20201231"
      decimals="2"
      id="Fxbrl_20221209105741931_xbrl_20221209105432641"
      unitRef="USD_Per_Share">13.43</cef:LowestPriceOrBid>
    <cef:LowestPriceOrBidNav
      contextRef="C_20201001to20201231"
      decimals="2"
      id="Fxbrl_20221209105741931_xbrl_20221209105451232"
      unitRef="USD_Per_Share">13.25</cef:LowestPriceOrBidNav>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20201001to20201231"
      decimals="4"
      id="Fxbrl_20221209105741931_xbrl_20221209105504591"
      unitRef="Pure">0.0136</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="C_20210101to20210331"
      decimals="2"
      id="Fxbrl_20221209105743730_xbrl_20221209105303397"
      unitRef="USD_Per_Share">17.92</cef:HighestPriceOrBid>
    <cef:HighestPriceOrBidNav
      contextRef="C_20210101to20210331"
      decimals="2"
      id="Fxbrl_20221209105743730_xbrl_20221209105328471"
      unitRef="USD_Per_Share">15.29</cef:HighestPriceOrBidNav>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20210101to20210331"
      decimals="4"
      id="Fxbrl_20221209105743730_xbrl_20221209105410129"
      unitRef="Pure">0.172</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBid
      contextRef="C_20210101to20210331"
      decimals="2"
      id="Fxbrl_20221209105743730_xbrl_20221209105432641"
      unitRef="USD_Per_Share">14.29</cef:LowestPriceOrBid>
    <cef:LowestPriceOrBidNav
      contextRef="C_20210101to20210331"
      decimals="2"
      id="Fxbrl_20221209105743730_xbrl_20221209105451232"
      unitRef="USD_Per_Share">14.63</cef:LowestPriceOrBidNav>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20210101to20210331"
      decimals="4"
      id="Fxbrl_20221209115102859"
      unitRef="Pure">-0.0232</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="C_20210401to20210630"
      decimals="2"
      id="Fxbrl_20221209105746378_xbrl_20221209105303397"
      unitRef="USD_Per_Share">16.69</cef:HighestPriceOrBid>
    <cef:HighestPriceOrBidNav
      contextRef="C_20210401to20210630"
      decimals="2"
      id="Fxbrl_20221209105746378_xbrl_20221209105328471"
      unitRef="USD_Per_Share">15.56</cef:HighestPriceOrBidNav>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20210401to20210630"
      decimals="4"
      id="Fxbrl_20221209105746378_xbrl_20221209105410129"
      unitRef="Pure">0.0726</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBid
      contextRef="C_20210401to20210630"
      decimals="2"
      id="Fxbrl_20221209105746378_xbrl_20221209105432641"
      unitRef="USD_Per_Share">14.86</cef:LowestPriceOrBid>
    <cef:LowestPriceOrBidNav
      contextRef="C_20210401to20210630"
      decimals="2"
      id="Fxbrl_20221209105746378_xbrl_20221209105451232"
      unitRef="USD_Per_Share">15.15</cef:LowestPriceOrBidNav>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20210401to20210630"
      decimals="4"
      id="Fxbrl_20221209115118483"
      unitRef="Pure">-0.0191</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="C_20210701to20210930"
      decimals="2"
      id="Fxbrl_20221209105748594_xbrl_20221209105303397"
      unitRef="USD_Per_Share">17.38</cef:HighestPriceOrBid>
    <cef:HighestPriceOrBidNav
      contextRef="C_20210701to20210930"
      decimals="2"
      id="Fxbrl_20221209105748594_xbrl_20221209105328471"
      unitRef="USD_Per_Share">16.22</cef:HighestPriceOrBidNav>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20210701to20210930"
      decimals="4"
      id="Fxbrl_20221209105748594_xbrl_20221209105410129"
      unitRef="Pure">0.0715</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBid
      contextRef="C_20210701to20210930"
      decimals="2"
      id="Fxbrl_20221209105748594_xbrl_20221209105432641"
      unitRef="USD_Per_Share">16.13</cef:LowestPriceOrBid>
    <cef:LowestPriceOrBidNav
      contextRef="C_20210701to20210930"
      decimals="2"
      id="Fxbrl_20221209105748594_xbrl_20221209105451232"
      unitRef="USD_Per_Share">15.45</cef:LowestPriceOrBidNav>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20210701to20210930"
      decimals="4"
      id="Fxbrl_20221209105748594_xbrl_20221209105504591"
      unitRef="Pure">0.044</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="C_20211001to20211231"
      decimals="2"
      id="Fxbrl_20221209105750466_xbrl_20221209105303397"
      unitRef="USD_Per_Share">17.08</cef:HighestPriceOrBid>
    <cef:HighestPriceOrBidNav
      contextRef="C_20211001to20211231"
      decimals="2"
      id="Fxbrl_20221209105750466_xbrl_20221209105328471"
      unitRef="USD_Per_Share">15.63</cef:HighestPriceOrBidNav>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20211001to20211231"
      decimals="4"
      id="Fxbrl_20221209105750466_xbrl_20221209105410129"
      unitRef="Pure">0.0928</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBid
      contextRef="C_20211001to20211231"
      decimals="2"
      id="Fxbrl_20221209105750466_xbrl_20221209105432641"
      unitRef="USD_Per_Share">15.51</cef:LowestPriceOrBid>
    <cef:LowestPriceOrBidNav
      contextRef="C_20211001to20211231"
      decimals="2"
      id="Fxbrl_20221209105750466_xbrl_20221209105451232"
      unitRef="USD_Per_Share">14.75</cef:LowestPriceOrBidNav>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20211001to20211231"
      decimals="4"
      id="Fxbrl_20221209105750466_xbrl_20221209105504591"
      unitRef="Pure">0.0515</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="C_20220101to20220331"
      decimals="2"
      id="Fxbrl_20221209105752315_xbrl_20221209105303397"
      unitRef="USD_Per_Share">16.34</cef:HighestPriceOrBid>
    <cef:HighestPriceOrBidNav
      contextRef="C_20220101to20220331"
      decimals="2"
      id="Fxbrl_20221209105752315_xbrl_20221209105328471"
      unitRef="USD_Per_Share">15.63</cef:HighestPriceOrBidNav>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20220101to20220331"
      decimals="4"
      id="Fxbrl_20221209105752315_xbrl_20221209105410129"
      unitRef="Pure">0.0454</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBid
      contextRef="C_20220101to20220331"
      decimals="2"
      id="Fxbrl_20221209105752315_xbrl_20221209105432641"
      unitRef="USD_Per_Share">13.29</cef:LowestPriceOrBid>
    <cef:LowestPriceOrBidNav
      contextRef="C_20220101to20220331"
      decimals="2"
      id="Fxbrl_20221209105752315_xbrl_20221209105451232"
      unitRef="USD_Per_Share">13.86</cef:LowestPriceOrBidNav>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20220101to20220331"
      decimals="4"
      id="Fxbrl_20221209115212674"
      unitRef="Pure">-0.0411</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="C_20220401to20220630"
      decimals="2"
      id="Fxbrl_20221209105754425_xbrl_20221209105303397"
      unitRef="USD_Per_Share">10.39</cef:HighestPriceOrBid>
    <cef:HighestPriceOrBidNav
      contextRef="C_20220401to20220630"
      decimals="2"
      id="Fxbrl_20221209105754425_xbrl_20221209105328471"
      unitRef="USD_Per_Share">14.49</cef:HighestPriceOrBidNav>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20220401to20220630"
      decimals="4"
      id="Fxbrl_20221209105754425_xbrl_20221209105410129"
      unitRef="Pure">0.097</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBid
      contextRef="C_20220401to20220630"
      decimals="2"
      id="Fxbrl_20221209105754425_xbrl_20221209105432641"
      unitRef="USD_Per_Share">14</cef:LowestPriceOrBid>
    <cef:LowestPriceOrBidNav
      contextRef="C_20220401to20220630"
      decimals="2"
      id="Fxbrl_20221209105754425_xbrl_20221209105451232"
      unitRef="USD_Per_Share">12.4</cef:LowestPriceOrBidNav>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="C_20220401to20220630"
      decimals="4"
      id="Fxbrl_20221209105754425_xbrl_20221209105504591"
      unitRef="Pure">0.129</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:SeniorSecuritiesNoteTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221209111153102">

&lt;div&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&lt;strong&gt;SENIOR SECURITIES&lt;/strong&gt;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;Information about our senior securities is shown in the following table
as of the end of the last 10 fiscal years. The information in this table for the fiscal years ended 2021, 2020, 2019, 2018 and 2017 has
been audited by Deloitte &amp;amp; Touche LLP, independent registered public accounting firm. The Trust&#x2019;s audited financial statements
appearing in the Trust&#x2019;s Annual Report to Shareholders for the year ended September&#160;30, 2021, including the report of Deloitte
&amp;amp; Touche LLP thereon, including accompanying notes thereto, are incorporated by reference in the SAI. The &#x201c;--&#x201d; indicates
information that the SEC expressly does not require to be disclosed for certain types of senior securities.&lt;/p&gt;

&lt;div&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse"&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="width:32%"&gt;&lt;strong&gt;Class&#160;and Year&lt;/strong&gt;&lt;/td&gt;
    &lt;td style="width:17%"&gt;&lt;strong&gt;Total Amount Outstanding&lt;br/&gt;Exclusive of Treasury Securities(1)&lt;/strong&gt;&lt;/td&gt;
    &lt;td style="width:17%"&gt;&lt;strong&gt;Asset Coverage Per&lt;br/&gt;$1,000 of Indebtedness&lt;/strong&gt;&lt;/td&gt;
    &lt;td style="width:17%"&gt;&lt;strong&gt;Involuntary&lt;br/&gt;Liquidating&lt;br/&gt;Preferences Per Unit&lt;/strong&gt;&lt;/td&gt;
    &lt;td style="width:17%"&gt;&lt;strong&gt;Average Market&lt;br/&gt;Value(2)&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td&gt;Loan Facility 2021&lt;/td&gt;
    &lt;td&gt;$120&lt;/td&gt;
    &lt;td&gt;$5,714&lt;/td&gt;
    &lt;td&gt;$&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20221209173039070"&gt;N/A&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td&gt;Loan Facility 2020&lt;/td&gt;
    &lt;td&gt;$120&lt;/td&gt;
    &lt;td&gt;$4,554&lt;/td&gt;
    &lt;td&gt;$&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20221209173120190"&gt;N/A&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td&gt;Loan Facility 2019&lt;/td&gt;
    &lt;td&gt;$120&lt;/td&gt;
    &lt;td&gt;$4,396&lt;/td&gt;
    &lt;td&gt;$&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20221209173123789"&gt;N/A&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td&gt;Loan Facility 2018&lt;/td&gt;
    &lt;td&gt;$120&lt;/td&gt;
    &lt;td&gt;$4,861&lt;/td&gt;
    &lt;td&gt;$&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20221209173241279"&gt;N/A&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td&gt;Loan Facility 2017&lt;/td&gt;
    &lt;td&gt;$120&lt;/td&gt;
    &lt;td&gt;$4,999&lt;/td&gt;
    &lt;td&gt;$&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20221209173248397"&gt;N/A&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td&gt;Loan Facility 2016&lt;/td&gt;
    &lt;td&gt;$120&lt;/td&gt;
    &lt;td&gt;$5,160&lt;/td&gt;
    &lt;td&gt;$&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20221209173251957"&gt;N/A&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;_______________&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;margin-top:0pt;margin-bottom:0pt"&gt;
  &lt;tr style="vertical-align:top"&gt;
    &lt;td style="width:0.25in"&gt;(1)&lt;/td&gt;
    &lt;td&gt;Total amount in $ millions of each class of senior securities outstanding at the end of the period presented.&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:top"&gt;
    &lt;td&gt;(2)&lt;/td&gt;
    &lt;td&gt;Not applicable because the senior securities are not registered for public trading.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;  &lt;/div&gt; </cef:SeniorSecuritiesNoteTextBlock>
    <cef:SeniorSecuritiesTableTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221209112119281">

&lt;div&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse"&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td style="width:32%"&gt;&lt;strong&gt;Class&#160;and Year&lt;/strong&gt;&lt;/td&gt;
    &lt;td style="width:17%"&gt;&lt;strong&gt;Total Amount Outstanding&lt;br/&gt;Exclusive of Treasury Securities(1)&lt;/strong&gt;&lt;/td&gt;
    &lt;td style="width:17%"&gt;&lt;strong&gt;Asset Coverage Per&lt;br/&gt;$1,000 of Indebtedness&lt;/strong&gt;&lt;/td&gt;
    &lt;td style="width:17%"&gt;&lt;strong&gt;Involuntary&lt;br/&gt;Liquidating&lt;br/&gt;Preferences Per Unit&lt;/strong&gt;&lt;/td&gt;
    &lt;td style="width:17%"&gt;&lt;strong&gt;Average Market&lt;br/&gt;Value(2)&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td&gt;Loan Facility 2021&lt;/td&gt;
    &lt;td&gt;$120&lt;/td&gt;
    &lt;td&gt;$5,714&lt;/td&gt;
    &lt;td&gt;$&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20221209173039070"&gt;N/A&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td&gt;Loan Facility 2020&lt;/td&gt;
    &lt;td&gt;$120&lt;/td&gt;
    &lt;td&gt;$4,554&lt;/td&gt;
    &lt;td&gt;$&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20221209173120190"&gt;N/A&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td&gt;Loan Facility 2019&lt;/td&gt;
    &lt;td&gt;$120&lt;/td&gt;
    &lt;td&gt;$4,396&lt;/td&gt;
    &lt;td&gt;$&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20221209173123789"&gt;N/A&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td&gt;Loan Facility 2018&lt;/td&gt;
    &lt;td&gt;$120&lt;/td&gt;
    &lt;td&gt;$4,861&lt;/td&gt;
    &lt;td&gt;$&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20221209173241279"&gt;N/A&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td&gt;Loan Facility 2017&lt;/td&gt;
    &lt;td&gt;$120&lt;/td&gt;
    &lt;td&gt;$4,999&lt;/td&gt;
    &lt;td&gt;$&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20221209173248397"&gt;N/A&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:bottom"&gt;
    &lt;td&gt;Loan Facility 2016&lt;/td&gt;
    &lt;td&gt;$120&lt;/td&gt;
    &lt;td&gt;$5,160&lt;/td&gt;
    &lt;td&gt;$&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20221209173251957"&gt;N/A&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;_______________&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;margin-top:0pt;margin-bottom:0pt"&gt;
  &lt;tr style="vertical-align:top"&gt;
    &lt;td style="width:0.25in"&gt;(1)&lt;/td&gt;
    &lt;td&gt;Total amount in $ millions of each class of senior securities outstanding at the end of the period presented.&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align:top"&gt;
    &lt;td&gt;(2)&lt;/td&gt;
    &lt;td&gt;Not applicable because the senior securities are not registered for public trading.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; </cef:SeniorSecuritiesTableTextBlock>
    <cef:SeniorSecuritiesAmount
      contextRef="C_20201001to20210930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="-6"
      id="Fxbrl_20221209112210937"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmount>
    <cef:SeniorSecuritiesCoveragePerUnit
      contextRef="C_20201001to20210930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="0"
      id="Fxbrl_20221209112229768"
      unitRef="USD_Per_Share">5714</cef:SeniorSecuritiesCoveragePerUnit>
    <cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit
      contextRef="C_20201001to20210930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="0"
      id="Fxbrl_20221209112250751"
      unitRef="USD_Per_Share">0</cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit>
    <cef:SeniorSecuritiesAmount
      contextRef="C_20191001to20200930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="-6"
      id="Fxbrl_20221209112259390_xbrl_20221209112210937"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmount>
    <cef:SeniorSecuritiesCoveragePerUnit
      contextRef="C_20191001to20200930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="0"
      id="Fxbrl_20221209112259390_xbrl_20221209112229768"
      unitRef="USD_Per_Share">4554</cef:SeniorSecuritiesCoveragePerUnit>
    <cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit
      contextRef="C_20191001to20200930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="0"
      id="Fxbrl_20221209112259390_xbrl_20221209112250751"
      unitRef="USD_Per_Share">0</cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit>
    <cef:SeniorSecuritiesAmount
      contextRef="C_20181001to20190930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="-6"
      id="Fxbrl_20221209112302627_xbrl_20221209112210937"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmount>
    <cef:SeniorSecuritiesCoveragePerUnit
      contextRef="C_20181001to20190930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="0"
      id="Fxbrl_20221209112302627_xbrl_20221209112229768"
      unitRef="USD_Per_Share">4396</cef:SeniorSecuritiesCoveragePerUnit>
    <cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit
      contextRef="C_20181001to20190930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="0"
      id="Fxbrl_20221209112302627_xbrl_20221209112250751"
      unitRef="USD_Per_Share">0</cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit>
    <cef:SeniorSecuritiesAmount
      contextRef="C_20171001to20180930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="-6"
      id="Fxbrl_20221209112304686_xbrl_20221209112210937"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmount>
    <cef:SeniorSecuritiesCoveragePerUnit
      contextRef="C_20171001to20180930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="0"
      id="Fxbrl_20221209112304686_xbrl_20221209112229768"
      unitRef="USD_Per_Share">4861</cef:SeniorSecuritiesCoveragePerUnit>
    <cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit
      contextRef="C_20171001to20180930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="0"
      id="Fxbrl_20221209112304686_xbrl_20221209112250751"
      unitRef="USD_Per_Share">0</cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit>
    <cef:SeniorSecuritiesAmount
      contextRef="C_20161001to20170930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="-6"
      id="Fxbrl_20221209112306740_xbrl_20221209112210937"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmount>
    <cef:SeniorSecuritiesCoveragePerUnit
      contextRef="C_20161001to20170930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="0"
      id="Fxbrl_20221209112306740_xbrl_20221209112229768"
      unitRef="USD_Per_Share">4999</cef:SeniorSecuritiesCoveragePerUnit>
    <cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit
      contextRef="C_20161001to20170930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="0"
      id="Fxbrl_20221209112306740_xbrl_20221209112250751"
      unitRef="USD_Per_Share">0</cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit>
    <cef:SeniorSecuritiesAmount
      contextRef="C_20151001to20160930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="-6"
      id="Fxbrl_20221209112309132_xbrl_20221209112210937"
      unitRef="USD">120000000</cef:SeniorSecuritiesAmount>
    <cef:SeniorSecuritiesCoveragePerUnit
      contextRef="C_20151001to20160930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="0"
      id="Fxbrl_20221209112309132_xbrl_20221209112229768"
      unitRef="USD_Per_Share">5160</cef:SeniorSecuritiesCoveragePerUnit>
    <cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit
      contextRef="C_20151001to20160930_cefSecurityAxis_ck0001635977LoanFacilityMember"
      decimals="0"
      id="Fxbrl_20221209112309132_xbrl_20221209112250751"
      unitRef="USD_Per_Share">0</cef:SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit>
    <cef:EffectsOfLeverageTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221209170401245">

&lt;div&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&lt;i&gt;Effects of Leverage&lt;/i&gt;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;Assuming that leverage will represent approximately 20% of Managed Assets
and that the Trust will bear expenses relating to that leverage at an annual cost of 1.00%, Trust performance before leverage (net of
expenses) must exceed 0.2% in order to cover the expenses specifically related to the Trust&#x2019;s use of leverage. Actual leverage expenses
will vary frequently and may be significantly higher or lower than the rate estimated above.&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;As of September&#160;30, 2022 and the most recently signed line of credit
agreement, the Trust projects an annual leverage expense of 3.59%. The Trust had $120,000,000 of funds drawn on its line of credit which
was 18.9% of Managed Assets as of September&#160;30, 2022.&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;div&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;The following table is furnished in response to requirements of the SEC.
It is designed to illustrate the effects of leverage on total returns from an investment in the Trust assuming investment portfolio returns
before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage representing 20% of the Trust&#x2019;s Managed
Assets and the Trust&#x2019;s currently projected annual leverage expense of 1.00%.&lt;/p&gt;

&lt;div&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse"&gt;
  &lt;tr style="vertical-align:top"&gt;
    &lt;td style="border:black 1pt solid;width:50%"&gt;
        &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;Assumed Trust Return Before Leverage&lt;/p&gt;
        &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;(Net of Expenses)&lt;/p&gt; &lt;/td&gt;
    &lt;td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;(10.00)%&lt;/td&gt;
    &lt;td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;(5.00)%&lt;/td&gt;
    &lt;td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;0.00%&lt;/td&gt;
    &lt;td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;5.00%&lt;/td&gt;
    &lt;td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;10.00%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="border-right:black 1pt solid;border-bottom:black 1pt solid;border-left:black 1pt solid"&gt;Assumed Trust Return Inclusive of Leverage&lt;/td&gt;
    &lt;td style="border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;(13.40)%&lt;/td&gt;
    &lt;td style="border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;(7.15)%&lt;/td&gt;
    &lt;td style="border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;(0.90)%&lt;/td&gt;
    &lt;td style="border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;5.35%&lt;/td&gt;
    &lt;td style="border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;11.60%&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;div/&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;Assumed Trust performance before and inclusive of leverage are hypothetical
and are pro-vided to assist investors in understanding the effects of leverage. Actual performance experienced by the Trust may be lesser
or greater than that shown above.&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt; </cef:EffectsOfLeverageTextBlock>
    <cef:EffectsOfLeverageTableTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221209170348825">

&lt;div&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;The following table is furnished in response to requirements of the SEC.
It is designed to illustrate the effects of leverage on total returns from an investment in the Trust assuming investment portfolio returns
before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage representing 20% of the Trust&#x2019;s Managed
Assets and the Trust&#x2019;s currently projected annual leverage expense of 1.00%.&lt;/p&gt;

&lt;div&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse"&gt;
  &lt;tr style="vertical-align:top"&gt;
    &lt;td style="border:black 1pt solid;width:50%"&gt;
        &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;Assumed Trust Return Before Leverage&lt;/p&gt;
        &lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;(Net of Expenses)&lt;/p&gt; &lt;/td&gt;
    &lt;td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;(10.00)%&lt;/td&gt;
    &lt;td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;(5.00)%&lt;/td&gt;
    &lt;td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;0.00%&lt;/td&gt;
    &lt;td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;5.00%&lt;/td&gt;
    &lt;td style="border-top:black 1pt solid;width:10%;border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;10.00%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="border-right:black 1pt solid;border-bottom:black 1pt solid;border-left:black 1pt solid"&gt;Assumed Trust Return Inclusive of Leverage&lt;/td&gt;
    &lt;td style="border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;(13.40)%&lt;/td&gt;
    &lt;td style="border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;(7.15)%&lt;/td&gt;
    &lt;td style="border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;(0.90)%&lt;/td&gt;
    &lt;td style="border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;5.35%&lt;/td&gt;
    &lt;td style="border-right:black 1pt solid;border-bottom:black 1pt solid"&gt;11.60%&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;div/&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;Assumed Trust performance before and inclusive of leverage are hypothetical
and are pro-vided to assist investors in understanding the effects of leverage. Actual performance experienced by the Trust may be lesser
or greater than that shown above.&lt;/p&gt; &lt;/div&gt; </cef:EffectsOfLeverageTableTextBlock>
    <cef:EffectsOfLeveragePurposeTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221209170422129">

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;The following table is furnished in response to requirements of the SEC.
It is designed to illustrate the effects of leverage on total returns from an investment in the Trust assuming investment portfolio returns
before leverage of (10)%, (5)%, 0%, 5% and 10%. The table further reflects the use of leverage representing 20% of the Trust&#x2019;s Managed
Assets and the Trust&#x2019;s currently projected annual leverage expense of 1.00%.&lt;/p&gt; </cef:EffectsOfLeveragePurposeTextBlock>
    <cef:ReturnAtMinusTenPercent
      contextRef="C_20221206to20221206"
      decimals="4"
      id="Fxbrl_20221209110827193"
      unitRef="Pure">-0.134</cef:ReturnAtMinusTenPercent>
    <cef:ReturnAtMinusFivePercent
      contextRef="C_20221206to20221206"
      decimals="4"
      id="Fxbrl_20221209110833929"
      unitRef="Pure">-0.0715</cef:ReturnAtMinusFivePercent>
    <cef:ReturnAtZeroPercent
      contextRef="C_20221206to20221206"
      decimals="4"
      id="Fxbrl_20221209110838143"
      unitRef="Pure">-0.009</cef:ReturnAtZeroPercent>
    <cef:ReturnAtPlusFivePercent
      contextRef="C_20221206to20221206"
      decimals="4"
      id="Fxbrl_20221209110841702"
      unitRef="Pure">0.0535</cef:ReturnAtPlusFivePercent>
    <cef:ReturnAtPlusTenPercent
      contextRef="C_20221206to20221206"
      decimals="4"
      id="Fxbrl_20221209110845087"
      unitRef="Pure">0.116</cef:ReturnAtPlusTenPercent>
    <cef:CapitalStockTableTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221209182229492">

&lt;div&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;The Trust&#x2019;s capitalization consists of an unlimited number of Shares
of beneficial interest, $0.01 par value. Each Share represents an equal proportionate beneficial interest in the Trust and, when issued
and outstanding, will be fully paid and non-assessable by the Trust. Upon
any liquidation of the Trust, Shareholders will be entitled to share pro rata in the net assets of the Trust available for distribution
after paying or adequately providing for the payment of all liabilities. The Trust will send annual and semi-annual financial
statements to Shareholders and may also issue more abbreviated interim reports to update Shareholders on a quarterly basis. The Trust
will hold annual meetings of its Shareholders in accordance with the provisions of the Trust&#x2019;s By-laws and the rules&#160;of the
NYSE.&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;Shareholders
are entitled to one vote for each whole Share held and a proportionate fractional vote for each fractional Share held. The Trust&#x2019;s
Shares do not have cumulative voting rights, which means that the holders of more than 50% of the Shares of the Trust voting for the election
of Trustees can elect all of the Trustees, and, in such event, the holders of the remaining Shares will not be able to elect any Trustees.
The Trust has a classified Board of three classes, whereby one class of Trustees is elected each year.&lt;/p&gt; &lt;/div&gt; </cef:CapitalStockTableTextBlock>
    <cef:SecurityLiquidationRightsTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221209183002623">Upon
any liquidation of the Trust, Shareholders will be entitled to share pro rata in the net assets of the Trust available for distribution
after paying or adequately providing for the payment of all liabilities.</cef:SecurityLiquidationRightsTextBlock>
    <cef:SecurityVotingRightsTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221209182946095">Shareholders
are entitled to one vote for each whole Share held and a proportionate fractional vote for each fractional Share held. The Trust&#x2019;s
Shares do not have cumulative voting rights, which means that the holders of more than 50% of the Shares of the Trust voting for the election
of Trustees can elect all of the Trustees, and, in such event, the holders of the remaining Shares will not be able to elect any Trustees.</cef:SecurityVotingRightsTextBlock>
    <cef:SecurityDividendsTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221212174858245">

&lt;div&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&lt;strong&gt;Distributions&lt;/strong&gt;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;Dividends paid from investment company taxable income as calculated for
federal income tax purposes generally will be taxable to Shareholders as ordinary income whether paid in cash or reinvested in the Trust&#x2019;s
Shares. The Trust intends to distribute to its Shareholders substantially all of its investment company taxable income(including distributions
of net short-term capital gains), if any, for each year. It is anticipated that the Trust&#x2019;s income distributions will be paid annually
in additional Shares unless the Shareholder elects payment in cash.&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;A portion of the dividends paid by the Trust may be treated as &#x201c;qualified
dividend income&#x201d; which is taxable to individuals at the same rates that are applicable to long-term capital gains. A Trust distribution
is treated as qualified dividend income to the extent that the Trust receives dividend income from taxable domestic corporations and certain
qualified foreign corporations, provided that certain holding period and other requirements are met by both the Trust and the Shareholder.
Trust distributions generally will not qualify as qualified dividend income to the extent attributable to interest, capital gains, REIT
distributions and distributions from certain non-U.S. corporations.&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;If a portion of the Trust&#x2019;s income consists of dividends paid by
U.S. corporations, a portion of the dividends paid by the Trust may be eligible for the corporate dividends-received deduction provided
that certain holding period and other requirements are met by both the Trust and the corporate Shareholder.&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;Distributions of the excess, if any, of net long-term capital gains over
net short-term capital losses reported by the Trust as capital gain dividends will be taxable to Shareholders as long-term capital gains,
whether paid in cash or reinvested in the Trust&#x2019;s Shares, regardless of how long the Shareholders have held the Trust&#x2019;s Shares
and will not be eligible for the dividends received deduction for corporations.&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;Each year, Shareholders will be notified as to the amount and federal
tax status of all dividends and capital gains paid during the prior year. Such dividends and capital gains may also be subject to state
or local taxes. Dividends declared in October, November, or December&#160;with a record date in such month and paid during the following
January&#160;will be treated as having been paid by the Trust and received by Shareholders on December&#160;31 of the calendar year in
which declared, rather than the calendar year in which the dividends are actually received.&lt;/p&gt;

&lt;div/&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;Gain or loss realized upon the sale or exchange of Shares will be a capital
gain or loss if the Shares are capital assets in the Shareholder&#x2019;s hands and generally will be long-term or short-term, depending
upon the Shareholder&#x2019;s holding period for the Shares. You should be aware that any loss realized upon the sale or exchange of Shares
held for six months or less will be treated as a long-term capital loss to the extent of any distributions or deemed distributions of
long-term capital gain to the Shareholder with respect to such Shares. In addition, any loss realized on a sale or exchange of Shares
will be disallowed to the extent the Shares disposed of are replaced within a period of 61 days beginning 30 days before and ending 30
days after the Shares are disposed of, such as pursuant to the Plan. In such case, the basis of Shares acquired will be adjusted to reflect
the disallowed loss.&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;An additional 3.8% Medicare tax is imposed on certain net investment income
(including ordinary dividends and capital gain distributions received from the Trust and net gains from redemptions or other taxabledispositions
of Trust Shares) of U.S. individuals, estates and trusts to the extent that such person&#x2019;s &#x201c;modified adjusted gross income&#x201d;
(in the case of an individual) or &#x201c;adjusted gross income&#x201d; (in the case of an estate or trust) exceeds certain threshold amounts.&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;If a Shareholder has not furnished a certified correct taxpayer identification
number (generally a Social Security number) and has not certified that withholding does not apply, or if the Internal Revenue Service
has notified the Trust that the taxpayer identification number listed on the account is incorrect according to their records or that the
Shareholder is subject to backup withholding, federal law generally requires the Trust to withhold 24% from any dividends and/or redemptions
(including exchange redemptions). Amounts withheld are applied to federal tax liability; a refund may be obtained from the Service if
withholding results in overpayment of taxes. Federal law also requires the Trust to withhold up to 30% or the applicable tax treaty rate
from ordinary dividends paid to certain nonresident alien and other non-U.S. Shareholder accounts.&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;This is a brief summary of some of the tax laws that affect an investment
in the Trust. Moreover, the foregoing does not address the many factors that may determine whether an investor will be liable for the
federal alternative minimum tax. Please see the SAI and a tax adviser for further information.&lt;/p&gt; &lt;/div&gt; </cef:SecurityDividendsTextBlock>
    <cef:InvestmentObjectivesAndPracticesTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221209105424414">

&lt;div&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&lt;span style="text-transform:uppercase"&gt;&lt;strong&gt;INVESTMENT
OBJECTIVE AND POLICIES&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&lt;span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400"&gt;Please
refer to&#160;&lt;/span&gt;&lt;a href="https://www.sec.gov/Archives/edgar/data/1635977/000110465921146323/tm2129557d1_ncsr.htm"&gt;&lt;span style="font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;font-weight:400;text-align:start;white-space:normal;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;color:#0070c0"&gt;&lt;span style="text-decoration:underline"&gt;the&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#0070c0"&gt;&lt;span style="text-decoration:underline"&gt;section
of the Trust&#x2019;s most recent annual report on Form N-CSR entitled &#x201c;Investment Objective, Policies and Risk Factors&#x2014;Investment
Objective and Policies,&#x201d;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400"&gt;&#160;which
is incorporated by reference herein, for discussion of the Trust&#x2019;s investment objective and policies.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; </cef:InvestmentObjectivesAndPracticesTextBlock>
    <cef:RiskFactorsTableTextBlock
      contextRef="C_20221206to20221206"
      id="Fxbrl_20221209105433017">

&lt;div&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&lt;span style="text-transform:uppercase"&gt;&lt;strong&gt;RISK
FACTORS&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&lt;span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400"&gt;An
investment in common shares of the Trust involves risk. Please refer&#160;&lt;/span&gt;&lt;span style="color:#0070c0"&gt;&lt;span style="text-decoration:underline"&gt;&lt;a href="https://www.sec.gov/Archives/edgar/data/1635977/000110465921146323/tm2129557d1_ncsr.htm"&gt;&lt;span style="color:#0070c0"&gt;&lt;span style="text-decoration:underline"&gt;to
the section of the Trust&#x2019;s most recent annual report on Form N-CSR entitled &#x201c;Investment Objectives, Policies and Risks&#x2014;Risk
Factors,&#x201d;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400"&gt;&#160;which
is incorporated by reference herein, for a discussion of the risks of investing in the Trust.&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; </cef:RiskFactorsTableTextBlock>
    <cef:InvestmentObjectivesAndPracticesTextBlock
      contextRef="C_20221213to20221213"
      id="Fxbrl_20221212113412854">

&lt;table style="font:13px Times New Roman, Times, serif;text-decoration-style:initial;text-decoration-color:initial;width:100%;border-collapse:collapse;border:0px"&gt;
  &lt;tr&gt;
    &lt;td colspan="2" style="padding-right:7px;padding-left:7px"&gt;Please refer to&#160;&lt;span style="color:#0070c0"&gt;&lt;a href="https://www.sec.gov/Archives/edgar/data/1635977/000110465921146323/tm2129557d1_ncsr.htm"&gt;&lt;span style="color:#0070c0"&gt;the
        section of the Trust&#x2019;s most recent annual report on Form&#160;N-CSR entitled &#x201c;Investment Objective, Policies, and Risk Factors&#x2014;Investment
        Objective and Policies&#x201d;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;span style="text-decoration:underline"&gt;&lt;span style="text-decoration:underline"&gt;,&lt;/span&gt;&lt;/span&gt;&#160;which
        is incorporated by reference herein, for a discussion of the Trust&#x2019;s investment objective and policies.&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </cef:InvestmentObjectivesAndPracticesTextBlock>
    <cef:RiskFactorsTableTextBlock
      contextRef="C_20221213to20221213"
      id="Fxbrl_20221212113837813">

&lt;table style="font:13px Times New Roman, Times, serif;text-decoration-style:initial;text-decoration-color:initial;width:100%;border-collapse:collapse;border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-right:7px;padding-left:7px"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;See &#x201c;Risks Factors&#x201d; beginning
        on page&#160;15 of the accompanying Prospectus for a discussion of factors you should carefully consider before deciding to invest in
        the Trust&#x2019;s Common Shares.&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </cef:RiskFactorsTableTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fxbrl_20221209055556812"
          xlink:label="Fxbrl_20221209055556812"
          xlink:type="locator"/>
        <link:footnote id="FN20221209055746247" xlink:label="FN20221209055746247" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents the estimated commission with respect to the Common Shares being sold under this Prospectus Supplement and the accompanying Prospectus. There is no guarantee that there will be any sales of Common Shares under this Prospectus Supplement and the accompanying Prospectus. Actual sales of Common Shares under this Prospectus Supplement and the accompanying Prospectus, if any, may be less than as set forth under &#x201c;Capitalization&#x201d; below. In addition, the price per Common Share of any such sale may be greater or less than the price set forth under &#x201c;Capitalization&#x201d; below, depending on market price of the Common Shares at the time of any such sale.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209055556812"
          xlink:to="FN20221209055746247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209055609172"
          xlink:label="Fxbrl_20221209055609172"
          xlink:type="locator"/>
        <link:footnote id="FN20221209055759475" xlink:label="FN20221209055759475" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The expenses of administering the Trust&#x2019;s Dividend Reinvestment and Stock Purchase Plan are included in &#x201c;Other Expenses.&#x201d; You will pay brokerage charges if you direct your broker or the plan agent to sell your Common Shares that you acquired pursuant to the Trust&#x2019;s Dividend Reinvestment and Stock Purchase Plan. You may also pay a pro rata share of brokerage commissions incurred in connection with open-market purchases pursuant to the Trust&#x2019;s Dividend Reinvestment and Stock Purchase Plan.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209055609172"
          xlink:to="FN20221209055759475"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209055614851"
          xlink:label="Fxbrl_20221209055614851"
          xlink:type="locator"/>
        <link:footnote id="FN20221209055813226" xlink:label="FN20221209055813226" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The management fee is charged as a percentage of the Trust&#x2019;s average daily Managed Assets (as defined herein), as opposed to net assets. If leverage is used, Managed Assets will be greater in amount than net assets, because Managed Assets includes borrowings for investment purposes. &#x201c;Managed Assets&#x201d; means the total assets of the Trust (including any assets attributable to borrowings for investment purposes) minus the sum of the Trust&#x2019;s accrued liabilities (other than liabilities representing borrowings for investment purposes).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209055614851"
          xlink:to="FN20221209055813226"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209055614851"
          xlink:to="FN20221209055759475"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209055621581"
          xlink:label="Fxbrl_20221209055621581"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209055621581"
          xlink:to="FN20221209055759475"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209055626506"
          xlink:label="Fxbrl_20221209055626506"
          xlink:type="locator"/>
        <link:footnote id="FN20221209055826642" xlink:label="FN20221209055826642" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"> &#x201c;Other Expenses&#x201d; have been estimated for the current fiscal year.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209055626506"
          xlink:to="FN20221209055826642"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209055626506"
          xlink:to="FN20221209055759475"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209055631106"
          xlink:label="Fxbrl_20221209055631106"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209055631106"
          xlink:to="FN20221209055759475"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209112210937"
          xlink:label="Fxbrl_20221209112210937"
          xlink:type="locator"/>
        <link:footnote id="FN20221209120220138" xlink:label="FN20221209120220138" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Total amount in $ millions of each class of senior securities outstanding at the end of the period presented.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209112210937"
          xlink:to="FN20221209120220138"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209112259390_xbrl_20221209112210937"
          xlink:label="Fxbrl_20221209112259390_xbrl_20221209112210937"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209112259390_xbrl_20221209112210937"
          xlink:to="FN20221209120220138"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209112302627_xbrl_20221209112210937"
          xlink:label="Fxbrl_20221209112302627_xbrl_20221209112210937"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209112302627_xbrl_20221209112210937"
          xlink:to="FN20221209120220138"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209112304686_xbrl_20221209112210937"
          xlink:label="Fxbrl_20221209112304686_xbrl_20221209112210937"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209112304686_xbrl_20221209112210937"
          xlink:to="FN20221209120220138"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209112306740_xbrl_20221209112210937"
          xlink:label="Fxbrl_20221209112306740_xbrl_20221209112210937"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209112306740_xbrl_20221209112210937"
          xlink:to="FN20221209120220138"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209112309132_xbrl_20221209112210937"
          xlink:label="Fxbrl_20221209112309132_xbrl_20221209112210937"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209112309132_xbrl_20221209112210937"
          xlink:to="FN20221209120220138"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209173039070"
          xlink:label="Fxbrl_20221209173039070"
          xlink:type="locator"/>
        <link:footnote id="FN20221209174101721" xlink:label="FN20221209174101721" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Not applicable because the senior securities are not registered for public trading.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209173039070"
          xlink:to="FN20221209174101721"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209173120190"
          xlink:label="Fxbrl_20221209173120190"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209173120190"
          xlink:to="FN20221209174101721"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209173123789"
          xlink:label="Fxbrl_20221209173123789"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209173123789"
          xlink:to="FN20221209174101721"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209173241279"
          xlink:label="Fxbrl_20221209173241279"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209173241279"
          xlink:to="FN20221209174101721"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209173248397"
          xlink:label="Fxbrl_20221209173248397"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209173248397"
          xlink:to="FN20221209174101721"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209173251957"
          xlink:label="Fxbrl_20221209173251957"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209173251957"
          xlink:to="FN20221209174101721"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105303397"
          xlink:label="Fxbrl_20221209105303397"
          xlink:type="locator"/>
        <link:footnote id="FN20221209105548339" xlink:label="FN20221209105548339" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As reported by Bloomberg LLP.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105303397"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105328471"
          xlink:label="Fxbrl_20221209105328471"
          xlink:type="locator"/>
        <link:footnote id="FN20221209105630283" xlink:label="FN20221209105630283" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Based on the Trust&#x2019;s computations, on the day that the high or low market price was recorded.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105328471"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105410129"
          xlink:label="Fxbrl_20221209105410129"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105410129"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105432641"
          xlink:label="Fxbrl_20221209105432641"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105432641"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105451232"
          xlink:label="Fxbrl_20221209105451232"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105451232"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105504591"
          xlink:label="Fxbrl_20221209105504591"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105504591"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105735391_xbrl_20221209105451232"
          xlink:label="Fxbrl_20221209105735391_xbrl_20221209105451232"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105735391_xbrl_20221209105451232"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105735391_xbrl_20221209105432641"
          xlink:label="Fxbrl_20221209105735391_xbrl_20221209105432641"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105735391_xbrl_20221209105432641"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105735391_xbrl_20221209105328471"
          xlink:label="Fxbrl_20221209105735391_xbrl_20221209105328471"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105735391_xbrl_20221209105328471"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105735391_xbrl_20221209105303397"
          xlink:label="Fxbrl_20221209105735391_xbrl_20221209105303397"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105735391_xbrl_20221209105303397"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105737683_xbrl_20221209105451232"
          xlink:label="Fxbrl_20221209105737683_xbrl_20221209105451232"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105737683_xbrl_20221209105451232"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105737683_xbrl_20221209105432641"
          xlink:label="Fxbrl_20221209105737683_xbrl_20221209105432641"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105737683_xbrl_20221209105432641"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105737683_xbrl_20221209105410129"
          xlink:label="Fxbrl_20221209105737683_xbrl_20221209105410129"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105737683_xbrl_20221209105410129"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105737683_xbrl_20221209105328471"
          xlink:label="Fxbrl_20221209105737683_xbrl_20221209105328471"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105737683_xbrl_20221209105328471"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105737683_xbrl_20221209105303397"
          xlink:label="Fxbrl_20221209105737683_xbrl_20221209105303397"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105737683_xbrl_20221209105303397"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105739625_xbrl_20221209105504591"
          xlink:label="Fxbrl_20221209105739625_xbrl_20221209105504591"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105739625_xbrl_20221209105504591"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105739625_xbrl_20221209105451232"
          xlink:label="Fxbrl_20221209105739625_xbrl_20221209105451232"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105739625_xbrl_20221209105451232"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105739625_xbrl_20221209105432641"
          xlink:label="Fxbrl_20221209105739625_xbrl_20221209105432641"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105739625_xbrl_20221209105432641"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105739625_xbrl_20221209105410129"
          xlink:label="Fxbrl_20221209105739625_xbrl_20221209105410129"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105739625_xbrl_20221209105410129"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105739625_xbrl_20221209105328471"
          xlink:label="Fxbrl_20221209105739625_xbrl_20221209105328471"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105739625_xbrl_20221209105328471"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105739625_xbrl_20221209105303397"
          xlink:label="Fxbrl_20221209105739625_xbrl_20221209105303397"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105739625_xbrl_20221209105303397"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105741931_xbrl_20221209105504591"
          xlink:label="Fxbrl_20221209105741931_xbrl_20221209105504591"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105741931_xbrl_20221209105504591"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105741931_xbrl_20221209105451232"
          xlink:label="Fxbrl_20221209105741931_xbrl_20221209105451232"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105741931_xbrl_20221209105451232"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105741931_xbrl_20221209105432641"
          xlink:label="Fxbrl_20221209105741931_xbrl_20221209105432641"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105741931_xbrl_20221209105432641"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105741931_xbrl_20221209105410129"
          xlink:label="Fxbrl_20221209105741931_xbrl_20221209105410129"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105741931_xbrl_20221209105410129"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105741931_xbrl_20221209105328471"
          xlink:label="Fxbrl_20221209105741931_xbrl_20221209105328471"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105741931_xbrl_20221209105328471"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105741931_xbrl_20221209105303397"
          xlink:label="Fxbrl_20221209105741931_xbrl_20221209105303397"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105741931_xbrl_20221209105303397"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105743730_xbrl_20221209105451232"
          xlink:label="Fxbrl_20221209105743730_xbrl_20221209105451232"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105743730_xbrl_20221209105451232"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105743730_xbrl_20221209105432641"
          xlink:label="Fxbrl_20221209105743730_xbrl_20221209105432641"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105743730_xbrl_20221209105432641"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105743730_xbrl_20221209105410129"
          xlink:label="Fxbrl_20221209105743730_xbrl_20221209105410129"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105743730_xbrl_20221209105410129"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105743730_xbrl_20221209105328471"
          xlink:label="Fxbrl_20221209105743730_xbrl_20221209105328471"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105743730_xbrl_20221209105328471"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105743730_xbrl_20221209105303397"
          xlink:label="Fxbrl_20221209105743730_xbrl_20221209105303397"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105743730_xbrl_20221209105303397"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105746378_xbrl_20221209105451232"
          xlink:label="Fxbrl_20221209105746378_xbrl_20221209105451232"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105746378_xbrl_20221209105451232"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105746378_xbrl_20221209105432641"
          xlink:label="Fxbrl_20221209105746378_xbrl_20221209105432641"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105746378_xbrl_20221209105432641"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105746378_xbrl_20221209105410129"
          xlink:label="Fxbrl_20221209105746378_xbrl_20221209105410129"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105746378_xbrl_20221209105410129"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105746378_xbrl_20221209105328471"
          xlink:label="Fxbrl_20221209105746378_xbrl_20221209105328471"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105746378_xbrl_20221209105328471"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105746378_xbrl_20221209105303397"
          xlink:label="Fxbrl_20221209105746378_xbrl_20221209105303397"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105746378_xbrl_20221209105303397"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105748594_xbrl_20221209105504591"
          xlink:label="Fxbrl_20221209105748594_xbrl_20221209105504591"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105748594_xbrl_20221209105504591"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105748594_xbrl_20221209105451232"
          xlink:label="Fxbrl_20221209105748594_xbrl_20221209105451232"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105748594_xbrl_20221209105451232"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105748594_xbrl_20221209105432641"
          xlink:label="Fxbrl_20221209105748594_xbrl_20221209105432641"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105748594_xbrl_20221209105432641"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105748594_xbrl_20221209105410129"
          xlink:label="Fxbrl_20221209105748594_xbrl_20221209105410129"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105748594_xbrl_20221209105410129"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105748594_xbrl_20221209105328471"
          xlink:label="Fxbrl_20221209105748594_xbrl_20221209105328471"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105748594_xbrl_20221209105328471"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105748594_xbrl_20221209105303397"
          xlink:label="Fxbrl_20221209105748594_xbrl_20221209105303397"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105748594_xbrl_20221209105303397"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105750466_xbrl_20221209105504591"
          xlink:label="Fxbrl_20221209105750466_xbrl_20221209105504591"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105750466_xbrl_20221209105504591"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105750466_xbrl_20221209105451232"
          xlink:label="Fxbrl_20221209105750466_xbrl_20221209105451232"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105750466_xbrl_20221209105451232"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105750466_xbrl_20221209105432641"
          xlink:label="Fxbrl_20221209105750466_xbrl_20221209105432641"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105750466_xbrl_20221209105432641"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105750466_xbrl_20221209105410129"
          xlink:label="Fxbrl_20221209105750466_xbrl_20221209105410129"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105750466_xbrl_20221209105410129"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105750466_xbrl_20221209105328471"
          xlink:label="Fxbrl_20221209105750466_xbrl_20221209105328471"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105750466_xbrl_20221209105328471"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105750466_xbrl_20221209105303397"
          xlink:label="Fxbrl_20221209105750466_xbrl_20221209105303397"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105750466_xbrl_20221209105303397"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105752315_xbrl_20221209105451232"
          xlink:label="Fxbrl_20221209105752315_xbrl_20221209105451232"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105752315_xbrl_20221209105451232"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105752315_xbrl_20221209105432641"
          xlink:label="Fxbrl_20221209105752315_xbrl_20221209105432641"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105752315_xbrl_20221209105432641"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105752315_xbrl_20221209105410129"
          xlink:label="Fxbrl_20221209105752315_xbrl_20221209105410129"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105752315_xbrl_20221209105410129"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105752315_xbrl_20221209105328471"
          xlink:label="Fxbrl_20221209105752315_xbrl_20221209105328471"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105752315_xbrl_20221209105328471"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105752315_xbrl_20221209105303397"
          xlink:label="Fxbrl_20221209105752315_xbrl_20221209105303397"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105752315_xbrl_20221209105303397"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105754425_xbrl_20221209105504591"
          xlink:label="Fxbrl_20221209105754425_xbrl_20221209105504591"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105754425_xbrl_20221209105504591"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105754425_xbrl_20221209105451232"
          xlink:label="Fxbrl_20221209105754425_xbrl_20221209105451232"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105754425_xbrl_20221209105451232"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105754425_xbrl_20221209105432641"
          xlink:label="Fxbrl_20221209105754425_xbrl_20221209105432641"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105754425_xbrl_20221209105432641"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105754425_xbrl_20221209105410129"
          xlink:label="Fxbrl_20221209105754425_xbrl_20221209105410129"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105754425_xbrl_20221209105410129"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105754425_xbrl_20221209105328471"
          xlink:label="Fxbrl_20221209105754425_xbrl_20221209105328471"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105754425_xbrl_20221209105328471"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209105754425_xbrl_20221209105303397"
          xlink:label="Fxbrl_20221209105754425_xbrl_20221209105303397"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209105754425_xbrl_20221209105303397"
          xlink:to="FN20221209105548339"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209114948366"
          xlink:label="Fxbrl_20221209114948366"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209114948366"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209115004831"
          xlink:label="Fxbrl_20221209115004831"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209115004831"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209115026176"
          xlink:label="Fxbrl_20221209115026176"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209115026176"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209115102859"
          xlink:label="Fxbrl_20221209115102859"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209115102859"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209115118483"
          xlink:label="Fxbrl_20221209115118483"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209115118483"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221209115212674"
          xlink:label="Fxbrl_20221209115212674"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221209115212674"
          xlink:to="FN20221209105630283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221212110750235"
          xlink:label="Fxbrl_20221212110750235"
          xlink:type="locator"/>
        <link:footnote id="FN20221212115720547" xlink:label="FN20221212115720547" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The expenses of administering the Trust&#x2019;s Dividend Reinvestment and Stock Purchase Plan are included in &#x201c;Other Expenses.&#x201d; You will pay brokerage charges if you direct your broker or the plan agent to sell your Shares that you acquired pursuant to the Trust&#x2019;s Dividend Reinvestment and Stock Purchase Plan. You may also pay a pro rata share of brokerage commissions incurred in connection with open-market purchases pursuant to the Trust&#x2019;s Dividend Reinvestment and Stock Purchase Plan. See &#x201c;Dividend Reinvestment and Stock Purchase Plan.&#x201d;</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221212110750235"
          xlink:to="FN20221212115720547"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221212110756531"
          xlink:label="Fxbrl_20221212110756531"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221212110756531"
          xlink:to="FN20221212115720547"
          xlink:type="arc"/>
        <link:footnote id="FN20221212120008060" xlink:label="FN20221212120008060" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">&#x201c;Other Expenses&#x201d; for the current fiscal year.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221212110756531"
          xlink:to="FN20221212120008060"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221212110803558"
          xlink:label="Fxbrl_20221212110803558"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221212110803558"
          xlink:to="FN20221212115720547"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221212110810366"
          xlink:label="Fxbrl_20221212110810366"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221212110810366"
          xlink:to="FN20221212115720547"
          xlink:type="arc"/>
        <link:footnote id="FN20221212115946892" xlink:label="FN20221212115946892" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The management fee is charged as a percentage of the Trust&#x2019;s average daily Managed Assets, as opposed to net assets. If leverage is used, Managed Assets will be greater in amount than net assets, because Managed Assets includes borrowings for investment purposes.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221212110810366"
          xlink:to="FN20221212115946892"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20221212110818655"
          xlink:label="Fxbrl_20221212110818655"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20221212110818655"
          xlink:to="FN20221212115720547"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>27</ContextCount>
  <ElementCount>56</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="tm2226039d6_424b5.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995470 - Disclosure - N-2</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cef/role/N2</Role>
      <ShortName>N-2</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="424B5" original="tm2226039d6_424b5.htm">tm2226039d6_424b5.htm</File>
    <File>ck0001635977-20221213.xsd</File>
    <File>ck0001635977-20221213_def.xml</File>
    <File>ck0001635977-20221213_lab.xml</File>
    <File>ck0001635977-20221213_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="172">http://xbrl.sec.gov/cef/2022</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2226039d6_424b5.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 27,
   "dts": {
    "definitionLink": {
     "local": [
      "ck0001635977-20221213_def.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2226039d6_424b5.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ck0001635977-20221213_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ck0001635977-20221213_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ck0001635977-20221213.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/2006/xbrldi-2006.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/cef/2022/cef-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022_lab.xsd"
     ]
    }
   },
   "elementCount": 190,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/cef/2022": 6,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 9
   },
   "keyCustom": 0,
   "keyStandard": 56,
   "memberCustom": 1,
   "memberStandard": 0,
   "nsprefix": "ck0001635977",
   "nsuri": "http://www.teklacap.com/20221213",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "strong",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tm2226039d6_424b5.htm",
      "contextRef": "C_20221213to20221213",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "true",
     "longName": "995470 - Disclosure - N-2",
     "role": "http://xbrl.sec.gov/cef/role/N2",
     "shortName": "N-2",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "strong",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tm2226039d6_424b5.htm",
      "contextRef": "C_20221213to20221213",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 1,
   "tag": {
    "cef_AcquiredFundFeesAndExpensesNoteTextBlock": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees and Expenses, Note [Text Block]"
       }
      }
     },
     "localname": "AcquiredFundFeesAndExpensesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AcquiredFundFeesAndExpensesPercent": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees and Expenses [Percent]"
       }
      }
     },
     "localname": "AcquiredFundFeesAndExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_AcquiredFundFeesEstimatedNoteTextBlock": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees Estimated, Note [Text Block]"
       }
      }
     },
     "localname": "AcquiredFundFeesEstimatedNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AcquiredFundIncentiveAllocationNoteTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Incentive Allocation, Note [Text Block]"
       }
      }
     },
     "localname": "AcquiredFundIncentiveAllocationNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AcquiredFundTotalAnnualExpensesNoteTextBlock": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Total Annual Expenses, Note [Text Block]"
       }
      }
     },
     "localname": "AcquiredFundTotalAnnualExpensesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AllRisksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Risks:"
       }
      }
     },
     "localname": "AllRisksMember",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "cef_AllSecuritiesMember": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Securities:"
       }
      }
     },
     "localname": "AllSecuritiesMember",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "cef_AnnualCoverageReturnRatePercent": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Coverage Return Rate [Percent]"
       }
      }
     },
     "localname": "AnnualCoverageReturnRatePercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_AnnualDividendPayment": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment"
       }
      }
     },
     "localname": "AnnualDividendPayment",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_AnnualDividendPaymentCurrent": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment, Current"
       }
      }
     },
     "localname": "AnnualDividendPaymentCurrent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_AnnualDividendPaymentInitial": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment, Initial"
       }
      }
     },
     "localname": "AnnualDividendPaymentInitial",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_AnnualExpensesTableTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Expenses [Table Text Block]"
       }
      }
     },
     "localname": "AnnualExpensesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AnnualInterestRateCurrentPercent": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate, Current [Percent]"
       }
      }
     },
     "localname": "AnnualInterestRateCurrentPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_AnnualInterestRateInitialPercent": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate, Initial [Percent]"
       }
      }
     },
     "localname": "AnnualInterestRateInitialPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_AnnualInterestRatePercent": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate [Percent]"
       }
      }
     },
     "localname": "AnnualInterestRatePercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_BasisOfTransactionFeesNoteTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Transaction Fees, Note [Text Block]"
       }
      }
     },
     "localname": "BasisOfTransactionFeesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_BdcFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BDC File Number"
       }
      }
     },
     "localname": "BdcFileNumber",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "cef_BusinessDevelopmentCompanyFlag": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Development Company [Flag]"
       }
      }
     },
     "localname": "BusinessDevelopmentCompanyFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock, Long-Term Debt, and Other Securities [Abstract]"
       }
      }
     },
     "localname": "CapitalStockLongTermDebtAndOtherSecuritiesAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_CapitalStockTableTextBlock": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock [Table Text Block]"
       }
      }
     },
     "localname": "CapitalStockTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_DistributionServicingFeesPercent": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution/Servicing Fees [Percent]"
       }
      }
     },
     "localname": "DistributionServicingFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_DistributionsMayReducePrincipalTextBlock": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributions May Reduce Principal [Text Block]"
       }
      }
     },
     "localname": "DistributionsMayReducePrincipalTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_DividendAndInterestExpensesOnShortSalesPercent": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend and Interest Expenses on Short Sales [Percent]"
       }
      }
     },
     "localname": "DividendAndInterestExpensesOnShortSalesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_DividendExpenseOnPreferredSharesPercent": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Expenses on Preferred Shares [Percent]"
       }
      }
     },
     "localname": "DividendExpenseOnPreferredSharesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_DividendReinvestmentAndCashPurchaseFees": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Reinvestment and Cash Purchase Fees"
       }
      }
     },
     "localname": "DividendReinvestmentAndCashPurchaseFees",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_EffectsOfLeveragePurposeTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage, Purpose [Text Block]"
       }
      }
     },
     "localname": "EffectsOfLeveragePurposeTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_EffectsOfLeverageTableTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage [Table Text Block]"
       }
      }
     },
     "localname": "EffectsOfLeverageTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_EffectsOfLeverageTextBlock": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage [Text Block]"
       }
      }
     },
     "localname": "EffectsOfLeverageTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_ExpenseExampleTableTextBlock": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example [Table Text Block]"
       }
      }
     },
     "localname": "ExpenseExampleTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_ExpenseExampleYear01": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Year 01"
       }
      }
     },
     "localname": "ExpenseExampleYear01",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_ExpenseExampleYears1to10": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 10"
       }
      }
     },
     "localname": "ExpenseExampleYears1to10",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_ExpenseExampleYears1to3": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 3"
       }
      }
     },
     "localname": "ExpenseExampleYears1to3",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_ExpenseExampleYears1to5": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 5"
       }
      }
     },
     "localname": "ExpenseExampleYears1to5",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_FeeTableAbstract": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Table [Abstract]"
       }
      }
     },
     "localname": "FeeTableAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_FinancialHighlightsAbstract": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Highlights [Abstract]"
       }
      }
     },
     "localname": "FinancialHighlightsAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_GeneralDescriptionOfRegistrantAbstract": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Description of Registrant [Abstract]"
       }
      }
     },
     "localname": "GeneralDescriptionOfRegistrantAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_HighestPriceOrBid": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid"
       }
      }
     },
     "localname": "HighestPriceOrBid",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_HighestPriceOrBidNav": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid, NAV"
       }
      }
     },
     "localname": "HighestPriceOrBidNav",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_HighestPriceOrBidPremiumDiscountToNavPercent": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid, Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "localname": "HighestPriceOrBidPremiumDiscountToNavPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IncentiveAllocationMaximumPercent": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation Maximum [Percent]"
       }
      }
     },
     "localname": "IncentiveAllocationMaximumPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IncentiveAllocationMinimumPercent": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation Minimum [Percent]"
       }
      }
     },
     "localname": "IncentiveAllocationMinimumPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IncentiveAllocationPercent": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation [Percent]"
       }
      }
     },
     "localname": "IncentiveAllocationPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IncentiveFeesPercent": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Fees [Percent]"
       }
      }
     },
     "localname": "IncentiveFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_InterestExpensesOnBorrowingsPercent": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expenses on Borrowings [Percent]"
       }
      }
     },
     "localname": "InterestExpensesOnBorrowingsPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IntervalFundFlag": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interval Fund [Flag]"
       }
      }
     },
     "localname": "IntervalFundFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_InvestmentObjectivesAndPracticesTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Objectives and Practices [Text Block]"
       }
      }
     },
     "localname": "InvestmentObjectivesAndPracticesTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LatestNav": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest NAV"
       }
      }
     },
     "localname": "LatestNav",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_LatestPremiumDiscountToNavPercent": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "localname": "LatestPremiumDiscountToNavPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_LatestSharePrice": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Share Price"
       }
      }
     },
     "localname": "LatestSharePrice",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_LoanServicingFeesPercent": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Servicing Fees [Percent]"
       }
      }
     },
     "localname": "LoanServicingFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_LongTermDebtDividendsAndCovenantsTextBlock": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Dividends and Covenants [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtDividendsAndCovenantsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtIssuanceAndSubstitutionTextBlock": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Issuance and Substitution [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtIssuanceAndSubstitutionTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtPrincipal": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Principal"
       }
      }
     },
     "localname": "LongTermDebtPrincipal",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_LongTermDebtRightsLimitedByOtherSecuritiesTextBlock": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Rights Limited by Other Securities [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtStructuringTextBlock": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Structuring [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtStructuringTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtTableTextBlock": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt [Table Text Block]"
       }
      }
     },
     "localname": "LongTermDebtTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtTitleTextBlock": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Title [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LowestPriceOrBid": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid"
       }
      }
     },
     "localname": "LowestPriceOrBid",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_LowestPriceOrBidNav": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid, NAV"
       }
      }
     },
     "localname": "LowestPriceOrBidNav",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_LowestPriceOrBidPremiumDiscountToNavPercent": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid, Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "localname": "LowestPriceOrBidPremiumDiscountToNavPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Fee not based on Net Assets, Note [Text Block]"
       }
      }
     },
     "localname": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_ManagementFeesPercent": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Fees [Percent]"
       }
      }
     },
     "localname": "ManagementFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_NetExpenseOverAssetsPercent": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Expense over Assets [Percent]"
       }
      }
     },
     "localname": "NetExpenseOverAssetsPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_NewCefOrBdcRegistrantFlag": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New CEF or BDC Registrant [Flag]"
       }
      }
     },
     "localname": "NewCefOrBdcRegistrantFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_NoPublicTradingTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Public Trading [Text Block]"
       }
      }
     },
     "localname": "NoPublicTradingTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_NoTradingHistoryTextBlock": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading History [Text Block]"
       }
      }
     },
     "localname": "NoTradingHistoryTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherAnnualExpense1Percent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "order": 1.0,
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 1 [Percent]"
       }
      }
     },
     "localname": "OtherAnnualExpense1Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherAnnualExpense2Percent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "order": 2.0,
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 2 [Percent]"
       }
      }
     },
     "localname": "OtherAnnualExpense2Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherAnnualExpense3Percent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "order": 3.0,
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 3 [Percent]"
       }
      }
     },
     "localname": "OtherAnnualExpense3Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherAnnualExpensesAbstract": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherAnnualExpensesAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_OtherAnnualExpensesPercent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expenses [Percent]"
       }
      }
     },
     "localname": "OtherAnnualExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherExpensesNoteTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses, Note [Text Block]"
       }
      }
     },
     "localname": "OtherExpensesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherFeederFundExpensesPercent": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Feeder Fund Expenses [Percent]"
       }
      }
     },
     "localname": "OtherFeederFundExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherMasterFundExpensesPercent": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Master Fund Expenses [Percent]"
       }
      }
     },
     "localname": "OtherMasterFundExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherSecuritiesTableTextBlock": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Securities [Table Text Block]"
       }
      }
     },
     "localname": "OtherSecuritiesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherSecurityDescriptionTextBlock": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Security, Description [Text Block]"
       }
      }
     },
     "localname": "OtherSecurityDescriptionTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherSecurityTitleTextBlock": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Security, Title [Text Block]"
       }
      }
     },
     "localname": "OtherSecurityTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherTransactionExpense1Percent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "order": 1.0,
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 1 [Percent]"
       }
      }
     },
     "localname": "OtherTransactionExpense1Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionExpense2Percent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "order": 2.0,
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 2 [Percent]"
       }
      }
     },
     "localname": "OtherTransactionExpense2Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionExpense3Percent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "order": 3.0,
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 3 [Percent]"
       }
      }
     },
     "localname": "OtherTransactionExpense3Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionExpensesAbstract": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherTransactionExpensesAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_OtherTransactionExpensesPercent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expenses [Percent]"
       }
      }
     },
     "localname": "OtherTransactionExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionFeesBasisMaximum": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Maximum"
       }
      }
     },
     "localname": "OtherTransactionFeesBasisMaximum",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_OtherTransactionFeesBasisMaximumPercent": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Maximum [Percent]"
       }
      }
     },
     "localname": "OtherTransactionFeesBasisMaximumPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionFeesBasisNoteTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Note [Text Block]"
       }
      }
     },
     "localname": "OtherTransactionFeesBasisNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherTransactionFeesNoteTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees, Note [Text Block]"
       }
      }
     },
     "localname": "OtherTransactionFeesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OutstandingSecuritiesTableTextBlock": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Securities [Table Text Block]"
       }
      }
     },
     "localname": "OutstandingSecuritiesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OutstandingSecurityAuthorizedShares": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Authorized [Shares]"
       }
      }
     },
     "localname": "OutstandingSecurityAuthorizedShares",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sharesItemType"
    },
    "cef_OutstandingSecurityHeldShares": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Held [Shares]"
       }
      }
     },
     "localname": "OutstandingSecurityHeldShares",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sharesItemType"
    },
    "cef_OutstandingSecurityNotHeldShares": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Not Held [Shares]"
       }
      }
     },
     "localname": "OutstandingSecurityNotHeldShares",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sharesItemType"
    },
    "cef_OutstandingSecurityTitleTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Title [Text Block]"
       }
      }
     },
     "localname": "OutstandingSecurityTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_PreferredStockRestrictionsArrearageTextBlock": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Restrictions, Arrearage [Text Block]"
       }
      }
     },
     "localname": "PreferredStockRestrictionsArrearageTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_PreferredStockRestrictionsOtherTextBlock": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Restrictions, Other [Text Block]"
       }
      }
     },
     "localname": "PreferredStockRestrictionsOtherTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_PrimaryShelfFlag": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary Shelf [Flag]"
       }
      }
     },
     "localname": "PrimaryShelfFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_PrimaryShelfQualifiedFlag": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary Shelf Qualified [Flag]"
       }
      }
     },
     "localname": "PrimaryShelfQualifiedFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_ProspectusLineItems": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prospectus [Line Items]"
       }
      }
     },
     "localname": "ProspectusLineItems",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "xbrltype": "stringItemType"
    },
    "cef_ProspectusTable": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prospectus:"
       }
      }
     },
     "localname": "ProspectusTable",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_PurposeOfFeeTableNoteTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purpose of Fee Table , Note [Text Block]"
       }
      }
     },
     "localname": "PurposeOfFeeTableNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_RegisteredClosedEndFundFlag": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registered Closed-End Fund [Flag]"
       }
      }
     },
     "localname": "RegisteredClosedEndFundFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_ReturnAtMinusFivePercent": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Minus Five [Percent]"
       }
      }
     },
     "localname": "ReturnAtMinusFivePercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ReturnAtMinusTenPercent": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Minus Ten [Percent]"
       }
      }
     },
     "localname": "ReturnAtMinusTenPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ReturnAtPlusFivePercent": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Plus Five [Percent]"
       }
      }
     },
     "localname": "ReturnAtPlusFivePercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ReturnAtPlusTenPercent": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Plus Ten [Percent]"
       }
      }
     },
     "localname": "ReturnAtPlusTenPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ReturnAtZeroPercent": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Zero [Percent]"
       }
      }
     },
     "localname": "ReturnAtZeroPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_RightsLimitedByOtherSecuritiesTextBlock": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Limited by Other Securities [Text Block]"
       }
      }
     },
     "localname": "RightsLimitedByOtherSecuritiesTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_RightsSubjectToOtherThanMajorityVoteTextBlock": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Subject to Other than Majority Vote [Text Block]"
       }
      }
     },
     "localname": "RightsSubjectToOtherThanMajorityVoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_RiskAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk [Axis]"
       }
      }
     },
     "localname": "RiskAxis",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_RiskFactorsTableTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk Factors [Table Text Block]"
       }
      }
     },
     "localname": "RiskFactorsTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_RiskTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk [Text Block]"
       }
      }
     },
     "localname": "RiskTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SalesLoadPercent": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Load [Percent]"
       }
      }
     },
     "localname": "SalesLoadPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_SecurityAxis": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security [Axis]"
       }
      }
     },
     "localname": "SecurityAxis",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_SecurityDividendsTextBlock": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Dividends [Text Block]"
       }
      }
     },
     "localname": "SecurityDividendsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityLiabilitiesTextBlock": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Liabilities [Text Block]"
       }
      }
     },
     "localname": "SecurityLiabilitiesTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityLiquidationRightsTextBlock": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Liquidation Rights [Text Block]"
       }
      }
     },
     "localname": "SecurityLiquidationRightsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityObligationsOfOwnershipTextBlock": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Obligations of Ownership [Text Block]"
       }
      }
     },
     "localname": "SecurityObligationsOfOwnershipTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityPreemptiveAndOtherRightsTextBlock": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Preemptive and Other Rights [Text Block]"
       }
      }
     },
     "localname": "SecurityPreemptiveAndOtherRightsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityTitleTextBlock": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Title [Text Block]"
       }
      }
     },
     "localname": "SecurityTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityVotingRightsTextBlock": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Voting Rights [Text Block]"
       }
      }
     },
     "localname": "SecurityVotingRightsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesAmount": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Amount"
       }
      }
     },
     "localname": "SeniorSecuritiesAmount",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_SeniorSecuritiesAverageMarketValuePerUnit": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Average Market Value per Unit"
       }
      }
     },
     "localname": "SeniorSecuritiesAverageMarketValuePerUnit",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_SeniorSecuritiesAveragingMethodNoteTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Averaging Method, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesAveragingMethodNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesCoveragePerUnit": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Coverage per Unit"
       }
      }
     },
     "localname": "SeniorSecuritiesCoveragePerUnit",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_SeniorSecuritiesHeadingsNoteTextBlock": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Headings, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesHeadingsNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesHighlightsAnnualizedNoteTextBlock": {
     "auth_ref": [
      "r47",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Highlights Annualized, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesHighlightsAnnualizedNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesHighlightsAuditedNoteTextBlock": {
     "auth_ref": [
      "r48",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Highlights Audited, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesHighlightsAuditedNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Involuntary Liquidating Preference per Unit"
       }
      }
     },
     "localname": "SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_SeniorSecuritiesNoteTextBlock": {
     "auth_ref": [
      "r46",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesTableTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities [Table Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SharePriceTableTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price [Table Text Block]"
       }
      }
     },
     "localname": "SharePriceTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SharePricesNotActualTransactionsTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Prices Not Actual Transactions [Text Block]"
       }
      }
     },
     "localname": "SharePricesNotActualTransactionsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_ShareholderTransactionExpensesTableTextBlock": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Transaction Expenses [Table Text Block]"
       }
      }
     },
     "localname": "ShareholderTransactionExpensesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_TotalAnnualExpensesPercent": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Annual Expenses [Percent]"
       }
      }
     },
     "localname": "TotalAnnualExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_UnderwritersCompensationPercent": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriters Compensation [Percent]"
       }
      }
     },
     "localname": "UnderwritersCompensationPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_WaiversAndReimbursementsOfFeesPercent": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Waivers and Reimbursements of Fees [Percent]"
       }
      }
     },
     "localname": "WaiversAndReimbursementsOfFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_WarrantsOrRightsCalledAmount": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Amount"
       }
      }
     },
     "localname": "WarrantsOrRightsCalledAmount",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_WarrantsOrRightsCalledPeriodDate": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Period [Date]"
       }
      }
     },
     "localname": "WarrantsOrRightsCalledPeriodDate",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "dateItemType"
    },
    "cef_WarrantsOrRightsCalledTitleTextBlock": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Title"
       }
      }
     },
     "localname": "WarrantsOrRightsCalledTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_WarrantsOrRightsExercisePrice": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Exercise Price"
       }
      }
     },
     "localname": "WarrantsOrRightsExercisePrice",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "ck0001635977_LoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents as a loan facility.",
        "label": "Loan Facility [Member]"
       }
      }
     },
     "localname": "LoanFacilityMember",
     "nsuri": "http://www.teklacap.com/20221213",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AdditionalSecurities462b": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "localname": "AdditionalSecurities462b",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "localname": "AdditionalSecurities462bFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "localname": "AdditionalSecuritiesEffective413b",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings.",
        "label": "Approximate Date of Commencement of Proposed Sale to Public"
       }
      }
     },
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "dateOrAsapItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r2",
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DelayedOrContinuousOffering": {
     "auth_ref": [
      "r4",
      "r5",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "localname": "DelayedOrContinuousOffering",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "auth_ref": [
      "r4",
      "r5",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EffectiveAfter60Days486a": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "localname": "EffectiveAfter60Days486a",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveOnDate486a": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "localname": "EffectiveOnDate486a",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EffectiveOnDate486b": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "localname": "EffectiveOnDate486b",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EffectiveOnSetDate486a": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "localname": "EffectiveOnSetDate486a",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveOnSetDate486b": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "localname": "EffectiveOnSetDate486b",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveUponFiling462e": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "localname": "EffectiveUponFiling462e",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveUponFiling486b": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "localname": "EffectiveUponFiling486b",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "localname": "EffectiveWhenDeclaredSection8c",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityInvCompanyType": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product).",
        "label": "Entity Inv Company Type"
       }
      }
     },
     "localname": "EntityInvCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "invCompanyType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_ExhibitsOnly462d": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "localname": "ExhibitsOnly462d",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "localname": "ExhibitsOnly462dFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_InvestmentCompanyActFileNumber": {
     "auth_ref": [
      "r5",
      "r72",
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "localname": "InvestmentCompanyActFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_InvestmentCompanyActRegistration": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "localname": "InvestmentCompanyActRegistration",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "localname": "InvestmentCompanyRegistrationAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "auth_ref": [
      "r5",
      "r72",
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "localname": "NewEffectiveDateForPreviousFiling",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_NoSubstantiveChanges462c": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "localname": "NoSubstantiveChanges462c",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "localname": "NoSubstantiveChanges462cFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_PostEffectiveAmendment": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "localname": "PostEffectiveAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PostEffectiveAmendmentNumber": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective.",
        "label": "Post-Effective Amendment Number"
       }
      }
     },
     "localname": "PostEffectiveAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "dei_PreEffectiveAmendment": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "localname": "PreEffectiveAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreEffectiveAmendmentNumber": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective.",
        "label": "Pre-Effective Amendment Number"
       }
      }
     },
     "localname": "PreEffectiveAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sequenceNumberItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r10": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "3",
   "Subsection": "1"
  },
  "r11": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "4",
   "Subsection": "1"
  },
  "r12": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "5",
   "Subsection": "1"
  },
  "r13": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "6",
   "Subsection": "1"
  },
  "r14": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "Instruction 2",
   "Subsection": "1"
  },
  "r15": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "1",
   "Subsection": "1"
  },
  "r16": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "2",
   "Subsection": "1"
  },
  "r17": {
   "Name": "Form N-2",
   "Paragraph": "c",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "1"
  },
  "r18": {
   "Name": "Form N-2",
   "Paragraph": "d",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "1"
  },
  "r19": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r20": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "2"
  },
  "r21": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "2"
  },
  "r22": {
   "Name": "Form N-2",
   "Paragraph": "c",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "2"
  },
  "r23": {
   "Name": "Form N-2",
   "Paragraph": "e",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "2"
  },
  "r24": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "3"
  },
  "r25": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "5"
  },
  "r26": {
   "Name": "Form N-2",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "5"
  },
  "r27": {
   "Name": "Form N-2",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "5"
  },
  "r28": {
   "Name": "Form N-2",
   "Paragraph": "3",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "5"
  },
  "r29": {
   "Name": "Form N-2",
   "Paragraph": "4",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "5"
  },
  "r3": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r30": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subsection": "1"
  },
  "r31": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 1",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subsection": "1"
  },
  "r32": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 10",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subparagraph": "a",
   "Subsection": "1"
  },
  "r33": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 10",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subparagraph": "a, g, h",
   "Subsection": "1"
  },
  "r34": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 10",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subparagraph": "f",
   "Subsection": "1"
  },
  "r35": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 10",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subparagraph": "g",
   "Subsection": "1"
  },
  "r36": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 10",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subparagraph": "i",
   "Subsection": "1"
  },
  "r37": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 11",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subsection": "1"
  },
  "r38": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 4",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subsection": "1"
  },
  "r39": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 5",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subsection": "1"
  },
  "r4": {
   "Name": "Form F-3",
   "Publisher": "SEC"
  },
  "r40": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 6",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subsection": "1"
  },
  "r41": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 7",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subparagraph": "a",
   "Subsection": "1"
  },
  "r42": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 7",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subparagraph": "b",
   "Subsection": "1"
  },
  "r43": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 8",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subsection": "1"
  },
  "r44": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 9",
   "Publisher": "SEC",
   "Section": "Item 3",
   "Subsection": "1"
  },
  "r45": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "Section": "Item 4"
  },
  "r46": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 2",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "1"
  },
  "r47": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 3",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "1"
  },
  "r48": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 8",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "1"
  },
  "r49": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "3"
  },
  "r5": {
   "Name": "Form N-2",
   "Publisher": "SEC"
  },
  "r50": {
   "Name": "Form N-2",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "3"
  },
  "r51": {
   "Name": "Form N-2",
   "Paragraph": "3",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subparagraph": "Instruction 2",
   "Subsection": "3"
  },
  "r52": {
   "Name": "Form N-2",
   "Paragraph": "4",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subparagraph": "Instruction 3",
   "Subsection": "3"
  },
  "r53": {
   "Name": "Form N-2",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "3"
  },
  "r54": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 1",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "3"
  },
  "r55": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 4",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "3"
  },
  "r56": {
   "Name": "Form N-2",
   "Paragraph": "Instruction 5",
   "Publisher": "SEC",
   "Section": "Item 4",
   "Subsection": "3"
  },
  "r57": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "Section": "Item 8"
  },
  "r58": {
   "Name": "Form N-2",
   "Paragraph": "b, d",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subsection": "2"
  },
  "r59": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subsection": "3"
  },
  "r6": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "Section": "Item 10"
  },
  "r60": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subsection": "3"
  },
  "r61": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subparagraph": "1",
   "Subsection": "3"
  },
  "r62": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subparagraph": "2",
   "Subsection": "3"
  },
  "r63": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subparagraph": "3",
   "Subsection": "3"
  },
  "r64": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subsection": "5"
  },
  "r65": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subparagraph": "4",
   "Subsection": "5"
  },
  "r66": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subparagraph": "Instruction 2",
   "Subsection": "5"
  },
  "r67": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subparagraph": "Instruction 3",
   "Subsection": "5"
  },
  "r68": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subparagraph": "Instruction 4",
   "Subsection": "5"
  },
  "r69": {
   "Name": "Form N-2",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subparagraph": "Instructions 4, 5",
   "Subsection": "5"
  },
  "r7": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subsection": "1"
  },
  "r70": {
   "Name": "Form N-2",
   "Paragraph": "c",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subsection": "5"
  },
  "r71": {
   "Name": "Form N-2",
   "Paragraph": "e",
   "Publisher": "SEC",
   "Section": "Item 8",
   "Subsection": "5"
  },
  "r72": {
   "Name": "Form N-3",
   "Publisher": "SEC"
  },
  "r73": {
   "Name": "Form N-4",
   "Publisher": "SEC"
  },
  "r74": {
   "Name": "Form N-6",
   "Publisher": "SEC"
  },
  "r75": {
   "Name": "Form S-3",
   "Publisher": "SEC"
  },
  "r76": {
   "Name": "Investment Company Act",
   "Number": "270",
   "Publisher": "SEC"
  },
  "r77": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "313"
  },
  "r78": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r79": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "413",
   "Subsection": "b"
  },
  "r8": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "1",
   "Subsection": "1"
  },
  "r80": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "b"
  },
  "r81": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "c"
  },
  "r82": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "d"
  },
  "r83": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "e"
  },
  "r84": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "486",
   "Subsection": "a"
  },
  "r85": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "486",
   "Subsection": "b"
  },
  "r86": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r87": {
   "Name": "Securities Act",
   "Publisher": "SEC",
   "Section": "8",
   "Subsection": "c"
  },
  "r9": {
   "Name": "Form N-2",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "Item 10",
   "Subparagraph": "2",
   "Subsection": "1"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001104659-22-126998-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-126998-xbrl.zip
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M< IT#N*40:YT1@P51-GSBD;[YF]02P,$%     @ TH6.5:+L=/7] 0  ! <
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MAV&[A<,(QZ'?ZMR;W2 T^80QFC_]>O@Y7Z)LCQ[^X.7W18(P=J?.5B4%+*!
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M"2,7$,;I A"&0S=$'F,\NE'?@*=&3B<R(I\>/(.OX:LF@,4)C;8#S,<(?8
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M'Y>JY0R<;R&B/\':0G:T=G?H>FX(N\>UXAI:P3B,<#=6]6-HG+L/+A!:UV@
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M+6K7RIJ J'O2+O5X*SY>> YPDO;SJUK=8NO8#C;Z(50D,B(^ XQ;,I@)!Z,
M$D@2[UQ8$LU(;55T::0O+V];7MXNO[Q]<7G+!K'CU-V=(]66-8A%F,/?N(#
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MQJTD*!Z=MA&Z$6AMV@%U_($?G 3W[?UR[O@X!XKUA\01DM "%ZG/>.,)*7@
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MIB.UA09\8ER BN_+0 .0[&$MS/;N&2A=<%M:6?#8B5*UHJ*1B(B7*L8>],9
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M)PPPQV+E[O-Z?9'-#29)([N.80A>;D(C:2=I&32$VI7%,/!"PC2PKC-P'YR
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M[A@=Z&2=T\;+&==TATT;-A*[)I_\%J^6,7.M"^2-RJ8=^<OGX:]%)%M=W?;
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MW,K 7U7:01:MW.[.*K.]Y]?F2J5"J:K2P2VS?][T+ARFR[W2;+=4-0Z-2-Q
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MQ/E9<*\U56XT@.O&GV;!:_6#;L*FQJZU8&K\$3)VYV?U-_K[]"913%7_%I#
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MPKJF:0A4LK-_O%.8*DC-G#*GM,">^-=(MFF1#L:4_@K;8(^03#%["A46%N_
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ML*)*T+7FH8^FHY\IM</YC%".LZ5)Z'D8RH)K2.H&Z-QBN',Z4=(29I,E<1R
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MU\ -RC-V337;=X)[OB<S(&1!'-X8,N*<,<T63<1!Y]3#"/MF! LO0"5+)>E
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MR7%[C6':0BZ/4E(:_!2)R">?N_X<@W&\L:U6#P3J0 \$#Y/5D*0E>S-[H\:
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M-@JHYE^K'%-)6L5DHG)DB@9;75IOO6N%DRBD;0\M6C$F^^RQ=W2=RXI8E]T
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M#AE9O7>?CHZQ=VOO_/-I8WWMX(^S\\_OCGK'\-G3WO'9^\-3K_?[X?%YPU,
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MN8+3,56:I]+H*+6!(=P.+K<W!:%NV#6T527'85I[_>1>!X[2:7*-$1-UZQR
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ML'U'MMA(THI*!E=<PC836W#_,@J'AZZ%-(ZKJ9"3DGFT4/!V*8<MUA4K2U7
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MGEMVB^ES?0\5SH5KS)5S(Y?-L<3IFK-U3U#ID?5>^(W^R)8OGC/.($EO#[V
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M!#=?1@A^LJ/Y",C#3 %NI752S,N$Y>KZ!1:+9$@AO<CYHWU#7+=G_;:#.G1
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M"JXNQZL9>%T,<!V76NXQ>25((2+^4<"*'72(PV($H*$Y<47?6EWLA3^.&1S
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M 9OPK@KY^61BN#L4E:"#.H^5D51W4DL6+E)#QR_6G!0>M.&-#=H#D3R*RKX
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M5QCG]3!%D$:9GQ/Z*]RBE\RA]T*)NS^JD+.BN[U7#A(74U5(8^!R/W_Y8D3
M*E:,"A'^=;'DN*'&I,HM(NEQ7DVM&MP>NFI)_78FT)KJ=+=>:'B0:4$P6D*(
MC>),1)PCWH*X _VL=)RMNRTY/6:3-,+4GOP*[V$>"16,IC>T!0@)QV"S3'[+
M 68_;PEHI?6W!AY)[+@DJ(Y'Z+XH99"TV[,V;MV:3<7C(W%'MFF10B-E=L(
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M>]9O.W;P@";Q^&VV,F,U1)#2U&9/V2KML81WHI>:SR/3-E?).E(E_2P- 5G
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M*#(.W+C4S,HA*_$F0@P!OF5 KI?>QF==&KFT/)I%2GLF<7,,&_FH,=FX<XK
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M"*&X3.9H^S;O=YNEYFX T8C*PE2%*0@E3H@';U$;Z"'I1U^Z7]V6L!Y75G.
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MHCXR<-Q(D]Q1VCK2J  =</E<./E!P[R]RSX[!*<+AD;*QB Z@Z#D#$#:HQ5
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MU*8C0Z:_''IL]8Z"C--(_V\QZW2W&#\56RC;$_W.X-AH+1H[+:O-LHLPQ.D
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M2K-LLNW3;AVZVB.?N91@?V8Q>'R0LF*KNL<IZH@$3>O"D^?3=-V=, %-WZ[
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M[UPF<*)D&?^RNAYCK079^QH+\O[=V0F"A41_/SE_!7?JF*=.:6=XP/'I&U@
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MY7/ZKJMUMMNN-CA2&$K)H]-!Y!KH.+9%FN.^: Z^9X_%-5S/<OUR%K,/N-K
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M,]3MK7I"H/;4.^ (YX<)WA<DECVD'DG",_+CQ78K'BZ1QE#/-K85^F8A;F[
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MO8.'!T^_^6%(P3 OH$H3#!N9:E!3%]Z-[Z"EUS]2&!>I'0Q_H.;%N).@G;V
MD:/ZX<=@T"5"BP%#;-5PXG[Z>-7,6J-'$<?#AQ'W1I>0B5E*]PHN*I1Q#C!"
M>(4[D.N8?TJ*>5(MW$CN.Z7ZT[Q(_; [ T3*=!WA+"C/7;7:I)'MDK]."K@F
M<[?@T<F48I.MZ8@*=LOO(GG8G._FAN#9M/[[][L+2NWB>@#-+6CUGR.2*L8.
MU,;CWO<K1/]HG5K"B C.@PXFI*)L+8]"O_*-JK"D<UEY,<Y\2K:0*MS6$-SY
M8PSE@X-=5+<P#%"B\&B:T/)&A;CU\' R",'6G3!99R F(O K/A#6UV59C@BT
M=#Y.$(I$0;-P3^#^HD=(&+W!9I B;LDUP3@E:\TZ7)/D2E91CJ[>#818+0F=
M%&E!Y%!)R(B070)!TCH./DAANZW=T<2'+._.X"CZ\DZ,SMDCO-$D>GY('>&>
M<=B[):A(Z$:>SIM+A&;XI2")S3R>&VI NB8$ZD 0Z[&6N=//HFM8UU8-?U"_
MC_[SR@MPR15,QCJ4TR62%"/4L.+A6T,E3#"=+37=H[Y#NOK.,R\JAOYM&[9F
M9'YC";6O1]-:N6#-8$&S9',8-0VQHU?S*9]MUMWF3763?%!F /;5AF7-/3V#
MZ SF(*/U]^M#45X3<99:N^9IZO[B>H_2=,;P2\IO3^LR2Q:68]2!L!5I.G*6
M-N*"P X/HA<L!] 7.G@B2T722'<Z;J\NB6<OBQ&[L1@BT(L YAG )]#$N+;X
M"\9])X CI"Q6#/5L>C&'!6-BTC29UDZKJ0*H&X(V$6ID-GO$8>-K".)F-T_F
M!:+LY4E1,,Z)N,%(R8(IJ!+U',5DKM#K3H8$-Z/;U7BY@8&4I%9$^0\@$A!C
MS@&H$,P\ <:9NT R4K$<WZJ0[O:QT#!<(XOVKWAY!#^N"-/O#8/DO]?IL!23
M!31%?7P:=%RT;138P9BL.;.Z!];91=O1X;E+5$! LVB3T#L8)G7C(*E ">8+
M%*P8T$"P8:(CKR+18.UK/:,=Q972&P,KA@FK<NAZ*.AA9X+; V^:"Z+NL-&
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MIYW->]J[>5TF;-U"NV6M.FYX+T'1' 95[/&ZVXBX(A)YX\\PM&Q/=A>^^-[
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M%.XN,^4:T8IOP0W;V]O?_?8A_G<M2B[^*'P%Q(/[SN\:<0\'WM<9<<]7?M>
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MDA.I#H;R+]">[/!*$EKHL&2QH$#L[0TAJ*BN;*D$!VDDRZ*&%\H,LF*5!YN
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M^P,#'),(3L@HR6#;2!Z%P3)WI-AM'T6'<K0<Q*W]L4+:$A(RAU@MT% 0A3.
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M:CL[(9H'N..'T.3A/334H/0J\8'L6KN@U" E@Z[13IN\JH&8A!:N\P6\5FE
MZU$UO<9?$8L(9P2$@F]67%<+6/D16DSK,;G3S.FS4O92*R5:/VKV#!*K9Z'!
M=D_"H$XQYCC>WEI>T^S'M.NBCWD;<4=5HANSY0V>'6&L5P.?"27DM9K5$Q,*
M*4!P%\\ #*Y6/Q U*8'T>V<2[H,_A1]R&C[-SXO8SLT=R^S6.-^^&',!KA_V
MS87-"S\G_[0KT1[X<([ H?R69EYHUK!J,^00>1]%N+ZG0W.Z,3#G#Y,XRQL9
M2 03G"XL\.(D#I[W[88 LQ=RVP>G=EK7'^W:,GU$3@"]39A#XCM) Y3SY8S"
M *KT8T@_ZH:+DJ+H'!O8'[S/51;V7A8^PO1 _\JFQ)2S_+<ONJY W"AJ^3Z5
M,';F)"N@/;DGR\_7X8QMZ$WS+@'E27A(%!NA"H:4K 5)FA0# 3 &E3>TVB#:
M!HH,&:@N/ %5/$D5!!,;J:K3I>JK[&1PQJ@(ME39:R"XK/]H5'+M-H\%H1,A
M@V.LDV1A4J3@_N G!QN,62*=>A<]V"Z#DJ]OA"?&J:[4K>V #!\*JY,4]]/_
MT2GN7YN.X=W9^0_O?CI]M[UU?G;\]L/QR?GIN[<?P,CP_=F[_WAS=OSC5X+]
M_Q K.*U^/!:;CA.CG?V0'K;&"D6IM_4:[O!>977LIHR2&E4-=0GCFOR<@X5!
M3I%0DB<S7XO]E*'CN$WLT;CX@,R'.XBGM&R-<-AQQ]-])9]XLQ-WZ&02=%BQ
ML$NG9U'X-B/N+@16F7YF$9>TOY)X=^TBP^"G( @9DDPF-J&R3"X-XYH@V++T
MD8_KRLK')9$26,K&A?NG;=767O?+#"&-!'#?AMT^=+5V&#VN9D>U@&'1QF2#
M*_=5#'K, @QE?!YP/E]QT>X((S3I .2-"['B5@[::W+/PRI3=@ I7N%OHT@7
MI;09MF=SY_A1?2VI$?93]/[2D&W%4-%Z^DEN(_VK"7A3M1]A%DG4GG&/%U.*
M/E-I>6Y,]BQB&K>3TKJ:KCMZD@^@BY&^;.8H&'=+(G7A9=$@>RZU),7@*MC@
MM#-NR83++3Q( CY(3P7+F4D:V)85]KGT[8BA)TX<0DF)H A?\SC&6N*,M[>Z
M5'Q9(",B9MV( 3F0[!G\-H[NU9DG(YMVUZ+H"%%(A%<ELZ02(H0XZ-11V3*D
MII*T=.D1$F[B&ANCJ!QGV#(ZU+7J!)9_>GAOU66.I;!8-QBV&"T'<6\M,.Q0
M(20R*N?\7JN\@V C1>IX$=G1F&CLZ@-#,?C*.WJQ4RJ[QX1UJP-**;4'Z!C"
MYX<O'S]A*W0&(I)=)W-N)34QE!'T@?LNIE-ZIAK6I1E5+40S2B[Y,DW),;X/
M46C6+P ?*ZGH9C3O-90Z;BL*%P9W>,3P6XVS1J<*3O]X2=X07?!BGA,OPVS&
MM.KAB9?!2;_&OPDVFA54U6B^#F@G*OM!/)H^7E7E%$ANG.V"<0\D\&W7^[7H
MKBJ^,LRFGJTHK@$<D%*3 V/3+N@4Q_,;%X)Y&X)^FRRGMS!#H_)U/F?!8*\$
M)=..^)WWDKG1*+SRRU4U+=<]+[HTQ-+9^@2\(ZKW>D:!,5>Q&#H<9;JGPJC"
M=<I6T'7!U_PT^"Y@:8Q5P1&YOIDV88R"4A1Z3M9%L)9-E9**X85'#1>3HP9)
M@9Q% TVJ[WO-,[X*NP[H_N![465$W6RD_L$$GY82UM C-#3$H#\HX$S(J3@I
MX-BKJA17 1.@U6KWA"/%J5Q:%E2%2'KK2T9B0) 8QQM_$J1Z?CMY?QS6+XU8
MHXG(S\/QE5!:N 6FG"1/F([P0Y8S^Z''[SLN ;XXZ#G2:2,)"%#L@"T)-K8H
MXRWO4%45SN.HA/:0/"S*#*-:\L]CY1"4F&$_,-JF1&V(DXD%';/+E4W&=PNB
MV+E1'IZZ_8[4]F,+D%<1=,9H%.92#'\."F(YT*O$%(B'+5[8>WOM=I6EB!X\
M5I+[X\NFY "^J44):=SB,M"0&;[D-0D2*N/EB&GDBHQA'_.]7D1,I#\L3@+E
M/O*GXPZ5&^TP.JTXBQZ-@:PLZ]A>^M^A+359.NWZE]^VLHFVIP23IUG1PA]B
MQ!QVWY#?]_UM!M1V0A#)BMVXC#LHH5EZFYBX](\5=O\2H6F:7RD)TC4DU%]P
MY?4O/T:BVBF#4_8^R?H^P.2[0%73%ZA3A="GAO!ZJ5D@( <8 >5XO9XU:I"X
M')A0L NRQV<<4Q2ENJP]W]U0*J 6=.Z0/VB"+[Q0U4**,.I N:Z<F:RWC+_M
MM322*K&RBW^#[^PUW&21""R[@LEA30K0A2HP?%.N.(MSM(:E=HYW9+?QYI#Y
MO$KQ-*3T2UA/.63&M;LV7!"^12-9=4>A@U!E%S\A]19[RRE(/LV.]-('X':]
M30<Q.I'N."4Y4#JSC/0I'-.SV-/G0W:)QN\!.D$M#R(K6AR.U9SQD:F;6U6.
M'J0R7BN.*IF?SQ1H$32[H(H.TB*,%8BO:=18(XM(=@S0B^4%H2,YGT;UB@X;
MGV*U\B( 1_WFRK=OK\3N+)=7(R6P+X(7H>5G3U1/,_?[N*U&V<(TU,>),ABT
M!AI>ND@"2=/B1CUD]E!'53-:SF@I0,"!@I&+<D%#9WW!Q\<YS+X*95!.VQ(_
MVA_\T>R%_B,[-(XY$_!QAV(L*911LB<!07+=-@YI&UOT] @LY]OREDZ)#:C#
M->(]OPQ#/T(=M)=$IEJ+P4]T0Q#90R"3]7'54Q&4:*M(UE9SEOL2!6BHF-Q0
ME<S>KT+80$SN^U\FDC;L/S7 WD;A39301>G[<4%ZV53Y^]2<V(>18(QIQP$-
MH$X+M<:Y@C^(NEFT#\#XQ>ZC,\*6,.L!,<AZ!F./+D9D:UN8T,G<:5H''&>^
MO16'F/">,+G&FB5820VT#"#K5MK7.*N]937X\*^-@ET5TDH+0(3(>:B=TDB$
M+\JK8CKI,H.ZS+R.W$*D=E"KUH.8X6=/$4?J@&V2WC?>8/+WHE8,"$B>#K5I
M+52X*\60N6;<I) Q3.,42*#H7Q2^%:,K\SM\D;Q EZ21SEA,";6Q?56&]+.[
MS4=@/PTT?RR.-;\XF,;^3#WD@WT^^-E#/MB>!F., 1)20X%_]I+6:I5#:JS%
M2S"HIYY;,+7'.CX-7)"V<K]:8\JK9=0LIV0,<Q'!6/T?/" \:[:<7O)8Z&"6
MT,D;>D?:";TK%;S.N,[+G-W*.@KG)T]<C,;].*RI)Z ==LF?PR\+JZF"Z2]>
MO5416*24ZMT[_7'[!PV</>.<PC=17"05#$BP$LU6-5O.8(A5GP>@52<'9F&Z
MDWAI%U,UJ*93!O^1CFS*DGG8(8J51MLCBU9>.LM)/HUADUE<LI1=HJ<0?G/X
MK4KF@E"$KF"J4Q-$>-=IT1H.W*@Z;LKRHQ2$T^^"';Z<E=WCY9X@<[J-VTGS
M-[<[%8ZRGM+@RX:J,L.M7 1;!5'_:@96/G3+N:8HB3&SC9'EUX,>5DBJ5!:*
MI:(,1S7U!GID -4>3C)7.!J% !2@=8PNF2E?$X.FZV))O9@6 K6QPT6U8*0A
M('ID'JM"0G"D:,8PV9AQ89$R)L&78UM-GMN443:UV/\<892PO'L1%<YC[CTR
M::]W=1T\[#6IO>#+GD=24-&&K#-LNBR*K=:*P 03#DCK\L53 <[>^3L,UL]
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M4UOYPQK)[D"\:;1#3U R=#T"7&>OO@FG)B]L7(T6$D1(/[)1BAF264,YUI_
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MZ%IAIG7OZB;^N&/X$7"9-CY!1XCQIZH5^G##2S".1[6 E;?S(O>RB0#<3Y5
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M2P$"% ,4    " #2A8Y5: $AG+L#   2$0  &0              @ $
M8VLP,# Q-C,U.3<W+3(P,C(Q,C$S+GAS9%!+ 0(4 Q0    ( -*%CE6B['3U
M_0$   0'   =              "  ?(#  !C:S P,#$V,S4Y-S<M,C R,C$R
M,3-?9&5F+GAM;%!+ 0(4 Q0    ( -*%CE4$(G3E+0(  *4*   =
M      "  2H&  !C:S P,#$V,S4Y-S<M,C R,C$R,3-?;&%B+GAM;%!+ 0(4
M Q0    ( -*%CE6L;S*NV@$  &@%   =              "  9((  !C:S P
M,#$V,S4Y-S<M,C R,C$R,3-?<')E+GAM;%!+ 0(4 Q0    ( -*%CE5FI5?1
MZ"\" /K>#  5              "  :<*  !T;3(R,C8P,SED-E\T,C1B-2YH
8=&U02P4&      4 !0!K 0  PCH"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
